US20190218261A1 - Targeted enhanced dna demethylation - Google Patents

Targeted enhanced dna demethylation Download PDF

Info

Publication number
US20190218261A1
US20190218261A1 US16/333,137 US201716333137A US2019218261A1 US 20190218261 A1 US20190218261 A1 US 20190218261A1 US 201716333137 A US201716333137 A US 201716333137A US 2019218261 A1 US2019218261 A1 US 2019218261A1
Authority
US
United States
Prior art keywords
domain
sequence
demethylation
complex
puf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US16/333,137
Inventor
Albert Cheng
Aziz Taghbalout
Nathaniel Jillette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jackson Laboratory
Original Assignee
Jackson Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jackson Laboratory filed Critical Jackson Laboratory
Priority to US16/333,137 priority Critical patent/US20190218261A1/en
Publication of US20190218261A1 publication Critical patent/US20190218261A1/en
Assigned to THE JACKSON LABORATORY reassignment THE JACKSON LABORATORY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHENG, ALBERT, JILLETTE, Nathaniel, TAGHBALOUT, Aziz
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0032—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with oxygen as acceptor (1.5.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2497—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing N- glycosyl compounds (3.2.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/02—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2)
    • C12Y302/02029—Thymine-DNA glycosylase (3.2.2.29)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/1102—Cysteine dioxygenase (1.13.11.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)

Definitions

  • Cas9 protein and sgRNA constitute a sufficient two-component DNA endonuclease whose specificity is provided by target-matching sequence on the sgRNA while endonuclease activity resides on the Cas9 protein.
  • Nuclease-defective or nuclease-deficient Cas9 protein e.g., dCas9 with mutations on its nuclease domains retains DNA binding activity when complexed with sgRNA.
  • dCas9 protein can tether and localize effector domains or protein tags by means of protein fusions to sites matched by sgRNA, thus constituting an RNA-guided DNA binding enzyme.
  • dCas9 can be fused to transcriptional activation domain (e.g., VP64) or repressor domain (e.g., KRAB), and be guided by sgRNA to activate or repress target genes, respectively.
  • transcriptional activation domain e.g., VP64
  • repressor domain e.g., KRAB
  • dCas9 can also be fused with fluorescent proteins and achieve live-cell fluorescent labeling of chromosomal regions.
  • Cas9-effector fusion is possible because sgRNA:Cas9 pairing is exclusive.
  • multimerization of effector or protein tags by direct fusion with dCas9 protein is technically limited, by constraints such as difficulty in delivering the large DNA encoding such fusions, or difficulty in translating or translocating such large proteins into the nucleus due to protein size.
  • Methylcytosine is an epigenetic mark generated via a process that covalently adds a methyl group at position 5 of the cytosine ring of a CpG DNA sequence.
  • formation of 5-methylcytosine (5mC) is catalyzed and maintained by DNA methyltransferases.
  • Demethylation pathways which remove the methyl group to restore unmethylated DNA, involve the ten-eleven translocation (TET) family of proteins. These are TET methylcytosine dioxygenases that catalyze the initial and critical step leading to replacing 5mC with unmethylated cytosine.
  • CpG methylation is part of the multifaceted epigenetic modifications of chromatin that shape cellular differentiation, gene expression, and maintenance of cellular homeostasis.
  • DNA methylation is a major mechanism in imprinting, tuning allelic expression of genes. Aberrant DNA methylation is implicated in various diseases including but not limited to cancer, imprinting disorders and neurological diseases (Robertson, K. D., DNA methylation and human disease . Nat Rev Genet, 2005. 6(8): p. 597-610).
  • a demethylation complex in one aspect, includes:
  • a method of demethylating a target nucleic acid sequence in a mammalian cell includes:
  • a demethylation complex in one aspect, includes:
  • a method of demethylating a target nucleic acid sequence in a mammalian cell includes:
  • a demethylation complex in one aspect, includes:
  • a method of demethylating a target nucleic acid sequence in a mammalian cell includes:
  • kits in another aspect, includes:
  • kits in another aspect, includes:
  • a cell including a demethylation complex as provided herein including embodiments thereof is provided.
  • FIGS. 1A-1D show that insertion of PUF binding site (PBS) sequences to sgRNA 3′-end did not substantially impact dCas9/sgRNA function, and that independent recruitment and multimerization of activators can be achieved using the subject 3-component CRISPR/Cas complex/system.
  • FIG. 1A is a schematic drawing showing the subject 3-component CRISPR/Cas complex/system (upper right), which improves the conventional two-hybrid dCas9 fusion design (upper left) by splitting it into a three-hybrid system, in which sgRNA-PBS bridges the DNA binding activity of dCas9/sgRNA with the effector function provided by a PUF fusion.
  • the middle panels represent the structure of a representative PUF (i.e., Pumilio /FBF) domain, showing the 8 repeats in the C to N direction and the corresponding interaction with the 8-mer target RNA in the 5′ to 3′ direction.
  • PUF RNA recognition code table shows exemplary di-residues and the corresponding RNA base recognized.
  • PBS PUF binding sites
  • 1B upper panel, is a schematic for the experiment to test the ability of dCas9-VP64 to bind and activate a tdTomato transgene after inserting varying number of PBS at the 3′ end of the sgRNA, e.g., experimental set up for testing the effect of sgRNA-PBS (with 0, 5, 15, 25, or 47 PBS) on the ability of the dCas9::VP64 construct to activate a TetO::tdTomato transgene.
  • the lower panel is column plot showing the mean fold changes ( ⁇ S.E.M.) in tdTomato fluorescence (relative to the dCas9-VP64/sgCtl-0 ⁇ PBSa control), as measured by fluorescence activated cell sorting (FACS), of cells transfected with the different constructs indicated in the legend below the plot.
  • the legend describes the sgRNA used in three parameters: sgRNA match refers to the DNA target recognized by the sgRNA; #PBS and PBS Type indicate the number and the types of PBS, respectively, appended to the end of the sgRNA.
  • FIG. 1C upper panel, is a schematic describing the experiment to test activation of a TetO::tdTomato transgene by the subject activator with different numbers of appended PBS.
  • the lower panel is a column plot showing the fold changes ( ⁇ S.E.M.) of tdTomato fluorescence (relative to control dCas9/PUFb-VP64/sgCtl-0 ⁇ PBSb) of cells transfected with the different constructs indicated in the legend blow the plot.
  • the legend describes the PUF isotype (PUF-VP64) used and the sgRNA-PBS used in terms of the number and type of PBS as well as the DNA target recognized by sgRNA indicated by shaded boxes.
  • 1D upper panel, is a schematic illustrating the experiment to test the independency of the subject activator isotypes in activating a TetO::tdTomato transgene.
  • the lower panel is a column plot showing the mean fold changes ( ⁇ S.E.M.) of tdTomato fluorescence (relative to the respective controls dCas9/PUFx-VP64/sgCtl-5 ⁇ PBSx for PUF/PBS isotype x) of cells transfected with the different constructs indicated in the legend below the plot.
  • PUF-VP64 the PUF isotype used (PUF-VP64), the PBS isotype (5 ⁇ PBS; “-” indicates sgRNA without PBS) and DNA target indicated by shaded boxes (sgRNA Match). All plots show results of three replicate measurements.
  • FIGS. 2A-2C relate to the assembly of the subject 3-component CRISPR/Cas complex/system comprising VP64 and P65-HSF1.
  • FIG. 2A is a schematic of the experiment testing the assembly of PUF(3-2)::VP64 and PUF(6-2/7-2)::P65-HSF1 via recruitment by sgRNA containing both PBS32 and PBS6272. The activity was measured by the tdTomato fluorescent reporter activity.
  • FIG. 2A is a schematic of the experiment testing the assembly of PUF(3-2)::VP64 and PUF(6-2/7-2)::P65-HSF1 via recruitment by sgRNA containing both PBS32 and PBS6272. The activity was measured by the tdTomato fluorescent reporter activity.
  • FIG. 2B is a column chart showing the relative mean tdTomato fluorescence resulting from transfecting the activator protein(s) with non-targeting (sgControl) and Tet-targeting (sgTetO) sgRNAs with 4 ⁇ [PBS32-PBS6272] heterodimer sites.
  • FIG. 2C shows comparison of the subject 3-component system activator using VP64 (PUFa::VP64) versus p65HSF1 (PUFa::p65HSF1) as the activation domain in conjunction with Control sgRNA with 5 ⁇ PBSa or TetO-targeting sgRNA with 0, 1, 5, 15, or 25 copies of PBSa.
  • FIGS. 3A-3C The figures show Casilio-ME outperforms dCas9-direct tethering system in delivering TET1(CD) to genomic loci and mediating gene activation.
  • FIG. 3A is a schematic representation of the hMLH1 promoter with regions of CpG hypermethylation shown by lollipops. Numbering of nucleotide is according to previous study reporting a strong association of hypermethylation in region C with hMLH1 silencing (Deng, G., et al., Methylation of CpG in a small region of the hMLH 1 promoter invariably correlates with the absence of gene expression . Cancer Res, 1999. 59(9): p. 2029-33).
  • FIG. 3B shows relative change in hMLH1 mRNA levels in cells transfected with Casilio components PUFa-TET1(CD), TET1(CD)-PUFa or PUFa-p65HSF1 and the combination of sgRNAs indicated by shaded boxes under the graph.
  • Drawings depict the Casilio system showing the effector modules used in each set of experiments and data were plotted that reflect the respective effector in application.
  • 3C shows relative change in hMLH1 mRNA levels in cells transfected with dCas9-tethered effectors dCas9-TET1(CD)C-terminal fusion, TET1(CD)-dCas9 N-terminal fusion or dCas9-p65HSF1 and the combination of sgRNAs indicated by shaded boxes under the graph.
  • Drawings depict the dCas9 fusion used for each set of experiments and data were plotted to reflect the respective effector used.
  • N i.e., N-terminus
  • C i.e., C-terminus
  • FIGS. 4A-4C The figures show that Casilio-ME mediates robust demethylation of methylcytosine via targeting TET1 activity to hMLH1 promoter region.
  • FIG. 4A is a time course of relative change in hMLH1 mRNA levels in cells transfected with Casilio components PUFa-TET1(CD) and the combination of sgRNAs indicated by shaded boxes under the graph. Drawing over the plot depicts the Casilio-ME system showing the carboxyterminal-TET1(CD) fusion module used and relative changes in hMLH1 mRNA levels were plotted against post-transfection time in which cells were harvested for analyses. Error bars indicate s.e.m derived from triplicate experiments.
  • FIG. 4A is a time course of relative change in hMLH1 mRNA levels in cells transfected with Casilio components PUFa-TET1(CD) and the combination of sgRNAs indicated by shaded boxes under the graph. Drawing over the plot depicts the Ca
  • FIG. 4B is Western blot analysis of protein extracted from indicated cell samples using anti-hMLH1 or anti-3 Actin monoclonal antibodies as shown. Proteins extracted form untransfected cells HEK293T (untreated) or treated with 2.5 ⁇ M 5′-Azacytidine (AzaC), HEK293 cells (293), and transfected HEK293T cells in the presence of a non-targeting control guide RNA (NTC) were analyzed in parallel with extracts from time course samples that were transfected with Casilio-Me components targeting the hMLH1 promoter region.
  • FIG. 4C shows frequency of cytosine to thymine bisulfite-mediated conversion of individual CpGs of the hMLH1 promoter region.
  • FIGS. 5A-5C The figures show that different configurations of Casilio-ME Dnmt effectors were tested.
  • FIG. 5A shows a direct fusions of C-terminal regions of (i) Dnmt3a, (ii) Dnmt3L, and (iii) Dnmt3a-3L (hybrid) to N-terminus of dCas9; (iv) Dnmt3a, (v) Dnmt3L, and (vi) Dnmt3a-3L hybrid to C-terminus of dCas9.
  • FIG. 5A shows a direct fusions of C-terminal regions of (i) Dnmt3a, (ii) Dnmt3L, and (iii) Dnmt3a-3L (hybrid) to N-terminus of dCas9; (iv) Dnmt3a, (v) Dnmt3L, and (vi) Dnmt3
  • FIG. 5B shows PUF effector fusion of C-terminal regions of (i) Dnmt3a, (ii) Dnmt3L, and (iii) Dnmt3a-3L to N-terminus of PUF domain; (iv) Dnmt3a, (v) Dnmt3L and (vi) Dnmt3a-3L to C-terminus of PUF domain.
  • FIG. 5C shows Casilio can potentially recruit different Dnmt effectors fused to different PUF domains via a guide containing the corresponding PBS.
  • FIGS. 6A-6B show SOX2 gene expression changes induced by targeting of Casilio-ME Dnmt modules to SOX2 promoter.
  • FIG. 6A shows relative SOX2 expression level in cells transfected with different dCas9-Dnmt enzymes and control guides or guides targeting SOX2 promoter.
  • FIG. 6B shows relative SOX2 expression level in cells transfected with different dCas9-Dnmt enzymes and control guides or guides targeting SOX2 promoter.
  • FIGS. 7A-7E show that GADD45A boosts Casilio-ME capability to impart TET1-mediated activation to methylation-silenced gene.
  • FIG. 7A depicts the Casilio and Casilio-ME platforms to show the various combinations of effector modules used in each set of experiment. Engineered protein fusions are shown with amino-termini and carboxyl-termini located at the left and right sides of each drawing respectively. The scaffold of the gRNA was altered to include 5 copies of PUFa or PUFa and PUFc binding sites.
  • FIG. 7B is a schematic representation of the hMLH1 promoter with regions of CpG hypermethylation shown by lollipops. Numbering of nucleotide is based on a strong association of hypermethylation in region C with hMLH1 silencing (Deng, Cancer Res. 59(9):2029-2033, 1999). sgRNAs designed around the hypermethylated region B and C are shown by numbers over short lines.
  • FIG. 7B is a schematic representation of the hMLH1 promoter with regions of CpG hypermethylation shown by lollipops. Numbering of nucleotide is based on a strong association of hypermethylation in region C with hMLH1 silencing (Deng, Cancer Res. 59(9):2029-2033, 1999). sgRNAs designed around the hypermethylated region B and C are shown by numbers over short lines.
  • FIG. 7C shows relative change in hMLH1 mRNA levels in HEK293T cells transfected with Casilio-ME components as indicated. Shaded boxes in the matrix under the graph indicate effectors and sgRNAs used in each experiment. Error bars indicate s.e.m derived from triplicate experiments.
  • FIG. 7D shows results of Western blot analysis of whole cell extracts from HEK293T cells transfected with the indicated Casilio-ME effector modules.
  • Lane 1-untransfected cells Lane 2-PUFa-GADD45A-TET1(CD); Lane 3-PUFa-GADDA45A-TET1(CD) with a slight variation in the Glycine-Serine linker; Lane 4-GADD45A-PUFa-TET1(CD); and Lane 5-PUFa-TET1(CD). 50 ⁇ g of protein were separated on 10% SDS-PAGE and immunoblotted with the indicated antibodies. Size marker in kDa is shown.
  • FIG. 7E shows relative change in hMLH1 mRNA levels in HEK293T cells transfected with Casilio-ME components as indicated.
  • FIG. 8A-8D NEIL2, but not NEIL1, NEIL3 or TDG, enhances Casilio-ME efficiency to deliver TET1-mediated activation to methylation-silenced gene.
  • FIG. 8A Drawings depict the Casilio-ME platform to show the PUFa-TET1(CD) effector and NEIL-based effector modules used in each experiment. For simplicity, NEIL1, NEIL2 and NEIL3 were depicted as NEIL. Engineered protein fusions are shown with amino and carboxyl termini located at the left and right sides of each drawing respectively. The shown gRNA scaffold was altered to include 5 copies of PUFa-binding sites (5 ⁇ PBSa).
  • Shapes are arbitrary drawn not to scale with NEIL1, NEIL2, and NEIL3 (NEIL), TET1(CD) (Ten eleven methylcytosine dioxygenase catalytic domain (1418 to 2136)), and PUFa are shown.
  • FIG. 8B Relative change in hMLH1 mRNA levels in HEK293T cells transfected with Casilio-ME components as indicated. Column shadings reflect different group of indicated PUFa fusions. Error bars indicate S.E.M derived from triplicate experiments.
  • FIG. 8C Drawings depict the Casilio-ME platform to show the PUFa-TET1(CD) and TDG-based PUFa fusions effectors used in each experiment.
  • Protein fusions are shown with amino and carboxyl termini located at the left and right sides of each drawing respectively.
  • the shown gRNA scaffold was altered to include 5 copies of PUFa-binding sites (5 ⁇ PBSa). Shapes are arbitrary drawn not to scale with TDG, TET1(CD) (Ten eleven methylcytosine dioxygenase catalytic domain (1418 to 2136)), and PUFa are shown.
  • FIG. 8D Relative change in hMLH1 mRNA levels in HEK293T cells transfected with Casilio-ME components as indicated. Column shadings reflect indicated PUFa fusions. Error bars indicate S.E.M. derived from triplicate experiments.
  • FIG. 9A-9B NEIL2 two-in-one effector enhances Casilio-ME efficiency to deliver TET1-mediated activation to methylation-silenced MLH1 gene.
  • FIG. 9A Drawings depict the Casilio-ME platform to show the PUFa-TET1(CD) effector and NEIL2-based effector modules used in each experiment. Protein fusions are shown with amino and carboxyl termini located at the left and right sides of each drawing respectively. The shown gRNA scaffold was altered to include 5 copies of PUFa-binding sites (5 ⁇ PBSa). Shapes are arbitrary drawn not to scale with NEIL2, TET1(CD), and PUFa are shown.
  • FIG. 9A Drawings depict the Casilio-ME platform to show the PUFa-TET1(CD) effector and NEIL2-based effector modules used in each experiment. Protein fusions are shown with amino and carboxyl termini located at the left and right sides of each drawing respectively. The shown gRNA scaffold was altered to include
  • FIG. 10A-10B Co-targeting of NEIL2 and TET1 effector modules robustly enhances TET1 mediated MLH1 activation.
  • FIG. 10A Drawings depict the Casilio-ME platform to show the PUFa-TET1(CD) effector and NEIL2 effector modules used in each experiment. Engineered protein fusions are shown with amino and carboxyl termini located at the left and right sides of each drawing respectively. The shown gRNA scaffold was altered to include 5 copies of PUFa and PUFc-binding sites (5 ⁇ PBSa and 5 ⁇ PBSc). Shapes are arbitrary drawn not to scale with NEIL2, TET1(CD), PUFa, and PUFc are shown.
  • FIG. 10A Drawings depict the Casilio-ME platform to show the PUFa-TET1(CD) effector and NEIL2 effector modules used in each experiment. Engineered protein fusions are shown with amino and carboxyl termini located at the left and right sides of each drawing respectively. The shown
  • FIG. 11A-11B TET1 mediated MLH1 activation without NEIL2 recruitment to target site.
  • FIG. 11A Drawings depict the Casilio-ME platform to show the PUFa-TET1(CD) effector and NEIL2 effector modules used in each experiment. Protein fusions are shown with amino and carboxyl termini located at the left and right sides of each drawing respectively. The shown gRNA scaffold was altered to include 5 copies of PUFa-binding sites (5 ⁇ PBSa) with no PUFc-binding site. Shapes are arbitrary drawn not to scale with NEIL2, TET1(CD), PUFa, and PUFc are shown.
  • FIG. 11A Drawings depict the Casilio-ME platform to show the PUFa-TET1(CD) effector and NEIL2 effector modules used in each experiment. Protein fusions are shown with amino and carboxyl termini located at the left and right sides of each drawing respectively. The shown gRNA scaffold was altered to include 5 copies of PUFa-binding sites
  • compositions and methods provided herein including embodiments thereof provide a methylation-editing (ME) platform allowing for targeted delivery of enhanced demethylation activity by delivering a TET demethylation domain (e.g., TET catalytic domain) or functional fragment thereof together with a demethylation enhancer domain (e.g., a GADD45A domain, a NEIL2 domain), to specific genomic loci, such as CpG islands, and thereby inducing enhanced demethylation DNA of said loci relative to the absence of said enhancer domain.
  • a TET demethylation domain e.g., TET catalytic domain
  • a demethylation enhancer domain e.g., a GADD45A domain, a NEIL2 domain
  • demethylation domains and demethylation enhancer domains provided herein may be delivered to a specific site in the genome of a mammalian cell by using a complex which includes a polynucleotide (e.g., guide RNA) bound to a nuclease-deficient DNA endonuclease (e.g., dCas9) and protein conjugates including a PUF domain, a demethylation domain (e.g., TET1 catalytic domain) and a demethylation enhancer domain (e.g., a GADD45A domain or a NEIL2 domain).
  • a polynucleotide e.g., guide RNA
  • a nuclease-deficient DNA endonuclease e.g., dCas9
  • protein conjugates including a PUF domain, a demethylation domain (e.g., TET1 catalytic domain) and a demethylation enhancer domain (e.g.,
  • the demethylation protein conjugate includes: (i) a PUF domain having a C-terminus and a N-terminus; (ii) a TET demethylation domain operably linked to the C-terminus of the PUF domain; and (iii) a demethylation enhancer domain operably linked to the N-terminus of the PUF domain, to form a protein conjugate, and the demethylation protein conjugate binds to the ribonucleoprotein complex via the PUF domain binding to the one or more PBS sequences to form a demethylation complex.
  • the demethylation protein conjugate includes (i) a PUF domain having a C-terminus; (ii) a demethylation enhancer domain, having a N-terminus and a C-terminus, wherein the N-terminus of the demethylation enhancer domain is operably linked to the C-terminus of the PUF domain; and (iii) a TET demethylation domain operably linked to the C-terminus of said demethylation enhancer domain; and the demethylation protein conjugate binds to the ribonucleoprotein complex via the PUF domain binding to the one or more PBS sequences to form a demethylation complex.
  • a demethylation protein conjugate includes (i) a first PUF domain having a C-terminus, and (ii) a TET demethylation domain operably linked to the C-terminus of the first PUF domain, wherein the demethylation protein conjugate binds to the ribonucleoprotein complex via the first PUF domain binding to the first PBS sequence; and a demethylation enhancer conjugate including (i) a second PUF domain; and (ii) a demethylation enhancer domain operably linked to the second PUF domain, wherein the demethylation enhancer conjugate binds to the ribonucleoprotein complex via the second PUF domain binding to the second PBS sequence to form a demethylation complex.
  • the demethylation enhancer domain may be linked to the same PUF domain as the demethylation domain (demethylation protein conjugate).
  • the demethylation enhancer domain may be connected to the guide RNA through a separate PUF domain (demethylation enhancer conjugate).
  • the demethylation complexes provided herein including embodiments thereof are based on a three-component hybrid system that includes CRISPR/Cas9 and Pumilio proteins.
  • the three-component hybrid system that includes CRISPR/Cas9 and Pumilio proteins may also be referred to interchangeably as the Casilio system, and the methylation-editing (ME) platform based on the Casilio system is sometimes referred to as Casilio-ME.
  • the demethylation domain e.g., TET demethylase
  • PAF domains Pumilio proteins or functional fragments thereof
  • compositions and methods provided herein including embodiments thereof are advantageous over the past attempts to modulate methylation status of a target gene by introducing a DNA demethylase into a target cell, in that the present invention allows for increased demethylation of the targeted gene locus by delivering a demethylation enzyme together with an enhancer of said demethylation enzyme.
  • Such system provides a superior demethylation activity to a target gene to alter the methylation status.
  • the demethylation efficiency of complexes including a TET demethylation domain can be significantly increased by including demethylation enhancers in the complex.
  • the present inventors discovered that the increase in demethylation efficiency upon inclusion of an enhancer domain depends on: (i) the type of enhancer protein present; (ii) the orientation in which the enhancer domain is linked to the PUF domain of the demethylation protein conjugate and (iii) the manner in which the demethylation enhancer domain is linked to the PUF domain and connected to the demethylation domain (e.g., from N- to C-terminus the conjugate may include a PUF domain linked to a demethylation enhancer domain linked to a demethylation domain, or a PUF domain linked to a demethylation domain linked to a demethylation enhancer domain).
  • Applicants have found that complexes where the demethylation domain (e.g., TET1 catalytic domain) is linked to the C-terminus of the PUF domain are significantly more effective relative to complexes with the demethylation domain (e.g., TET1 catalytic domain) linked to the N-terminus of the PUF domain.
  • C-terminal linked TET activity demethylation activity of TET1, TET2, or TET3
  • specific demethylation enhancers e.g., GADD45A, NEIL2
  • the enhancer is a NEIL glycosylase (e.g., NEIL1, NEIL2, or NEIL3)
  • NEIL1 NEIL2
  • NEIL3 NEIL3 glycosylase
  • a demethylation domain as referred to herein is a protein domain capable of demethylating a target nucleic acid.
  • the demethylation domain includes the catalytic domain of a demethylation enzyme (e.g., the catalytic domain of TET1).
  • the demethylation domain is the catalytic domain of a demethylation enzyme.
  • a “demethylation enhancer domain”, “demethylation enhancer protein” or “demethylation enhancer enzyme” as provided herein refers to a protein, protein domain or protein moiety capable of positively affecting (e.g. increasing) the activity or function of a demethylation enzyme or demethylation domain, relative to the activity or function of the demethylation enzyme or demethylation domain in the absence of the activator (e.g. demethylation enhancer domain described herein).
  • the demethylation enhancer domain may, at least in part, partially or totally increase stimulation, increase or enable activation, or activate the demethylation enzyme.
  • the amount of increase in activity may be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more in comparison to a control in the absence of the demethylation enhancer domain.
  • the activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more than the activity in the absence of the demethylation enhancer domain.
  • the demethylation enhancer domain increases demethylation of the TET demethylation domain by 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, 14-, 15-, 16-, 17-, 18-, 19-, or 20-fold.
  • the demethylation enhancer domain increases demethylation of the TET demethylation domain at least by 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, 14-, 15-, 16-, 17-, 18-, 19-, or 20-fold.
  • demethylation protein conjugates and demethylation enhancer conjugates useful for demethylating target loci in a cell.
  • the demethylation protein conjugates include a PUF domain described herein, a TET demethylation domain (e.g., a TET1 domain, a TET1 catalytic domain) linked to the C-terminus of the PUF domain and a demethylation enhancer domain (e.g., a NEIL2 domain or a GADD45A domain).
  • the demethylation enhancer domain may be linked to the N-terminus or the C-terminus of the PUF domain.
  • the demethylation enhancer domain is linked to the N-terminus of the PUF domain the TET demethylation domain and the demethylation enhancer domain are not directly linked, but connected through the PUF domain.
  • the demethylation enhancer domain is linked to the C-terminus of the PUF domain it connects the PUF domain to the TET demethylation domain.
  • the C-terminus of the PUF domain is linked to the demethylation enhancer domain and the C-terminus of the demethylation enhancer domain is linked to the TET demethylation domain.
  • the complexes provided herein may include a demethylation protein conjugate including a first PUF domain and a demethylation domain (e.g., a TET1 domain), wherein the TET demethylation domain is linked to the C-terminus of the PUF domain, and a demethylation enhancer conjugate including a second PUF domain and a demethylation enhancer domain (e.g., a NEIL2 domain or a GADD45A domain).
  • a demethylation protein conjugate including a first PUF domain and a demethylation domain (e.g., a TET1 domain), wherein the TET demethylation domain is linked to the C-terminus of the PUF domain
  • a demethylation enhancer conjugate including a second PUF domain and a demethylation enhancer domain (e.g., a NEIL2 domain or a GADD45A domain).
  • the demethylation enhancer domain is operably linked to the N-terminus of the PUF domain. In certain embodiments, the demethylation enhancer domain is operably linked to the C-terminus of the PUF domain. In certain embodiments, the demethylation enhancer domain is operably linked to the N-terminus of the second PUF domain. In certain embodiments, the demethylation enhancer domain is operably linked to the C-terminus of the second PUF domain.
  • the demethylation enhancer domain is a Growth Arrest and DNA-Damage-inducible Alpha (GADD45A) domain.
  • the GADD45 domain has the amino acid sequence of SEQ ID NO:85.
  • the demethylation enhancer domain is a NEIL2 domain.
  • the NEIL2 domain has the amino acid sequence of SEQ ID NO:86.
  • the demethylation enhancer domain is not a NEIL1 domain. In certain embodiments, the demethylation enhancer domain is not a NEIL3 domain.
  • demethylation conjugates e.g., demethylation protein conjugate, demethylation enhancer conjugate
  • demethylation conjugates including (i) a PUF domain operably linked to a demethylation domain and a demethylation enhancer domain (demethylation protein conjugate), (ii) a first PUF domain operably linked to a demethylation domain (demethylation protein conjugate) or (iii) a second PUF domain operably linked to a demethylation enhancer domain, respectively (demethylation enhancer conjugate).
  • a demethylation protein conjugate as provided herein includes (i) a PUF domain linked to demethylation domain and a demethylation enhancer domain or (ii) a first PUF domain linked to a demethylation domain.
  • a demethylation enhancer domain includes a second PUF domain linked to a demethylation enhancer domain.
  • the demethylation domain is operably linked to the C-terminus of the PUF domain to form a protein conjugate.
  • the demethylation enhancer domain may be linked to the C-terminus of the PUF domain, to the N-terminus of the PUF domain, or the demethylation enhancer domain may bind the polynucleotide (e.g., gRNA) linked to a separate PUF domain (i.e., a PUF domain not linked to the demethylation domain).
  • the demethylation domain forms part of a demethylation protein conjugate and is linked to a first PUF domain
  • the demethylation enhancer domain forms part of a demethylation enhancer protein conjugate and is linked to a second PUF domain.
  • the demethylation protein conjugate binds the polynucleotide through binding of the first PUF domain to the first PBS sequence and the demethylation enhancer protein conjugate binds the polynucleotide through binding of the second PUF domain to the second PBS sequence.
  • a demethylation complex includes:
  • a demethylation complex in one aspect, includes:
  • a demethylation complex in one aspect, includes:
  • the TET demethylation domain is a TET1 domain (i.e., TET1 catalytic domain), a TET2 domain (i.e., TET2 catalytic domain) or a TET3 domain (i.e., TET3 catalytic domain).
  • the TET demethylation domain is a TET1 domain.
  • the TET demethylation domain is a TET2 domain.
  • the TET demethylation domain is a TET3 domain.
  • the TET demethylation domain is a TET1 catalytic domain.
  • the TET demethylation domain is a TET2 catalytic domain.
  • the TET demethylation domain is a TET3 catalytic domain. In certain embodiments, the TET1 domain has the sequence of SEQ ID NO:51. In certain embodiments, the demethylation enhancer domain is a Growth Arrest and DNA-Damage-inducible Alpha (GADD45A) domain. In certain embodiments, the GADD45 domain has the amino acid sequence of SEQ ID NO:85. In certain embodiments, the demethylation enhancer domain is a NEIL2 domain. In certain embodiments, the NEIL2 domain has the amino acid sequence of SEQ ID NO:86.
  • a “ribonucleoprotein complex” as provided herein refers to a complex including a nucleoprotein and a ribonucleic acid.
  • a “nucleoprotein” as provided herein refers to a protein capable of binding a nucleic acid (e.g., RNA, DNA). Where the nucleoprotein binds a ribonucleic acid it is referred to as “ribonucleoprotein.”
  • the interaction between the ribonucleoprotein and the ribonucleic acid may be direct, e.g., by covalent bond, or indirect, e.g., by non-covalent bond (e.g. electrostatic interactions (e.g.
  • the ribonucleoprotein includes an RNA-binding motif non-covalently bound to the ribonucleic acid.
  • positively charged aromatic amino acid residues e.g., lysine residues
  • the RNA-binding motif may form electrostatic interactions with the negative nucleic acid phosphate backbones of the RNA, thereby forming a ribonucleoprotein complex.
  • Non-limiting examples of ribonucleoproteins include ribosomes, telomerase, RNAseP, hnRNP, CRISPR associated protein 9 (Cas9) and small nuclear RNPs (snRNPs).
  • the ribonucleoprotein may be an enzyme.
  • the ribonucleoprotein is an endonuclease.
  • the ribonucleoprotein is a nuclease-deficient RNA-guided DNA endonuclease enzyme.
  • the ribonucleoprotein complex includes an nuclease-deficient RNA-guided DNA endonuclease enzyme and a ribonucleic acid.
  • the nuclease-deficient RNA-guided DNA endonuclease enzyme includes a nuclear localization signal (NLS).
  • the nuclear localization signal (NLS) provided herein provides for nuclear transport of the protein domain or protein, for example the nuclease-deficient RNA-guided DNA endonuclease enzyme, the NLS is linked to.
  • the nuclease-deficient RNA-guided DNA endonuclease enzyme is nuclease-deficient CRISPR associated protein 9 (dCas9). In certain embodiments, the nuclease-deficient RNA-guided DNA endonuclease enzyme is nuclease-deficient Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (Cpfl).
  • the polynucleotide provided herein includes (1) a DNA-targeting sequence that is complementary to a target polynucleotide sequence, (2) a binding sequence for the nuclease-deficient RNA-guided DNA endonuclease enzyme (e.g., dCas9), and (3) one or more PUF binding site (PBS) sequences (e.g., a first (3) and a second (4) PBS sequence).
  • the complex includes dCas9 bound to the polynucleotide thereby forming a ribonucleoprotein complex.
  • the polynucleotide is a ribonucleic acid.
  • the polynucleotide is a guide RNA.
  • a “guide RNA” or “gRNA” as provided herein refers to a ribonucleotide sequence capable of binding a nucleoprotein, thereby forming ribonucleoprotein complex.
  • the polynucleotide (e.g., gRNA) is a single-stranded ribonucleic acid. In certain embodiments, the polynucleotide (e.g., gRNA) is 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more nucleic acid residues in length. In certain embodiments, the polynucleotide (e.g., gRNA) is from 10 to 30 nucleic acid residues in length. In certain embodiments, the polynucleotide (e.g., gRNA) is 20 nucleic acid residues in length.
  • the length of the polynucleotide can be at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more nucleic acid residues or sugar residues in length.
  • the polynucleotide (e.g., gRNA) is from 5 to 50, 10 to 50, 15 to 50, 20 to 50, 25 to 50, 30 to 50, 35 to 50, 40 to 50, 45 to 50, 5 to 75, 10 to 75, 15 to 75, 20 to 75, 25 to 75, 30 to 75, 35 to 75, 40 to 75, 45 to 75, 50 to 75, 55 to 75, 60 to 75, 65 to 75, 70 to 75, 5 to 100, 10 to 100, 15 to 100, 20 to 100, 25 to 100, 30 to 100, 35 to 100, 40 to 100, 45 to 100, 50 to 100, 55 to 100, 60 to 100, 65 to 100, 70 to 100, 75 to 100, 80 to 100, 85 to 100, 90 to 100, 95 to 100, or more residues in length.
  • the polynucleotide (e.g., gRNA) is from 10 to 15, 10 to 20, 10 to 30, 10 to 40, or 10 to 50 residues in length.
  • transcription of the polynucleotide is under the control of a constitutive promoter, such as a CMV promoter or a Ubc promoter, or an inducible promoter, such as a tetracycline-responsive promoter or a steroid-responsive promoter.
  • a constitutive promoter such as a CMV promoter or a Ubc promoter
  • an inducible promoter such as a tetracycline-responsive promoter or a steroid-responsive promoter.
  • the polynucleotide is a vector.
  • the vector encoding the polynucleotide (for use in the methods of the invention) is active in a cell from a mammal (a human; a non-human primate; a non-human mammal; a rodent such as a mouse, a rat, a hamster, a guinea pig; a livestock mammal such as a pig, a sheep, a goat, a horse, a camel, cattle; or a pet mammal such as a cat or a dog); a bird, a fish, an insect, a worm, a yeast, or a bacterium.
  • a mammal a human; a non-human primate; a non-human mammal; a rodent such as a mouse, a rat, a hamster, a guinea pig; a livestock mammal such as a pig, a sheep, a goat, a horse, a camel, cattle; or
  • the vector is a plasmid, a viral vector (such as adenoviral, retroviral, or lentiviral vector, or AAV vector), or a transposon (such as piggyBac transposon).
  • the vector can be transiently transfected into a host cell, or be integrated into a host genome by infection or transposition.
  • the polynucleotide includes a nucleotide sequence complementary to a target site (e.g., target polynucleotide sequence), which is referred to herein as “DNA-targeting sequence.”
  • the DNA-targeting sequence may mediate binding of the ribonucleoprotein complex to a complementary target polynucleotide sequence thereby providing the sequence specificity of the ribonucleoprotein complex.
  • the polynucleotide e.g., gRNA
  • the polynucleotide e.g., gRNA
  • the polynucleotide binds a target polynucleotide sequence.
  • the complement of the polynucleotide has a sequence identity of 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to the target polynucleotide sequence.
  • the complement of the DNA-targeting sequence has a sequence identity of 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to the target polynucleotide sequence.
  • the DNA-targeting sequence may or may not be 100% complementary to the target polynucleotide sequence.
  • the DNA-targeting sequence is complementary to the target polynucleotide sequence over 8-25 nucleotides (nts), 12-22 nucleotides, 14-20 nts, 16-20 nts, 18-20 nts, or 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nts.
  • the complementary region comprises a continuous stretch of 12-22 nts, preferably at the 3′ end of the DNA-targeting sequence.
  • the 5′ end of the DNA-targeting sequence has up to 8 nucleotide mismatches with the target polynucleotide sequence.
  • the DNA-binding sequence is 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% complementary to the target polynucleotide sequence.
  • nuclease-deficient RNA-guided DNA endonuclease in the complex is a nuclease-deficient wildtype Cas9 protein (nuclease-deficient wt Cas9 protein) which, under the circumstance, binds but does not cut a target DNA (e.g., dCas9 protein).
  • the nuclease-deficient RNA-guided DNA endonuclease is a nuclease-deficient Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (Cpfl).
  • the DNA-targeting sequence is functionally similar or equivalent to the crRNA or guide RNA or gRNA of the CRISPR/Cas complex/system.
  • the DNA-targeting sequence may not originate from any particular crRNA or gRNA, but can be arbitrarily designed based on the sequence of the target polynucleotide sequence.
  • the DNA-targeting sequence includes a nucleotide sequence that is complementary to a specific sequence within a target DNA (or the complementary strand of the target DNA).
  • the DNA-targeting sequence interacts with a target polynucleotide sequence of the target DNA in a sequence-specific manner via hybridization (i.e., base pairing).
  • the nucleotide sequence of the DNA-targeting sequence may vary, and it determines the location within the target DNA that the subject polynucleotide and the target DNA will interact.
  • the DNA-targeting sequence can be modified or designed (e.g., by genetic engineering) to hybridize to any desired sequence within the target DNA.
  • the target polynucleotide sequence is immediately 3′ to a PAM (protospacer adjacent motif) sequence of the complementary strand, which can be 5′-CCN-3′, wherein N is any DNA nucleotide. That is, in this embodiment, the complementary strand of the target polynucleotide sequence is immediately 5′ to a PAM sequence that is 5′-NGG-3′, wherein N is any DNA nucleotide.
  • the PAM sequence of the complementary strand matches the nuclease-deficient wt Cas9 protein or dCas9.
  • the DNA-targeting sequence can have a length of from 12 nucleotides to 100 nucleotides.
  • the DNA-targeting sequence can have a length of from 12 nucleotides (nt) to 80 nt, from 12 nt to 50 nt, from 12 nt to 40 nt, from 12 nt to 30 nt, from 12 nt to 25 nt, from 12 nt to 20 nt, or from 12 nt to 19 nt.
  • the DNA-targeting sequence can have a length of from 19 nt to 20 nt, from 19 nt to 25 nt, from 19 nt to 30 nt, from 19 nt to 35 nt, from 19 nt to 40 nt, from 19 nt to 45 nt, from 19 nt to 50 nt, from 19 nt to 60 nt, from 19 nt to 70 nt, from 19 nt to 80 nt, from 19 nt to 90 nt, from 19 nt to 100 nt, from 20 nt to 25 nt, from 20 nt to 30 nt, from 20 nt to 35 nt, from 20 nt to 40 nt, from 20 nt to 45 nt, from 20 nt to 50 nt, from 20 nt to 60 nt, from 20 nt to 70 nt, from 20 nt to 80 nt, from 20 nt to 90 n, from
  • the nucleotide sequence of the DNA-targeting sequence that is complementary to a target polynucleotide sequence of the target DNA can have a length of at least 12 nt.
  • the DNA-targeting sequence that is complementary to a target polynucleotide sequence of the target DNA can have a length at least 12 nt, at least 15 nt, at least 18 nt, at least 19 nt, at least 20 nt, at least 25 nt, at least 30 nt, at least 35 nt or at least 40 nt.
  • the DNA-targeting sequence that is complementary to a target polynucleotide sequence of a target DNA can have a length of from 12 nucleotides (nt) to 80 nt, from 12 nt to 50 nt, from 12 nt to 45 nt, from 12 nt to 40 nt, from 12 nt to 35 nt, from 12 nt to 30 nt, from 12 nt to 25 nt, from 12 nt to 20 nt, from 12 nt to 19 nt, from 19 nt to 20 nt, from 19 nt to 25 nt, from 19 nt to 30 nt, from 19 nt to 35 nt, from 19 nt to 40 nt, from 19 nt to 45 nt, from 19 nt to 50 nt, from 19 nt to 60 nt, from 20 nt to 25 nt, from 20 nt to 30 nt, from 20 nt, from
  • the DNA-targeting sequence that is complementary to a target polynucleotide sequence of the target DNA is 20 nucleotides in length. In some cases, the DNA-targeting sequence that is complementary to a target polynucleotide sequence of the target DNA is 19 nucleotides in length.
  • the percent complementarity between the DNA-targeting sequence and the target polynucleotide sequence of the target DNA can be at 50% (e.g., at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%). In some cases, the percent complementarity between the DNA-targeting sequence and the target polynucleotide sequence is 100% over the seven or eight contiguous 5′-most nucleotides of the target polynucleotide sequence.
  • the percent complementarity between the DNA-targeting sequence and the target polynucleotide sequence is at least 60% over 20 contiguous nucleotides. In some cases, the percent complementarity between the DNA-targeting sequence and the target polynucleotide sequence is 100% over the 7, 8, 9, 10, 11, 12, 13, or 14 contiguous 5′-most nucleotides of the target polynucleotide sequence (i.e., the 7, 8, 9, 10, 11, 12, 13, or 14 contiguous 3′-most nucleotides of the DNA-targeting sequence), and as low as 0% over the remainder. In such a case, the DNA-targeting sequence can be considered to be 7, 8, 9, 10, 11, 12, 13, or 14 nucleotides in length, respectively.
  • a “target polynucleotide sequence” as provided herein is a nucleic acid sequence expressed by a cell.
  • the target polynucleotide sequence is an exogenous nucleic acid sequence.
  • the target polynucleotide sequence is an endogenous nucleic acid sequence.
  • the target polynucleotide sequence forms part of a cellular gene.
  • the target polynucleotide sequence is part of a gene.
  • the target polynucleotide sequence is part of a Sox gene.
  • the target polynucleotide sequence is part of a transcriptional regulatory sequence.
  • the target polynucleotide sequence is part of a promoter, enhancer or silencer. In certain embodiments, the target polynucleotide sequence is a hypermethylated nucleic acid sequence. In certain embodiments, the target polynucleotide sequence is a hypermethylated CpG sequence. In certain embodiments, the target polynucleotide sequence is part of an hMLH1 promoter.
  • the target sequence is an RNA.
  • the target sequence is a DNA.
  • the first segment is generally referred to as the “DNA-targeting sequence” when the target sequence is a DNA (such as a genomic DNA).
  • the description herein below applies generally as well except that the reference to “DNA-targeting sequence” is replaced with “RNA-targeting sequence,” in order to avoid redundancy. That is, the polynucleotide includes a nucleotide sequence complementary to the target polynucleotide sequence (DNA or RNA).
  • the three segments (1)-(3) are arranged, in that order, from 5′ to 3′. In certain embodiments, the three segments (1)-(4) are arranged, in that order, from 5′ to 3′.
  • the polynucleotide of the invention can be a single RNA molecule (single RNA polynucleotide), which may include a “single-guide RNA,” or “sgRNA.”
  • the polynucleotide of the invention includes two RNA molecules (e.g., joined together via hybridization at the binding sequence (e.g., nuclease-deficient wt Cas9 protein- or dCas9-binding sequence)).
  • the subject polynucleotide is inclusive, referring both to two-molecule polynucleotides and to single-molecule polynucleotides (e.g., sgRNAs).
  • the target polynucleotide sequence is at, near, or within a promoter sequence. In certain embodiments, the target polynucleotide sequence is within a CpG island. In certain embodiments, the target polynucleotide sequence is known to be associated with a disease or condition characterized by DNA hypo- or hyper-methylation. In certain embodiments, the target polynucleotide sequence is within a tumor suppressor gene or an oncogene, such as within a transcriptional regulatory sequence/element of the tumor suppressor gene or oncogene.
  • the target polynucleotide sequence is immediately 3′ to a PAM (protospacer adjacent motif) sequence of the target polynucleotide sequence.
  • the PAM sequence of the target polynucleotide sequence is 5′-CCN-3′, wherein N is any DNA nucleotide.
  • the PAM sequence of the target polynucleotide sequence matches the specific nuclease-deficient wt Cas9 protein or dCas9 protein or homologs or orthologs to be used.
  • the target polynucleotide sequence in the genomic DNA must be complementary to the guide RNA sequence and must be immediately followed by the correct protospacer adjacent motif or PAM sequence.
  • the PAM sequence is present in the target polynucleotide sequence but not in the guide RNA sequence. Any DNA sequence with the correct target polynucleotide sequence followed by the PAM sequence will be bound by nuclease-deficient wt Cas9 protein or dCas9 protein.
  • the PAM sequence is any of the PAM sequences disclosed in international application PCT/US2016/021491 and published as WO2016148994 A8, which is hereby incorporated by reference and for all purposes.
  • the polynucleotide (e.g., gRNA) is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to the target polynucleotide sequence.
  • the polynucleotide (e.g., gRNA) is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% complementary to the sequence of a cellular gene.
  • the polynucleotide (e.g., gRNA) binds a cellular gene sequence.
  • the complex includes dCas9 bound to the polynucleotide through binding a binding sequence of the polynucleotide and thereby forming a ribonucleoprotein complex.
  • the binding sequence forms a hairpin structure.
  • the binding sequence is 30-100 nt, 35-50 nt, 37-47 nt, or 42 nt in length.
  • An exemplary binding sequence is the sequence of SEQ ID NO:6 GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTA.
  • Another exemplary binding sequence is the sequence of SEQ ID NO:7 GTTTAAGAGCTATGCTGGAAACAGCATAGCAAGTTTAAATAAGGCTA.
  • the binding sequence includes the sequence of SEQ ID NO: 6. In certain embodiments, the binding sequence includes the sequence of SEQ ID NO: 7. In certain embodiments, the binding sequence is the sequence of SEQ ID NO: 6. In certain embodiments, the binding sequence is the sequence of SEQ ID NO: 7.
  • the binding sequence (protein-binding segment or protein-binding sequence) of the subject polynucleotide binds to a modified dCas9 protein (e.g., nuclease-deficient nickase or dCas9) which has reduced endonuclease activity, or lacks endonuclease activity.
  • a modified dCas9 protein e.g., nuclease-deficient nickase or dCas9
  • the binding sequence (protein-binding segment or protein-binding sequence) which may bind to modified Cas9 proteins (e.g., dCas9 protein) may simply be referred to as “Cas9-binding sequence” or “binding sequence” herein.
  • the binding sequence (Cas9-binding sequence) of the invention binds to a dCas9, it is not prevented from binding to a wt Cas9 or a Cas9 nickase.
  • the binding sequence (Cas9-binding sequence) of the invention binds to dCas9 as well as wt Cas9 and/or Cas9 nickase.
  • the binding sequence interacts with or binds to a Cas9 protein (e.g., nuclease-deficient wt Cas9 protein, or dCas9 protein), and together they bind to the target polynucleotide sequence recognized by the DNA-targeting sequence.
  • the binding sequence includes two complementary stretches of nucleotides that hybridize to one another to form a double stranded RNA duplex (a dsRNA duplex).
  • nucleotides may be covalently linked by intervening nucleotides known as linkers or linker nucleotides (e.g., in the case of a single-molecule polynucleotide), and hybridize to form the double stranded RNA duplex (dsRNA duplex, or “Cas9-binding hairpin”) of the binding sequence (Cas9-binding sequence), thus resulting in a stem-loop structure.
  • linkers or linker nucleotides e.g., in the case of a single-molecule polynucleotide
  • Cas9-binding hairpin double stranded RNA duplex
  • the two complementary stretches of nucleotides may not be covalently linked, but instead are held together by hybridization between complementary sequences (e.g., in the case of a two-molecule polynucleotide of the invention).
  • the binding sequence can have a length of from 10 nucleotides to 100 nucleotides, e.g., from 10 nucleotides (nt) to 20 nt, from 20 nt to 30 nt, from 30 nt to 40 nt, from 40 nt to 50 nt, from 50 nt to 60 nt, from 60 nt to 70 nt, from 70 nt to 80 nt, from 80 nt to 90 nt, or from 90 nt to 100 nt.
  • 10 nucleotides (nt) to 20 nt from 20 nt to 30 nt, from 30 nt to 40 nt, from 40 nt to 50 nt, from 50 nt to 60 nt, from 60 nt to 70 nt, from 70 nt to 80 nt, from 80 nt to 90 nt, or from 90 nt to 100 nt.
  • the Cas9-binding sequence can have a length of from 15 nucleotides (nt) to 80 nt, from 15 nt to 50 nt, from 15 nt to 40 nt, from 15 nt to 30 nt, from 37 nt to 47 nt (e.g., 42 nt), or from 15 nt to 25 nt.
  • the dsRNA duplex of the binding sequence can have a length from 6 base pairs (bp) to 50 bp.
  • the dsRNA duplex of the binding sequence can have a length from 6 bp to 40 bp, from 6 bp to 30 bp, from 6 bp to 25 bp, from 6 bp to 20 bp, from 6 bp to 15 bp, from 8 bp to 40 bp, from 8 bp to 30 bp, from 8 bp to 25 bp, from 8 bp to 20 bp or from 8 bp to 15 bp.
  • the dsRNA duplex of the binding sequence can have a length from 8 bp to 10 bp, from 10 bp to 15 bp, from 15 bp to 18 bp, from 18 bp to 20 bp, from 20 bp to 25 bp, from 25 bp to 30 bp, from 30 bp to 35 bp, from 35 bp to 40 bp, or from 40 bp to 50 bp.
  • the dsRNA duplex of the binding sequence (Cas9-binding sequence) has a length of 36 base pairs.
  • the percent complementarity between the nucleotide sequences that hybridize to form the dsRNA duplex of the binding sequence can be at least 60%.
  • the percent complementarity between the nucleotide sequences that hybridize to form the dsRNA duplex of the binding sequence can be at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%.
  • the percent complementarity between the nucleotide sequences that hybridize to form the dsRNA duplex of the binding sequence is 100%.
  • the polynucleotide further includes a linker sequence linking the DNA-targeting sequence to the binding sequence (Cas9-binding sequence).
  • the linker can have a length of from 3 nucleotides to 100 nucleotides.
  • the linker can have a length of 3 nucleotides (nt) to 90 nt, from 3 nucleotides (nt) to 80 nt, from 3 nucleotides (nt) to 70 nt, from 3 nucleotides (nt) to 60 nt, from 3 nucleotides (nt) to 50 nt, from 3 nucleotides (nt) to 40 nt, from 3 nucleotides (nt) to 30 nt, from 3 nucleotides (nt) to 20 nt or from 3 nucleotides (nt) to 10 nt.
  • the linker can have a length of from 3 nt to 5 nt, from 5 nt to 10 nt, from 10 nt to 15 nt, from 15 nt to 20 nt, from 20 nt to 25 nt, from 25 nt to 30 nt, from 30 nt to 35 nt, from 35 nt to 40 nt, from 40 nt to 50 nt, from 50 nt to 60 nt, from 60 nt to 70 nt, from 70 nt to 80 nt, from 80 nt to 90 nt, or from 90 nt to 100 nt.
  • the linker is 4 nt.
  • Non-limiting examples of nucleotide sequences that can be included in a suitable binding sequence are set forth in SEQ ID NOs: 563-682 of WO 2013/176772 (see, for examples, FIGS. 8 and 9 of WO 2013/176772), which is hereby incorporated by reference in its entirety and for all purposes.
  • a suitable binding sequence includes a nucleotide sequence that differs by 1, 2, 3, 4, or 5 nucleotides from any one of the above-listed sequences.
  • PBS Pumilio /fem-3 mRNA binding factor
  • a PUF binding site may form part of a guide RNA and provide for the binding of a PUF protein or PUF domain as provided herein (e.g., PUFa, PUFb, PUFc or functional fragments thereof) to said guide RNA.
  • the PUF binding site includes a nucleic acid sequence (i.e., a PBS sequence or PUF binding site sequence) which is characteristic of the PBS and may be bound directly by the PUF protein.
  • the polynucleotide (e.g., gRNA) provided herein further includes one or more PUF binding site (PBS) sequences.
  • the demethylation complex includes the demethylation enhancer domain linked to a different PUF domain than the demethylation domain. Therefore, the demethylation domain may be bound to the polynucleotide through a first PUF domain binding a first PBS sequence and the demethylation enhancer domain may be bound to the polynucleotide through a second PUF domain bound to a second PBS sequence.
  • the first and the second PBS sequence may be different or may be the same.
  • the one or more PBS sequences (e.g., first or second PBS sequence) contain 8 nucleotides in length.
  • the one or more PBS sequences are identical.
  • the polynucleotide includes 1 to 50 PBS sequences.
  • one or more PBS sequences (e.g., first or second PBS sequence) comprise the nucleotide sequence of SEQ ID NO: 1. Any one of the PBS sequences (e.g., first or second PBS sequence) disclosed in international application PCT/US2016/021491 and published as WO2016148994 A8, which is hereby incorporated by reference in its entirety and for all purposes, are contemplated for the compositions and methods provided herein.
  • each of the one or more PBS sequences has 8 nucleotides.
  • One exemplary PBS sequence may have a sequence of SEQ ID NO:8 (5′-UGUAUGUA-3′), which can be bound by the PUF domain PUF(3-2).
  • Another exemplary PBS may have a sequence of SEQ ID NO:9 (5′-UUGAUAUA-3′), which can be bound by the PUF domain PUF(6-2/7-2). Additional PBS sequences and the corresponding PUF domains are described in international application PCT/US2016/021491 and published as WO2016148994 A8, which is hereby incorporated by reference in its entirety and for all purposes.
  • the polynucleotide of the invention may have more than one copy of the PBS sequences.
  • the polynucleotide comprises 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 46, 47, 48, 49, or 50 copies of PBS sequences, such as 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 copies of PBS sequences.
  • the range of the PBS sequence copy number is L to H, wherein L is any one of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, or 40, and wherein H is any one of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 80, 90, or 100, so long as H is greater than L.
  • L is any one of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, or 40
  • H is any one of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 80, 90, or 100, so long as H is greater than L.
  • Each PBS sequence may be the same or different.
  • the polynucleotide includes 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 46, 47, 48, 49, or 50 copies, or 1-50, 2-45, 3-40, 5-35, 5-10, 10-20 copies of identical or different PBS sequences.
  • the polynucleotide includes 5-15 copies of PBS sequences, or 5-14 copies, 5-13 copies, 5-12 copies, 5-11 copies, 5-10 copies, or 5-9 copies of PBS sequences.
  • the amount of the gRNA-PBS sequences and/or the amount of the protein conjugate (methylation or demethylation protein conjugate) transfected or expressed is adjusted to maximize PBS/PUF domain binding. For example, this can be achieved by increasing the expression of the PUF domain by a stronger promoter or using an inducible promoter, such as a Dox-inducible promoter.
  • the spacing between PBS sequences and/or spacer sequences are optimized to improve system efficiency.
  • spacing optimization can be subject to particular protein conjugates (methylation or demethylation protein conjugates), and can be different between protein conjugates (methylation or demethylation protein conjugate) that work as individual proteins and those protein conjugates (methylation or demethylation protein conjugate) that may need to be positioned close enough to function (e.g., protein complexes).
  • one or more spacer region(s) separate two adjacent PBS sequences.
  • the spacer regions may have a length of from 3 nucleotides to 100 nucleotides.
  • the spacer can have a length of from 3 nucleotides (nt) to 90 nt, from 3 nucleotides (nt) to 80 nt, from 3 nucleotides (nt) to 70 nt, from 3 nucleotides (nt) to 60 nt, from 3 nucleotides (nt) to 50 nt, from 3 nucleotides (nt) to 40 nt, from 3 nucleotides (nt) to 30 nt, from 3 nucleotides (nt) to 20 nt or from 3 nucleotides (nt) to 10 nt.
  • the spacer can have a length of from 3 nt to 5 nt, from 5 nt to 10 nt, from 10 nt to 15 nt, from 15 nt to 20 nt, from 20 nt to 25 nt, from 25 nt to 30 nt, from 30 nt to 35 nt, from 35 nt to 40 nt, from 40 nt to 50 nt, from 50 nt to 60 nt, from 60 nt to 70 nt, from 70 nt to 80 nt, from 80 nt to 90 nt, or from 90 nt to 100 nt.
  • the spacer is 4 nt.
  • the PBS sequence includes the sequence of SEQ ID NO: 1, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, or SEQ ID NO:27.
  • the PBS sequence is the sequence of SEQ ID NO: 1, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, or SEQ ID NO:27.
  • the first or the second PBS sequence contains 8 nucleotides in length. In certain embodiments, the first or the second PBS sequences includes the nucleotide sequence of SEQ ID NO:1.
  • PUF proteins (named after Drosophila Pumilio and C. elegans fern-3 binding factor) are known to be involved in mediating mRNA stability and translation. These proteins contain a unique RNA-binding domain known as the PUF domain.
  • the RNA-binding PUF domain such as that of the human Pumilio 1 protein (referred here also as PUM), contains 8 repeats (each repeat called a PUF motif or a PUF repeat) that bind consecutive bases in an anti-parallel fashion, with each repeat recognizing a single base—i.e., PUF repeats R1 to R8 recognize nucleotides N8 to Ni, respectively.
  • PUM is composed of eight tandem repeats, each repeat consisting of 34 amino acids that folds into tightly packed domains composed of alpha helices.
  • the complexes provided herein including embodiments thereof include demethylation protein conjugates (e.g., demethylation protein conjugate, demethylation enhancer conjugate) including (i) a PUF domain operably linked to a demethylation domain and a demethylation enhancer domain or (ii) a first PUF domain operably linked to a demethylation domain and a second PUF domain operably linked to a demethylation enhancer domain, respectively.
  • demethylation protein conjugates e.g., demethylation protein conjugate, demethylation enhancer conjugate
  • the protein conjugate is a demethylation conjugate
  • the demethylation domain is operably linked to the C-terminus of the PUF domain to form a protein conjugate.
  • the demethylation enhancer domain may be linked to the C-terminus of the PUF domain, to the N-terminus of the PUF domain, or the demethylation enhancer domain may bind the polynucleotide (e.g., gRNA) linked to a separate PUF domain (i.e., a PUF domain not linked to the demethylation domain).
  • the demethylation enhancer domain and the demethylation domain bind the polynucleotide separately, the demethylation domain forms part of a demethylation protein conjugate and is linked to a first PUF domain, and the demethylation enhancer domain forms part of a demethylation enhancer protein conjugate and is linked to a second PUF domain.
  • the demethylation protein conjugate binds the polynucleotide through binding of the first PUF domain to the first PBS sequence and the demethylation enhancer protein conjugate binds the polynucleotide through binding of the second PUF domain to the second PBS sequence.
  • the term “PUF domain” refers to a wildtype or naturally existing PUF domain, as well as a PUF homologue domain that is based on/derived from a natural or existing PUF domain, such as the prototype human Pumilio 1 PUF domain.
  • the PUF domain of the invention specifically binds to an RNA sequence (e.g., an 8-mer RNA sequence), wherein the overall binding specificity between the PUF domain and the RNA sequence is defined by sequence specific binding between each PUF motif/PUF repeat within the PUF domain and the corresponding single RNA nucleotide.
  • the term “functional variant” as used herein refers to a PUF domain having substantial or significant sequence identity or similarity to a parent PUF domain, which functional variant retains the biological activity of the PUF domain of which it is a variant—e.g., one that retains the ability to recognize target RNA to a similar extent, the same extent, or to a higher extent in terms of binding affinity, and/or with substantially the same or identical binding specificity, as the parent PUF domain.
  • the functional variant PUF domain can, for instance, be at least 30%, 50%, 75%, 80%, 90%, 98% or more identical in amino acid sequence to the parent PUF domain.
  • the functional variant can, for example, comprise the amino acid sequence of the parent PUF domain with at least one conservative amino acid substitution, for example, conservative amino acid substitutions in the scaffold of the PUF domain (i.e., amino acids that do not interact with the RNA).
  • the functional variants can comprise the amino acid sequence of the parent PUF domain with at least one non-conservative amino acid substitution. In this case, it is preferable for the non-conservative amino acid substitution to not interfere with or inhibit the biological activity of the functional variant.
  • the non-conservative amino acid substitution may enhance the biological activity of the functional variant, such that the biological activity of the functional variant is increased as compared to the parent PUF domain, or may alter the stability of the PUF domain to a desired level (e.g., due to substitution of amino acids in the scaffold).
  • the PUF domain can consist essentially of the specified amino acid sequence or sequences described herein, such that other components, e.g., other amino acids, do not materially change the biological activity of the functional variant.
  • the PUF domain is a Pumilio homology domain (PU-HUD).
  • the PU-HUD is a human Pumilio 1 domain.
  • the PUF domain has the sequence of any one of the PUF domains disclosed in international application PCT/US2016/021491, published as WO2016148994 A8, in international application PCT/US2011/040933, published as WO 2011/160052A2, and Spassov & Jurecic (“Cloning and comparative sequence analysis of PUM1 and PUM2 genes, human members of the Pumilio family of RNA-binding proteins,” Gene, 299:195-204, October 2002), which are hereby incorporated by reference in their entirety and for all purposes.
  • the PUF domain includes a PUFa domain, a PUFb domain, a PUFc domain, or a PUFw domain.
  • the PUFa domain has the amino acid sequence of SEQ ID NO:2.
  • the PUFb domain has the amino acid sequence of SEQ ID NO:3.
  • the PUFc domain has the amino acid sequence of SEQ ID NO:4.
  • the PUFw domain has the amino acid sequence of SEQ ID NO:5.
  • the first PUF domain is a PUFa domain.
  • the PUFa domain has the sequence of SEQ ID NO:2.
  • the second PUF domain is a PUFc domain.
  • the PUFc domain has the sequence of SEQ ID NO:4.
  • the first or the second PUF domain includes a PUFa domain, a PUFb domain, a PUFc domain, or a PUFw domain.
  • the first or the second PUFa domain has the amino acid sequence of SEQ ID NO:2.
  • the first or the second PUFb domain has the amino acid sequence of SEQ ID NO:3.
  • the first or the second PUFc domain has the amino acid sequence of SEQ ID NO:4.
  • the first or the second PUFw domain has the amino acid sequence of SEQ ID NO:5.
  • the subject polynucleotide includes one or more tandem sequences, each of which can be specifically recognized and bound by a specific PUF domain (infra). Since a PUF domain can be engineered to bind virtually any PBS sequence based on the nucleotide-specific interaction between the individual PUF motifs of PUF domain and the single RNA nucleotide they recognize, the PBS sequences can be any designed sequence that bind their corresponding PUF domain.
  • a PBS of the invention has a nucleotide length of 8-mer. In other embodiments, a PBS of the invention has 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or more RNA nucleotides. In certain embodiments, the PBS of the invention has the sequence of SEQ ID NO:10 (5′-UGUAUAUA-3′), and binds the wt human Pumilio 1 PUF domain.
  • the PBS sequence of the invention has the sequence of SEQ ID NO:8 (5′-UGUAUGUA-3′), and binds the PUF domain PUF(3-2).
  • the PBS sequence of the invention has the sequence of SEQ ID NO:9 (5′-UUGAUAUA-3′), and binds the PUF domain PUF(6-2/7-2).
  • the PBS sequence of the invention has the sequence of SEQ ID NO:11 (5′-UGGAUAUA-3′), and binds the PUF domain PUF(6-2).
  • the PBS sequence of the invention has the sequence of SEQ ID NO:12 (5′-UUUAUAUA-3′), and binds the PUF domain PUF(7-2).
  • the PBS sequence of the invention has the sequence of SEQ ID NO:13 (5′-UGUGUGUG-3′), and binds the PUF domain PUF 531 .
  • the PBS sequence of the invention has the sequence of SEQ ID NO:14 (5′-UGUAUAUG-3′), and binds the PUF domain PUF(1-1).
  • the PBS sequence of the invention has the sequence of SEQ ID NO:12 (5′-UUUAUAUA-3′) or sequence of SEQ ID NO:15 (5′-UAUAUAUA-3′), and binds the PUF domain PUF(7-1).
  • the PBS sequence of the invention has the sequence of SEQ ID NO:16 (5′-UGUAUUUA-3′), and binds the PUF domain PUF(3-1).
  • the PBS sequence of the invention has the sequence of SEQ ID NO:17 (5′-UUUAUUUA-3′), and binds the PUF domain PUF(7-2/3-1).
  • the PUF domain PUF(3-2) has the sequence of SEQ ID NO:18.
  • the PUF domain PUF(6-2/7-2) has the sequence of SEQ ID NO: 19.
  • the PUF domain PUF 531 has the sequence of SEQ ID NO:22.
  • the PUF domain includes the sequence of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:22, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30 or SEQ ID NO:31.
  • the PUF domain is the sequence of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:22, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30 or SEQ ID NO:31.
  • Applicant has created 65,536 8-mer PBS sequence and their corresponding PUF domain sequences (see below) that can bind the specific PBS sequence. Applicant has also created a python script to retrieve any of the 65,536 individual PUF domain sequences that binds a given 8-mer PBS sequence. For example, for the 8-mer UUGAUGUA (SEQ ID NO:27), one possible PUF domain sequence can be SEQ ID NO:28:
  • PUF(3-2) (SEQ ID NO:18) has two point mutations (C935S/Q939E) in the PUF repeat 3, and recognizes a cognate RNA with a mutation at position 6 of the NRE (A6G; SEQ ID NO:27 (5′-UGUAUGUA-3′)).
  • PUF (6-2/7-2) (SEQ ID NO:19) has double point mutations (N1043S/Q1047E and S1079N/E1083Q) in repeats 6 and 7, respectively, and recognizes a cognate RNA sequence with two mutations at positions 2 and 3 of the NRE (GU/UG; SEQ ID NO:9 (5′-UUGAUAUA-3′)).
  • a related PUF (6-2) has point mutations (N1043S/Q1047E) in repeats 6, and recognizes a cognate RNA sequence with a mutation at position 3 of the NRE (SEQ ID NO: 11 (5′-UGGAUAUA-3′)).
  • Another related PUF (7-2) has point mutations (S1079N/E1083Q) in repeats 7, and recognizes a cognate RNA sequence with a mutation at position 2 of the NRE (SEQ ID NO: 12 (5′-UUUAUAUA-3′)).
  • the PUF domain PUF 531 (SEQ ID NO:22) has mutations (Q867E/Q939E/C935S/Q1011E/C1007S) in wild type PUF repeats 1, 3 and 5, and recognizes the sequence of SEQ ID NO:13 (5′-UGUGUGUG-3′).
  • the PUF 531 can recognize its new target sequence with very high affinity, compared to the wild type PUF RNA.
  • Another modified PUF domain PUF(1-1) has one point mutation (Q867E) in the PUF repeat 1, and recognizes a cognate RNA with a mutation at position 8 of the NRE (A8G; SEQ ID NO:14 (5′-UGUAUAUG-3′)).
  • Yet another modified PUF domain PUF(7-1) has one point mutation (E1083Q) in the PUF repeat 7, and recognizes a cognate RNA with a mutation at position 2 of the NRE (G2U; SEQ ID NO:12 (5′-UUUAUAUA-3′); or G2A; SEQ ID NO:15 (5′-UAUAUAUA-3′)).
  • Still another modified PUF domain PUF(3-1) has one point mutation (C935N) in the PUF repeat 3, and recognizes a cognate RNA with a mutation at position 6 of the NRE (A6U; SEQ ID NO:16 (5′-UGUAUUUA-3′)).
  • a further modified PUF (7-2/3-1) has point mutations (C935N/S1079N/E1083Q) in repeats 7 and 3, and recognizes a cognate RNA sequence with mutations at positions 2 and 6 of the NRE (SEQ ID NO:17 (5′-UUUAUUUA-3′)).
  • the PUF domain has a sequence of SEQ ID NO:29.
  • the demethylation domain (e.g., TET1 domain), or methylation domain (e.g., Dnmt3a domain) or demethylation enhancer domain (e.g., NEIL2 domain, GADD45A domain) provided herein may be linked to a PUF domain as provided herein including embodiments thereof.
  • the demethylation domain e.g., TET1 domain
  • methylation domain e.g., Dnmt3a domain
  • demethylation enhancer domain e.g., NEIL2 domain, GADD45A domain
  • dCas9 nuclease-deficient RNA-guided DNA endonuclease
  • a chemical linker may link the demethylation domain or methylation domain to the nuclease-deficient RNA-guided DNA endonuclease.
  • the chemical linker is a peptide linker.
  • the chemical linker is a poly-glycine linker.
  • the demethylation domain or demethylation enhancer domain is linked to the C-terminus of the nuclease-deficient RNA-guided DNA endonuclease (e.g., dCas9). In certain embodiments, the demethylation domain or demethylation enhancer domain is linked to the N-terminus of the nuclease-deficient RNA-guided DNA endonuclease (e.g., dCas9).
  • the demethylation domain or demethylation enhancer domain provided herein is directly linked (fused) to the nuclease-deficient RNA-guided DNA endonuclease (e.g., dCas9)
  • the demethylation domain or demethylation enhancer domain and the nuclease-deficient RNA-guided DNA endonuclease (e.g., dCas9) form a dCas9-demethylation domain conjugate or a dCas9-demethylation enhancer domain conjugate.
  • the dCas9-demethylation domain (e.g., TET1 domain) conjugate has the sequence of SEQ ID NO:52.
  • the dCas9-demethylation domain conjugate has the sequence of SEQ ID NO:53. In certain embodiments, the dCas9-methylation (e.g., Dnmt3a) domain conjugate has the sequence of SEQ ID NO:59. In certain embodiments, the dCas9-methylation domain conjugate has the sequence of SEQ ID NO:60. In certain embodiments, the dCas9-methylation domain conjugate has the sequence of SEQ ID NO:61. In certain embodiments, the dCas9-methylation domain conjugate has the sequence of SEQ ID NO:62. In certain embodiments, the dCas9-methylation domain conjugate has the sequence of SEQ ID NO:63. In certain embodiments, the dCas9-methylation domain conjugate has the sequence of SEQ ID NO:64.
  • the complexes provided herein may include an additional bioactive domain operably linked to the PUF domain or the nuclease-deficient RNA-guided DNA endonuclease (e. g., dCas9 protein).
  • a heterologous polypeptide also referred to as a “fusion partner” can be fused to the PUF domain of the demethylation or demethylation enhancer protein conjugate provided herein including embodiments thereof, that binds to at least one of the PBS on the subject polynucleotide.
  • the same or different fusion partner can also optionally be fused to the nuclease-deficient RNA-guided DNA endonuclease (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein).
  • nuclease-deficient RNA-guided DNA endonuclease e.g., nuclease-deficient wt Cas9 protein or dCas9 protein.
  • any of the fusion partners are intended to be fused to the PUF domain of the demethylation or demethylation enhancer protein conjugate provided herein including embodiments thereof, and optionally also fused to the nuclease-deficient RNA-guided DNA endonuclease (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein).
  • the fusion partner fused to the PUF domain can be the same or different from the optional fusion partner fused to the nuclease-deficient RNA-guided DNA endonuclease (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein) (infra).
  • the fusion partner is a bioactive moiety.
  • the fusion partner is a detectable moiety or a therapeutic moiety.
  • the fusion partner may exhibit an activity (e.g., enzymatic activity).
  • Suitable fusion partners include, but are not limited to, a polypeptide that provides for methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylation activity, deadenylation activity, SUMOylating activity, deSUMOylating activity, ribosylation activity, deribosylation activity, myristoylation activity, or demyristoylation activity, any of which can be directed at modifying the DNA directly (e.g., methylation of DNA) or at modifying a DNA-associated polypeptide (e.g., a histone or DNA binding protein).
  • a DNA-associated polypeptide e.g., a histone or DNA binding protein
  • Additional fusion partners may include the various fluorescent protein, polypeptides, variants, or functional domains thereof, such as GFP, Superfolder GFP, EGFP, BFP, EBFP, EBFP2, Azurite, mKalama1, CFP, ECFP, Cerulean, CyPet, mTurquoise2, YFP, Citrine, Venus, Ypet, BFPms1, roGFP, and bilirubin-inducible fluorescent proteins such as UnaG, dsRed, eqFP611, Dronpa, TagRFPs, KFP, EosFP, Dendra, IrisFP, etc.
  • the fusion partner is a demethylation domain. In certain embodiments, the fusion partner is a demethylation enahncer domain.
  • any of the subject PUF domain can be made using, for example, a Golden Gate Assembly kit (see Abil et al., Journal of Biological Engineering 8:7, 2014), which is available at Addgene (Kit #1000000051).
  • demethylation protein conjugates and demethylation enhancer conjugates useful for demethylating target loci in a cell.
  • the demethylation protein conjugates include a PUF domain described herein, a TET demethylation domain (e.g., a TET1 domain) and a demethylation enhancer domain (e.g., a NEIL2 domain or a GADD45A domain).
  • the complexes provided herein include a demethylation protein conjugate including a first PUF domain and a demethylation domain (e.g., a TET1 domain) and a demethylation enhancer conjugate including a second PUF domain and a demethylation enhancer domain (e.g., a NEIL2 domain or a GADD45A domain).
  • a demethylation protein conjugate including a first PUF domain and a demethylation domain (e.g., a TET1 domain) and a demethylation enhancer conjugate including a second PUF domain and a demethylation enhancer domain (e.g., a NEIL2 domain or a GADD45A domain).
  • the demethylation enhancer domain is operably linked to the N-terminus of the PUF domain. In certain embodiments, the demethylation enhancer domain is operably linked to the C-terminus of the PUF domain. In certain embodiments, the demethylation enhancer domain is operably linked to the N-terminus of the second PUF domain. In certain embodiments, the demethylation enhancer domain is operably linked to the C-terminus of the second PUF domain.
  • the demethylation enhancer domain is a Growth Arrest and DNA-Damage-inducible Alpha (GADD45A) domain.
  • the GADD45 domain has the amino acid sequence of SEQ ID NO:85.
  • the demethylation enhancer domain is a NEIL2 domain.
  • the NEIL2 domain has the amino acid sequence of SEQ ID NO:86.
  • the demethylation enhancer domain is not a NEIL1 domain. In certain embodiments, the demethylation enhancer domain is not a NEIL3 domain.
  • a “demethylation enhancer domain”, “demethylation enhancer protein” or “demethylation enhancer enzyme” as provided herein refers to a protein, protein domain or protein moiety capable of positively affecting (e.g. increasing) the activity or function of a demethylation enzyme or demethylation domain, relative to the activity or function of the demethylation enzyme or demethylation domain in the absence of the activator (e.g. demethylation enhancer domain described herein).
  • the demethylation enhancer domain may, at least in part, partially or totally increase stimulation, increase or enable activation, or activate the demethylation enzyme.
  • the amount of increase in activity may be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more in comparison to a control in the absence of the demethylation enhancer domain.
  • the activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more than the activity in the absence of the demethylation enhancer domain.
  • the DNA demethylation domain may include a Ten-Eleven translocation 1 (TET1) domain.
  • the DNA demethylation domain includes a Ten-Eleven translocation 2 (TET2) domain.
  • the DNA demethylation domain includes a Ten-Eleven translocation 3 (TET3) domain.
  • the TET1 domain includes the sequence of SEQ ID NO:51. In certain embodiments, the TET1 domain is the sequence of SEQ ID NO:51.
  • the TET protein is a TET methylcytosine dioxygenase.
  • TET methylcytosine dioxygenase catalyzes the initial and critical step leading to replacing 5mC with unmethylated cytosine.
  • the demethylation protein conjugate includes a TET1 functional domain fused to the C-terminus of the PUF domain.
  • the PUF domain is PUFa.
  • transcription of the target gene is increased by more than 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 50-fold, 75-fold, 100-fold, 125-fold, 135-fold, 150-fold, 200-fold or more.
  • the target gene is SOX.
  • the target gene comprises two or more target polynucleotide sequences. In certain embodiments, at least two of said same or different PUF domains are fused to a demethylase domain or a demethylase enhancer domain.
  • the demethylation protein conjugate includes the sequence of SEQ ID NO:54 or SEQ ID NO:55. In certain embodiments, the demethylation protein conjugate is the sequence of SEQ ID NO:54 or SEQ ID NO:55.
  • demethylation protein conjugate includes the sequence of SEQ ID NO: 104. In certain embodiments, demethylation protein conjugate is the sequence of SEQ ID NO: 104. In certain embodiments, demethylation protein conjugate includes the sequence of SEQ ID NO: 105. In certain embodiments, demethylation protein conjugate is the sequence of SEQ ID NO: 105.
  • demethylation enhancer conjugate includes the sequence of SEQ ID NO: 106. In certain embodiments, demethylation enhancer conjugate is the sequence of SEQ ID NO: 106. In certain embodiments, demethylation enhancer conjugate includes the sequence of SEQ ID NO: 107. In certain embodiments, demethylation enhancer conjugate is the sequence of SEQ ID NO:107.
  • demethylation enhancer conjugate includes the sequence of SEQ ID NO: 108. In certain embodiments, demethylation enhancer conjugate is the sequence of SEQ ID NO: 108. In certain embodiments, demethylation enhancer conjugate includes the sequence of SEQ ID NO: 109. In certain embodiments, demethylation enhancer conjugate is the sequence of SEQ ID NO:109.
  • Another aspect of the invention provides a complex comprising any one of the polynucleotide of the invention, and the modified Cas9 protein, e.g., nuclease-deficient wt Cas9 protein or dCas9 protein.
  • the complex comprises a nuclease-deficient wt Cas9 protein.
  • the complex may further comprise one or more PUF domain or fusion thereof bound to the one or more PBS(s).
  • each of the PUF domain is fused to an effector domain.
  • at least two of the PUF domains are fused to different effector domains.
  • the nuclease-deficient wt Cas9 protein e.g., nuclease-deficient wt Cas9 protein or dCas9 protein
  • the PUF domain, and/or the effector domain further comprises a nuclear localization signal (NLS).
  • NLS nuclear localization signal
  • the complex is bound to the target polynucleotide sequence through the DNA-targeting sequence of the polynucleotide.
  • the effector domain is a TET (Ten-Eleven Translocation) protein, or a fragment thereof that retains demethylase catalytic activity.
  • the TET protein may be a TET methylcytosine dioxygenase.
  • the PUF domain fusion protein comprises a TET1 functional domain fused to the C-terminus of the PUF domain (e.g., PUFa).
  • the PUF domain fusion protein comprises a Dnmt functional domain fused to the N-terminus of the PUF domain (e.g., PUFa).
  • a cell including a demethylation complex as provided herein including embodiments thereof is provided.
  • the cell is a mammalian cell.
  • the cell is a cancer cell.
  • the cell is a cancer cell, and/or the target gene is hMLH1 with a hypermethylated promoter region.
  • the target polynucleotide sequence may be within the hypermethylated promoter region of hMLH1, and methylation of the target polynucleotide sequence is associated with down-regulation of hMLH1 in cancer cells.
  • the cancer cell is from a stomach cancer, esophageal cancer, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), and colorectal cancer (such as HNPCC).
  • the stomach cancer may include foveolar type tumors, and stomach cancer in high-incidence Kashmir Valley.
  • Another aspect of the invention provides a host cell including any one of the subject vector, polynucleotide, and complex.
  • the host cell further includes a second vector encoding the nuclease-deficient wt Cas9 protein (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein).
  • the second vector further encodes a demethylation (effector) domain fused to the nuclease-deficient wt Cas9 protein (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein).
  • the expression of the Cas9 protein e.g., wt, nickase, or dCas9 protein
  • the host cell may further include a third vector encoding the one or more PUF domains, each fused to demethylation (effector) domain.
  • the expression of the one or more PUF domains can be independently under the control of a constitutive promoter or an inducible promoter.
  • the second vector may further encode a nuclear localization signal (NLS) fused to the nuclease-deficient wt Cas9 protein (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein) or the methylation or demethylation (effector) domain
  • the third vector may further encode a nuclear localization signal (NLS) fused to the PUF domain or the methylation or demethylation (effector) domain.
  • sequences that can be encoded by different vectors may be on the same vector.
  • the second vector may be the same as the vector
  • the third vector may be the same as the vector or the second vector.
  • the host cell may be in a live animal, or may be a cultured cell.
  • demethylation protein conjugates including a demethylation domain and a demethylation enhancer domain (e.g., demethylation enzymes and demethylation enhancers or functional fragments thereof) or a combination of a demethylation protein conjugate and a demethylation enhancer conjugate, may be delivered to a cell sequentially or concomitantly. Delivery of a demethylation protein conjugate provided herein or a combination of a demethylation protein conjugate and a demethylation enhancer conjugate to a cell, allows for fine tuning the methylation status of a targeted gene locus.
  • a demethylation enhancer domain e.g., demethylation enzymes and demethylation enhancers or functional fragments thereof
  • a combination of a demethylation protein conjugate and a demethylation enhancer conjugate may be delivered to a cell sequentially or concomitantly. Delivery of a demethylation protein conjugate provided herein or a combination of a demethylation protein conjugate and a demethylation enhancer conjugate to
  • the invention further provides for the delivery of a plurality of demethylation protein conjugates, wherein the conjugates may be the same or different.
  • the conjugates may form part of a plurality of conjugates, each linked to a PUF domain, and/or they may be directly fused to the nuclease-deficient RNA-guided DNA endonuclease enzyme (e.g., dCas9).
  • the present invention allows for the delivery of enhanced demethylation activities to different target sites in a cell at the same time.
  • demethylation domains e.g., TET1 domain
  • enhancer proteins e.g., GADD45A or NEIL2
  • demethylation using the complexes provided herein is more efficient compared to, for example, demethylation in the absence of the enhancer domain or compared to directly linking demethylation activities to the nuclease-deficient RNA-guided DNA endonuclease enzyme (e.g., dCas9).
  • the method includes delivering a first polynucleotide encoding a nuclease-deficient RNA-guided DNA endonuclease enzyme as provided herein including embodiments thereof (e.g., dCas9).
  • the method may include delivering a second polynucleotide, which is the polynucleotide described herein including embodiments thereof and which encodes a DNA-targeting sequence, a binding sequence and one or more PUF binding site (PBS) sequences provided herein.
  • PBS PUF binding site
  • a method of demethylating a target nucleic acid sequence in a mammalian cell includes:
  • a demethylation complex in one aspect, includes:
  • a method of demethylating a target nucleic acid sequence in a mammalian cell includes:
  • the demethylation protein conjugate binds to the ribonucleoprotein complex via the PUF domain binding to the one or more PBS sequences to form a demethylation complex.
  • the first polynucleotide is contained within a first vector.
  • the second polynucleotide is contained within a second vector.
  • the third polynucleotide is contained within a third vector.
  • the first, second or third vector is the same.
  • the delivering is performed by transfection.
  • the demethylation protein conjugate binds to the ribonucleoprotein complex via the first PUF domain binding to the first PBS sequence. In certain embodiments, the demethylation enhancer conjugate binds to the ribonucleoprotein complex via the second PUF domain binding to the second PBS sequence. In certain embodiments, the demethylation enhancer domain is operably linked to the N-terminus of the second PUF domain. In certain embodiments, the demethylation enhancer domain is operably linked to the C-terminus of the second PUF domain. In certain embodiments, the first polynucleotide is contained within a first vector. In certain embodiments, the second polynucleotide is contained within a second vector.
  • the third polynucleotide is contained within a third vector.
  • the fourth polynucleotide is contained within a fourth vector.
  • either the first, second, third or fourth vector is the same.
  • the delivering is performed by transfection.
  • the method of the invention utilizes a plurality or a library of the vectors, each encoding a polynucleotide of the invention, wherein two of the vectors differ in the encoded polynucleotides in their respective DNA-targeting sequences, Cas9-binding sequences, and/or the copy number, identity (sequence, binding specificity, etc.), or relative order of the PBS.
  • non-vector coding sequences are used instead of using vectors.
  • the method further comprises introducing into the cell a plurality of any one of the subject vectors, wherein two of the vectors differ in the encoded polynucleotides in their respective DNA-targeting sequences, Cas9-binding sequences, and/or the copy number, identity, or relative order of the PBS.
  • non-vector coding sequences are used instead of using vectors.
  • the methods of enhanced demethylating a target nucleic acid in a cell may be used, inter alia, for the treatment of diseases related to or caused by abnormal DNA methylation (e.g., cancer).
  • diseases related to or caused by abnormal DNA methylation e.g., cancer
  • a role for both epigenetic (DNA methylation) and genetic (mutations) actions of cytidine deaminases in cancer has been proposed, and a possible role in demethylation which is widespread.
  • the present invention has practical application in ameliorating/treating the cancer disease process by altering the demethylation or demethylation status within the cancer cell.
  • methylated genes can be targeted for demethylation in vivo, which may lead to their expression (methylation being a repressive modification most of the time).
  • Targeting of cytidine deaminase activity to genes of interest in cancer can include, for example, fusion of the cytidine deaminase to a tumor suppressor DNA binding domain, (such as the zinc finger DNA core binding region of the p53 protein). It is believed that in many cancers, mutation of the DNA binding domain of p53 can contribute to transformation. In addition, the promoter regions of many tumor suppressor genes, including p53 targets, are methylated in cancer cells.
  • the molecules and pharmaceutical compositions of the present invention can be assessed for their anti-cancer/anti-tumorigenic effects by utilizing in vitro and ex vivo assays.
  • a nucleic acid vector that expresses a molecule of the invention is transfected into a cancer cell.
  • Appropriate controls are established comprising the cancer cell line transfected with vector backbone only, or vector plus a molecule of the invention in which the cytidine deaminase domain is rendered non-functional described in more detail below.
  • Induced apoptosis in the cancer cell line transfected with the molecules of the invention but not in the control cells would be indicative of an anti-cancer effect for the molecule of the invention.
  • a method of treating cancer in a subject in need thereof includes, administering to a subject a therapeutically effective amount of a demethylation complex or methylation complex as provided herein including embodiments thereof, thereby treating cancer in the subject.
  • the method includes administering to a subject a therapeutically effective amount of a demethylation complex as provided herein.
  • composition in another aspect, includes therapeutically effective amount of a demethylation complex as provided herein including embodiments thereof and a pharmaceutically acceptable excipient.
  • Additional applications for the methods and compositions provided herein include modulating gene expression during development.
  • the presence of a site specific DNA binding domain allows for targeted demethylation of specific subsets of genes activated at particular times in development or during the cell cycle.
  • the DNA binding domains of the (e.g., Oct4 or SOX-2) proteins when fused to a PUF domain could provide for a demethylation activity that is directed towards genes that are involved in cell fate decisions relating to promotion of a pluripotent or stem cell-like phenotype.
  • the demethylation domain may be linked via a linker to PUF binding domain.
  • DNA binding domains that could optionally be utilized include those from T-box transcription factors or steroid hormone receptor DNA binding domains such as the RAR and RXR DNA binding domains. Nevertheless, the present demethylation protein conjugate may be sufficient to demethylate the promoters of a pluripotent gene and alter the methylation status of a cell during differentiation.
  • Another aspect of the invention provides a method of modulating transcription and/or methylation state of a target gene in a cancer cell according to any method of the invention, wherein the cancer cell is associated with or characterized by abonormal DNA methylation.
  • a related aspect of the invention provides a method of modulating transcription and/or methylation state of a target gene in a cancer cell in a patient according to any method of the invention, wherein the cancer cell is associated with or characterized by abonormal DNA methylation.
  • Another related aspect of the invention provides a method for treating a patient in need of treatment a disease or condition associated with abnormal DNA methylation, such as CpG methylation, of a target gene, the method comprising allowing the formation of the complex of the invention near or at the target gene to modulate transcription and/or methylation state of the target gene in the patient.
  • a disease or condition associated with abnormal DNA methylation such as CpG methylation
  • Another related aspect of the invention provides a method for treating a patient in need of treatment a disease or condition associated with abnormal DNA methylation (such as CpG methylation) of a target gene, the method comprising modulating transcription and/or methylation state of the target gene in the patient according to any of the subject methods.
  • a disease or condition associated with abnormal DNA methylation such as CpG methylation
  • Another related aspect of the invention provides a method for treating a patient in need of treatment a disease or condition associated with abnormal DNA methylation (such as CpG methylation) of a target gene, the method comprising allowing the formation of the complex of the invention near or at the target gene to modulate transcription and/or methylation state of the target gene in the patient.
  • a disease or condition associated with abnormal DNA methylation such as CpG methylation
  • the invention provides a method of treating cancer in a patient in need of treatment, wherein said cancer is associated with or characterized by abnormal DNA methylation of hMLH1, the method comprising modulating transcription and/or methylation state of hMLH1 in the patient according to any one of the methods of the invention.
  • the PUF domain fusion protein may comprise a TET1 functional domain fused to the C-terminus of the PUF domain such as PUFa.
  • the methylation level of the hypermethylated promoter region of hMLH1 is decreased.
  • transcription/translation of hMLH1 is increased.
  • the target gene is hMLH1.
  • the disease is a cancer. In certain embodiments, the disease is an imprinting disorder. In certain embodiments, the disease is a neurological disease.
  • the cancer is associated with or characterized by hyper- or hypomethylation of a tumor suppressor gene or an oncogene, respectively.
  • the cancer is a stomach cancer (including foveolar type tumors, and stomach cancer in high-incidence Kashmir Valley), esophageal cancer, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), and colorectal cancer (such as HNPCC).
  • stomach cancer including foveolar type tumors, and stomach cancer in high-incidence Kashmir Valley
  • esophageal cancer head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), and colorectal cancer (such as HNPCC).
  • HNSCC head and neck squamous cell carcinoma
  • NSCLC non-small cell lung cancer
  • colorectal cancer such as HNPCC
  • Yet another aspect of the invention provides a method of assembling the complex of the invention at the target polynucleotide sequence, the method comprising contacting or bringing to the vicinity of the target polynucleotide sequence: (1) any one of the subject polynucleotide, or any one of the subject vector, or the plurality of vectors; (2) the nuclease-deficient wt Cas9 protein (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein), or any one of the subject second vector encoding the nuclease-deficient wt Cas9 protein (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein); and, (3) one or more of the PUF domains, each fused to an effector domain, or any one of the third vector encoding the PUF domain fusions.
  • the fusion is with a DNA methyltransferase or a demethylas
  • the complex is assembled inside a cell
  • the target polynucleotide sequence is a part of the genomic DNA of the cell
  • the subject vector, second vector, and third vector are introduced into the cell.
  • a related aspect of the invention provides a method of modulating transcription of a plurality of target genes in a cell, the method comprising: introducing into the cell the subject plurality of the vectors, a coding sequence for a dCas9 protein, and a coding sequence for one or more PUF domain fusions, wherein each of the target genes comprises a target polynucleotide sequence that permits (1) the assembly, at the target polynucleotide sequence, of a tripartite complex of a polynucleotide encoded by one of the plurality of the vector, the dCas9 protein, and a PUF domain fusion; and (2) transcription modulation of the target gene comprising the target polynucleotide sequence.
  • the invention also provides a method of epigenetic modulation (e.g., modulating the epigenetic states of chromatin not directly related to transcriptional activity), at a plurality of target genes in a cell, the method comprising: introducing into the cell the subject plurality of the vectors, a coding sequence for a nuclease-deficient wt Cas9 protein, and a coding sequence for one or more PUF domain fusions, wherein each of the target genes comprises a target polynucleotide sequence that permits (1) the assembly, at the target polynucleotide sequence, of a tripartite complex of a polynucleotide encoded by one of the plurality of the vector, the wt Cas9 protein or the Cas9 nickase, and a PUF domain fusion; and (2) epigenetic modulation of the target gene comprising the target polynucleotide sequence.
  • epigenetic modulation e.g., modulating the epigenetic states of chromatin
  • the method can be useful, for example, to change epigenetic state (e.g., opening up the chromatin) at the same time to gain access/stability of nuclease-deficient wt Cas9 protein (e.g., dCas9) binding to closed chromatin sites (e.g., to increase cut and genome editing at those sites).
  • epigenetic state e.g., opening up the chromatin
  • nuclease-deficient wt Cas9 protein e.g., dCas9 protein binding to closed chromatin sites (e.g., to increase cut and genome editing at those sites).
  • the transcription of at least one target gene is enhanced/stimulated, while the transcription of at least another target gene is inhibited.
  • the method comprises:
  • the coding sequence for a PUF domain fusion protein can be introduced into the cell together (e.g., by including all coding sequences on the same vector, by co-transfecting different vectors encoding different coding sequences, etc.), or separately, in any order or sequence as desired.
  • the coding sequence for a PUF domain fusion protein, the coding sequence for a nuclease-deficient RNA-guided DNA endonuclease (dCas9 protein), and the polynucleotide (or a vector encoding the polynucleotide) are co-introduced into the cell.
  • the target polynucleotide sequence can be any DNA sequence.
  • the target polynucleotide sequence comprises, or is adjacent to, one or more transcription regulatory element(s).
  • the transcription regulatory element(s) comprises one or more of: a core promoter, a proximal promoter element, an enhancer, a silencer, an insulator, and a locus control region.
  • kits in another aspect, includes:
  • kits in another aspect, includes:
  • a subject kit may include: a) a polynucleotide of the present invention, or a nucleic acid (e.g., vector) including a nucleotide sequence encoding the same; optionally, b) a subject nuclease-deficient wt Cas9 protein (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein), or a vector encoding the same (including an expressible mRNA encoding the same); and optionally, c) one or more subject demethylation or methylation protein conjugate (PUF domain fusion) each including a PUF domain fused to a demethylation or methylation domain (effector domain) that may be the same or different among the different demethylation or methylation protein conjugates (PUF domain fusions), or a vector encoding the same (including an expressible mRNA encoding the same).
  • one or more of a)-c) may be encoded by the same vector.
  • the kit also comprises one or more buffers or reagents that facilitate the introduction of any one of a)-c) into a host cell, such as reagents for transformation, transfection, or infection.
  • a subject kit can further include one or more additional reagents, where such additional reagents can be selected from: a buffer; a wash buffer; a control reagent; a control expression vector or RNA polynucleotide; a reagent for in vitro production of the nuclease-deficient wt Cas9 protein or dCas9 or PUF domain fusion from DNA; and the like.
  • additional reagents can be selected from: a buffer; a wash buffer; a control reagent; a control expression vector or RNA polynucleotide; a reagent for in vitro production of the nuclease-deficient wt Cas9 protein or dCas9 or PUF domain fusion from DNA; and the like.
  • Components of a subject kit can be in separate containers; or can be combined in a single container.
  • a subject kit can further include instructions for using the components of the kit to practice the subject methods.
  • the instructions for practicing the subject methods are generally recorded on a suitable recording medium.
  • the instructions may be printed on a substrate, such as paper or plastic, etc.
  • the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or subpackaging) etc.
  • the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. CD-ROM, diskette, flash drive, etc.
  • the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided.
  • An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.
  • Nucleic acid refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single-, double- or multiple-stranded form, or complements thereof.
  • polynucleotide refers to a linear sequence of nucleotides.
  • nucleotide typically refers to a single unit of a polynucleotide, i.e., a monomer. Nucleotides can be ribonucleotides, deoxyribonucleotides, or modified versions thereof.
  • nucleic acids can be linear or branched.
  • nucleic acids can be a linear chain of nucleotides or the nucleic acids can be branched, e.g., such that the nucleic acids comprise one or more arms or branches of nucleotides.
  • the branched nucleic acids are repetitively branched to form higher ordered structures such as dendrimers and the like.
  • Nucleic acids, including nucleic acids with a phosphothioate backbone can include one or more reactive moieties.
  • the term reactive moiety includes any group capable of reacting with another molecule, e.g., a nucleic acid or polypeptide through covalent, non-covalent or other interactions.
  • the nucleic acid can include an amino acid reactive moiety that reacts with an amio acid on a protein or polypeptide through a covalent, non-covalent or other interaction.
  • nucleic acids containing known nucleotide analogs or modified backbone residues or linkages which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides.
  • Examples of such analogs include, without limitation, phosphodiester derivatives including, e.g., phosphoramidate, phosphorodiamidate, phosphorothioate (also known as phosphothioate), phosphorodithioate, phosphonocarboxylic acids, phosphonocarboxylates, phosphonoacetic acid, phosphonoformic acid, methyl phosphonate, boron phosphonate, or O-methylphosphoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press); and peptide nucleic acid backbones and linkages.
  • phosphodiester derivatives including, e.g., phosphoramidate, phosphorodiamidate, phosphorothioate (also known as phosphothioate), phosphorodithioate, phosphonocarboxylic acids, phosphonocarboxylates, phosphonoacetic acid, phosphonoformic acid, methyl phospho
  • nucleic acids include those with positive backbones; non-ionic backbones, modified sugars, and non-ribose backbones (e.g. phosphorodiamidate morpholino oligos or locked nucleic acids (LNA)), including those described in U.S. Pat. Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580 , Carbohydrate Modifications in Antisense Research , Sanghui & Cook, eds. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids.
  • LNA locked nucleic acids
  • Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g., to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip.
  • Mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made.
  • the internucleotide linkages in DNA are phosphodiester, phosphodiester derivatives, or a combination of both.
  • the range of values provided includes the specified value. As recognized by a person of ordinary skill in the art such specified value would reasonably include a standard deviation using measurements generally acceptable in the art. In certain embodiments, the standard deviation includes a range extending to +/ ⁇ 10% of the specified value.
  • polypeptide refers to a polymer of amino acid residues, wherein the polymer may be conjugated to a moiety that does not consist of amino acids.
  • the terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers.
  • the terms apply to macrocyclic peptides, peptides that have been modified with non-peptide functionality, peptidomimetics, polyamides, and macrolactams.
  • a “fusion protein” refers to a chimeric protein encoding two or more separate protein sequences that are recombinantly expressed as a single moiety.
  • peptidyl and “peptidyl moiety” means a monovalent peptide.
  • amino acid refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids.
  • Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, ⁇ -carboxyglutamate, and O-phosphoserine.
  • Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid.
  • Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.
  • the terms “non-naturally occurring amino acid” and “unnatural amino acid” refer to amino acid analogs, synthetic amino acids, and amino acid mimetics which are not found in nature.
  • Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
  • amino acid or nucleotide base “position” is denoted by a number that sequentially identifies each amino acid (or nucleotide base) in the reference sequence based on its position relative to the N-terminus (or 5′-end). Due to deletions, insertions, truncations, fusions, and the like that must be taken into account when determining an optimal alignment, in general the amino acid residue number in a test sequence determined by simply counting from the N-terminus will not necessarily be the same as the number of its corresponding position in the reference sequence. For example, in a case where a variant has a deletion relative to an aligned reference sequence, there will be no amino acid in the variant that corresponds to a position in the reference sequence at the site of deletion.
  • numbered with reference to or “corresponding to,” when used in the context of the numbering of a given amino acid or polynucleotide sequence refers to the numbering of the residues of a specified reference sequence when the given amino acid or polynucleotide sequence is compared to the reference sequence.
  • “Conservatively modified variants” applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide.
  • nucleic acid variations are “silent variations,” which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid.
  • each codon in a nucleic acid except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan
  • TGG which is ordinarily the only codon for tryptophan
  • amino acid sequences one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.
  • the following eight groups each contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M).
  • Percentage of sequence identity is determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.
  • nucleic acids or polypeptide sequences refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., 60% identity, optionally 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identity over a specified region, e.g., of the entire polypeptide sequences of the invention or individual domains of the polypeptides of the invention), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection.
  • sequences are then said to be “substantially identical.”
  • This definition also refers to the complement of a test sequence.
  • the identity exists over a region that is at least 50 nucleotides in length, or more preferably over a region that is 100 to 500 or 1000 or more nucleotides in length.
  • sequence comparison typically one sequence acts as a reference sequence, to which test sequences are compared.
  • test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated.
  • sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.
  • a “comparison window”, as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of, e.g., a full length sequence or from 20 to 600, 50 to 200, or 100 to 150 amino acids or nucleotides in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.
  • Methods of alignment of sequences for comparison are well known in the art.
  • Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol.
  • HSPs high scoring sequence pairs
  • T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always ⁇ 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score.
  • Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.
  • the BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment.
  • the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5787).
  • One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.
  • P(N) the smallest sum probability
  • a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than 0.2, more preferably less than 0.01, and most preferably less than 0.001.
  • nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross-reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below.
  • a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions.
  • Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below.
  • Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequence.
  • a “label” or a “detectable moiety” is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means.
  • useful labels include 32 P, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins or other entities which can be made detectable, e.g., by incorporating a radiolabel into a peptide or antibody specifically reactive with a target peptide. Any appropriate method known in the art for conjugating an antibody to the label may be employed, e.g., using methods described in Hermanson, Bioconjugate Techniques 1996, Academic Press, Inc., San Diego.
  • a “bioactive moiety” as provided herein refers to a moiety that upon administration to a cell, tissue or organism has a detectable effect on the biological function of said cell, tissue or organism.
  • the detectable effect is a biological effect.
  • the detectable effect is a therapeutic effect.
  • the detectable effect is a diagnostic effect.
  • a “labeled protein or polypeptide” is one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the labeled protein or polypeptide may be detected by detecting the presence of the label bound to the labeled protein or polypeptide.
  • methods using high affinity interactions may achieve the same results where one of a pair of binding partners binds to the other, e.g., biotin, streptavidin.
  • Bio sample refers to materials obtained from or derived from a subject or patient.
  • a biological sample includes sections of tissues such as biopsy and autopsy samples, and frozen sections taken for histological purposes.
  • samples include bodily fluids such as blood and blood fractions or products (e.g., serum, plasma, platelets, red blood cells, and the like), sputum, tissue, cultured cells (e.g., primary cultures, explants, and transformed cells) stool, urine, synovial fluid, joint tissue, synovial tissue, synoviocytes, fibroblast-like synoviocytes, macrophage-like synoviocytes, immune cells, hematopoietic cells, fibroblasts, macrophages, T cells, etc.
  • blood and blood fractions or products e.g., serum, plasma, platelets, red blood cells, and the like
  • sputum tissue
  • cultured cells e.g., primary cultures, explants, and transformed cells
  • a biological sample is typically obtained from a eukaryotic organism, such as a mammal such as a primate e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish.
  • a mammal such as a primate e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish.
  • a cell can be identified by well-known methods in the art including, for example, presence of an intact membrane, staining by a particular dye, ability to produce progeny or, in the case of a gamete, ability to combine with a second gamete to produce a viable offspring.
  • Cells may include prokaryotic and eukaryotic cells.
  • Prokaryotic cells include but are not limited to bacteria.
  • Eukaryotic cells include but are not limited to yeast cells and cells derived from plants and animals, for example mammalian, insect (e.g., spodoptera ) and human cells.
  • the word “expression” or “expressed” as used herein in reference to a gene means the transcriptional and/or translational product of that gene.
  • the level of expression of a DNA molecule in a cell may be determined on the basis of either the amount of corresponding mRNA that is present within the cell or the amount of protein encoded by that DNA produced by the cell (Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 18.1-18.88).
  • transfected gene expression of a transfected gene can occur transiently or stably in a cell.
  • transient expression the transfected gene is not transferred to the daughter cell during cell division. Since its expression is restricted to the transfected cell, expression of the gene is lost over time.
  • stable expression of a transfected gene can occur when the gene is co-transfected with another gene that confers a selection advantage to the transfected cell.
  • selection advantage may be a resistance towards a certain toxin that is presented to the cell.
  • exogenous refers to a molecule or substance (e.g., nucleic acid or protein) that originates from outside a given cell or organism.
  • endogenous refers to a molecule or substance that is native to, or originates within, a given cell or organism.
  • transfection can be used interchangeably and are defined as a process of introducing a nucleic acid molecule and/or a protein to a cell.
  • Nucleic acids may be introduced to a cell using non-viral or viral-based methods.
  • the nucleic acid molecule can be a sequence encoding complete proteins or functional portions thereof.
  • a nucleic acid vector comprising the elements necessary for protein expression (e.g., a promoter, transcription start site, etc.).
  • Non-viral methods of transfection include any appropriate method that does not use viral DNA or viral particles as a delivery system to introduce the nucleic acid molecule into the cell.
  • Exemplary non-viral transfection methods include calcium phosphate transfection, liposomal transfection, nucleofection, sonoporation, transfection through heat shock, magnetifection and electroporation.
  • any useful viral vector can be used in the methods described herein.
  • examples of viral vectors include, but are not limited to retroviral, adenoviral, lentiviral and adeno-associated viral vectors.
  • the nucleic acid molecules are introduced into a cell using a retroviral vector following standard procedures well known in the art.
  • the terms “transfection” or “transduction” also refer to introducing proteins into a cell from the external environment.
  • transduction or transfection of a protein relies on attachment of a peptide or protein capable of crossing the cell membrane to the protein of interest. See, e.g., Ford et al. (2001) Gene Therapy 8:1-4 and Prochiantz (2007) Nat. Methods 4:119-20.
  • a nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence.
  • DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide;
  • a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or
  • a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.
  • “operably linked” means that the DNA sequences being linked are near each other, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
  • gene means the segment of DNA involved in producing a protein; it includes regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons).
  • the leader, the trailer as well as the introns include regulatory elements that are necessary during the transcription and the translation of a gene.
  • a “protein gene product” is a protein expressed from a particular gene.
  • the named protein includes any of the protein's naturally occurring forms, or variants or homologs that maintain the protein transcription factor activity (e.g., within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to the native protein).
  • variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g. a 50, 100, 150 or 200 continuous amino acid portion) compared to a naturally occurring form.
  • the protein is the protein as identified by its NCBI sequence reference.
  • the protein is the protein as identified by its NCBI sequence reference or functional fragment or homolog thereof.
  • a “methylcytosine dioxygenase TET1” or “TET1” protein as referred to herein includes any of the recombinant or naturally-occurring forms of the TET1 dioxygenase or variants or homologs thereof that maintain TET1 dioxygenase enzyme activity (e.g. within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to TET1).
  • the variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g.
  • the TET1 protein is substantially identical to the protein identified by the UniProt reference number Q8NFU7 or a variant or homolog having substantial identity thereto.
  • a “methylcytosine dioxygenase TET2” or “TET2” protein as referred to herein includes any of the recombinant or naturally-occurring forms of the TET2 dioxygenase or variants or homologs thereof that maintain TET2 dioxygenase enzyme activity (e.g. within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to TET2).
  • the variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g.
  • the TET2 protein is substantially identical to the protein identified by the UniProt reference number Q6N021 or a variant or homolog having substantial identity thereto.
  • a “methylcytosine dioxygenase TET3” or “TET3” protein as referred to herein includes any of the recombinant or naturally-occurring forms of the TET3 dioxygenase or variants or homologs thereof that maintain TET3 dioxygenase enzyme activity (e.g. within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to TET3).
  • the variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g.
  • the TET3 protein is substantially identical to the protein identified by the UniProt reference number 043151 or a variant or homolog having substantial identity thereto.
  • TET1 The TET family of enzymes (e.g., TET1, TET2, TET3) catalyze the conversion of 5mC to 5hmC as well as its further oxidation into 5-formylcytosine (5fC) and 5 carboxylcytosine (5caC) (Ito et al., 2010).
  • TET dioxygenases oxidize the methyl group at C5 to yield 5-hydroxymethyl-(hmC) (Kriaucionis and Heintz, 2009), 5-formyl-(fC) (Maiti and Drohat, 2011) and 5-carboxylcytosine (caC) (He et al., 2011).
  • a “Growth Arrest and DNA-Damage-inducible Alpha” or “GADD45A” protein as referred to herein includes any of the recombinant or naturally-occurring forms of the GADD45A protein or variants or homologs thereof that maintain GADD45A protein activity/function (e.g. within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to GADD45A).
  • the variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g.
  • the GADD45A protein is substantially identical to the protein identified by the UniProt reference number P24522 or a variant or homolog having substantial identity thereto.
  • GADD45A forms part of the regulatory protein family in NER- and BER-based DNA demethylation (e.g., Growth Arrest and DNA Damage Protein 45a,-b,-g). GADD45 proteins are devoid of any obvious enzymatic activity and act as adapters between demethylation target genes and the DNA repair machinery. Without being bound to any particular theory, it is generally believed that GADD45a and TET1 directly bind each other.
  • NEIL2 glycosylase or “NEIL2” protein as referred to herein includes any of the recombinant or naturally-occurring forms of the NEIL2 glycosylase or variants or homologs thereof that maintain NEIL2 glycosylase enzyme activity (e.g. within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to NEIL2).
  • the variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g.
  • the NEIL2 glycosylase is substantially identical to the protein identified by the UniProt reference number Q969S2 or a variant or homolog having substantial identity thereto.
  • NEIL glycosylases are capable of excising formylated and carboxylated cytosine in chromatins. NEIL glycosylases can also initiate BER after TET-mediated cytosine oxidation. NEIL glycosylases may therefore constitute an alternative pathway for active demethylation and reactivation of epigenetically silenced genes.
  • a “DNMT3a”, “DNA (cytosine-5)-methyltransferase 3A” or “DNA methyltransferase 3a” protein as referred to herein includes any of the recombinant or naturally-occurring forms of the DNMT3a enzyme or variants or homologs thereof that maintain DNMT3a enzyme activity (e.g. within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to DNMT3a).
  • the variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g.
  • the DNMT3a protein is substantially identical to the protein identified by the UniProt reference number Q9Y6K1 or a variant or homolog having substantial identity thereto.
  • a “DNMT3L”, “DNA (cytosine-5)-methyltransferase 3L” or “DNA methyltransferase 3L” protein as referred to herein includes any of the recombinant or naturally-occurring forms of the DNMT3L enzyme or variants or homologs thereof that maintain DNMT3L enzyme activity (e.g. within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to DNMT3L).
  • the variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g.
  • the DNMT3L protein is substantially identical to the protein identified by the UniProt reference number Q9UJW3 or a variant or homolog having substantial identity thereto.
  • MLH1 (MutL homolog 1) is a human homolog of the E. coli DNA mismatch repair gene, mutL, which mediates protein-protein interactions during mismatch recognition, strand discrimination, and strand removal.
  • the human gene, hMLH1 is located on Chromosome 3. Defects in hMLH1 are commonly associated with the microsatellite instability (MSI) observed in hereditary nonpolyposis colorectal cancer (HNPCC).
  • hMLH1 deficient expression of the hMLH1 has been observed in many cancers, including stomach cancer (including foveolar type tumors, and stomach cancer in high-incidence Kashmir Valley), esophageal cancer, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), and colorectal cancer (such as HNPCC).
  • stomach cancer including foveolar type tumors, and stomach cancer in high-incidence Kashmir Valley
  • esophageal cancer head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), and colorectal cancer (such as HNPCC).
  • HNSCC head and neck squamous cell carcinoma
  • NSCLC non-small cell lung cancer
  • colorectal cancer colorectal cancer
  • Cas9 protein as referred to herein includes a nuclease-deficient wt Cas9 protein in which one of the two catalytic sites for endonuclease activity (RuvC and HNH) is defective or lacks activity, and a dCas9 protein in which both catalytic sites for endonuclease activity are defective or lack activity.
  • the Cas9 protein is a nuclease-deficient wt Cas9 protein.
  • the Cas9 protein lacks nuclease activity or is nuclease-deficient.
  • the Cas9 protein is a nickase (e.g., for example, the nickase can be a Cas9 Nickase with a mutation at a position corresponding to D10A of S. pyogenes Cas9; or the nickase can be a Cas9 Nickase with a mutation at a position corresponding to H840A of S. pyogenes Cas9).
  • the Cas9 protein is a dCas9 (e.g., a dCas9 with mutations at positions corresponding to D10A and H840A of S. pyogenes Cas9).
  • a “modified Cas9 protein” refers to a Cas9 that is not a wt Cas9 protein.
  • the modified Cas9 protein is a dCas9.
  • the modified Cas9 protein is a nickase.
  • the modified Cas9 protein (nickase or dCas9) may have reduced nuclease activity, or lacks nuclease activity at one or both endonuclease catalytic sites.
  • the dCas9 protein lacks endonuclease activity due to point mutations at both endonuclease catalytic sites (RuvC and HNH) of wild type Cas9.
  • the point mutations may be D10A and H840A, respectively, in the S. pyogenes Cas9, or in the corresponding residues in species other than S. pyogenes .
  • the modified Cas9 protein lacks endonuclease catalytic activity at one but not both sites of wt Cas9, and is able to create a nick on a dsDNA target (Cas9 nickase).
  • the Cas9 nickase protein lacks endonuclease activity due to point mutations at one endonuclease catalytic sites (RuvC and HNH) of wild type Cas9.
  • the point mutations can be D10A or H840A.
  • the dCas9 protein is nuclease-deficient but retains DNA-binding ability when complexed with the polynucleotide.
  • the dCas9 protein lacks endonuclease activity due to point mutations at both endonuclease catalytic sites (RuvC and HNH) of wild type Cas9.
  • the point mutations can be D10A and H840A.
  • the modified Cas9 protein has reduced or lacks endonuclease (e.g., endodeoxyribonuclease) activity.
  • a modified Cas9 suitable for use in a method of the present invention may be a Cas9 nickase, or exhibits less than 20%, less than 15%, less than 10%, less than 5%, less than 1%, or less than 0.1%, of the endonuclease (e.g., endodeoxyribonuclease) activity of a wild-type Cas9 polypeptide, e.g., a wild-type Cas9 polypeptide comprising an amino acid sequence as depicted in FIG.
  • the dCas9 has substantially no detectable endonuclease (e.g., endodeoxyribonuclease) activity.
  • a dCas9 has reduced catalytic activity
  • a Cas9 protein has a D10, G12, G17, E762, H840, N854, N863, H982, H983, A984, D986, and/or a A987 mutation, e.g., D10A, G12A, G17A, E762A, H840A, N854A, N863A, H982A, H983A, A984A, and/or D986A
  • the polypeptide can still bind to target DNA in a site-specific manner, because it is still guided to a target polynucleotide sequence by a DNA-targeting sequence of the subject polynucleotide, as long as it retains the ability to interact with the Cas9-binding sequence of the subject polynucleotide.
  • the nuclease-deficient wt Cas9 protein (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein) is optionally a fusion polypeptide including: i) a Cas9 protein (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein) a covalently linked heterologous polypeptide (also referred to as a “fusion partner”), which can be the same or different from the fusion partner fused to the PUF domains (infra).
  • a Cas9 protein e.g., nuclease-deficient wt Cas9 protein or dCas9 protein
  • a covalently linked heterologous polypeptide also referred to as a “fusion partner”
  • “Patient” or “subject in need thereof” refers to a living organism suffering from or prone to a disease or condition that can be treated by administration of a composition or pharmaceutical composition as provided herein.
  • Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals.
  • a patient is human.
  • the terms “disease” or “condition” refer to a state of being or health status of a patient or subject capable of being treated with a compound, pharmaceutical composition, or method provided herein.
  • the disease is cancer (e.g. lung cancer, ovarian cancer, osteosarcoma, bladder cancer, cervical cancer, liver cancer, kidney cancer, skin cancer (e.g., Merkel cell carcinoma), testicular cancer, leukemia, lymphoma (Mantel cell lymphoma), head and neck cancer, colorectal cancer, prostate cancer, pancreatic cancer, melanoma, breast cancer, neuroblastoma).
  • cancer e.g. lung cancer, ovarian cancer, osteosarcoma, bladder cancer, cervical cancer, liver cancer, kidney cancer, skin cancer (e.g., Merkel cell carcinoma), testicular cancer, leukemia, lymphoma (Mantel cell lymphoma), head and neck cancer, colorectal cancer, prostate cancer, pancreatic cancer, melanoma, breast cancer, neuroblastoma).
  • cancer refers to all types of cancer, neoplasm or malignant tumors found in mammals, including leukemias, lymphomas, melanomas, neuroendocrine tumors, carcinomas and sarcomas.
  • Exemplary cancers that may be treated with a compound, pharmaceutical composition, or method provided herein include lymphoma (e.g., Mantel cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, marginal zona lymphoma, Burkitt's lymphoma), sarcoma, bladder cancer, bone cancer, brain tumor, cervical cancer, colon cancer, esophageal cancer, gastric cancer, head and neck cancer, kidney cancer, myeloma, thyroid cancer, leukemia, prostate cancer, breast cancer (e.g., lymphoma (e.g., Mantel cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, marginal zona lymphoma, Burkitt's lymphoma), sarcoma, bladder cancer, bone cancer, brain tumor, cervical cancer, colon cancer, esophageal cancer, gastric cancer, head and neck cancer, kidney cancer, myeloma, thyroid cancer, leukemia, prostate cancer
  • ER positive triple negative
  • ER negative chemotherapy resistant
  • herceptin resistant HER2 positive
  • doxorubicin resistant tamoxifen resistant
  • ductal carcinoma lobular carcinoma, primary, metastatic
  • ovarian cancer pancreatic cancer
  • liver cancer e.g., hepatocellular carcinoma
  • lung cancer e.g.
  • non-small cell lung carcinoma squamous cell lung carcinoma, adenocarcinoma, large cell lung carcinoma, small cell lung carcinoma, carcinoid, sarcoma), glioblastoma multiforme, glioma, melanoma, prostate cancer, castration-resistant prostate cancer, breast cancer, triple negative breast cancer, glioblastoma, ovarian cancer, lung cancer, squamous cell carcinoma (e.g., head, neck, or esophagus), colorectal cancer, leukemia (e.g., lymphoblastic leukemia, chronic lymphocytic leukemia, hairy cell leukemia), acute myeloid leukemia, lymphoma, B cell lymphoma, or multiple myeloma.
  • leukemia e.g., lymphoblastic leukemia, chronic lymphocytic leukemia, hairy cell leukemia
  • acute myeloid leukemia lymphoma, B cell lymphoma, or multiple
  • Additional examples include, cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head & neck, esophagus, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus or Medulloblastoma, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial
  • a disease e.g., cancer (e.g. leukemia, lymphoma, B cell lymphoma, or multiple myeloma)
  • cancer e.g. leukemia, lymphoma, B cell lymphoma, or multiple myeloma
  • the disease e.g. cancer, (e.g. leukemia, lymphoma, B cell lymphoma, or multiple myeloma)
  • a symptom of the disease is caused by (in whole or in part) the substance or substance activity or function.
  • treatment or “treating,” or “palliating” or “ameliorating” are used interchangeably herein. These terms refer to an approach for obtaining beneficial or desired results including but not limited to therapeutic benefit and/or a prophylactic benefit.
  • therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated.
  • a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder.
  • the compositions may be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.
  • Treatment includes preventing the disease, that is, causing the clinical symptoms of the disease not to develop by administration of a protective composition prior to the induction of the disease; suppressing the disease, that is, causing the clinical symptoms of the disease not to develop by administration of a protective composition after the inductive event but prior to the clinical appearance or reappearance of the disease; inhibiting the disease, that is, arresting the development of clinical symptoms by administration of a protective composition after their initial appearance; preventing re-occurring of the disease and/or relieving the disease, that is, causing the regression of clinical symptoms by administration of a protective composition after their initial appearance.
  • certain methods herein treat cancer (e.g. lung cancer, ovarian cancer, osteosarcoma, bladder cancer, cervical cancer, liver cancer, kidney cancer, skin cancer (e.g., Merkel cell carcinoma), testicular cancer, leukemia, lymphoma, head and neck cancer, colorectal cancer, prostate cancer, pancreatic cancer, melanoma, breast cancer, neuroblastoma).
  • cancer e.g. lung cancer, ovarian cancer, osteosarcoma, bladder cancer, cervical cancer, liver cancer, kidney cancer, skin cancer (e.g., Merkel cell carcinoma), testicular cancer, leukemia, lymphoma, head and neck cancer, colorectal cancer, prostate cancer, pancreatic cancer, melanoma, breast cancer, neuroblastoma.
  • cancer e.g. lung cancer, ovarian cancer, osteosarcoma, bladder cancer, cervical cancer, liver cancer, kidney cancer, skin cancer (e.g., Merkel cell carcinoma), testicular cancer, leukemia, lymphoma, head and neck
  • lung cancer ovarian cancer, osteosarcoma, bladder cancer, cervical cancer, liver cancer, kidney cancer, skin cancer (e.g., Merkel cell carcinoma), testicular cancer, leukemia, lymphoma, head and neck cancer, colorectal cancer, prostate cancer, pancreatic cancer, melanoma, breast cancer, neuroblastoma) would be known or may be determined by a person of ordinary skill in the art.
  • skin cancer e.g., Merkel cell carcinoma
  • testicular cancer e.g., leukemia, lymphoma, head and neck cancer, colorectal cancer, prostate cancer, pancreatic cancer, melanoma, breast cancer, neuroblastoma
  • treatment refers to a method of reducing the effects of one or more symptoms of a disease or condition characterized by expression of the protease or symptom of the disease or condition characterized by expression of the protease.
  • treatment can refer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of an established disease, condition, or symptom of the disease or condition.
  • a method for treating a disease is considered to be a treatment if there is a 10% reduction in one or more symptoms of the disease in a subject as compared to a control.
  • the reduction can be a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any percent reduction in between 10% and 100% as compared to native or control levels. It is understood that treatment does not necessarily refer to a cure or complete ablation of the disease, condition, or symptoms of the disease or condition. Further, as used herein, references to decreasing, reducing, or inhibiting include a change of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater as compared to a control level and such terms can include but do not necessarily include complete elimination.
  • an “effective amount” is an amount sufficient to accomplish a stated purpose (e.g. achieve the effect for which it is administered, treat a disease, reduce enzyme activity, reduce one or more symptoms of a disease or condition).
  • An example of an “effective amount” is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which could also be referred to as a “therapeutically effective amount.”
  • a “reduction” of a symptom or symptoms means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s).
  • a “prophylactically effective amount” of a drug is an amount of a drug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of an injury, disease, pathology or condition, or reducing the likelihood of the onset (or reoccurrence) of an injury, disease, pathology, or condition, or their symptoms.
  • the full prophylactic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses.
  • a prophylactically effective amount may be administered in one or more administrations.
  • An “activity decreasing amount,” as used herein, refers to an amount of antagonist required to decrease the activity of an enzyme or protein relative to the absence of the antagonist.
  • a “function disrupting amount,” as used herein, refers to the amount of antagonist required to disrupt the function of an enzyme or protein relative to the absence of the antagonist.
  • Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products. For example, for the given parameter, an effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Efficacy can also be expressed as “-fold” increase or decrease. For example, a therapeutically effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control.
  • administering means oral administration, administration as a suppository, topical contact, intravenous, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject.
  • Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal).
  • Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial.
  • compositions described herein are administered at the same time, just prior to, or just after the administration of one or more additional therapies, for example cancer therapies such as chemotherapy, hormonal therapy, radiotherapy, or immunotherapy.
  • additional therapies such as chemotherapy, hormonal therapy, radiotherapy, or immunotherapy.
  • the compounds of the invention can be administered alone or can be co-administered to the patient.
  • Co-administration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound).
  • the preparations can also be combined, when desired, with other active substances (e.g. to reduce metabolic degradation).
  • compositions of the present invention can be delivered by transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
  • Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the complexes provided herein suspended in diluents, such as water, saline or PEG 400; (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as liquids, solids, granules or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions.
  • Tablet forms can include one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers.
  • Lozenge forms can comprise the active ingredient in a flavor, e.g., sucrose, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, carriers known in the art.
  • a flavor e.g., sucrose
  • an inert base such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, carriers known in the art.
  • compositions can also include large, slowly metabolized macromolecules such as proteins, polysaccharides such as chitosan, polylactic acids, polyglycolic acids and copolymers (such as latex functionalized SepharoseTM, agarose, cellulose, and the like), polymeric amino acids, amino acid copolymers, and lipid aggregates (such as oil droplets or liposomes). Additionally, these carriers can function as immunostimulating agents (i.e., adjuvants).
  • Suitable formulations for rectal administration include, for example, suppositories, which consist of the packaged nucleic acid with a suppository base.
  • Suitable suppository bases include natural or synthetic triglycerides or paraffin hydrocarbons.
  • gelatin rectal capsules which consist of a combination of the compound of choice with a base, including, for example, liquid triglycerides, polyethylene glycols, and paraffin hydrocarbons.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
  • compositions can be administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically or intrathecally.
  • Parenteral administration, oral administration, and intravenous administration are the preferred methods of administration.
  • the formulations of compounds can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials.
  • Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
  • Cells transduced by nucleic acids for ex vivo therapy can also be administered intravenously or parenterally as described above.
  • the pharmaceutical preparation is preferably in unit dosage form.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • the composition can, if desired, also contain other compatible therapeutic agents.
  • the combined administration contemplates co-administration, using separate formulations or a single pharmaceutical formulation, and consecutive administration in either order, wherein preferably there is a time period while both (or all) active agents simultaneously exert their biological activities.
  • Effective doses of the compositions provided herein vary depending upon many different factors, including means of administration, target site, physiological state of the patient, whether the patient is human or an animal, other medications administered, and whether treatment is prophylactic or therapeutic. However, a person of ordinary skill in the art would immediately recognize appropriate and/or equivalent doses looking at dosages of approved compositions for treating and preventing cancer for guidance.
  • “Pharmaceutically acceptable excipient” and “pharmaceutically acceptable carrier” refer to a substance that aids the administration of an active agent to and absorption by a subject and can be included in the compositions of the present invention without causing a significant adverse toxicological effect on the patient.
  • Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer's, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, polyvinyl pyrrolidine, and colors, and the like.
  • Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances, and the like, that do not deleteriously react with the compounds of the invention.
  • auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances, and the like.
  • pharmaceutically acceptable salt refers to salts derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
  • preparation is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
  • carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
  • the pharmaceutical preparation is optionally in unit dosage form.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • the unit dosage form can be of a frozen dispersion.
  • compositions of the present invention may additionally include components to provide sustained release and/or comfort.
  • Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Pat. Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes.
  • the compositions of the present invention can also be delivered as microspheres for slow release in the body.
  • microspheres can be administered via intradermal injection of drug-containing microspheres, which slowly release subcutaneously (see Rao, J. Biomater Sci. Polym . Ed.
  • the formulations of the compositions of the present invention can be delivered by the use of liposomes which fuse with the cellular membrane or are endocytosed, i.e., by employing receptor ligands attached to the liposome, that bind to surface membrane protein receptors of the cell resulting in endocytosis.
  • compositions of the present invention can focus the delivery of the compositions of the present invention into the target cells in vivo.
  • the compositions of the present invention can also be delivered as nanoparticles.
  • the polynucleotides may include a stability control sequence (e.g., transcriptional terminator segment) which influences the stability of the respective polynucleotide it forms part of (e.g., an RNA (e.g., a subject polynucleotide).
  • a stability control sequence e.g., transcriptional terminator segment
  • transcriptional terminator segment i.e., a transcription termination sequence
  • a transcriptional terminator segment of a subject polynucleotide can have a total length of from 10 nucleotides to 100 nucleotides, e.g., from 10 nucleotides (nt) to 20 nt, from 20 nt to 30 nt, from 30 nt to 40 nt, from 40 nt to 50 nt, from 50 nt to 60 nt, from 60 nt to 70 nt, from 70 nt to 80 nt, from 80 nt to 90 nt, or from 90 nt to 100 nt.
  • 10 nucleotides (nt) to 20 nt from 20 nt to 30 nt, from 30 nt to 40 nt, from 40 nt to 50 nt, from 50 nt to 60 nt, from 60 nt to 70 nt, from 70 nt to 80 nt, from 80 nt to 90 nt, or from 90 nt to 100
  • the transcriptional terminator segment can have a length of from 15 nucleotides (nt) to 80 nt, from 15 nt to 50 nt, from 15 nt to 40 nt, from 15 nt to 30 nt or from 15 nt to 25 nt.
  • the transcription termination sequence is one that is functional in a eukaryotic cell. In some cases, the transcription termination sequence is one that is functional in a prokaryotic cell.
  • a stability control sequence e.g., transcriptional termination segment, or in any segment of the DNA-targeting RNA to provide for increased stability
  • nucleotide sequences that can be included in a stability control sequence include sequences set forth in SEQ ID NO: 683-696 of WO 2013/176772 (incorporated herein by reference in its entirety and for all purposes), see, for example, SEQ ID NO: 795 of WO 2013/176772, a Rho-independent transcription termination site.
  • the demethylation of methylation protein conjugates provided herein are targeted by the DNA-targeting sequence of the subject polynucleotide to a specific location (i.e., target polynucleotide sequence) in the target DNA, and exert locus-specific modification of the target DNA (e.g., modifying the local chromatin status).
  • the changes are transient (e.g., transcription repression or activation).
  • the changes are inheritable (e.g., when epigenetic modifications are made to the target DNA or to proteins associated with the target DNA, e.g., nucleosomal histones).
  • the biological effects of a method using the complexes provided herein including embodiments thereof can be detected by any convenient method (e.g., gene expression assays; chromatin-based assays, e.g., Chromatin immunoPrecipitation (ChiP), Chromatin in vivo Assay (CiA), etc.; and the like).
  • any convenient method e.g., gene expression assays; chromatin-based assays, e.g., Chromatin immunoPrecipitation (ChiP), Chromatin in vivo Assay (CiA), etc.; and the like).
  • a transcription modulation method of the present invention provides for selective modulation (e.g., reduction or increase) of a target nucleic acid in a host cell.
  • selective modulation e.g., reduction or increase
  • “selective” reduction of transcription of a target nucleic acid reduces transcription of the target nucleic acid by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or greater than 90%, compared to the level of transcription of the target nucleic acid in the absence of a DNA-targeting sequence/modified Cas9 polypeptide/PUF domain-fusion complex.
  • Selective reduction of transcription of a target nucleic acid reduces transcription of the target nucleic acid, but does not substantially reduce transcription of a non-target nucleic acid, e.g., transcription of a non-target nucleic acid is reduced, if at all, by less than 10% compared to the level of transcription of the non-target nucleic acid in the absence of the DNA-targeting sequence/modified Cas9 polypeptide/PUF domain-fusion complex.
  • “selective” increased transcription of a target DNA can increase transcription of the target DNA by at least 1.1 fold (e.g., at least 1.2 fold, at least 1.3 fold, at least 1.4 fold, at least 1.5 fold, at least 1.6 fold, at least 1.7 fold, at least 1.8 fold, at least 1.9 fold, at least 2 fold, at least 2.5 fold, at least 3 fold, at least 3.5 fold, at least 4 fold, at least 4.5 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, at least 10 fold, at least 12 fold, at least 15 fold, or at least 20-fold) compared to the level of transcription of the target DNA in the absence of the complexes provided herein including embodiments thereof (e.g., DNA-targeting sequence/modified Cas9 polypeptide/PUF domain-fusion complex).
  • Selective increase of transcription of a target DNA increases transcription of the target DNA, but does not substantially increase transcription of a non-target DNA, e.g., transcription of a non-target DNA is increased, if at all, by less than 5-fold (e.g., less than 4-fold, less than 3-fold, less than 2-fold, less than 1.8-fold, less than 1.6-fold, less than 1.4-fold, less than 1.2-fold, or less than 1.1-fold) compared to the level of transcription of the non-targeted DNA in the absence of the complexes provided herein including embodiments thereof (e.g., DNA-targeting sequence/modified Cas9 polypeptide/PUF domain-fusion complex).
  • multiple subject polynucleotides are used simultaneously in the same cell to simultaneously modulate transcription at different locations on the same target DNA or on different target DNAs.
  • two or more subject polynucleotides target the same gene or transcript or locus.
  • two or more subject polynucleotides target different unrelated loci.
  • two or more subject polynucleotides target different, but related loci.
  • the subject polynucleotides are small and robust, they can be simultaneously present on the same expression vector and can even be under the same transcriptional control if so desired.
  • two or more (e.g., 3 or more, 4 or more, 5 or more, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, or 50 or more) subject polynucleotides are simultaneously expressed in a target cell, from the same or different vectors.
  • the expressed subject polynucleotides can be differently recognized by orthogonal nuclease-deficient RNA-guided DNA endonucleases (dCas9 proteins) from different bacteria, such as S. pyogenes, S. thermophilus, L. innocua , and N. meningitidis.
  • dCas9 proteins orthogonal nuclease-deficient RNA-guided DNA endonucleases
  • RNA processing system mediated by the Csy4 endoribonuclease described in international application PCT/US2016/021491 and published as WO2016148994 A8, which is hereby incorporated by reference and for all purposes, may be used for the invention provided herein.
  • a method of the present invention to modulate transcription may be employed to induce transcriptional modulation in mitotic or post-mitotic cells in vivo and/or ex vivo and/or in vitro.
  • a mitotic and/or post-mitotic cell can be any of a variety of host cell, where suitable host cells include, but are not limited to, a bacterial cell; an archaeal cell; a single-celled eukaryotic organism; a plant cell; an algal cell, e.g., Botryococcus braunii, Chlamydomonas reinhardtii, Nannochloropsis gaditana, Chlorella pyrenoidosa, Sargassum patens, C.
  • a fungal cell e.g., an insect, a cnidarian, an echinoderm, a nematode, etc.
  • a eukaryotic parasite e.g., a malarial parasite, e.g., Plasmodium falciparum ; a helminth; etc.
  • a cell from a vertebrate animal e.g., fish, amphibian, reptile, bird, mammal
  • a mammalian cell e.g., a rodent cell, a human cell, a non-human primate cell, etc.
  • Suitable host cells include naturally-occurring cells; genetically modified cells (e.g., cells genetically modified in a laboratory, e.g., by the “hand of man”); and cells manipulated in vitro in any way. In some cases, a host cell is isolated or cultured.
  • a stem cell e.g. an embryonic stem (ES) cell, an induced pluripotent stem (iPS) cell, a germ cell; a somatic cell, e.g. a fibroblast, a hematopoietic cell, a neuron, a muscle cell, a bone cell, a hepatocyte, a pancreatic cell; an in vitro or in vivo embryonic cell of an embryo at any stage, e.g., a 1-cell, 2-cell, 4-cell, 8-cell, etc. stage zebrafish embryo; etc.).
  • ES embryonic stem
  • iPS induced pluripotent stem
  • a germ cell e.g. a somatic cell, e.g. a fibroblast, a hematopoietic cell, a neuron, a muscle cell, a bone cell, a hepatocyte, a pancreatic cell
  • an in vitro or in vivo embryonic cell of an embryo at any stage e
  • Cells may be from established cell lines or they may be primary cells, where “primary cells,” “primary cell lines,” and “primary cultures” are used interchangeably herein to refer to cells and cells cultures that have been derived from a subject and allowed to grow in vitro for a limited number of passages, i.e. splittings, of the culture.
  • primary cultures include cultures that may have been passaged 0 times, 1 time, 2 times, 4 times, 5 times, 10 times, or 15 times, but not enough times go through the crisis stage.
  • Primary cell lines can be are maintained for fewer than 10 passages in vitro.
  • Target cells are in many embodiments unicellular organisms, or are grown in culture.
  • the cells may be harvest from an individual by any convenient method.
  • leukocytes may be conveniently harvested by apheresis, leukocytapheresis, density gradient separation, etc., while cells from tissues such as skin, muscle, bone marrow, spleen, liver, pancreas, lung, intestine, stomach, etc. are most conveniently harvested by biopsy.
  • An appropriate solution may be used for dispersion or suspension of the harvested cells.
  • Such solution will generally be a balanced salt solution, e.g.
  • fetal calf serum or other naturally occurring factors, in conjunction with an acceptable buffer at low concentration, e.g., from 5-25 mM.
  • Convenient buffers include HEPES, phosphate buffers, lactate buffers, etc.
  • the cells may be used immediately, or they may be stored, frozen, for long periods of time, being thawed and capable of being reused.
  • the cells will usually be frozen in 10% dimethyl sulfoxide (DMSO), 50% serum, 40% buffered medium, or other solutions commonly used in the art to preserve cells at such freezing temperatures, and thawed in a manner as commonly known in the art for thawing frozen cultured cells.
  • DMSO dimethyl sulfoxide
  • a subject polynucleotide, a nucleic acid comprising a nucleotide sequence encoding same, or a nucleic acid comprising a nucleotide sequence encoding the subject nuclease-deficient RNA-guided DNA endonuclease (dCas9 protein) or demethylation or methylation protein conjugate (PUF domain fusion), can be introduced into a host cell by any of a variety of well-known methods.
  • nucleic acid e.g., vector or expression construct
  • Suitable methods include, include e.g., viral or bacteriophage infection, transfection, conjugation, protoplast fusion, lipofection, electroporation, calcium phosphate precipitation, polyethyleneimine (PEI)-mediated transfection, DEAE-dextran mediated transfection, liposome-mediated transfection, particle gun technology, calcium phosphate precipitation, direct micro injection, nanoparticle-mediated nucleic acid delivery (see, e.g., Panyam et al., Adv. Drug Deliv. Rev., pii: S 0169-409 ⁇ (12)00283-9.doi:10.1016/j.addr.2012.09.023), and the like.
  • PKI polyethyleneimine
  • a subject nucleic acid also comprises a nucleotide sequence encoding a nuclease-deficient RNA-guided DNA endonuclease (dCas9 protein) and/or a demethylation or methylation protein conjugate (PUF domain fusion).
  • dCas9 protein nuclease-deficient RNA-guided DNA endonuclease
  • PEF domain fusion a demethylation or methylation protein conjugate
  • a subject method involves introducing into a host cell (or a population of host cells) one or more nucleic acids (e.g., vectors) comprising nucleotide sequences encoding a subject polynucleotide and/or a nuclease-deficient RNA-guided DNA endonuclease (dCas9 protein) and/or a demethylation or methylation protein conjugate (PUF domain fusion).
  • a host cell comprising a target DNA is in vitro.
  • a host cell comprising a target DNA is in vivo.
  • Suitable nucleic acids comprising nucleotide sequences encoding a subject polynucleotide and/or a nuclease-deficient RNA-guided DNA endonuclease (dCas9 protein) and/or a subject demethylation or methylation protein conjugate (PUF domain fusion) include expression vectors, where the expression vectors may be recombinant expression vector.
  • dCas9 protein nuclease-deficient RNA-guided DNA endonuclease
  • PEF domain fusion a subject demethylation or methylation protein conjugate
  • the recombinant expression vector is a viral construct, e.g., a recombinant adeno-associated virus construct (see, e.g., U.S. Pat. No. 7,078,387), a recombinant adenoviral construct, a recombinant lentiviral construct, a recombinant retroviral construct, etc.
  • a viral construct e.g., a recombinant adeno-associated virus construct (see, e.g., U.S. Pat. No. 7,078,387), a recombinant adenoviral construct, a recombinant lentiviral construct, a recombinant retroviral construct, etc.
  • Suitable expression vectors include, but are not limited to, viral vectors (e.g. viral vectors based on vaccinia virus; poliovirus; adenovirus (see, e.g., Li et al., Invest Opthalmol. Vis. Sci., 35:2543-2549, 1994; Borras et al., Gene Ther., 6:515-524, 1999; Li and Davidson, Proc. Natl. Acad. Sci. USA, 92:7700-7704, 1995; Sakamoto et al., Hum.
  • viral vectors e.g. viral vectors based on vaccinia virus; poliovirus; adenovirus (see, e.g., Li et al., Invest Opthalmol. Vis. Sci., 35:2543-2549, 1994; Borras et al., Gene Ther., 6:515-524, 1999; Li and Davidson, Proc. Natl. Acad. Sci. USA,
  • a retroviral vector e.g., Murine Leukemia Virus, spleen necrosis virus, and vectors derived from retroviruses such as Rous Sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, a lentivirus, HIV virus, myeloproliferative sarcoma virus, and mammary tumor virus; and the like.
  • Suitable expression vectors are known to those skilled in the art, and many are commercially available.
  • the following vectors are provided by way of example; for eukaryotic host cells: pXT1, pSGS (Stratagene), pSVK3, pBPV, pMSG, and pSVLSV40 (Pharmacia).
  • any other vector may be used so long as it is compatible with the host cell.
  • a method for modulating transcription according to the present invention finds use in a variety of applications, including research applications; diagnostic applications; industrial applications; and treatment applications.
  • Research applications may include, e.g., determining the effect of reducing or increasing transcription of a target nucleic acid on, e.g., development, metabolism, expression of a downstream gene, and the like.
  • High through-put genomic analysis can be carried out using a subject transcription modulation method, in which only the DNA-targeting sequence of the subject polynucleotide needs to be varied, while the binding sequence (Cas9-binding sequence) and the PBS sequence can (in some cases) be held constant.
  • a library e.g., a subject library
  • comprising a plurality of nucleic acids used in the genomic analysis would include: a promoter operably linked to a subject polynucleotide-encoding nucleotide sequence, where each nucleic acid would include a different DNA-targeting sequence, a common binding sequence (Cas9-binding sequence), and a common PBS sequence.
  • a chip could contain over 5 ⁇ 10 4 unique polynucleotide of the invention.
  • a subject transcription modulation method can also be used for drug discovery and target validation as described in international application PCT/US2016/021491 and published as WO2016148994 A8, which is hereby incorporated by reference and for all purposes.
  • Example 1 sgRNA Scaffold Remains Functional with Insertion of 47 Copies of Engineered Pumilio Binding Sites
  • the subject 3-component CRISPR/Cas complex/system can have at least 47 copies of the engineered 8-mer Pumilio homologue domain-binding sequences (PBSs) at the 3′ end of sgRNA, without substantially affecting the function of the dCas9/sgRNA complex.
  • PBSs Pumilio homologue domain-binding sequences
  • FIG. 1B Cells were transfected with dCas9-VP64 with the different sgRNA scaffolds, and were analyzed by fluorescent-activated cell sorting (FACS) two days after transfection ( FIG. 1B ). All the control non-targeting sgRNAs did not activate tdTomato expression. Meanwhile, all the Tet-targeting sgRNAs with different number of PBS could direct dCas9-VP64 to activate tdTomato expression, showing that insertion of at least 47 copies of 8-mer sites do not substantially impact the activity of sgRNA in directing dCas9-VP64 to its targets ( FIG. 1C ).
  • Example 2 The Subject 3-Component CRISPR/Cas Complexes/Systems are Orthogonal to Each Other Due to the Specificity of the Engineered Pumilio with the Cognate 8-Mer Binding Sites
  • PUF::VP64 can activate tdTomato expression only when the sgRNA with the cognate binding sites were provided.
  • PBSa and PBSw binding sites only differ by one nucleotide, their gene activation remains target-specific, demonstrating the high specificity of the subject 3-component CRISPR/Cas complex/system.
  • Example 3 The Subject 3-Component CRISPR/Cas Complex/System Allows Assembly of Protein Complex at Target Loci
  • p65-HSF1 has recently been shown to be a potent activator domain.
  • Co-transfection of both PUF(3-2)::VP64 and PUF(6-2/7-2)::p65-HSF1 induced a tdTomato fluorescence, with an intensity the sum of the fluorescent intensity resulting from transfecting the single activators alone. This indicates that sgRNA with binding sites for both PUF(3-2) and PUF(6-2/7-2) allows both fusion proteins of both types to assemble on the targeted genomic locus.
  • PUFa [PUF(3-2)] and PUFb [PUF(6-2/7-2)] with N-terminal NLS were amplified from constructs containing these coding sequences with primers containing SgrAI and PacI sites and were used to replace SgrAI-dCas9-FseI from pAC164:pmax-dCas9Master_VP64 to create pAC1355:pmax-NLSPUFa_VP64 and pAC1356:pmax-NLSPUFb_VP64.
  • a fusion PCR with 5′ fragment up to repeat 4 of NLSPUFb and 3′ fragment from repeat 5 to the end of NLSPUFa was used to create pAC1357:pmax-NLSPUFw_VP64.
  • a fusion PCR of 5′ fragment of NLSPUFa with 3′ fragment of NLSPUb was used to create pAC1358:pmax-NLSPUFc_VP64.
  • p65HSF1 activator ORF was amplified from MS2-P65-HSF1_GFP (Addgene: 61423) with FseI PacI sites to replace VP64 fragment in pAC164 to create pAC1410:pmax-dCas9_p65HSF1, and replace VP64 in pAC1355 and pAC1358 to create pAC1393: pmax-NLSPUFa_p65HSF1 and pAC1411:pmax-NLSPUFc_p65HSF1, respectively.
  • the FseI-p65HSF1-PacI fragment was released from pAC1393 and ligated with SgrAI-NLSPUMb fragment released from pAC1356 and pAC1360 digested with SgrAI-PacI as vector to create pAC1413: PB3-neo(-)-pmax-NLSPUFb_p65HSF1.
  • the BFPKRAB fragment was amplified from pHR-SFFV-dCas9-BFP-KRAB (Addgene #46911) and was used to replace Clover fragment from pAC1360 to create pAC1414: PB3-neo(-)-pmax-BFPKRAB_NLSPUFa.
  • an NheI-CAGGS-NLSPUFb_p65HSF1-NheI fragment was amplified from pAC1413 and inserted into pAC1414 digested with NheI to create a dual expression vector for BFPKRAB-NLSPUFa and NLSPUFb-p65HSF1 (pAC1414: PB3-NLSPUFb_p65HSF1(-)neo(-)-BFPKRAB2_NLSPUFa).
  • HAT sequence was amplified with another pair of primers containing SgrAI-AclI site and cloned into SgrAI-ClaI site of pAC1405 to create pAC1416: pCR8-CBPHAT_4 ⁇ NLSPUFa_2 ⁇ NLS.
  • pAC1415 and pAC1416 were recombined into pAC90:pmax-DEST (Addgene #48222) to create expression vectors pAC1417: pmax-4 ⁇ NLSPUFa_2 ⁇ NLS_CBPHAT and pAC1418: pmax-CBPHAT_4 ⁇ NLSPUFa_2 ⁇ NLS, respectively.
  • FseI-mCherry-PacI fragment was amplified from a plasmid containing mCherry sequence and ligated with SgrAI-dCas9-FseI to PB3-neo(-)-pmax to generate pAC1419: PB3-neo(-)-pmax-dCas9Master_mCherry.
  • Expression vectors for sgRNA-PBS were constructed as follows: First, a sgRNA scaffold based on sgF+E with BbsI for oligo cloning of guide sequence and with 3′ BsaI (right upstream of the terminator) for insertion of PBS were ordered as a gBlock (IDT), and were cloned into pX330 (Addgene #42230) replacing the AflIII-NotI region to create vector pAC1394: pX-sgFE-BsaI(AGAT).
  • oligos encoding 5 ⁇ PBSa sites each separated by ggc-spacer flanked by 5′-AGAT-3′ overhangs on one side and 5′-ATCT-3′ on the other side were treated with T4PNK and annealed and ligated into pAC1394 digested with BsaI (to create compatible overhangs).
  • Clones were then screened for 1 copy (5 ⁇ PBS), 2 copies (10 ⁇ PBS), etc of the oligo insertions for the different number of PBS.
  • 1 ⁇ PBS and 2 ⁇ PBS vectors they were constructed using oligo containing one PBS site. Guide sequence for each target were then cloned onto the sgRNA-PBS expression vectors via BbsI site as previously described.
  • sgRNA expression vectors with GFP expression markers they were constructed by transferring the sgRNA-PBS expression cassette from the pX vectors onto a PB-GFP vector via AscI site.
  • the different sgRNA expression constructs are listed in Table S1.
  • HEK293T cells were cultivated in Dulbecco's modified Eagle's medium (DMEM)(Sigma) with 10% fetal bovine serum (FBS)(Lonza), 4% Glutamax (Gibco), 1% Sodium Pyruvate (Gibco) and penicillin-streptomycin (Gibco). Incubator conditions were 37° C. and 5% CO 2 .
  • DMEM Dulbecco's modified Eagle's medium
  • FBS fetal bovine serum
  • Gibco fetal bovine serum
  • Gibco fetal bovine serum
  • 1% Sodium Pyruvate Gibco
  • penicillin-streptomycin Gabco
  • Incubator conditions were 37° C. and 5% CO 2 .
  • cells were seeded into 12-well plates at 100,000 cells per well the day before being transfected with 200 ng of dCas9 construct, 100 ng of modified sgRNA and 100 ng of
  • RNA extraction After transfection, cells were grown for 48 hrs and harvested for either RNA extraction or fluorescent-activated cell sorting (FACS). For dual activation-repression experiments, transfection remained the same, however cells were seeded into 12-well plates at 150,000 cells per well and were grown for 72 hrs before being harvested for FACS. For experiments with OCT4 and SOX2 dual activation-repression, cells were triple-sorted by BFP (for the activator-repressor module PUFb-p65HSF1/BFPKRAB-PUFa), mCherry (for dCas9mCherry) and GFP (for the sgRNA-PBS on vectors co-expressing EGFP) before RNA extraction.
  • BFP for the activator-repressor module PUFb-p65HSF1/BFPKRAB-PUFa
  • mCherry for dCas9mCherry
  • GFP for the sgRNA-PBS on vectors co-expressing EGFP
  • cells were seeded into 6-well plates with 22 ⁇ 22 ⁇ 1 microscope cover glass at 300,000 cells per well the day before being transfected with 50 ng of dCas9 construct, 500 ng of modified sgRNA, and 50 ng of a PUF-fluorescent fusion with Attractene transfection reagent. After transfection, cells were grown for 48 hrs then immunostained.
  • a cDNA library was made using Applied Biosystems High Capacity RNA-to-cDNA kit with 1 ⁇ g of RNA.
  • TaqMan Gene expression assays were designed using GAPDH (Hs03929097, VIC) as endogenous control and OCT4 (Hs00999632, FAM) and SOX2 (Hs01053049, FAM) as targets.
  • Fluorescent-Activated Cell Sorting Cells were trypisinized and fixed for 10 min with 2% paraformaldehyde. Afterwards, the cells were centrifuged at 125 g for 5 min and resuspended in dPBS. Samples were analyzed on a FACScalibur flow cytometer using CellQuest Pro software (BD Bioscience). thousands events were collected in each run.
  • NLS PUFa VP64 SEQ ID NO: 32 MGILPPKKKRKVSRGRSRLLEDFRNNRYPNLQLREIAGHIMEFSQDQHGS RFIQLKLERATPAERQLVFNEILQAAYQLMVDVFGNYVIQKFFEFGSLEQ KLALAERIRGHVLSLALQMYGSRVIEKALEFIPSDQQNEMVRELDGHVLK CVKDQNGNHVVQKCIECVQPQFIIDAFKGQVFALSTHPYGCRVIQRI LEHCLPDQTLPILEELHQHTEQLVQDQYGNYVIQHVLEHGRPEDKSKIVA EIRGNVLVLSQHKFASNVVEKCVTHASRTERAVLIDEVCTMNDGPHSALY TMMKDQYANYVVQKMIDVAEPGQRKIVMHKIRPHIATLRKYTYGKHILAK LEKYYMKNGVDLGGPAGSGR ADALDDFDLD
  • NLS sequence is residues 6-12
  • PUFa SEQ ID NO:2
  • VP64 is residues 371-421.
  • NLS PUFb VP64 SEQ ID NO: 33 MGILPPKKKRKVSRGRSRLLEDFRNNRYPNLQLREIAGHIMEFSQDQHGS RFIQLKLERATPAERQLVFNEILQAAYQLMVDVFGNYVIQKFFEFGSLEQ KLALAERIRGHVLSLALQMYGCRVIQKALEFIPSDQQNEMVRELDGHVLK CVKDQNGNHVVQKCIECVQPQFIIDAFKGQVFALSTHPYGCRVIQRI LEHCLPDQTLPILEELHQHTEQLVQDQYGSYVIEHVLEHGRPEDKSKIVA EIRGNVLVLSQHKFANNVVQKCVTHASRTERAVLIDEVCTMNDGPHSALY TMMKDQYANYVVQKMIDVAEPGQRKIVMHKIRPHIATLRKYTYGKHILAK LEKYYMKNGVDLGGPAGSGR ADALDDFD
  • NLS sequence is residues 6-12
  • PUFb SEQ ID NO:3
  • VP64 is residues 371-421.
  • NLS PUFw VP64 SEQ ID NO: 34 MGILPPKKKRKVSRGRSRLLEDFRNNRYPNLQLREIAGHIMEFSQDQHGS RFIQLKLERATPAERQLVFNEILQAAYQLMVDVFGNYVIQKFFEFGSLEQ KLALAERIRGHVLSLALQMYGCRVIQKALEFIPSDQQNEMVRELDGHVLK CVKDQNGNHVVQKCIECVQPQSLQFIIDAFKGQVFALSTHPYGCRVIQRI LEHCLPDQTLPILEELHQHTEQLVQDQYGNYVIQHVLEHGRPEDKSKIVA EIRGNVLVLSQHKFASNVVEKCVTHASRTERAVLIDEVCTMNDGPHSALY TMMKDQYANYVVQKMIDVAEPGQRKIVMHKIRPHIATLRKYTYGKHILAK LEKYYMKNGVDLGGPAGSGR ADALDDFDLD
  • NLS sequence is residues 6-12
  • PUFw SEQ ID NO:5
  • VP64 is residues 371-421.
  • NLS PUFc VP64 SEQ ID NO: 35 MGILPPKKKRKVSRGRSRLLEDFRNNRYPNLQLREIAGHIMEFSQDQHGS RFIQLKLERATPAERQLVFNEILQAAYQLMVDVFGNYVIQKFFEFGSLEQ KLALAERIRGHVLSLALQMYGSRVIEKALEFIPSDQQNEMVRELDGHVLK CVKDQNGNHVVQKCIECVQPQFIIDAFKGQVFALSTHPYGCRVIQRI LEHCLPDQTLPILEELHQHTEQLVQDQYGSYVIEHVLEHGRPEDKSKIVA EIRGNVLVLSQHKFANNVVQKCVTHASRTERAVLIDEVCTMNDGPHSALY TMMKDQYANYVVQKMIDVAEPGQRKIVMHKIRPHIATLRKYTYGKHILAK LEKYYMKNGVDLGGPAGSGR ADALDDFD
  • NLS sequence is residues 6-12
  • PUFc SEQ ID NO:4
  • VP64 is residues 371-421.
  • Example 4 Targeted DNA Demethylation and Methylation Using the Subject 3-Component CRISPR/Cas Complex/System (Casilio) and dCas9-Tethered Enzymes
  • CRISPR/Cas Complex/System may also be referred to as “Casilio” herein.
  • the Example demonstrated a robust activation of hMLH1 transcription, a gene that is epigenetically silenced in HEK293T cells and other cancer cells due to hypermethylation in the promoter regions. Reactivation of hMLH1 transcription leads to (restoration of) expression of MLH1 protein.
  • the Example showed that Casilio-ME-mediated delivery of TET1 activity to hMLH1 promoter region induced a robust cytosine demethylation within the targeted CpG island, providing a proof-of-principal that Casilio-ME is a robust platform to editing methylcytosine mark of the epigenome.
  • dCas9 nuclease-deficient dCas9, modified sgRNAs containing sites for Pumilio (PUF) RNA binding domain (sgRNA-PBS) and an effector module made of Pumilio RNA binding domain fused to an effector protein.
  • dCas9 binds DNA when complexed with sgRNA without producing double-stranded breaks, serving as a RNA-programmable DNA binding protein whose specificity is determined by a sequence in the sgRNA component of the system.
  • PUF domains can be programmed to bind to any 8-mer RNA sequences (PBS) appended in multiple copies to the 3′ end of the sgRNA without interfering with the sgRNA-mediated DNA binding of dCas9 (Cheng, A. W., et al., Casilio: a versatile CRISPR - Cas 9- Pumilio hybrid for gene regulation and genomic labeling . Cell Res, 2016. 26(2): p. 254-7).
  • PBS 8-mer RNA sequences
  • TET1-effector modules were constructed as N-terminal or C-terminal fusions of PUFa to TET1 catalytic domain that includes residues 1418 to 2136 (TET1(CD)).
  • the promoter region of hMLH1 whose hypermethylation is known to induce silencing of hMLH1 expression (Deng, G., et al., Methylation of CpG in a small region of the hMLH 1 promoter invariably correlates with the absence of gene expression . Cancer Res, 1999. 59(9): p. 2029-33), was chosen as the target for this study.
  • MLH1 protein is a component of the methyl directed mismatch repair system of the cell.
  • hMLH1 is in fact silenced in HEK293T cells as is in other cancer cells, and therefore represents a good cellular model to test TET1-effectors in their ability to induce demethylation-mediated gene activation.
  • Nine sgRNAs were designed around the promoter region whose methylation is associated with down-regulation of hMLH1 in cancer cells ( FIG. 3A ) (Deng, G., et al., Methylation of CpG in a small region of the hMLH 1 promoter invariably correlates with the absence of gene expression . Cancer Res, 1999. 59(9): p. 2029-33).
  • HEK293T cells were transfected with Casilio-ME components including Ct or Nt-fusion TET1-effector and a combination of 3 or 2 sgRNAs.
  • Relative levels of hMLH1 mRNA were determined in TaqMan assays by using RNA extracted from cells 60 hours post-transfection and GAPDH as endogenous control for normalization of qRT-PCR measurements. This showed that PUFa-TET1(CD)C-terminal fusion effector restored a robust hMLH1 expression that reached 135 fold over background in the presence sgRNAs 3+7 ( FIG. 3B ).
  • TET1(CD)-PUFa N-terminal effector fusion showed a much weaker activation (20 fold at best) in the presence of the same sgRNA combo, presumably due to steric hindrance as TET1(CD) is natively located at the C-terminus of TET1 full length protein.
  • Casilio-mediated delivery of demethylation enzymes to specific genomic locus enables robust alteration of gene expression.
  • TET1-mediated activation of hMLH1 expression was replaced by p65HSF1-effector.
  • this showed higher activation that reached 200-fold over the background ( FIG. 3B ).
  • Casilio-ME-mediated activation of hMLH1 expression can achieve about 70% of the activation obtained by a strong transcription activator module such as p65HSF1, indicating that Casilio-ME is an efficient tool enabling efficient targeting and delivery of demethylation enzymes to alter methylation state of the genome and the associated silencing activities.
  • dCas9-TET1(CD) direct fusion to activate hMLH1 expression in HEK293T cells in comparison to Casilio-ME
  • N-terminal and C-terminal fusions of dCas9 to TET1(CD) were constructed.
  • the dCas9-TET1(CD)C-terminal fusion showed a relatively weak activation of hMLH1, as indicated by the relative change in mRNA levels ( FIG. 3C ).
  • dCas9-TET1(CD)-induced activation represents at best about 14% of the obtained activation using the Casilio-ME with the same sgRNAs combination in parallel experiment (19-vs 135-fold change in mRNA levels).
  • TET1(CD)-dCas9 fusion showed a much weaker activation than its respective C-terminal fusion, indicating a possible steric hindrance affecting TET1 activity when N-terminally fused to either dCas9 or PUFa proteins ( FIGS. 3B & 3C ).
  • HEK293T cells were transfected with dCas9-p65HSF1 along with the same sgRNA combination. Analysis of mRNA levels showed that dCas9-TET1 activation of hMLH1 was at best twice the activity obtained with transcription activator dCas9 fusion ( FIG. 3C ), therefore indicating that TET1 targeting to specific locus can activate gene, presumably via alteration of epigenetic DNA methylation at the target site.
  • Casilio-mediated delivery of demethylation enzymes alters methylation state of targeted genomic locus.
  • Evidence that the shown Casilio-ME-induced activation of hMLH1 transcription is a result of TET1-mediated cytosine demethylation within the targeted promoter region came from DNA sequencing of hMLH1 promoter after bisulfite conversion.
  • Bisulfite treatment of genomic DNA deaminates unmethylated cytosines to produce uracils that are subsequently replicated as thymine.
  • methylated cytosines are protected from conversion to uracils, thus allowing one to determine cytosine methylation states at single-nucleotide resolution by direct sequencing.
  • HEK293T were transfected with Casilio-ME components that includes Ct-fusion PUFa-TET1 effector and a combination of 2 sgRNAs (RNA guides 3 and 7).
  • TaqMan assays showed that the activation of hMLH1 transcription was maintained during the course of these transient transfections ( FIG. 4A ), thus showing a sustained change of hMLH1 mRNA levels during the 6 days of the experiment.
  • Casilio-mediated delivery of methyltranferases silent gene expression Programmable methyltranferases were constructed by either direct fusions of catalytic domains of Dnmt3a, Dnmt3L, or a hybrid Dnmt3a-3L to N-terminus or C-terminus of dCas9 ( FIG. 5A ). N- or C-terminal fusions of these effectors to PUFa were also constructed, for use with dCas9 and sgRNA-PBS (Casilio-ME with Dnmt effectors; FIG. 5B ).
  • Casilio-ME with a Dnmt3a-PUF achieved more robust repression of SOX2 gene expression compared to direct fusions, demonstrating superior activity using Casilio-ME for directed DNA methylation ( FIGS. 6A and 6B ).
  • HEK293T cells were cultivated in Dulbecco's modified Eagle's medium (DMEM)(Sigma) with 10% fetal bovine serum (FBS)(Lonza), 4% Glutamax (Gibco), 1% Sodium Pyruvate (Gibco) and penicillin-streptomycin (Gibco) in an incubator set to 37° C. and 5% CO 2 .
  • DMEM Dulbecco's modified Eagle's medium
  • FBS fetal bovine serum
  • Gibco fetal bovine serum
  • Gibco fetal bovine serum
  • Gibco fetal bovine serum
  • 1% Sodium Pyruvate Gibco
  • penicillin-streptomycin Gibco
  • dCas9-direct fusion experiments cells were transfected with 200 ng dCas9-fusion constructs and 200 ng of modified sgRNA constructs. Transfected cells were harvested 60 hours after transfection, or otherwise indicated, and cell pellets were used for extractions of RNA, genomic DNA and protein.
  • GAPDH Hs03929097, VIC
  • hMLH1 Hs00179866, FAM
  • Genomic DNAs were extracted using all AllPrep DNA/RNA/Protein Mini Kit according the manufacturer's instructions (Qiagen). The kit allows extraction of genomic DNA as well as RNA and total protein from the same cellular pellet for parallel downstream analyses. Bisulfite conversion experiments were performed by using EpiTect Fast DNA Bisulfite Kit and extracted genomic DNAs according to manufacturer's instructions (Qiagen). Bisulfite treated DNAs served then as templates to PCR amplify two DNA fragments of 350-400 bp long that cover the whole hMLH1 promoter region using ZymoTaq PreMix according to manufacturer's instructions (Zymo Research).
  • PCR fragments were then cloned by SLIC into EcoRI-linearized PUC19 plasmid using T4 DNA polymerize (Jeong, J. Y., et al., One - step sequence - and ligation - independent cloning as a rapid and versatile cloning method for functional genomics studies . Appl Environ Microbiol, 2012. 78(15): p. 5440-3).
  • Six independent positive clones for each sample were then subjected to Singer sequencing for determination of the frequency of cytosine to thymine conversion at individual CpG of the hMLH1 promoter region.
  • dCas9-expressing cell line The day prior to transfection, Lenti -X 293T cells were seeded into 6-well plates at 1.2 million cells per well. The cells were transfected with the supercoiled packaging plasmids (pLP1 (gag/pol), pLP2 (rev), and VSV-G (envelope)) and a dCas9 lentiviral expression plasmid through Lipofectamine 3000 reagent (Invitrogen). At 6 h posttransfection, medium was exchanged for fresh. At 24 h posttransfection, 2 ml of medium containing the lentivirus were collected and centrifuged for 10 minutes at 2,000 rpm to remove cellular debris.
  • HEK293T cells seeded into a 12-well plate at 150,000 cells per well, were transduced with 500 ⁇ l of the dCas9 lentivirus in culture medium supplemented with 5 ⁇ g/ml polybrene for 12 hours, and subsequently selected with Blasticidin antibiotics on the third day post transduction.
  • HEK293T, and HEK293T/dCas9 cell lines were seeded into 12-well plates at 150,000 cells per well.
  • Cells were transfected with 200 ng of the Dnmt effector constructs and 200 ng of the sgRNA-PBS with Attractene transfection reagent (Qiagen).
  • Attractene transfection reagent Qiagen.
  • the cells were sorted for GFP (sgRNA expression constructs are marked by GFP) with fluorescence-activated cell sorting (FACS) and re-plated into 12 or 24-well plates.
  • GFP sgRNA expression constructs are marked by GFP
  • FACS fluorescence-activated cell sorting
  • sgRNA-PBS sequence sgSOX2-1-5xPBSa GCATGTGACGGGGGCTGTCAgtttAagagctaTGCTGGAAACAGCAta SEQ ID NO: 70 gcaagttTaaataaggctagtccgttatcaacttgaaaaagtggcacc gagtcggtgcCAATTGggtctccagatTGTATGTAGCCTGTATGTAGC CTGTATGTAGCCTGTATGTAGCCTGTATGTAagatCTTTTTTTTT sgSOX2-2-5xPBSa GCTGCCGGGTTTTGCATGAAgtttAagagctaTGCTGGAAACAGCAta SEQ ID NO: 71 gcaagttTaaataggctagtccgttatcaacttgaaaaagtggcacc gagtcggtgcCAATTGggtctccagatTGTATGTAGCCTGTATGTAGC CTGT
  • mC methylcytosine
  • TET1 TET1 mediated iterative mC oxidation
  • BER base-excision repair
  • NER nucleotide-excision repair
  • GADD45A protein Crowth Arrest and DNA-Damage-inducible Alpha
  • GADD45A protein Crowth Arrest and DNA-Damage-inducible Alpha
  • mC demethylation efficiency appears to be enhanced by GADD45A protein (Growth Arrest and DNA-Damage-inducible Alpha), a multi-faceted nuclear factor involved in maintenance of genomic stability, DNA repair and suppression of cell growth (Niehrs and Schafer, Trends Cell Biol 22(4): 220-227, 2012; Barreto et al., Nature 445(7128):671-675, 2007; Schuermann et al., DNA Repair ( Amst ) 44:92-102, 2016).
  • GADD45A was also found to interact with TET1 and with the BER enzyme Thymine DNA Glycosylase TDG (Kienhofer et al., Differentiation 90(1-3):59-68, 2015; Li et al., Nucleic Acids Res 43(8):3986-3997, 2015).
  • Another way to dually target the two components GADD45A and TET1(CD) to a genomic site to alter its methylation state and associated gene expression is to fuse the proteins to two independent PUFs, for example, PUFa for TET1(CD) and PUFc for GADD45A, and use a modified gRNA scaffold that comprises the corresponding PUF binding sites (PBS) ( FIG. 7A ).
  • PUFa-TET1(CD) and PUFc-GADD45A in the presence of corresponding gRNAs-PBSac showed significant stimulation of the TET1(CD) mediated hMLH1 activation, with GADD45A-PUFc showing higher activity compared to PUFc-GADD45A fusions ( FIG.
  • Methylcytosine is an epigenetic mark made by a process that covalently adds a methyl group at position 5 of cytosine ring of a CpG DNA sequence.
  • formation of 5-methylcytosine (5mC) mark is catalyzed and maintained by DNA methyltransferases.
  • Demethylation pathways which remove the methyl group to restore unmethylated DNA, involve the ten-eleven translocation (TET) family of proteins.
  • TET methylcytosine dioxygenases catalyze iterative oxidations of 5mC to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) intermediates.
  • the two latter intermediates, 5fC and 5caC seem to serve as substrates for the base-excision repair (BER) machinery which cleaves off the oxidized base and replaces it with unmethylated cytosines.
  • BER base-excision repair
  • DNA glycosylases catalyze the initial and important step that excise the damaged base and generate an apurinic/apyrimidinic site (AP site) substrate that is subsequently processed by the BER machinery to restore the base.
  • Thymine DNA glycosylase (TDG) based BER pathways have been functionally linked to TET1-mediated active demethylation as they have been shown to specifically act on 5fC and 5caC and that NEIL1 and NEIL2 glycosylase/AP-lyase activities facilitate the restoration of unmethylated cytosine by displacing TDG from AP site to create a single strand DNA break substrate for downstream processing of BER machinery.
  • NEIL2 to enhance TET1-mediated gene activation required targeting of NEIL2 effector to promoter regions.
  • Coupling TET1 oxidative activities with NEIL2 glycosylase/AP-lyase activities using a simple and programmable Casilio platform enables robust demethylation-mediated transcription activation of methylation-silenced gene, providing thus a proof-of-principal that Casilio platform allows an unprecedented feature to harnessing players of independent pathways to synergize their association activities. This finding augments the capability of our Casilio-ME platform and paves the way to developing new applications to study important biological processes and to developing new therapies for methylation associated diseases.
  • gRNA non-targeting guide RNA
  • Dual expression of PUFa-TET1(CD) and PUFc-NEIL2 in the presence of gRNAs with both PBSa/c showed significant stimulation of the TET1(CD) mediated hMLH1 activation ( FIG. 10B ).
  • NEIL2 when fused to either ends of PUFc, showed 7-fold increase in hMLH1 expression as indicated by RT-quantitative PCR ( FIG. 10B ).
  • Evidence that NEIL2-mediated stimulation requires co-targeting of the effectors came from experiments where NEIL2 and TET1(CD) PUF-fusions were expressed in the presence of gRNA scaffold that comprised PBSa but lacked PBSc ( FIG. 11A ).
  • HEK293T cells were cultivated in Dulbecco's modified Eagle's medium (DMEM) (Sigma) with 10% fetal bovine serum (FBS) (Lonza), 4% Glutamax (Gibco), 1% Sodium Pyruvate (Gibco) and penicillin-streptomycin (Gibco) in an incubator set to 37° C. and 5% CO2.
  • DMEM Dulbecco's modified Eagle's medium
  • FBS fetal bovine serum
  • Gibco fetal bovine serum
  • Gibco fetal bovine serum
  • penicillin-streptomycin Gibco
  • Cells were seeded into 12-well plates at 150,000 cells per well the day before being transfected with 100 ng of dCas9 construct, 100 ng of modified sgRNA construct and 200 ng of PUF-fusion with Attractene transfection reagent according to manufacturer's instructions (Qiagen). Transfected cells were harvested 3 days after trans
  • GAPDH Hs03929097, VIC
  • hMLH1 Hs00179866, FAM

Abstract

Provided herein are, inter alia, compositions and methods for the delivery of enhanced demethylation activity to target DNA sequences in a mammalian cell. The compositions and methods are, useful for activity modulation of a targeted gene, or to create a gene regulatory network.

Description

    CROSS-REFERENCES TO RELATED APPLICATIONS
  • This application claims the benefit of U.S. Provisional Application No. 62/393,944, filed on Sep. 13, 2016, U.S. Provisional Application No. 62/485,210, filed on Apr. 13, 2017, and U.S. Provisional Application No. 62/535,113, filed on Jul. 20, 2017, which are incorporated herein by reference in their entirety and for all purposes.
    • REFERENCE TO A “SEQUENCE LISTING,” A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED AS AN ASCII FILE
  • The Sequence Listing written in file 52867-501002WO, created Sep. 13 2017, 475 kilobytes, machine format IBM-PC, MS Windows operating system, is hereby incorporated by reference.
    • BACKGROUND
  • In the CRISPR/Cas system, Cas9 protein and sgRNA (single guide RNA) constitute a sufficient two-component DNA endonuclease whose specificity is provided by target-matching sequence on the sgRNA while endonuclease activity resides on the Cas9 protein.
  • Nuclease-defective or nuclease-deficient Cas9 protein (e.g., dCas9) with mutations on its nuclease domains retains DNA binding activity when complexed with sgRNA. dCas9 protein can tether and localize effector domains or protein tags by means of protein fusions to sites matched by sgRNA, thus constituting an RNA-guided DNA binding enzyme. dCas9 can be fused to transcriptional activation domain (e.g., VP64) or repressor domain (e.g., KRAB), and be guided by sgRNA to activate or repress target genes, respectively. dCas9 can also be fused with fluorescent proteins and achieve live-cell fluorescent labeling of chromosomal regions. However, in such systems, only one Cas9-effector fusion is possible because sgRNA:Cas9 pairing is exclusive. Also, in cases where multiple copies of protein tags or effector fusions are necessary to achieve some biological threshold or signal detection threshold, multimerization of effector or protein tags by direct fusion with dCas9 protein is technically limited, by constraints such as difficulty in delivering the large DNA encoding such fusions, or difficulty in translating or translocating such large proteins into the nucleus due to protein size.
  • Methylcytosine is an epigenetic mark generated via a process that covalently adds a methyl group at position 5 of the cytosine ring of a CpG DNA sequence. In mammalian cells, formation of 5-methylcytosine (5mC) is catalyzed and maintained by DNA methyltransferases. Demethylation pathways, which remove the methyl group to restore unmethylated DNA, involve the ten-eleven translocation (TET) family of proteins. These are TET methylcytosine dioxygenases that catalyze the initial and critical step leading to replacing 5mC with unmethylated cytosine.
  • CpG methylation is part of the multifaceted epigenetic modifications of chromatin that shape cellular differentiation, gene expression, and maintenance of cellular homeostasis. DNA methylation is a major mechanism in imprinting, tuning allelic expression of genes. Aberrant DNA methylation is implicated in various diseases including but not limited to cancer, imprinting disorders and neurological diseases (Robertson, K. D., DNA methylation and human disease. Nat Rev Genet, 2005. 6(8): p. 597-610).
  • Attempts have been made to modulate the methylation status in target cells by introducing DNA demethylase and/or DNA methyltransferase. However, such attempts result in non-specific global changes in methylation status of the target cells.
  • Meanwhile, the causal effects of CpG methylation events at a specific genomic locus have remained challenging to define essentially due to the lack of simple methods for targeted conversion of 5mC to unmethylated cytosine in living cells. Thus, there is a need in the art for tools that permit editing the methylation state at specific loci to understand the biology of cytosine methylation and to develop therapies for diseases associated with altered cytosine methylation/demethylation pathways.
  • Disclosed herein are, inter alia, solutions to these and other problems in the art.
    • BRIEF SUMMARY OF THE INVENTION
  • In one aspect, a demethylation complex is provided. The demethylation complex includes:
      • (a) a ribonucleoprotein complex including:
        • (i) a nuclease-deficient RNA-guided DNA endonuclease enzyme; and
        • (ii) a polynucleotide including:
          • (1) a DNA-targeting sequence that is complementary to a target polynucleotide sequence;
          • (2) a binding sequence for the nuclease-deficient RNA-guided DNA endonuclease enzyme; and
          • (3) one or more PUF binding site (PBS) sequences,
          • wherein the nuclease-deficient RNA-guided DNA endonuclease enzyme is bound to the polynucleotide via the binding sequence; and
      • (b) a demethylation protein conjugate including:
        • (i) a PUF domain having a C-terminus and a N-terminus;
        • (ii) a TET demethylation domain operably linked to the C-terminus of the PUF domain; and
        • (iii) a demethylation enhancer domain operably linked to the N-terminus of the PUF domain, to form a protein conjugate, and
        • wherein the demethylation protein conjugate binds to the ribonucleoprotein complex via the PUF domain binding to the one or more PBS sequences to form a demethylation complex.
  • In another aspect, a method of demethylating a target nucleic acid sequence in a mammalian cell is provided. The method includes:
      • (a) providing a mammalian cell containing a target nucleic acid requiring demethylation;
      • (b) delivering to the mammalian cell a first polynucleotide encoding a nuclease-deficient RNA-guided DNA endonuclease enzyme;
      • (c) delivering to the mammalian cell a second polynucleotide including:
        • (i) a DNA-targeting sequence that is complementary to a target polynucleotide sequence;
        • (ii) a binding sequence for the nuclease-deficient RNA-guide DNA endonuclease enzyme, and
        • (iii) one or more PUF binding site (PBS) sequences,
        • wherein the nuclease-deficient RNA-guided DNA endonuclease enzyme is bound to the second polynucleotide via the binding sequence;
      • (d) delivering to the mammalian cell a third polynucleotide encoding a demethylation protein conjugate including:
        • (i) a PUF domain having a C-terminus and a N-terminus;
        • (ii) a TET demethylation domain operably linked to the C-terminus of the PUF domain; and
        • (iii) a demethylation enhancer domain operably linked to the N-terminus of the PUF domain, to form a protein conjugate, and
        • whereby the delivered demethylation protein conjugate demethylates the target nucleic acid sequence in the cell.
  • In one aspect, a demethylation complex is provided. The demethylation complex includes:
      • (a) a ribonucleoprotein complex including:
        • (i) a nuclease-deficient RNA-guided DNA endonuclease enzyme; and
        • (ii) a polynucleotide including:
          • (1) a DNA-targeting sequence that is complementary to a target polynucleotide sequence;
          • (2) a binding sequence for the nuclease-deficient RNA-guided DNA endonuclease enzyme; and
          • (3) one or more PUF binding site (PBS) sequences,
          • wherein the nuclease-deficient RNA-guided DNA endonuclease enzyme is bound to the polynucleotide via the binding sequence; and
      • (b) a demethylation protein conjugate including:
        • (i) a PUF domain having a C-terminus;
        • (ii) a demethylation enhancer domain, having a N-terminus and a C-terminus,
        • wherein the N-terminus of the demethylation enhancer domain is operably linked to the C-terminus of the PUF domain; and
        • (iii) a TET demethylation domain operably linked to the C-terminus of the demethylation enhancer domain; and
        • wherein the demethylation protein conjugate binds to the ribonucleoprotein complex via the PUF domain binding to the one or more PBS sequences to form a demethylation complex.
  • In another aspect, a method of demethylating a target nucleic acid sequence in a mammalian cell is provided. The method includes:
      • (a) providing a mammalian cell containing a target nucleic acid requiring demethylation;
      • (b) delivering to the mammalian cell a first polynucleotide encoding a nuclease-deficient RNA-guided DNA endonuclease enzyme;
      • (c) delivering to the mammalian cell a second polynucleotide including:
        • (i) a DNA-targeting sequence that is complementary to a target polynucleotide sequence;
        • (ii) a binding sequence for the nuclease-deficient RNA-guide DNA endonuclease enzyme; and
        • (iii) one or more PUF binding site (PBS) sequences,
        • wherein the nuclease-deficient RNA-guided DNA endonuclease enzyme is bound to the second polynucleotide via the binding sequence;
      • (d) delivering to the mammalian cell a third polynucleotide encoding a demethylation protein conjugate comprising:
        • (i) a PUF domain having a C-terminus;
        • (ii) a demethylation enhancer domain, having a N-terminus and a C-terminus,
        • wherein the N-terminus of the demethylation enhancer domain is operably linked to the C-terminus of the PUF domain; and
        • (iii) a TET demethylation domain operably linked to the C-terminus of the demethylation enhancer domain, whereby the delivered demethylation protein conjugate demethylates the target nucleic acid sequence in the cell.
  • In one aspect, a demethylation complex is provided. The demethylation complex includes:
      • (a) a ribonucleoprotein complex including:
        • (i) a nuclease-deficient RNA-guided DNA endonuclease enzyme; and
        • (ii) a polynucleotide including:
          • (1) a DNA-targeting sequence that is complementary to a target polynucleotide sequence;
          • (2) a binding sequence for the nuclease-deficient RNA-guided DNA endonuclease enzyme;
          • (3) a first PUF binding site (PBS) sequence; and
          • (4) a second PUF binding site (PBS) sequence, wherein the nuclease-deficient RNA-guided DNA endonuclease enzyme is bound to the polynucleotide via the binding sequence;
      • (b) a demethylation protein conjugate including:
        • (i) a first PUF domain having a C-terminus, and
        • (ii) a TET demethylation domain operably linked to the C-terminus of the first PUF domain,
        • wherein the demethylation protein conjugate binds to the ribonucleoprotein complex via the first PUF domain binding to the first PBS sequence; and
      • (c) a demethylation enhancer conjugate including:
        • (i) a second PUF domain; and
        • (ii) a demethylation enhancer domain operably linked to the second PUF domain,
        • wherein the demethylation enhancer conjugate binds to the ribonucleoprotein complex via the second PUF domain binding to the second PBS sequence to form a demethylation complex.
  • In another aspect, a method of demethylating a target nucleic acid sequence in a mammalian cell is provided. The method includes:
      • (a) providing a mammalian cell containing a target nucleic acid requiring demethylation;
      • (b) delivering to the mammalian cell a first polynucleotide encoding a nuclease-deficient RNA-guided DNA endonuclease enzyme;
      • (c) delivering to the mammalian cell a second polynucleotide including:
        • (i) a DNA-targeting sequence that is complementary to a target polynucleotide sequence;
        • (ii) a binding sequence for the nuclease-deficient RNA-guide DNA endonuclease enzyme;
        • (iii) a first PUF binding site (PBS) sequence, and
        • (iv) a second PUF binding site (PBS) sequence,
        • wherein the nuclease-deficient RNA-guided DNA endonuclease enzyme is bound to the second polynucleotide via the binding sequence;
      • (d) delivering to the mammalian cell a third polynucleotide encoding a demethylation protein conjugate including:
        • (i) a first PUF domain; and
        • (ii) a demethylation domain, the demethylation domain operably linked to the C-terminus of the first PUF domain, and
      • (e) delivering to the mammalian cell a fourth polynucleotide encoding a demethylation enhancer conjugate including:
        • (i) a second PUF domain; and
        • (ii) a demethylation enhancer domain operably linked to the second PUF domain,
        • whereby the delivered demethylation protein conjugate demethylates the target nucleic acid sequence in the cell.
  • In another aspect, a kit is provided. The kit includes:
      • (i) a ribonucleoprotein complex as provided herein including embodiments thereof or a nucleic acid encoding the same; and
      • (ii) a demethylation protein conjugate as provided herein including embodiments thereof or a nucleic acid encoding the same.
  • In another aspect, a kit is provided. The kit includes:
      • (i) a ribonucleoprotein complex as provided herein including embodiments thereof or a nucleic acid encoding the same;
      • (ii) a demethylation protein conjugate as provided herein including embodiments thereof or a nucleic acid encoding the same; and
      • (iii) a demethylation enhancer conjugate as provided herein including embodiments thereof or a nucleic acid encoding the same.
  • In another aspect, a cell including a demethylation complex as provided herein including embodiments thereof is provided.
  • It should be understood that any embodiments described herein, including those only described in the Example section or only under one aspect of the invention, can be combined with any one or more other embodiments, unless specifically disclaimed or otherwise improper.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIGS. 1A-1D. The figures show that insertion of PUF binding site (PBS) sequences to sgRNA 3′-end did not substantially impact dCas9/sgRNA function, and that independent recruitment and multimerization of activators can be achieved using the subject 3-component CRISPR/Cas complex/system. FIG. 1A is a schematic drawing showing the subject 3-component CRISPR/Cas complex/system (upper right), which improves the conventional two-hybrid dCas9 fusion design (upper left) by splitting it into a three-hybrid system, in which sgRNA-PBS bridges the DNA binding activity of dCas9/sgRNA with the effector function provided by a PUF fusion. The middle panels represent the structure of a representative PUF (i.e., Pumilio/FBF) domain, showing the 8 repeats in the C to N direction and the corresponding interaction with the 8-mer target RNA in the 5′ to 3′ direction. PUF RNA recognition code table shows exemplary di-residues and the corresponding RNA base recognized. In the lower panel, a table of notation adopted for simplicity to describe the 4 PUF isotypes and the corresponding PUF binding sites (PBS) and their sequences. FIG. 1B, upper panel, is a schematic for the experiment to test the ability of dCas9-VP64 to bind and activate a tdTomato transgene after inserting varying number of PBS at the 3′ end of the sgRNA, e.g., experimental set up for testing the effect of sgRNA-PBS (with 0, 5, 15, 25, or 47 PBS) on the ability of the dCas9::VP64 construct to activate a TetO::tdTomato transgene. The lower panel is column plot showing the mean fold changes (±S.E.M.) in tdTomato fluorescence (relative to the dCas9-VP64/sgCtl-0×PBSa control), as measured by fluorescence activated cell sorting (FACS), of cells transfected with the different constructs indicated in the legend below the plot. The legend describes the sgRNA used in three parameters: sgRNA match refers to the DNA target recognized by the sgRNA; #PBS and PBS Type indicate the number and the types of PBS, respectively, appended to the end of the sgRNA. FIG. 1C, upper panel, is a schematic describing the experiment to test activation of a TetO::tdTomato transgene by the subject activator with different numbers of appended PBS. The lower panel is a column plot showing the fold changes (±S.E.M.) of tdTomato fluorescence (relative to control dCas9/PUFb-VP64/sgCtl-0×PBSb) of cells transfected with the different constructs indicated in the legend blow the plot. The legend describes the PUF isotype (PUF-VP64) used and the sgRNA-PBS used in terms of the number and type of PBS as well as the DNA target recognized by sgRNA indicated by shaded boxes. FIG. 1D, upper panel, is a schematic illustrating the experiment to test the independency of the subject activator isotypes in activating a TetO::tdTomato transgene. The lower panel is a column plot showing the mean fold changes (±S.E.M.) of tdTomato fluorescence (relative to the respective controls dCas9/PUFx-VP64/sgCtl-5×PBSx for PUF/PBS isotype x) of cells transfected with the different constructs indicated in the legend below the plot. The legends indicate the PUF isotype used (PUF-VP64), the PBS isotype (5×PBS; “-” indicates sgRNA without PBS) and DNA target indicated by shaded boxes (sgRNA Match). All plots show results of three replicate measurements.
  • FIGS. 2A-2C. FIG. 2A and FIG. 2B relate to the assembly of the subject 3-component CRISPR/Cas complex/system comprising VP64 and P65-HSF1. FIG. 2A is a schematic of the experiment testing the assembly of PUF(3-2)::VP64 and PUF(6-2/7-2)::P65-HSF1 via recruitment by sgRNA containing both PBS32 and PBS6272. The activity was measured by the tdTomato fluorescent reporter activity. FIG. 2B is a column chart showing the relative mean tdTomato fluorescence resulting from transfecting the activator protein(s) with non-targeting (sgControl) and Tet-targeting (sgTetO) sgRNAs with 4×[PBS32-PBS6272] heterodimer sites. FIG. 2C shows comparison of the subject 3-component system activator using VP64 (PUFa::VP64) versus p65HSF1 (PUFa::p65HSF1) as the activation domain in conjunction with Control sgRNA with 5×PBSa or TetO-targeting sgRNA with 0, 1, 5, 15, or 25 copies of PBSa. Columns show mean fold change (with S.E.M.; n=3) of tdTomato fluorescence relative to experiments using control sgRNA (sgCtl). The legend indicates the number of PBSa (#PBSa) on the sgRNA-PBS as well as the DNA match indicated by the shaded boxes.
  • FIGS. 3A-3C. The figures show Casilio-ME outperforms dCas9-direct tethering system in delivering TET1(CD) to genomic loci and mediating gene activation. FIG. 3A is a schematic representation of the hMLH1 promoter with regions of CpG hypermethylation shown by lollipops. Numbering of nucleotide is according to previous study reporting a strong association of hypermethylation in region C with hMLH1 silencing (Deng, G., et al., Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res, 1999. 59(9): p. 2029-33). sgRNAs designed around the hypermethylated region C are shown by numbers over short lines, and sgRNA-1 and 2 target sense and anti-sense strands respectively. FIG. 3B shows relative change in hMLH1 mRNA levels in cells transfected with Casilio components PUFa-TET1(CD), TET1(CD)-PUFa or PUFa-p65HSF1 and the combination of sgRNAs indicated by shaded boxes under the graph. Drawings depict the Casilio system showing the effector modules used in each set of experiments and data were plotted that reflect the respective effector in application. FIG. 3C shows relative change in hMLH1 mRNA levels in cells transfected with dCas9-tethered effectors dCas9-TET1(CD)C-terminal fusion, TET1(CD)-dCas9 N-terminal fusion or dCas9-p65HSF1 and the combination of sgRNAs indicated by shaded boxes under the graph. Drawings depict the dCas9 fusion used for each set of experiments and data were plotted to reflect the respective effector used. The letters “N” (i.e., N-terminus) and “C” (i.e., C-terminus) of the PUMa (aka/PUFa), the TET1(CD) and the p65HSF1 domain in FIGS. 3B and 3C refer to the N-terminus and the C-terminus of the corresponding protein domain.
  • FIGS. 4A-4C. The figures show that Casilio-ME mediates robust demethylation of methylcytosine via targeting TET1 activity to hMLH1 promoter region. FIG. 4A is a time course of relative change in hMLH1 mRNA levels in cells transfected with Casilio components PUFa-TET1(CD) and the combination of sgRNAs indicated by shaded boxes under the graph. Drawing over the plot depicts the Casilio-ME system showing the carboxyterminal-TET1(CD) fusion module used and relative changes in hMLH1 mRNA levels were plotted against post-transfection time in which cells were harvested for analyses. Error bars indicate s.e.m derived from triplicate experiments. FIG. 4B is Western blot analysis of protein extracted from indicated cell samples using anti-hMLH1 or anti-3 Actin monoclonal antibodies as shown. Proteins extracted form untransfected cells HEK293T (untreated) or treated with 2.5 μM 5′-Azacytidine (AzaC), HEK293 cells (293), and transfected HEK293T cells in the presence of a non-targeting control guide RNA (NTC) were analyzed in parallel with extracts from time course samples that were transfected with Casilio-Me components targeting the hMLH1 promoter region. FIG. 4C shows frequency of cytosine to thymine bisulfite-mediated conversion of individual CpGs of the hMLH1 promoter region. Arrows indicate CpG that overlaps with the binding site of the targeting sgRNA. Coordinates indicate the position of the CpG relative to hMLH1 transcription start site (Deng, G., et al., Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res, 1999. 59(9): p. 2029-33). The distal part of hMLH1 promoter of HEK293 cells (293) was not included in this analysis. The letter “N” of the PUMa (aka PUFa) and the TET1(CD) domain in FIG. 4A refers to the N-terminus of the corresponding protein domain.
  • FIGS. 5A-5C. The figures show that different configurations of Casilio-ME Dnmt effectors were tested. FIG. 5A shows a direct fusions of C-terminal regions of (i) Dnmt3a, (ii) Dnmt3L, and (iii) Dnmt3a-3L (hybrid) to N-terminus of dCas9; (iv) Dnmt3a, (v) Dnmt3L, and (vi) Dnmt3a-3L hybrid to C-terminus of dCas9. FIG. 5B shows PUF effector fusion of C-terminal regions of (i) Dnmt3a, (ii) Dnmt3L, and (iii) Dnmt3a-3L to N-terminus of PUF domain; (iv) Dnmt3a, (v) Dnmt3L and (vi) Dnmt3a-3L to C-terminus of PUF domain. FIG. 5C shows Casilio can potentially recruit different Dnmt effectors fused to different PUF domains via a guide containing the corresponding PBS.
  • FIGS. 6A-6B. The figures show SOX2 gene expression changes induced by targeting of Casilio-ME Dnmt modules to SOX2 promoter. FIG. 6A shows relative SOX2 expression level in cells transfected with different dCas9-Dnmt enzymes and control guides or guides targeting SOX2 promoter. FIG. 6B shows relative SOX2 expression level in cells transfected with different dCas9-Dnmt enzymes and control guides or guides targeting SOX2 promoter.
  • FIGS. 7A-7E show that GADD45A boosts Casilio-ME capability to impart TET1-mediated activation to methylation-silenced gene. FIG. 7A depicts the Casilio and Casilio-ME platforms to show the various combinations of effector modules used in each set of experiment. Engineered protein fusions are shown with amino-termini and carboxyl-termini located at the left and right sides of each drawing respectively. The scaffold of the gRNA was altered to include 5 copies of PUFa or PUFa and PUFc binding sites. Shapes are arbitrary and drawn not to scale with DADD45A (G-45A), TET1(CD) (Ten eleven methylcytosine dioxygenase catalytic domain (1418 to 2136)), and p65HSF1 transcription activator are shown. FIG. 7B is a schematic representation of the hMLH1 promoter with regions of CpG hypermethylation shown by lollipops. Numbering of nucleotide is based on a strong association of hypermethylation in region C with hMLH1 silencing (Deng, Cancer Res. 59(9):2029-2033, 1999). sgRNAs designed around the hypermethylated region B and C are shown by numbers over short lines. FIG. 7C shows relative change in hMLH1 mRNA levels in HEK293T cells transfected with Casilio-ME components as indicated. Shaded boxes in the matrix under the graph indicate effectors and sgRNAs used in each experiment. Error bars indicate s.e.m derived from triplicate experiments. FIG. 7D shows results of Western blot analysis of whole cell extracts from HEK293T cells transfected with the indicated Casilio-ME effector modules. Lane 1-untransfected cells; Lane 2-PUFa-GADD45A-TET1(CD); Lane 3-PUFa-GADDA45A-TET1(CD) with a slight variation in the Glycine-Serine linker; Lane 4-GADD45A-PUFa-TET1(CD); and Lane 5-PUFa-TET1(CD). 50 μg of protein were separated on 10% SDS-PAGE and immunoblotted with the indicated antibodies. Size marker in kDa is shown. FIG. 7E shows relative change in hMLH1 mRNA levels in HEK293T cells transfected with Casilio-ME components as indicated. Shaded boxes in the matrix below the graph indicate effectors used in each experiment in the presence of non-targeting gRNA, or gRNAs comprising PUFa-binding site (PBSa) or PUFa and PUFc binding sites (PBSac). Column graph depicted to indicate experiments with PBSa-gRNAs or PBSac-gRNAs. Error bars indicate s.e.m derived from triplicate experiments.
  • FIG. 8A-8D: NEIL2, but not NEIL1, NEIL3 or TDG, enhances Casilio-ME efficiency to deliver TET1-mediated activation to methylation-silenced gene. FIG. 8A Drawings depict the Casilio-ME platform to show the PUFa-TET1(CD) effector and NEIL-based effector modules used in each experiment. For simplicity, NEIL1, NEIL2 and NEIL3 were depicted as NEIL. Engineered protein fusions are shown with amino and carboxyl termini located at the left and right sides of each drawing respectively. The shown gRNA scaffold was altered to include 5 copies of PUFa-binding sites (5×PBSa). Shapes are arbitrary drawn not to scale with NEIL1, NEIL2, and NEIL3 (NEIL), TET1(CD) (Ten eleven methylcytosine dioxygenase catalytic domain (1418 to 2136)), and PUFa are shown. FIG. 8B Relative change in hMLH1 mRNA levels in HEK293T cells transfected with Casilio-ME components as indicated. Column shadings reflect different group of indicated PUFa fusions. Error bars indicate S.E.M derived from triplicate experiments. FIG. 8C Drawings depict the Casilio-ME platform to show the PUFa-TET1(CD) and TDG-based PUFa fusions effectors used in each experiment. Protein fusions are shown with amino and carboxyl termini located at the left and right sides of each drawing respectively. The shown gRNA scaffold was altered to include 5 copies of PUFa-binding sites (5×PBSa). Shapes are arbitrary drawn not to scale with TDG, TET1(CD) (Ten eleven methylcytosine dioxygenase catalytic domain (1418 to 2136)), and PUFa are shown. FIG. 8D Relative change in hMLH1 mRNA levels in HEK293T cells transfected with Casilio-ME components as indicated. Column shadings reflect indicated PUFa fusions. Error bars indicate S.E.M. derived from triplicate experiments.
  • FIG. 9A-9B NEIL2 two-in-one effector enhances Casilio-ME efficiency to deliver TET1-mediated activation to methylation-silenced MLH1 gene. FIG. 9A Drawings depict the Casilio-ME platform to show the PUFa-TET1(CD) effector and NEIL2-based effector modules used in each experiment. Protein fusions are shown with amino and carboxyl termini located at the left and right sides of each drawing respectively. The shown gRNA scaffold was altered to include 5 copies of PUFa-binding sites (5×PBSa). Shapes are arbitrary drawn not to scale with NEIL2, TET1(CD), and PUFa are shown. FIG. 9B Relative change in hMLH1 mRNA levels in HEK293T cells transfected with indicated Casilio-ME components in the presence of MLH1 gRNAs (grey columns) or non-targeting gRNA (black columns). Error bars indicate s.e.m derived from triplicate experiments.
  • FIG. 10A-10B Co-targeting of NEIL2 and TET1 effector modules robustly enhances TET1 mediated MLH1 activation. FIG. 10A Drawings depict the Casilio-ME platform to show the PUFa-TET1(CD) effector and NEIL2 effector modules used in each experiment. Engineered protein fusions are shown with amino and carboxyl termini located at the left and right sides of each drawing respectively. The shown gRNA scaffold was altered to include 5 copies of PUFa and PUFc-binding sites (5×PBSa and 5×PBSc). Shapes are arbitrary drawn not to scale with NEIL2, TET1(CD), PUFa, and PUFc are shown. FIG. 10B Relative change in hMLH1 mRNA levels in HEK293T cells transfected with PUFa-TET1(CD) effector in the absence (while column) and presence of NEIL2 effector modules. PUFc-NEIL2 (black column) and NEIL2-PUFc (grey column) are shown. Error bars indicate S.E.M. derived from triplicate experiments.
  • FIG. 11A-11B TET1 mediated MLH1 activation without NEIL2 recruitment to target site. FIG. 11A Drawings depict the Casilio-ME platform to show the PUFa-TET1(CD) effector and NEIL2 effector modules used in each experiment. Protein fusions are shown with amino and carboxyl termini located at the left and right sides of each drawing respectively. The shown gRNA scaffold was altered to include 5 copies of PUFa-binding sites (5×PBSa) with no PUFc-binding site. Shapes are arbitrary drawn not to scale with NEIL2, TET1(CD), PUFa, and PUFc are shown. FIG. 11B Relative change in hMLH1 mRNA levels in HEK293T cells transfected with PUFa-TET1(CD) effector and gRNAs containing 5 copies of BPSa in the absence (white column) and presence of NEIL2 effector modules. PUFc-NEIL2 (black column) and NEIL2-PUFc (grey column) are shown. Error bars indicate S.E.M. derived from triplicate experiments.
    •  DETAILED DESCRIPTION Demethylation Enhancer Complexes
  • The compositions and methods provided herein including embodiments thereof provide a methylation-editing (ME) platform allowing for targeted delivery of enhanced demethylation activity by delivering a TET demethylation domain (e.g., TET catalytic domain) or functional fragment thereof together with a demethylation enhancer domain (e.g., a GADD45A domain, a NEIL2 domain), to specific genomic loci, such as CpG islands, and thereby inducing enhanced demethylation DNA of said loci relative to the absence of said enhancer domain. The demethylation domains and demethylation enhancer domains provided herein may be delivered to a specific site in the genome of a mammalian cell by using a complex which includes a polynucleotide (e.g., guide RNA) bound to a nuclease-deficient DNA endonuclease (e.g., dCas9) and protein conjugates including a PUF domain, a demethylation domain (e.g., TET1 catalytic domain) and a demethylation enhancer domain (e.g., a GADD45A domain or a NEIL2 domain).
  • In certain aspects, the demethylation protein conjugate includes: (i) a PUF domain having a C-terminus and a N-terminus; (ii) a TET demethylation domain operably linked to the C-terminus of the PUF domain; and (iii) a demethylation enhancer domain operably linked to the N-terminus of the PUF domain, to form a protein conjugate, and the demethylation protein conjugate binds to the ribonucleoprotein complex via the PUF domain binding to the one or more PBS sequences to form a demethylation complex.
  • In certain other aspects, the demethylation protein conjugate includes (i) a PUF domain having a C-terminus; (ii) a demethylation enhancer domain, having a N-terminus and a C-terminus, wherein the N-terminus of the demethylation enhancer domain is operably linked to the C-terminus of the PUF domain; and (iii) a TET demethylation domain operably linked to the C-terminus of said demethylation enhancer domain; and the demethylation protein conjugate binds to the ribonucleoprotein complex via the PUF domain binding to the one or more PBS sequences to form a demethylation complex.
  • In other certain aspects, a demethylation protein conjugate includes (i) a first PUF domain having a C-terminus, and (ii) a TET demethylation domain operably linked to the C-terminus of the first PUF domain, wherein the demethylation protein conjugate binds to the ribonucleoprotein complex via the first PUF domain binding to the first PBS sequence; and a demethylation enhancer conjugate including (i) a second PUF domain; and (ii) a demethylation enhancer domain operably linked to the second PUF domain, wherein the demethylation enhancer conjugate binds to the ribonucleoprotein complex via the second PUF domain binding to the second PBS sequence to form a demethylation complex.
  • The demethylation enhancer domain, may be linked to the same PUF domain as the demethylation domain (demethylation protein conjugate). In certain embodiments, the demethylation enhancer domain may be connected to the guide RNA through a separate PUF domain (demethylation enhancer conjugate).
  • The demethylation complexes provided herein including embodiments thereof are based on a three-component hybrid system that includes CRISPR/Cas9 and Pumilio proteins. For purpose of this invention, the three-component hybrid system that includes CRISPR/Cas9 and Pumilio proteins may also be referred to interchangeably as the Casilio system, and the methylation-editing (ME) platform based on the Casilio system is sometimes referred to as Casilio-ME. In essence, the demethylation domain (e.g., TET demethylase) is fused to Pumilio proteins or functional fragments thereof (PUF domains) that bind PBS in the Casilio system, thus bringing such domains to the vicinity of any target locus of interest that is specifically recognized by the Casilio system. Any aspects or embodiments of the three-component CRISPR/Cas complex system disclosed in international application PCT/US2016/021491 and published as WO2016148994 A8, which is hereby incorporated by reference and for all purposes, may be used for the invention provided herein.
  • The compositions and methods provided herein including embodiments thereof are advantageous over the past attempts to modulate methylation status of a target gene by introducing a DNA demethylase into a target cell, in that the present invention allows for increased demethylation of the targeted gene locus by delivering a demethylation enzyme together with an enhancer of said demethylation enzyme. Such system provides a superior demethylation activity to a target gene to alter the methylation status.
  • Applicants were the first to show that the demethylation efficiency of complexes including a TET demethylation domain can be significantly increased by including demethylation enhancers in the complex. Surprisingly, the present inventors discovered that the increase in demethylation efficiency upon inclusion of an enhancer domain depends on: (i) the type of enhancer protein present; (ii) the orientation in which the enhancer domain is linked to the PUF domain of the demethylation protein conjugate and (iii) the manner in which the demethylation enhancer domain is linked to the PUF domain and connected to the demethylation domain (e.g., from N- to C-terminus the conjugate may include a PUF domain linked to a demethylation enhancer domain linked to a demethylation domain, or a PUF domain linked to a demethylation domain linked to a demethylation enhancer domain). Applicants have found that complexes where the demethylation domain (e.g., TET1 catalytic domain) is linked to the C-terminus of the PUF domain are significantly more effective relative to complexes with the demethylation domain (e.g., TET1 catalytic domain) linked to the N-terminus of the PUF domain. Applicants further showed that C-terminal linked TET activity (demethylation activity of TET1, TET2, or TET3) can be increased by including specific demethylation enhancers (e.g., GADD45A, NEIL2) in the demethylation complex. Moreover, Applicants surprisingly showed that only specific demethylation enhancers are efficiently enhancing demethylation of the TET domain. In fact, if the enhancer is a NEIL glycosylase (e.g., NEIL1, NEIL2, or NEIL3), demethylation is only enhanced in the presence of NEIL2, but not NEIL1 or NEIL3, indicating specificity.
  • A demethylation domain as referred to herein is a protein domain capable of demethylating a target nucleic acid. In certain embodiments, the demethylation domain includes the catalytic domain of a demethylation enzyme (e.g., the catalytic domain of TET1). In certain embodiments, the demethylation domain is the catalytic domain of a demethylation enzyme.
  • A “demethylation enhancer domain”, “demethylation enhancer protein” or “demethylation enhancer enzyme” as provided herein refers to a protein, protein domain or protein moiety capable of positively affecting (e.g. increasing) the activity or function of a demethylation enzyme or demethylation domain, relative to the activity or function of the demethylation enzyme or demethylation domain in the absence of the activator (e.g. demethylation enhancer domain described herein). Thus, in certain embodiments, the demethylation enhancer domain may, at least in part, partially or totally increase stimulation, increase or enable activation, or activate the demethylation enzyme. The amount of increase in activity (activation) may be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more in comparison to a control in the absence of the demethylation enhancer domain. In certain embodiments, the activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more than the activity in the absence of the demethylation enhancer domain. Thus, in certain embodiments, the demethylation enhancer domain increases demethylation of the TET demethylation domain by 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, 14-, 15-, 16-, 17-, 18-, 19-, or 20-fold. In certain embodiments, the demethylation enhancer domain increases demethylation of the TET demethylation domain at least by 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-, 13-, 14-, 15-, 16-, 17-, 18-, 19-, or 20-fold.
  • Provided herein are demethylation protein conjugates and demethylation enhancer conjugates useful for demethylating target loci in a cell. The demethylation protein conjugates include a PUF domain described herein, a TET demethylation domain (e.g., a TET1 domain, a TET1 catalytic domain) linked to the C-terminus of the PUF domain and a demethylation enhancer domain (e.g., a NEIL2 domain or a GADD45A domain). The demethylation enhancer domain may be linked to the N-terminus or the C-terminus of the PUF domain. Where the demethylation enhancer domain is linked to the N-terminus of the PUF domain the TET demethylation domain and the demethylation enhancer domain are not directly linked, but connected through the PUF domain. Where the demethylation enhancer domain is linked to the C-terminus of the PUF domain it connects the PUF domain to the TET demethylation domain. In other words, the C-terminus of the PUF domain is linked to the demethylation enhancer domain and the C-terminus of the demethylation enhancer domain is linked to the TET demethylation domain. Alternatively, the complexes provided herein may include a demethylation protein conjugate including a first PUF domain and a demethylation domain (e.g., a TET1 domain), wherein the TET demethylation domain is linked to the C-terminus of the PUF domain, and a demethylation enhancer conjugate including a second PUF domain and a demethylation enhancer domain (e.g., a NEIL2 domain or a GADD45A domain).
  • In certain embodiments, the demethylation enhancer domain is operably linked to the N-terminus of the PUF domain. In certain embodiments, the demethylation enhancer domain is operably linked to the C-terminus of the PUF domain. In certain embodiments, the demethylation enhancer domain is operably linked to the N-terminus of the second PUF domain. In certain embodiments, the demethylation enhancer domain is operably linked to the C-terminus of the second PUF domain.
  • In certain embodiments, the demethylation enhancer domain is a Growth Arrest and DNA-Damage-inducible Alpha (GADD45A) domain. In certain embodiments, the GADD45 domain has the amino acid sequence of SEQ ID NO:85. In certain embodiments, the demethylation enhancer domain is a NEIL2 domain. In certain embodiments, the NEIL2 domain has the amino acid sequence of SEQ ID NO:86. In certain embodiments, the demethylation enhancer domain is not a NEIL1 domain. In certain embodiments, the demethylation enhancer domain is not a NEIL3 domain.
  • The complexes provided herein including embodiments thereof include demethylation conjugates (e.g., demethylation protein conjugate, demethylation enhancer conjugate) including (i) a PUF domain operably linked to a demethylation domain and a demethylation enhancer domain (demethylation protein conjugate), (ii) a first PUF domain operably linked to a demethylation domain (demethylation protein conjugate) or (iii) a second PUF domain operably linked to a demethylation enhancer domain, respectively (demethylation enhancer conjugate). Thus, a demethylation protein conjugate as provided herein includes (i) a PUF domain linked to demethylation domain and a demethylation enhancer domain or (ii) a first PUF domain linked to a demethylation domain. A demethylation enhancer domain includes a second PUF domain linked to a demethylation enhancer domain.
  • Where the protein conjugate is a demethylation conjugate the demethylation domain is operably linked to the C-terminus of the PUF domain to form a protein conjugate. The demethylation enhancer domain may be linked to the C-terminus of the PUF domain, to the N-terminus of the PUF domain, or the demethylation enhancer domain may bind the polynucleotide (e.g., gRNA) linked to a separate PUF domain (i.e., a PUF domain not linked to the demethylation domain). Where the demethylation enhancer domain and the demethylation domain bind the polynucleotide separately, the demethylation domain forms part of a demethylation protein conjugate and is linked to a first PUF domain, and the demethylation enhancer domain forms part of a demethylation enhancer protein conjugate and is linked to a second PUF domain. The demethylation protein conjugate binds the polynucleotide through binding of the first PUF domain to the first PBS sequence and the demethylation enhancer protein conjugate binds the polynucleotide through binding of the second PUF domain to the second PBS sequence.
  • Thus, in one aspect, a demethylation complex is provided. The demethylation complex includes:
      • (a) a ribonucleoprotein complex including:
        • (i) a nuclease-deficient RNA-guided DNA endonuclease enzyme; and
        • (ii) a polynucleotide including:
          • (1) a DNA-targeting sequence that is complementary to a target polynucleotide sequence;
          • (2) a binding sequence for the nuclease-deficient RNA-guided DNA endonuclease enzyme; and
          • (3) one or more PUF binding site (PBS) sequences,
          • wherein the nuclease-deficient RNA-guided DNA endonuclease enzyme is bound to the polynucleotide via the binding sequence; and
      • (b) a demethylation protein conjugate including:
        • (i) a PUF domain having a C-terminus and a N-terminus;
        • (ii) a TET demethylation domain operably linked to the C-terminus of the PUF domain; and
        • (iii) a demethylation enhancer domain operably linked to the N-terminus of the PUF domain, to form a protein conjugate, and
          wherein the demethylation protein conjugate binds to the ribonucleoprotein complex via the PUF domain binding to the one or more PBS sequences to form a demethylation complex.
  • In one aspect, a demethylation complex is provided. The demethylation complex includes:
      • (a) a ribonucleoprotein complex including:
        • (i) a nuclease-deficient RNA-guided DNA endonuclease enzyme; and
        • (ii) a polynucleotide including:
          • (1) a DNA-targeting sequence that is complementary to a target polynucleotide sequence;
          • (2) a binding sequence for the nuclease-deficient RNA-guided DNA endonuclease enzyme; and
          • (3) one or more PUF binding site (PBS) sequences,
          • wherein the nuclease-deficient RNA-guided DNA endonuclease enzyme is bound to the polynucleotide via the binding sequence; and
      • (b) a demethylation protein conjugate including:
        • (i) a PUF domain having a C-terminus;
        • (ii) a demethylation enhancer domain, having a N-terminus and a C-terminus,
        • wherein the N-terminus of the demethylation enhancer domain is operably linked to the C-terminus of the PUF domain; and
        • (iii) a TET demethylation domain operably linked to the C-terminus of the demethylation enhancer domain; and
        • wherein the demethylation protein conjugate binds to the ribonucleoprotein complex via the PUF domain binding to the one or more PBS sequences to form a demethylation complex.
  • In one aspect, a demethylation complex is provided. The demethylation complex includes:
      • (a) a ribonucleoprotein complex including:
        • (i) a nuclease-deficient RNA-guided DNA endonuclease enzyme; and
        • (ii) a polynucleotide including:
          • (1) a DNA-targeting sequence that is complementary to a target polynucleotide sequence;
          • (2) a binding sequence for the nuclease-deficient RNA-guided DNA endonuclease enzyme;
          • (3) a first PUF binding site (PBS) sequence; and
          • (4) a second PUF binding site (PBS) sequence,
          • wherein the nuclease-deficient RNA-guided DNA endonuclease enzyme is bound to the polynucleotide via the binding sequence;
      • (b) a demethylation protein conjugate including:
        • (i) a first PUF domain having a C-terminus, and
        • (ii) a TET demethylation domain operably linked to the C-terminus of the first PUF domain,
        • wherein the demethylation protein conjugate binds to the ribonucleoprotein complex via the first PUF domain binding to the first PBS sequence; and
      • (c) a demethylation enhancer conjugate including:
        • (i) a second PUF domain; and
        • (ii) a demethylation enhancer domain operably linked to the second PUF domain,
          wherein the demethylation enhancer conjugate binds to the ribonucleoprotein complex via the second PUF domain binding to the second PBS sequence to form a demethylation complex.
  • In certain embodiments, the TET demethylation domain is a TET1 domain (i.e., TET1 catalytic domain), a TET2 domain (i.e., TET2 catalytic domain) or a TET3 domain (i.e., TET3 catalytic domain). In certain embodiments, the TET demethylation domain is a TET1 domain. In certain embodiments, the TET demethylation domain is a TET2 domain. In certain embodiments, the TET demethylation domain is a TET3 domain. In certain embodiments, the TET demethylation domain is a TET1 catalytic domain. In certain embodiments, the TET demethylation domain is a TET2 catalytic domain. In certain embodiments, the TET demethylation domain is a TET3 catalytic domain. In certain embodiments, the TET1 domain has the sequence of SEQ ID NO:51. In certain embodiments, the demethylation enhancer domain is a Growth Arrest and DNA-Damage-inducible Alpha (GADD45A) domain. In certain embodiments, the GADD45 domain has the amino acid sequence of SEQ ID NO:85. In certain embodiments, the demethylation enhancer domain is a NEIL2 domain. In certain embodiments, the NEIL2 domain has the amino acid sequence of SEQ ID NO:86.
    • Ribonucleoprotein Complex
  • A “ribonucleoprotein complex” as provided herein refers to a complex including a nucleoprotein and a ribonucleic acid. A “nucleoprotein” as provided herein refers to a protein capable of binding a nucleic acid (e.g., RNA, DNA). Where the nucleoprotein binds a ribonucleic acid it is referred to as “ribonucleoprotein.” The interaction between the ribonucleoprotein and the ribonucleic acid may be direct, e.g., by covalent bond, or indirect, e.g., by non-covalent bond (e.g. electrostatic interactions (e.g. ionic bond, hydrogen bond, halogen bond), van der Waals interactions (e.g. dipole-dipole, dipole-induced dipole, London dispersion), ring stacking (pi effects), hydrophobic interactions and the like). In certain embodiments, the ribonucleoprotein includes an RNA-binding motif non-covalently bound to the ribonucleic acid. For example, positively charged aromatic amino acid residues (e.g., lysine residues) in the RNA-binding motif may form electrostatic interactions with the negative nucleic acid phosphate backbones of the RNA, thereby forming a ribonucleoprotein complex. Non-limiting examples of ribonucleoproteins include ribosomes, telomerase, RNAseP, hnRNP, CRISPR associated protein 9 (Cas9) and small nuclear RNPs (snRNPs). The ribonucleoprotein may be an enzyme. In certain embodiments, the ribonucleoprotein is an endonuclease. In certain embodiments, the ribonucleoprotein is a nuclease-deficient RNA-guided DNA endonuclease enzyme. Thus, in certain embodiments, the ribonucleoprotein complex includes an nuclease-deficient RNA-guided DNA endonuclease enzyme and a ribonucleic acid. In certain embodiments, the nuclease-deficient RNA-guided DNA endonuclease enzyme includes a nuclear localization signal (NLS). The nuclear localization signal (NLS) provided herein provides for nuclear transport of the protein domain or protein, for example the nuclease-deficient RNA-guided DNA endonuclease enzyme, the NLS is linked to.
  • In certain embodiments, the nuclease-deficient RNA-guided DNA endonuclease enzyme is nuclease-deficient CRISPR associated protein 9 (dCas9). In certain embodiments, the nuclease-deficient RNA-guided DNA endonuclease enzyme is nuclease-deficient Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (Cpfl).
    • Polynucleotide
  • The polynucleotide provided herein includes (1) a DNA-targeting sequence that is complementary to a target polynucleotide sequence, (2) a binding sequence for the nuclease-deficient RNA-guided DNA endonuclease enzyme (e.g., dCas9), and (3) one or more PUF binding site (PBS) sequences (e.g., a first (3) and a second (4) PBS sequence). In certain embodiments, the complex includes dCas9 bound to the polynucleotide thereby forming a ribonucleoprotein complex. In certain embodiments, the polynucleotide is a ribonucleic acid. In certain embodiments, the polynucleotide is a guide RNA. A “guide RNA” or “gRNA” as provided herein refers to a ribonucleotide sequence capable of binding a nucleoprotein, thereby forming ribonucleoprotein complex.
  • In certain embodiments, the polynucleotide (e.g., gRNA) is a single-stranded ribonucleic acid. In certain embodiments, the polynucleotide (e.g., gRNA) is 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more nucleic acid residues in length. In certain embodiments, the polynucleotide (e.g., gRNA) is from 10 to 30 nucleic acid residues in length. In certain embodiments, the polynucleotide (e.g., gRNA) is 20 nucleic acid residues in length. In certain embodiments, the length of the polynucleotide (e.g., gRNA) can be at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more nucleic acid residues or sugar residues in length. In certain embodiments, the polynucleotide (e.g., gRNA) is from 5 to 50, 10 to 50, 15 to 50, 20 to 50, 25 to 50, 30 to 50, 35 to 50, 40 to 50, 45 to 50, 5 to 75, 10 to 75, 15 to 75, 20 to 75, 25 to 75, 30 to 75, 35 to 75, 40 to 75, 45 to 75, 50 to 75, 55 to 75, 60 to 75, 65 to 75, 70 to 75, 5 to 100, 10 to 100, 15 to 100, 20 to 100, 25 to 100, 30 to 100, 35 to 100, 40 to 100, 45 to 100, 50 to 100, 55 to 100, 60 to 100, 65 to 100, 70 to 100, 75 to 100, 80 to 100, 85 to 100, 90 to 100, 95 to 100, or more residues in length. In certain embodiments, the polynucleotide (e.g., gRNA) is from 10 to 15, 10 to 20, 10 to 30, 10 to 40, or 10 to 50 residues in length.
  • In certain embodiments, transcription of the polynucleotide is under the control of a constitutive promoter, such as a CMV promoter or a Ubc promoter, or an inducible promoter, such as a tetracycline-responsive promoter or a steroid-responsive promoter. In certain embodiments, the polynucleotide is a vector.
  • In certain embodiments, the vector encoding the polynucleotide (for use in the methods of the invention) is active in a cell from a mammal (a human; a non-human primate; a non-human mammal; a rodent such as a mouse, a rat, a hamster, a guinea pig; a livestock mammal such as a pig, a sheep, a goat, a horse, a camel, cattle; or a pet mammal such as a cat or a dog); a bird, a fish, an insect, a worm, a yeast, or a bacterium.
  • In certain embodiments, the vector is a plasmid, a viral vector (such as adenoviral, retroviral, or lentiviral vector, or AAV vector), or a transposon (such as piggyBac transposon). The vector can be transiently transfected into a host cell, or be integrated into a host genome by infection or transposition.
    • DNA-Targeting Sequence
  • The polynucleotide includes a nucleotide sequence complementary to a target site (e.g., target polynucleotide sequence), which is referred to herein as “DNA-targeting sequence.” The DNA-targeting sequence may mediate binding of the ribonucleoprotein complex to a complementary target polynucleotide sequence thereby providing the sequence specificity of the ribonucleoprotein complex. Thus, in certain embodiments, the polynucleotide (e.g., gRNA) or parts thereof are complementary to a target polynucleotide sequence. In certain embodiments, the polynucleotide (e.g., gRNA) binds a target polynucleotide sequence. In certain embodiments, the complement of the polynucleotide has a sequence identity of 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to the target polynucleotide sequence. In certain embodiments, the complement of the DNA-targeting sequence has a sequence identity of 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to the target polynucleotide sequence.
  • It should be noted that the DNA-targeting sequence may or may not be 100% complementary to the target polynucleotide sequence. In certain embodiments, the DNA-targeting sequence is complementary to the target polynucleotide sequence over 8-25 nucleotides (nts), 12-22 nucleotides, 14-20 nts, 16-20 nts, 18-20 nts, or 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nts. In certain embodiments, the complementary region comprises a continuous stretch of 12-22 nts, preferably at the 3′ end of the DNA-targeting sequence. In certain embodiments, the 5′ end of the DNA-targeting sequence has up to 8 nucleotide mismatches with the target polynucleotide sequence. In certain embodiments, the DNA-binding sequence is 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% complementary to the target polynucleotide sequence.
  • In a related embodiment, there is no more than 15-nucleotide match at the 3′ end of the DNA-targeting sequence compared to the complementary target polynucleotide sequence, and the nuclease-deficient RNA-guided DNA endonuclease in the complex is a nuclease-deficient wildtype Cas9 protein (nuclease-deficient wt Cas9 protein) which, under the circumstance, binds but does not cut a target DNA (e.g., dCas9 protein). In certain embodiments, the nuclease-deficient RNA-guided DNA endonuclease is a nuclease-deficient Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (Cpfl).
  • The DNA-targeting sequence is functionally similar or equivalent to the crRNA or guide RNA or gRNA of the CRISPR/Cas complex/system. However, in the context of the instant invention, the DNA-targeting sequence may not originate from any particular crRNA or gRNA, but can be arbitrarily designed based on the sequence of the target polynucleotide sequence.
  • The DNA-targeting sequence includes a nucleotide sequence that is complementary to a specific sequence within a target DNA (or the complementary strand of the target DNA). In other words, the DNA-targeting sequence interacts with a target polynucleotide sequence of the target DNA in a sequence-specific manner via hybridization (i.e., base pairing). As such, the nucleotide sequence of the DNA-targeting sequence may vary, and it determines the location within the target DNA that the subject polynucleotide and the target DNA will interact. The DNA-targeting sequence can be modified or designed (e.g., by genetic engineering) to hybridize to any desired sequence within the target DNA. In certain embodiments, the target polynucleotide sequence is immediately 3′ to a PAM (protospacer adjacent motif) sequence of the complementary strand, which can be 5′-CCN-3′, wherein N is any DNA nucleotide. That is, in this embodiment, the complementary strand of the target polynucleotide sequence is immediately 5′ to a PAM sequence that is 5′-NGG-3′, wherein N is any DNA nucleotide. In related embodiments, the PAM sequence of the complementary strand matches the nuclease-deficient wt Cas9 protein or dCas9.
  • The DNA-targeting sequence can have a length of from 12 nucleotides to 100 nucleotides. For example, the DNA-targeting sequence can have a length of from 12 nucleotides (nt) to 80 nt, from 12 nt to 50 nt, from 12 nt to 40 nt, from 12 nt to 30 nt, from 12 nt to 25 nt, from 12 nt to 20 nt, or from 12 nt to 19 nt. For example, the DNA-targeting sequence can have a length of from 19 nt to 20 nt, from 19 nt to 25 nt, from 19 nt to 30 nt, from 19 nt to 35 nt, from 19 nt to 40 nt, from 19 nt to 45 nt, from 19 nt to 50 nt, from 19 nt to 60 nt, from 19 nt to 70 nt, from 19 nt to 80 nt, from 19 nt to 90 nt, from 19 nt to 100 nt, from 20 nt to 25 nt, from 20 nt to 30 nt, from 20 nt to 35 nt, from 20 nt to 40 nt, from 20 nt to 45 nt, from 20 nt to 50 nt, from 20 nt to 60 nt, from 20 nt to 70 nt, from 20 nt to 80 nt, from 20 nt to 90 nt, or from 20 nt to 100 nt.
  • The nucleotide sequence of the DNA-targeting sequence that is complementary to a target polynucleotide sequence of the target DNA can have a length of at least 12 nt. For example, the DNA-targeting sequence that is complementary to a target polynucleotide sequence of the target DNA can have a length at least 12 nt, at least 15 nt, at least 18 nt, at least 19 nt, at least 20 nt, at least 25 nt, at least 30 nt, at least 35 nt or at least 40 nt. For example, the DNA-targeting sequence that is complementary to a target polynucleotide sequence of a target DNA can have a length of from 12 nucleotides (nt) to 80 nt, from 12 nt to 50 nt, from 12 nt to 45 nt, from 12 nt to 40 nt, from 12 nt to 35 nt, from 12 nt to 30 nt, from 12 nt to 25 nt, from 12 nt to 20 nt, from 12 nt to 19 nt, from 19 nt to 20 nt, from 19 nt to 25 nt, from 19 nt to 30 nt, from 19 nt to 35 nt, from 19 nt to 40 nt, from 19 nt to 45 nt, from 19 nt to 50 nt, from 19 nt to 60 nt, from 20 nt to 25 nt, from 20 nt to 30 nt, from 20 nt to 35 nt, from 20 nt to 40 nt, from 20 nt to 45 nt, from 20 nt to 50 nt, or from 20 nt to 60 nt. The nucleotide sequence of the DNA-targeting sequence that is complementary to the target polynucleotide sequence of the target DNA can have a length of at least 12 nt.
  • In some cases, the DNA-targeting sequence that is complementary to a target polynucleotide sequence of the target DNA is 20 nucleotides in length. In some cases, the DNA-targeting sequence that is complementary to a target polynucleotide sequence of the target DNA is 19 nucleotides in length.
  • The percent complementarity between the DNA-targeting sequence and the target polynucleotide sequence of the target DNA can be at 50% (e.g., at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%). In some cases, the percent complementarity between the DNA-targeting sequence and the target polynucleotide sequence is 100% over the seven or eight contiguous 5′-most nucleotides of the target polynucleotide sequence. In some cases, the percent complementarity between the DNA-targeting sequence and the target polynucleotide sequence is at least 60% over 20 contiguous nucleotides. In some cases, the percent complementarity between the DNA-targeting sequence and the target polynucleotide sequence is 100% over the 7, 8, 9, 10, 11, 12, 13, or 14 contiguous 5′-most nucleotides of the target polynucleotide sequence (i.e., the 7, 8, 9, 10, 11, 12, 13, or 14 contiguous 3′-most nucleotides of the DNA-targeting sequence), and as low as 0% over the remainder. In such a case, the DNA-targeting sequence can be considered to be 7, 8, 9, 10, 11, 12, 13, or 14 nucleotides in length, respectively.
    • Target Polynucleotide Sequence
  • A “target polynucleotide sequence” as provided herein is a nucleic acid sequence expressed by a cell. In certain embodiments, the target polynucleotide sequence is an exogenous nucleic acid sequence. In certain embodiments, the target polynucleotide sequence is an endogenous nucleic acid sequence. In certain embodiments, the target polynucleotide sequence forms part of a cellular gene. In certain embodiments, the target polynucleotide sequence is part of a gene. In certain embodiments, the target polynucleotide sequence is part of a Sox gene. In certain embodiments, the target polynucleotide sequence is part of a transcriptional regulatory sequence. In certain embodiments, the target polynucleotide sequence is part of a promoter, enhancer or silencer. In certain embodiments, the target polynucleotide sequence is a hypermethylated nucleic acid sequence. In certain embodiments, the target polynucleotide sequence is a hypermethylated CpG sequence. In certain embodiments, the target polynucleotide sequence is part of an hMLH1 promoter.
  • In certain embodiments, the target sequence is an RNA. In certain embodiments, the target sequence is a DNA. In the description herein, the first segment is generally referred to as the “DNA-targeting sequence” when the target sequence is a DNA (such as a genomic DNA). In related embodiments in which the target sequence is an RNA, the description herein below applies generally as well except that the reference to “DNA-targeting sequence” is replaced with “RNA-targeting sequence,” in order to avoid redundancy. That is, the polynucleotide includes a nucleotide sequence complementary to the target polynucleotide sequence (DNA or RNA).
  • In certain embodiments, the three segments (1)-(3) are arranged, in that order, from 5′ to 3′. In certain embodiments, the three segments (1)-(4) are arranged, in that order, from 5′ to 3′.
  • In certain embodiments, the polynucleotide of the invention can be a single RNA molecule (single RNA polynucleotide), which may include a “single-guide RNA,” or “sgRNA.” In another embodiment, the polynucleotide of the invention includes two RNA molecules (e.g., joined together via hybridization at the binding sequence (e.g., nuclease-deficient wt Cas9 protein- or dCas9-binding sequence)). Thus the subject polynucleotide is inclusive, referring both to two-molecule polynucleotides and to single-molecule polynucleotides (e.g., sgRNAs).
  • In certain embodiments, the target polynucleotide sequence is at, near, or within a promoter sequence. In certain embodiments, the target polynucleotide sequence is within a CpG island. In certain embodiments, the target polynucleotide sequence is known to be associated with a disease or condition characterized by DNA hypo- or hyper-methylation. In certain embodiments, the target polynucleotide sequence is within a tumor suppressor gene or an oncogene, such as within a transcriptional regulatory sequence/element of the tumor suppressor gene or oncogene.
  • In certain embodiments, the target polynucleotide sequence is immediately 3′ to a PAM (protospacer adjacent motif) sequence of the target polynucleotide sequence. For example, in certain embodiments, the PAM sequence of the target polynucleotide sequence is 5′-CCN-3′, wherein N is any DNA nucleotide. In other embodiments, the PAM sequence of the target polynucleotide sequence matches the specific nuclease-deficient wt Cas9 protein or dCas9 protein or homologs or orthologs to be used.
  • As is known in the art, for nuclease-deficient wt Cas9 protein or dCas9 protein to successfully bind to DNA, the target polynucleotide sequence in the genomic DNA must be complementary to the guide RNA sequence and must be immediately followed by the correct protospacer adjacent motif or PAM sequence. The PAM sequence is present in the target polynucleotide sequence but not in the guide RNA sequence. Any DNA sequence with the correct target polynucleotide sequence followed by the PAM sequence will be bound by nuclease-deficient wt Cas9 protein or dCas9 protein. In certain embodiments, the PAM sequence is any of the PAM sequences disclosed in international application PCT/US2016/021491 and published as WO2016148994 A8, which is hereby incorporated by reference and for all purposes.
  • In embodiments, the polynucleotide (e.g., gRNA) is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% to the target polynucleotide sequence. In certain embodiments, the polynucleotide (e.g., gRNA) is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% complementary to the sequence of a cellular gene. In certain embodiments, the polynucleotide (e.g., gRNA) binds a cellular gene sequence.
    • Binding Sequence
  • In certain embodiments, the complex includes dCas9 bound to the polynucleotide through binding a binding sequence of the polynucleotide and thereby forming a ribonucleoprotein complex. In certain embodiments, the binding sequence forms a hairpin structure. In certain embodiments, the binding sequence is 30-100 nt, 35-50 nt, 37-47 nt, or 42 nt in length. An exemplary binding sequence is the sequence of SEQ ID NO:6 GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTA. Another exemplary binding sequence is the sequence of SEQ ID NO:7 GTTTAAGAGCTATGCTGGAAACAGCATAGCAAGTTTAAATAAGGCTA.
  • In certain embodiments, the binding sequence includes the sequence of SEQ ID NO: 6. In certain embodiments, the binding sequence includes the sequence of SEQ ID NO: 7. In certain embodiments, the binding sequence is the sequence of SEQ ID NO: 6. In certain embodiments, the binding sequence is the sequence of SEQ ID NO: 7.
  • The binding sequence (protein-binding segment or protein-binding sequence) of the subject polynucleotide binds to a modified dCas9 protein (e.g., nuclease-deficient nickase or dCas9) which has reduced endonuclease activity, or lacks endonuclease activity. For simplicity, the binding sequence (protein-binding segment or protein-binding sequence), which may bind to modified Cas9 proteins (e.g., dCas9 protein) may simply be referred to as “Cas9-binding sequence” or “binding sequence” herein. However, it should be understood that when the binding sequence (Cas9-binding sequence) of the invention binds to a dCas9, it is not prevented from binding to a wt Cas9 or a Cas9 nickase. In certain embodiments, the binding sequence (Cas9-binding sequence) of the invention binds to dCas9 as well as wt Cas9 and/or Cas9 nickase.
  • The binding sequence (Cas9-binding sequence) interacts with or binds to a Cas9 protein (e.g., nuclease-deficient wt Cas9 protein, or dCas9 protein), and together they bind to the target polynucleotide sequence recognized by the DNA-targeting sequence. The binding sequence (Cas9-binding sequence) includes two complementary stretches of nucleotides that hybridize to one another to form a double stranded RNA duplex (a dsRNA duplex). These two complementary stretches of nucleotides may be covalently linked by intervening nucleotides known as linkers or linker nucleotides (e.g., in the case of a single-molecule polynucleotide), and hybridize to form the double stranded RNA duplex (dsRNA duplex, or “Cas9-binding hairpin”) of the binding sequence (Cas9-binding sequence), thus resulting in a stem-loop structure. Alternatively, in some embodiment, the two complementary stretches of nucleotides may not be covalently linked, but instead are held together by hybridization between complementary sequences (e.g., in the case of a two-molecule polynucleotide of the invention).
  • The binding sequence (Cas9-binding sequence) can have a length of from 10 nucleotides to 100 nucleotides, e.g., from 10 nucleotides (nt) to 20 nt, from 20 nt to 30 nt, from 30 nt to 40 nt, from 40 nt to 50 nt, from 50 nt to 60 nt, from 60 nt to 70 nt, from 70 nt to 80 nt, from 80 nt to 90 nt, or from 90 nt to 100 nt. For example, the Cas9-binding sequence can have a length of from 15 nucleotides (nt) to 80 nt, from 15 nt to 50 nt, from 15 nt to 40 nt, from 15 nt to 30 nt, from 37 nt to 47 nt (e.g., 42 nt), or from 15 nt to 25 nt.
  • The dsRNA duplex of the binding sequence (Cas9-binding sequence) can have a length from 6 base pairs (bp) to 50 bp. For example, the dsRNA duplex of the binding sequence (Cas9-binding sequence) can have a length from 6 bp to 40 bp, from 6 bp to 30 bp, from 6 bp to 25 bp, from 6 bp to 20 bp, from 6 bp to 15 bp, from 8 bp to 40 bp, from 8 bp to 30 bp, from 8 bp to 25 bp, from 8 bp to 20 bp or from 8 bp to 15 bp. For example, the dsRNA duplex of the binding sequence (Cas9-binding sequence) can have a length from 8 bp to 10 bp, from 10 bp to 15 bp, from 15 bp to 18 bp, from 18 bp to 20 bp, from 20 bp to 25 bp, from 25 bp to 30 bp, from 30 bp to 35 bp, from 35 bp to 40 bp, or from 40 bp to 50 bp. In some embodiments, the dsRNA duplex of the binding sequence (Cas9-binding sequence) has a length of 36 base pairs. The percent complementarity between the nucleotide sequences that hybridize to form the dsRNA duplex of the binding sequence (Cas9-binding sequence) can be at least 60%. For example, the percent complementarity between the nucleotide sequences that hybridize to form the dsRNA duplex of the binding sequence (Cas9-binding sequence) can be at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%. In some cases, the percent complementarity between the nucleotide sequences that hybridize to form the dsRNA duplex of the binding sequence (Cas9-binding sequence) is 100%.
  • In certain embodiments, the polynucleotide further includes a linker sequence linking the DNA-targeting sequence to the binding sequence (Cas9-binding sequence). The linker can have a length of from 3 nucleotides to 100 nucleotides. For example, the linker can have a length of 3 nucleotides (nt) to 90 nt, from 3 nucleotides (nt) to 80 nt, from 3 nucleotides (nt) to 70 nt, from 3 nucleotides (nt) to 60 nt, from 3 nucleotides (nt) to 50 nt, from 3 nucleotides (nt) to 40 nt, from 3 nucleotides (nt) to 30 nt, from 3 nucleotides (nt) to 20 nt or from 3 nucleotides (nt) to 10 nt. For example, the linker can have a length of from 3 nt to 5 nt, from 5 nt to 10 nt, from 10 nt to 15 nt, from 15 nt to 20 nt, from 20 nt to 25 nt, from 25 nt to 30 nt, from 30 nt to 35 nt, from 35 nt to 40 nt, from 40 nt to 50 nt, from 50 nt to 60 nt, from 60 nt to 70 nt, from 70 nt to 80 nt, from 80 nt to 90 nt, or from 90 nt to 100 nt. In some embodiments, the linker is 4 nt.
  • Non-limiting examples of nucleotide sequences that can be included in a suitable binding sequence (Cas9-binding sequence, i.e., Cas9 handle) are set forth in SEQ ID NOs: 563-682 of WO 2013/176772 (see, for examples, FIGS. 8 and 9 of WO 2013/176772), which is hereby incorporated by reference in its entirety and for all purposes.
  • In some cases, a suitable binding sequence (Cas9-binding sequence) includes a nucleotide sequence that differs by 1, 2, 3, 4, or 5 nucleotides from any one of the above-listed sequences.
    • PBS Sequences
  • The term “PBS” or “PUF binding site” as provided herein refers to a site that is bound by a Pumilio/fem-3 mRNA binding factor (PUF). A PUF binding site (PBS) may form part of a guide RNA and provide for the binding of a PUF protein or PUF domain as provided herein (e.g., PUFa, PUFb, PUFc or functional fragments thereof) to said guide RNA. The PUF binding site includes a nucleic acid sequence (i.e., a PBS sequence or PUF binding site sequence) which is characteristic of the PBS and may be bound directly by the PUF protein. The polynucleotide (e.g., gRNA) provided herein further includes one or more PUF binding site (PBS) sequences. In aspects, the demethylation complex includes the demethylation enhancer domain linked to a different PUF domain than the demethylation domain. Therefore, the demethylation domain may be bound to the polynucleotide through a first PUF domain binding a first PBS sequence and the demethylation enhancer domain may be bound to the polynucleotide through a second PUF domain bound to a second PBS sequence. The first and the second PBS sequence may be different or may be the same. In certain embodiments, the one or more PBS sequences (e.g., first or second PBS sequence) contain 8 nucleotides in length. In certain embodiments, the one or more PBS sequences (e.g., first or second PBS sequence) are identical. In certain embodiments, the polynucleotide includes 1 to 50 PBS sequences. In certain embodiments, one or more PBS sequences (e.g., first or second PBS sequence) comprise the nucleotide sequence of SEQ ID NO: 1. Any one of the PBS sequences (e.g., first or second PBS sequence) disclosed in international application PCT/US2016/021491 and published as WO2016148994 A8, which is hereby incorporated by reference in its entirety and for all purposes, are contemplated for the compositions and methods provided herein.
  • In certain embodiments, each of the one or more PBS sequences (e.g., first or second PBS sequence) has 8 nucleotides. One exemplary PBS sequence may have a sequence of SEQ ID NO:8 (5′-UGUAUGUA-3′), which can be bound by the PUF domain PUF(3-2). Another exemplary PBS may have a sequence of SEQ ID NO:9 (5′-UUGAUAUA-3′), which can be bound by the PUF domain PUF(6-2/7-2). Additional PBS sequences and the corresponding PUF domains are described in international application PCT/US2016/021491 and published as WO2016148994 A8, which is hereby incorporated by reference in its entirety and for all purposes.
  • The polynucleotide of the invention may have more than one copy of the PBS sequences. In certain embodiments, the polynucleotide comprises 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 46, 47, 48, 49, or 50 copies of PBS sequences, such as 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 copies of PBS sequences. In certain embodiments, the range of the PBS sequence copy number is L to H, wherein L is any one of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, or 40, and wherein H is any one of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 80, 90, or 100, so long as H is greater than L. Each PBS sequence may be the same or different.
  • In certain embodiments, the polynucleotide includes 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 46, 47, 48, 49, or 50 copies, or 1-50, 2-45, 3-40, 5-35, 5-10, 10-20 copies of identical or different PBS sequences.
  • In certain embodiments, the polynucleotide includes 5-15 copies of PBS sequences, or 5-14 copies, 5-13 copies, 5-12 copies, 5-11 copies, 5-10 copies, or 5-9 copies of PBS sequences.
  • In certain embodiments, the amount of the gRNA-PBS sequences and/or the amount of the protein conjugate (methylation or demethylation protein conjugate) transfected or expressed is adjusted to maximize PBS/PUF domain binding. For example, this can be achieved by increasing the expression of the PUF domain by a stronger promoter or using an inducible promoter, such as a Dox-inducible promoter.
  • In certain embodiments, the spacing between PBS sequences and/or spacer sequences are optimized to improve system efficiency. For example, spacing optimization can be subject to particular protein conjugates (methylation or demethylation protein conjugates), and can be different between protein conjugates (methylation or demethylation protein conjugate) that work as individual proteins and those protein conjugates (methylation or demethylation protein conjugate) that may need to be positioned close enough to function (e.g., protein complexes).
  • In certain embodiments, one or more spacer region(s) separate two adjacent PBS sequences. The spacer regions may have a length of from 3 nucleotides to 100 nucleotides. For example, the spacer can have a length of from 3 nucleotides (nt) to 90 nt, from 3 nucleotides (nt) to 80 nt, from 3 nucleotides (nt) to 70 nt, from 3 nucleotides (nt) to 60 nt, from 3 nucleotides (nt) to 50 nt, from 3 nucleotides (nt) to 40 nt, from 3 nucleotides (nt) to 30 nt, from 3 nucleotides (nt) to 20 nt or from 3 nucleotides (nt) to 10 nt. For example, the spacer can have a length of from 3 nt to 5 nt, from 5 nt to 10 nt, from 10 nt to 15 nt, from 15 nt to 20 nt, from 20 nt to 25 nt, from 25 nt to 30 nt, from 30 nt to 35 nt, from 35 nt to 40 nt, from 40 nt to 50 nt, from 50 nt to 60 nt, from 60 nt to 70 nt, from 70 nt to 80 nt, from 80 nt to 90 nt, or from 90 nt to 100 nt. In some embodiments, the spacer is 4 nt.
  • In certain embodiments, the PBS sequence includes the sequence of SEQ ID NO: 1, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, or SEQ ID NO:27. In certain embodiments, the PBS sequence is the sequence of SEQ ID NO: 1, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, or SEQ ID NO:27.
  • In certain embodiments, the first or the second PBS sequence contains 8 nucleotides in length. In certain embodiments, the first or the second PBS sequences includes the nucleotide sequence of SEQ ID NO:1.
    • Protein Conjugates PUF Domains
  • PUF proteins (named after Drosophila Pumilio and C. elegans fern-3 binding factor) are known to be involved in mediating mRNA stability and translation. These proteins contain a unique RNA-binding domain known as the PUF domain. The RNA-binding PUF domain, such as that of the human Pumilio 1 protein (referred here also as PUM), contains 8 repeats (each repeat called a PUF motif or a PUF repeat) that bind consecutive bases in an anti-parallel fashion, with each repeat recognizing a single base—i.e., PUF repeats R1 to R8 recognize nucleotides N8 to Ni, respectively. For example, PUM is composed of eight tandem repeats, each repeat consisting of 34 amino acids that folds into tightly packed domains composed of alpha helices.
  • The complexes provided herein including embodiments thereof include demethylation protein conjugates (e.g., demethylation protein conjugate, demethylation enhancer conjugate) including (i) a PUF domain operably linked to a demethylation domain and a demethylation enhancer domain or (ii) a first PUF domain operably linked to a demethylation domain and a second PUF domain operably linked to a demethylation enhancer domain, respectively. Where the protein conjugate is a demethylation conjugate the demethylation domain is operably linked to the C-terminus of the PUF domain to form a protein conjugate. The demethylation enhancer domain may be linked to the C-terminus of the PUF domain, to the N-terminus of the PUF domain, or the demethylation enhancer domain may bind the polynucleotide (e.g., gRNA) linked to a separate PUF domain (i.e., a PUF domain not linked to the demethylation domain). Where the demethylation enhancer domain and the demethylation domain bind the polynucleotide separately, the demethylation domain forms part of a demethylation protein conjugate and is linked to a first PUF domain, and the demethylation enhancer domain forms part of a demethylation enhancer protein conjugate and is linked to a second PUF domain. The demethylation protein conjugate binds the polynucleotide through binding of the first PUF domain to the first PBS sequence and the demethylation enhancer protein conjugate binds the polynucleotide through binding of the second PUF domain to the second PBS sequence.
  • As used herein, the term “PUF domain” refers to a wildtype or naturally existing PUF domain, as well as a PUF homologue domain that is based on/derived from a natural or existing PUF domain, such as the prototype human Pumilio 1 PUF domain. The PUF domain of the invention specifically binds to an RNA sequence (e.g., an 8-mer RNA sequence), wherein the overall binding specificity between the PUF domain and the RNA sequence is defined by sequence specific binding between each PUF motif/PUF repeat within the PUF domain and the corresponding single RNA nucleotide.
  • Also included in the scope of the invention are functional variants of the subject PUF domains or fusions thereof. The term “functional variant” as used herein refers to a PUF domain having substantial or significant sequence identity or similarity to a parent PUF domain, which functional variant retains the biological activity of the PUF domain of which it is a variant—e.g., one that retains the ability to recognize target RNA to a similar extent, the same extent, or to a higher extent in terms of binding affinity, and/or with substantially the same or identical binding specificity, as the parent PUF domain. The functional variant PUF domain can, for instance, be at least 30%, 50%, 75%, 80%, 90%, 98% or more identical in amino acid sequence to the parent PUF domain. The functional variant can, for example, comprise the amino acid sequence of the parent PUF domain with at least one conservative amino acid substitution, for example, conservative amino acid substitutions in the scaffold of the PUF domain (i.e., amino acids that do not interact with the RNA). Alternatively or additionally, the functional variants can comprise the amino acid sequence of the parent PUF domain with at least one non-conservative amino acid substitution. In this case, it is preferable for the non-conservative amino acid substitution to not interfere with or inhibit the biological activity of the functional variant. The non-conservative amino acid substitution may enhance the biological activity of the functional variant, such that the biological activity of the functional variant is increased as compared to the parent PUF domain, or may alter the stability of the PUF domain to a desired level (e.g., due to substitution of amino acids in the scaffold). The PUF domain can consist essentially of the specified amino acid sequence or sequences described herein, such that other components, e.g., other amino acids, do not materially change the biological activity of the functional variant. In certain embodiments, the PUF domain is a Pumilio homology domain (PU-HUD). In a particular embodiment, the PU-HUD is a human Pumilio 1 domain. In certain embodiments, the PUF domain has the sequence of any one of the PUF domains disclosed in international application PCT/US2016/021491, published as WO2016148994 A8, in international application PCT/US2011/040933, published as WO 2011/160052A2, and Spassov & Jurecic (“Cloning and comparative sequence analysis of PUM1 and PUM2 genes, human members of the Pumilio family of RNA-binding proteins,” Gene, 299:195-204, October 2002), which are hereby incorporated by reference in their entirety and for all purposes.
  • In certain embodiments, the PUF domain includes a PUFa domain, a PUFb domain, a PUFc domain, or a PUFw domain. In certain embodiments, the PUFa domain has the amino acid sequence of SEQ ID NO:2. In certain embodiments, the PUFb domain has the amino acid sequence of SEQ ID NO:3. In certain embodiments, the PUFc domain has the amino acid sequence of SEQ ID NO:4. In certain embodiments, the PUFw domain has the amino acid sequence of SEQ ID NO:5. In certain embodiments, the first PUF domain is a PUFa domain. In certain embodiments, the PUFa domain has the sequence of SEQ ID NO:2. In certain embodiments, the second PUF domain is a PUFc domain. In certain embodiments, the PUFc domain has the sequence of SEQ ID NO:4.
  • In certain embodiments, the first or the second PUF domain includes a PUFa domain, a PUFb domain, a PUFc domain, or a PUFw domain. In certain embodiments, the first or the second PUFa domain has the amino acid sequence of SEQ ID NO:2. In certain embodiments, the first or the second PUFb domain has the amino acid sequence of SEQ ID NO:3. In certain embodiments, the first or the second PUFc domain has the amino acid sequence of SEQ ID NO:4. In certain embodiments, the first or the second PUFw domain has the amino acid sequence of SEQ ID NO:5.
  • The subject polynucleotide includes one or more tandem sequences, each of which can be specifically recognized and bound by a specific PUF domain (infra). Since a PUF domain can be engineered to bind virtually any PBS sequence based on the nucleotide-specific interaction between the individual PUF motifs of PUF domain and the single RNA nucleotide they recognize, the PBS sequences can be any designed sequence that bind their corresponding PUF domain.
  • In certain embodiments, a PBS of the invention has a nucleotide length of 8-mer. In other embodiments, a PBS of the invention has 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or more RNA nucleotides. In certain embodiments, the PBS of the invention has the sequence of SEQ ID NO:10 (5′-UGUAUAUA-3′), and binds the wt human Pumilio 1 PUF domain.
  • In certain embodiments, the PBS sequence of the invention has the sequence of SEQ ID NO:8 (5′-UGUAUGUA-3′), and binds the PUF domain PUF(3-2).
  • In certain embodiments, the PBS sequence of the invention has the sequence of SEQ ID NO:9 (5′-UUGAUAUA-3′), and binds the PUF domain PUF(6-2/7-2).
  • In certain embodiments, the PBS sequence of the invention has the sequence of SEQ ID NO:11 (5′-UGGAUAUA-3′), and binds the PUF domain PUF(6-2).
  • In certain embodiments, the PBS sequence of the invention has the sequence of SEQ ID NO:12 (5′-UUUAUAUA-3′), and binds the PUF domain PUF(7-2).
  • In certain embodiments, the PBS sequence of the invention has the sequence of SEQ ID NO:13 (5′-UGUGUGUG-3′), and binds the PUF domain PUF531.
  • In certain embodiments, the PBS sequence of the invention has the sequence of SEQ ID NO:14 (5′-UGUAUAUG-3′), and binds the PUF domain PUF(1-1).
  • In certain embodiments, the PBS sequence of the invention has the sequence of SEQ ID NO:12 (5′-UUUAUAUA-3′) or sequence of SEQ ID NO:15 (5′-UAUAUAUA-3′), and binds the PUF domain PUF(7-1).
  • In certain embodiments, the PBS sequence of the invention has the sequence of SEQ ID NO:16 (5′-UGUAUUUA-3′), and binds the PUF domain PUF(3-1).
  • In certain embodiments, the PBS sequence of the invention has the sequence of SEQ ID NO:17 (5′-UUUAUUUA-3′), and binds the PUF domain PUF(7-2/3-1).
  • In embodiments, the PUF domain PUF(3-2) has the sequence of SEQ ID NO:18. In certain embodiments, the PUF domain PUF(6-2/7-2) has the sequence of SEQ ID NO: 19. In certain embodiments, the PUF domain PUF531 has the sequence of SEQ ID NO:22. In certain embodiments, the PUF domain includes the sequence of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:22, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30 or SEQ ID NO:31. In certain embodiments, the PUF domain is the sequence of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:22, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30 or SEQ ID NO:31.
  • Applicant has created 65,536 8-mer PBS sequence and their corresponding PUF domain sequences (see below) that can bind the specific PBS sequence. Applicant has also created a python script to retrieve any of the 65,536 individual PUF domain sequences that binds a given 8-mer PBS sequence. For example, for the 8-mer UUGAUGUA (SEQ ID NO:27), one possible PUF domain sequence can be SEQ ID NO:28:
  • GRSRLLEDFRNNRYPNLQLREIAGHIMEFSQDQHGCRFIQLKLERATPAE
    RQLVFNEILQAAYQLMVDVFGNYVIQKFFEFGSLEQKLALAERIRGHVLS
    LALQMYGSRVIEKALEFIPSDQQNEMVRELDGHVLKCVKDQNGNHVVQKC
    IECVQPQSLQFIIDAFKGQVFALSTHPYGCRVIQRILEHCLPDQTLPILE
    ELHQHTEQLVQDQYGSYVIEHVLEHGRPEDKSKIVAEIRGNVLVLSQHKF
    ANNVVQKCVTHASRTERAVLIDEVCTMNDGPHSALYTMMKDQYANYVVQK
    MIDVAEPGQRKIVMHKIRPHIATLRKYTYGKHILAKLEKYYMKNGVDLG
    PUF (3-2)
    SEQ ID NO: 18
    Gly Arg Ser Arg Leu Leu Glu Asp Phe Arg Asn Asn
    Arg Tyr Pro Asn Leu Gln Leu Arg Glu Ile Ala Gly
    His Ile Met Glu Phe Ser Gln Asp Gln His Gly Ser
    Arg Phe Ile Gln Leu Lys Leu Glu Arg Ala Thr Pro
    Ala Glu Arg Gln Leu Val Phe Asn Glu Ile Leu Gln
    Ala Ala Tyr Gln Leu Met Val Asp Val Phe Gly Asn
    Tyr Val Ile Gln Lys Phe Phe Glu Phe Gly Ser Leu
    Glu Gln Lys Leu Ala Leu Ala Glu Arg Ile Arg Gly
    His Val Leu Ser Leu Ala Leu Gln Met Tyr Gly Ser
    Arg Val Ile Glu Lys Ala Leu Glu Phe Ile Pro Ser
    Asp Gln Gln Asn Glu Met Val Arg Glu Leu Asp Gly
    His Val Leu Lys Cys Val Lys Asp Gln Asn Gly Asn
    His Val Val Gln Lys Cys Ile Glu Cys Val Gln Pro
    Gln Ser Leu Gln Phe Ile Ile Asp Ala Phe Lys Gly
    Gln Val Phe Ala Leu Ser Thr His Pro Tyr Gly Cys
    Arg Val Ile Gln Arg Ile Leu Glu His Cys Leu Pro
    Asp Gln Thr Leu Pro Ile Leu Glu Glu Leu His Gln
    His Thr Glu Gln Leu Val Gln Asp Gln Tyr Gly Asn
    Tyr Val Ile Gln His Val Leu Glu His Gly Arg Pro
    Glu Asp Lys Ser Lys Ile Val Ala Glu Ile Arg Gly
    Asn Val Leu Val Leu Ser Gln His Lys Phe Ala Ser
    Asn Val Val Glu Lys Cys Val Thr His Ala Ser Arg
    Thr Glu Arg Ala Val Leu Ile Asp Glu Val Cys Thr
    Met Asn Asp Gly Pro His Ser Ala Leu Tyr Thr Met
    Met Lys Asp Gln Tyr Ala Asn Tyr Val Val Gln Lys
    Met Ile Asp Val Ala Glu Pro Gly Gln Arg Lys Ile
    Val Met His Lys Ile Arg Pro His Ile Ala Thr Leu
    Arg Lys Tyr Thr Tyr Gly Lys His Ile Leu Ala Lys
    Leu Glu Lys Tyr Tyr Met Lys Asn Gly Val Asp Leu
    Gly
  • PUF(3-2) (SEQ ID NO:18) has two point mutations (C935S/Q939E) in the PUF repeat 3, and recognizes a cognate RNA with a mutation at position 6 of the NRE (A6G; SEQ ID NO:27 (5′-UGUAUGUA-3′)).
  • PUF (6-2/7-2)
    SEQ ID NO: 19
    Gly Arg Ser Arg Leu Leu Glu Asp Phe Arg Asn Asn
    Arg Tyr Pro Asn Leu Gln Leu Arg Glu Ile Ala Gly
    His Ile Met Glu Phe Ser Gln Asp Gln His Gly Ser
    Arg Phe Ile Gln Leu Lys Leu Glu Arg Ala Thr Pro
    Ala Glu Arg Gln Leu Val Phe Asn Glu Ile Leu Gln
    Ala Ala Tyr Gln Leu Met Val Asp Val Phe Gly Asn
    Tyr Val Ile Gln Lys Phe Phe Glu Phe Gly Ser Leu
    Glu Gln Lys Leu Ala Leu Ala Glu Arg Ile Arg Gly
    His Val Leu Ser Leu Ala Leu Gln Met Tyr Gly Cys
    Arg Val Ile Gln Lys Ala Leu Glu Phe Ile Pro Ser
    Asp Gln Gln Asn Glu Met Val Arg Glu Leu Asp Gly
    His Val Leu Lys Cys Val Lys Asp Gln Asn Gly Asn
    His Val Val Gln Lys Cys Ile Glu Cys Val Gln Pro
    Gln Ser Leu Gln Phe Ile Ile Asp Ala Phe Lys Gly
    Gln Val Phe Ala Leu Ser Thr His Pro Tyr Gly Cys
    Arg Val Ile Gln Arg Ile Leu Glu His Cys Leu Pro
    Asp Gln Thr Leu Pro Ile Leu Glu Glu Leu His Gln
    His Thr Glu Gln Leu Val Gln Asp Gln Tyr Gly Ser
    Tyr Val Ile Glu His Val Leu Glu His Gly Arg Pro
    Glu Asp Lys Ser Lys Ile Val Ala Glu Ile Arg Gly
    Asn Val Leu Val Leu Ser Gln His Lys Phe Ala Asn
    Asn Val Val Gln Lys Cys Val Thr His Ala Ser Arg
    Thr Glu Arg Ala Val Leu Ile Asp Glu Val Cys Thr
    Met Asn Asp Gly Pro His Ser Ala Leu Tyr Thr Met
    Met Lys Asp Gln Tyr Ala Asn Tyr Val Val Gln Lys
    Met Ile Asp Val Ala Glu Pro Gly Gln Arg Lys Ile
    Val Met His Lys Ile Arg Pro His Ile Ala Thr Leu
    Arg Lys Tyr Thr Tyr Gly Lys His Ile Leu Ala Lys
    Leu Glu Lys Tyr Tyr Met Lys Asn Gly Val Asp Leu
    Gly
  • PUF (6-2/7-2) (SEQ ID NO:19) has double point mutations (N1043S/Q1047E and S1079N/E1083Q) in repeats 6 and 7, respectively, and recognizes a cognate RNA sequence with two mutations at positions 2 and 3 of the NRE (GU/UG; SEQ ID NO:9 (5′-UUGAUAUA-3′)).
  • A related PUF (6-2) has point mutations (N1043S/Q1047E) in repeats 6, and recognizes a cognate RNA sequence with a mutation at position 3 of the NRE (SEQ ID NO: 11 (5′-UGGAUAUA-3′)).
  • Another related PUF (7-2) has point mutations (S1079N/E1083Q) in repeats 7, and recognizes a cognate RNA sequence with a mutation at position 2 of the NRE (SEQ ID NO: 12 (5′-UUUAUAUA-3′)).
  • PUF531
    SEQ ID NO: 22
    Gly Arg Ser Arg Leu Leu Glu Asp Phe Arg Asn Asn
    Arg Tyr Pro Asn Leu Gln Leu Arg Glu Ile Ala Gly
    His Ile Met Glu Phe Ser Gln Asp Gln His Gly Ser
    Arg Phe Ile Glu Leu Lys Leu Glu Arg Ala Thr Pro
    Ala Glu Arg Gln Leu Val Phe Asn Glu Ile Leu Gln
    Ala Ala Tyr Gln Leu Met Val Asp Val Phe Gly Asn
    Tyr Val Ile Gln Lys Phe Phe Glu Phe Gly Ser Leu
    Glu Gln Lys Leu Ala Leu Ala Glu Arg Ile Arg Gly
    His Val Leu Ser Leu Ala Leu Gln Met Tyr Gly Ser
    Arg Val Ile Glu Lys Ala Leu Glu Phe Ile Pro Ser
    Asp Gln Gln Asn Glu Met Val Arg Glu Leu Asp Gly
    His Val Leu Lys Cys Val Lys Asp Gln Asn Gly Asn
    His Val Val Gln Lys Cys Ile Glu Cys Val Gln Pro
    Gln Ser Leu Gln Phe Ile Ile Asp Ala Phe Lys Gly
    Gln Val Phe Ala Leu Ser Thr His Pro Tyr Gly Ser
    Arg Val Ile Glu Arg Ile Leu Glu His Cys Leu Pro
    Asp Gln Thr Leu Pro Ile Leu Glu Glu Leu His Gln
    His Thr Glu Gln Leu Val Gln Asp Gln Tyr Gly Asn
    Tyr Val Ile Gln His Val Leu Glu His Gly Arg Pro
    Glu Asp Lys Ser Lys Ile Val Ala Glu Ile Arg Gly
    Asn Val Leu Val Leu Ser Gln His Lys Phe Ala Ser
    Asn Val Val Glu Lys Cys Val Thr His Ala Ser Arg
    Thr Glu Arg Ala Val Leu Ile Asp Glu Val Cys Thr
    Met Asn Asp Gly Pro His Ser Ala Leu Tyr Thr Met
    Met Lys Asp Gln Tyr Ala Asn Tyr Val Val Gln Lys
    Met Ile Asp Val Ala Glu Pro Gly Gln Arg Lys Ile
    Val Met His Lys Ile Arg Pro His Ile Ala Thr Leu
    Arg Lys Tyr Thr Tyr Gly Lys His Ile Leu Ala Lys
    Leu Glu Lys Tyr Tyr Met Lys Asn Gly Val Asp Leu
    Gly
  • The PUF domain PUF531 (SEQ ID NO:22) has mutations (Q867E/Q939E/C935S/Q1011E/C1007S) in wild type PUF repeats 1, 3 and 5, and recognizes the sequence of SEQ ID NO:13 (5′-UGUGUGUG-3′). The PUF531 can recognize its new target sequence with very high affinity, compared to the wild type PUF RNA.
  • Another modified PUF domain PUF(1-1) has one point mutation (Q867E) in the PUF repeat 1, and recognizes a cognate RNA with a mutation at position 8 of the NRE (A8G; SEQ ID NO:14 (5′-UGUAUAUG-3′)).
  • Yet another modified PUF domain PUF(7-1) has one point mutation (E1083Q) in the PUF repeat 7, and recognizes a cognate RNA with a mutation at position 2 of the NRE (G2U; SEQ ID NO:12 (5′-UUUAUAUA-3′); or G2A; SEQ ID NO:15 (5′-UAUAUAUA-3′)).
  • Still another modified PUF domain PUF(3-1) has one point mutation (C935N) in the PUF repeat 3, and recognizes a cognate RNA with a mutation at position 6 of the NRE (A6U; SEQ ID NO:16 (5′-UGUAUUUA-3′)).
  • A further modified PUF (7-2/3-1) has point mutations (C935N/S1079N/E1083Q) in repeats 7 and 3, and recognizes a cognate RNA sequence with mutations at positions 2 and 6 of the NRE (SEQ ID NO:17 (5′-UUUAUUUA-3′)).
  • In embodiments, the PUF domain has a sequence of SEQ ID NO:29.
  • Gly Arg Ser Arg Leu Leu Glu Asp Phe Arg Asn Asn
    Arg Tyr Pro Asn Leu Gln Leu Arg Glu Ile Ala Gly
    His Ile Met Glu Phe Ser Gln Asp Gln His Gly Ser
    Arg Phe Ile Glu Leu Lys Leu Glu Arg Ala Thr Pro
    Ala Glu Arg Gln Leu Val Phe Asn Glu Ile Leu Gln
    Ala Ala Tyr Gln Leu Met Val Asp Val Phe Gly Cys
    Arg Val Ile Gln Lys Phe Phe Glu Phe Gly Ser Leu
    Glu Gln Lys Leu Ala Leu Ala Glu Arg Ile Arg Gly
    His Val Leu Ser Leu Ala Leu Gln Met Tyr Gly Cys
    Arg Val Ile Gln Lys Ala Leu Glu Phe Ile Pro Ser
    Asp Gln Gln Asn Glu Met Val Arg Glu Leu Asp Gly
    His Val Leu Lys Cys Val Lys Asp Gln Asn Gly Asn
    His Val Val Gln Lys Cys Ile Glu Cys Val Gln Pro
    Gln Ser Leu Gln Phe Ile Ile Asp Ala Phe Lys Gly
    Gln Val Phe Ala Leu Ser Thr His Pro Tyr Gly Cys
    Arg Val Ile Gln Arg Ile Leu Glu His Cys Leu Pro
    Asp Gln Thr Leu Pro Ile Leu Glu Glu Leu His Gln
    His Thr Glu Gln Leu Val Gln Asp Gln Tyr Gly Ser
    Tyr Val Ile Glu His Val Leu Glu His Gly Arg Pro
    Glu Asp Lys Ser Lys Ile Val Ala Glu Ile Arg Gly
    Asn Val Leu Val Leu Ser Gln His Lys Phe Ala Asn
    Asn Val Val Gln Lys Cys Val Thr His Ala Ser Arg
    Thr Glu Arg Ala Val Leu Ile Asp Glu Val Cys Thr
    Met Asn Asp Gly Pro His Ser Ala Leu Tyr Thr Met
    Met Lys Asp Gln Tyr Ala Ser Tyr Val Val Glu Lys
    Met Ile Asp Val Ala Glu Pro Gly Gln Arg Lys Ile
    Val Met His Lys Ile Arg Pro His Ile Ala Thr Leu
    Arg Lys Tyr Thr Tyr Gly Lys His Ile Leu Ala Lys
    Leu Glu Lys Tyr Tyr
    SEQ ID NO: 30
    Gly Arg Ser Arg Leu Leu Glu Asp Phe Arg Asn Asn
    Arg Tyr Pro Asn Leu Gln Leu Arg Glu Ile Ala Gly
    His Ile Met Glu Phe Ser Gln Asp Gln His Gly Asn
    Arg Phe Ile Gln Leu Lys Leu Glu Arg Ala Thr Pro
    Ala Glu Arg Gln Leu Val Phe Asn Glu Ile Leu Gln
    Ala Ala Tyr Gln Leu Met Val Asp Val Phe Gly Ser
    Tyr Val Ile Glu Lys Phe Phe Glu Phe Gly Ser Leu
    Glu Gln Lys Leu Ala Leu Ala Glu Arg Ile Arg Gly
    His Val Leu Ser Leu Ala Leu Gln Met Tyr Gly Ser
    Arg Val Ile Glu Lys Ala Leu Glu Phe Ile Pro Ser
    Asp Gln Gln Asn Glu Met Val Arg Glu Leu Asp Gly
    His Val Leu Lys Cys Val Lys Asp Gln Asn Gly Asn
    His Val Val Gln Lys Cys Ile Glu Cys Val Gln Pro
    Gln Ser Leu Gln Phe Ile Ile Asp Ala Phe Lys Gly
    Gln Val Phe Ala Leu Ser Thr His Pro Tyr Gly Ser
    Arg Val Ile Glu Arg Ile Leu Glu His Cys Leu Pro
    Asp Gln Thr Leu Pro Ile Leu Glu Glu Leu His Gln
    His Thr Glu Gln Leu Val Gln Asp Gln Tyr Gly Ser
    Tyr Val Ile Glu His Val Leu Glu His Gly Arg Pro
    Glu Asp Lys Ser Lys Ile Val Ala Glu Ile Arg Gly
    Asn Val Leu Val Leu Ser Gln His Lys Phe Ala Cys
    Asn Val Val Gln Lys Cys Val Thr His Ala Ser Arg
    Thr Glu Arg Ala Val Leu Ile Asp Glu Cys Val Thr
    Met Asn Asp Gly Pro His Ser Ala Leu Tyr Thr Met
    Met Lys Asp Gln Tyr Ala Ser Tyr Val Val Glu Lys
    Met Ile Asp Val Ala Glu Pro Gly Gln Arg Lys Ile
    Val Met His Lys Ile Arg Pro His Ile Ala Thr Leu
    Arg Lys Tyr Thr Tyr Gly Lys His Ile Leu Ala Lys
    Leu Glu Lys Tyr Tyr
    SEQ ID NO: 31
    Gly Arg Ser Arg Leu Leu Glu Asp Phe Arg Asn Asn
    Arg Tyr Pro Asn Leu Gln Leu Arg Glu Ile Ala Gly
    His Ile Met Glu Phe Ser Gln Asp Gln His Gly Cys
    Arg Phe Ile Gln Leu Lys Leu Glu Arg Ala Thr Pro
    Ala Glu Arg Gln Leu Val Phe Asn Glu Ile Leu Gln
    Ala Ala Tyr Gln Leu Met Val Asp Val Phe Gly Ser
    Tyr Val Ile Glu Lys Phe Phe Glu Phe Gly Ser Leu
    Glu Gln Lys Leu Ala Leu Ala Glu Arg Ile Arg Gly
    His Val Leu Ser Leu Ala Leu Gln Met Tyr Gly Asn
    Arg Val Ile Gln Lys Ala Leu Glu Phe Ile Pro Ser
    Asp Gln Gln Asn Glu Met Val Arg Glu Leu Asp Gly
    His Val Leu Lys Cys Val Lys Asp Gln Asn Gly Asn
    His Val Val Gln Lys Cys Ile Glu Cys Val Gln Pro
    Gln Ser Leu Gln Phe Ile Ile Asp Ala Phe Lys Gly
    Gln Val Phe Ala Leu Ser Thr His Pro Tyr Gly Cys
    Arg Val Ile Gln Arg Ile Leu Glu His Cys Leu Pro
    Asp Gln Thr Leu Pro Ile Leu Glu Glu Leu His Gln
    His Thr Glu Gln Leu Val Gln Asp Gln Tyr Gly Ser
    Tyr Val Ile Glu His Val Leu Glu His Gly Arg Pro
    Glu Asp Lys Ser Lys Ile Val Ala Glu Ile Arg Gly
    Asn Val Leu Val Leu Ser Gln His Lys Phe Ala Cys
    Asn Val Val Gln Lys Cys Val Thr His Ala Ser Arg
    Thr Glu Arg Ala Val Leu Ile Asp Glu Cys Val Thr
    Met Asn Asp Gly Pro His Ser Ala Leu Tyr Thr Met
    Met Lys Asp Gln Tyr Ala Cys Tyr Val Val Gln Lys
    Met Ile Asp Val Ala Glu Pro Gly Gln Arg Lys Ile
    Val Met His Lys Ile Arg Pro His Ile Ala Thr Leu
    Arg Lys Tyr Thr Tyr Gly Lys His Ile Leu Ala Lys
    Leu Glu Lys Tyr Tyr
  • The demethylation domain (e.g., TET1 domain), or methylation domain (e.g., Dnmt3a domain) or demethylation enhancer domain (e.g., NEIL2 domain, GADD45A domain) provided herein may be linked to a PUF domain as provided herein including embodiments thereof. Alternatively, the demethylation domain (e.g., TET1 domain), or methylation domain (e.g., Dnmt3a domain) or demethylation enhancer domain (e.g., NEIL2 domain, GADD45A domain) provided herein may be linked to the nuclease-deficient RNA-guided DNA endonuclease (e.g., dCas9). Where the demethylation domain or demethylation enhancer domain provided herein is directly linked (fused) to the nuclease-deficient RNA-guided DNA endonuclease (e.g., dCas9) a chemical linker may link the demethylation domain or methylation domain to the nuclease-deficient RNA-guided DNA endonuclease. In certain embodiments, the chemical linker is a peptide linker. In certain embodiments, the chemical linker is a poly-glycine linker. In certain embodiments, the demethylation domain or demethylation enhancer domain is linked to the C-terminus of the nuclease-deficient RNA-guided DNA endonuclease (e.g., dCas9). In certain embodiments, the demethylation domain or demethylation enhancer domain is linked to the N-terminus of the nuclease-deficient RNA-guided DNA endonuclease (e.g., dCas9).
  • Where the demethylation domain or demethylation enhancer domain provided herein is directly linked (fused) to the nuclease-deficient RNA-guided DNA endonuclease (e.g., dCas9), the demethylation domain or demethylation enhancer domain and the nuclease-deficient RNA-guided DNA endonuclease (e.g., dCas9) form a dCas9-demethylation domain conjugate or a dCas9-demethylation enhancer domain conjugate. In certain embodiments, the dCas9-demethylation domain (e.g., TET1 domain) conjugate has the sequence of SEQ ID NO:52. In certain embodiments, the dCas9-demethylation domain conjugate has the sequence of SEQ ID NO:53. In certain embodiments, the dCas9-methylation (e.g., Dnmt3a) domain conjugate has the sequence of SEQ ID NO:59. In certain embodiments, the dCas9-methylation domain conjugate has the sequence of SEQ ID NO:60. In certain embodiments, the dCas9-methylation domain conjugate has the sequence of SEQ ID NO:61. In certain embodiments, the dCas9-methylation domain conjugate has the sequence of SEQ ID NO:62. In certain embodiments, the dCas9-methylation domain conjugate has the sequence of SEQ ID NO:63. In certain embodiments, the dCas9-methylation domain conjugate has the sequence of SEQ ID NO:64.
  • The complexes provided herein may include an additional bioactive domain operably linked to the PUF domain or the nuclease-deficient RNA-guided DNA endonuclease (e. g., dCas9 protein). Thus, according to the invention, a heterologous polypeptide (also referred to as a “fusion partner”) can be fused to the PUF domain of the demethylation or demethylation enhancer protein conjugate provided herein including embodiments thereof, that binds to at least one of the PBS on the subject polynucleotide. In addition, if desired, the same or different fusion partner can also optionally be fused to the nuclease-deficient RNA-guided DNA endonuclease (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein). Thus as described herein, unless specifically disclaimed, any of the fusion partners are intended to be fused to the PUF domain of the demethylation or demethylation enhancer protein conjugate provided herein including embodiments thereof, and optionally also fused to the nuclease-deficient RNA-guided DNA endonuclease (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein). The fusion partner fused to the PUF domain can be the same or different from the optional fusion partner fused to the nuclease-deficient RNA-guided DNA endonuclease (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein) (infra). In certain embodiments the fusion partner is a bioactive moiety. In certain embodiments the fusion partner is a detectable moiety or a therapeutic moiety.
  • The fusion partner may exhibit an activity (e.g., enzymatic activity). Suitable fusion partners include, but are not limited to, a polypeptide that provides for methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylation activity, deadenylation activity, SUMOylating activity, deSUMOylating activity, ribosylation activity, deribosylation activity, myristoylation activity, or demyristoylation activity, any of which can be directed at modifying the DNA directly (e.g., methylation of DNA) or at modifying a DNA-associated polypeptide (e.g., a histone or DNA binding protein). Additional fusion partners may include the various fluorescent protein, polypeptides, variants, or functional domains thereof, such as GFP, Superfolder GFP, EGFP, BFP, EBFP, EBFP2, Azurite, mKalama1, CFP, ECFP, Cerulean, CyPet, mTurquoise2, YFP, Citrine, Venus, Ypet, BFPms1, roGFP, and bilirubin-inducible fluorescent proteins such as UnaG, dsRed, eqFP611, Dronpa, TagRFPs, KFP, EosFP, Dendra, IrisFP, etc.
  • Any of the fusion partners described in international application PCT/US2016/021491 and published as WO2016148994 A8, which is hereby incorporated by reference and for all purposes, is contemplated for the invention.
  • In embodiments, the fusion partner is a demethylation domain. In certain embodiments, the fusion partner is a demethylation enahncer domain.
  • Any of the subject PUF domain can be made using, for example, a Golden Gate Assembly kit (see Abil et al., Journal of Biological Engineering 8:7, 2014), which is available at Addgene (Kit #1000000051).
    • Demethylation and Demethylation Enhancer Domains
  • Provided herein are demethylation protein conjugates and demethylation enhancer conjugates useful for demethylating target loci in a cell. The demethylation protein conjugates include a PUF domain described herein, a TET demethylation domain (e.g., a TET1 domain) and a demethylation enhancer domain (e.g., a NEIL2 domain or a GADD45A domain). Alternatively, the complexes provided herein include a demethylation protein conjugate including a first PUF domain and a demethylation domain (e.g., a TET1 domain) and a demethylation enhancer conjugate including a second PUF domain and a demethylation enhancer domain (e.g., a NEIL2 domain or a GADD45A domain).
  • In certain embodiments, the demethylation enhancer domain is operably linked to the N-terminus of the PUF domain. In certain embodiments, the demethylation enhancer domain is operably linked to the C-terminus of the PUF domain. In certain embodiments, the demethylation enhancer domain is operably linked to the N-terminus of the second PUF domain. In certain embodiments, the demethylation enhancer domain is operably linked to the C-terminus of the second PUF domain.
  • In certain embodiments, the demethylation enhancer domain is a Growth Arrest and DNA-Damage-inducible Alpha (GADD45A) domain. In certain embodiments, the GADD45 domain has the amino acid sequence of SEQ ID NO:85. In certain embodiments, the demethylation enhancer domain is a NEIL2 domain. In certain embodiments, the NEIL2 domain has the amino acid sequence of SEQ ID NO:86. In certain embodiments, the demethylation enhancer domain is not a NEIL1 domain. In certain embodiments, the demethylation enhancer domain is not a NEIL3 domain.
  • A “demethylation enhancer domain”, “demethylation enhancer protein” or “demethylation enhancer enzyme” as provided herein refers to a protein, protein domain or protein moiety capable of positively affecting (e.g. increasing) the activity or function of a demethylation enzyme or demethylation domain, relative to the activity or function of the demethylation enzyme or demethylation domain in the absence of the activator (e.g. demethylation enhancer domain described herein). Thus, in certain embodiments, the demethylation enhancer domain may, at least in part, partially or totally increase stimulation, increase or enable activation, or activate the demethylation enzyme. The amount of increase in activity (activation) may be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more in comparison to a control in the absence of the demethylation enhancer domain. In certain embodiments, the activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more than the activity in the absence of the demethylation enhancer domain.
  • For the conjugates provided herein, the DNA demethylation domain may include a Ten-Eleven translocation 1 (TET1) domain. In certain embodiments, the DNA demethylation domain includes a Ten-Eleven translocation 2 (TET2) domain. In certain embodiments, the DNA demethylation domain includes a Ten-Eleven translocation 3 (TET3) domain. In certain embodiments, the TET1 domain includes the sequence of SEQ ID NO:51. In certain embodiments, the TET1 domain is the sequence of SEQ ID NO:51.
  • In certain embodiments, the TET protein is a TET methylcytosine dioxygenase. TET methylcytosine dioxygenase catalyzes the initial and critical step leading to replacing 5mC with unmethylated cytosine.
  • It was discovered that, when the TET1 demethylase catalytic domain (CD) was fused to the C-terminus of the PUF domain, the observed demethylase activity was surprisingly higher as compared to when the TET1 demethylase catalytic domain (CD) was fused to the N-terminus of the PUF domain. Thus, in certain embodiments, the demethylation protein conjugate (PUF domain fusion protein) includes a TET1 functional domain fused to the C-terminus of the PUF domain. In certain embodiments, the PUF domain is PUFa. In certain embodiments, transcription of the target gene is increased by more than 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 50-fold, 75-fold, 100-fold, 125-fold, 135-fold, 150-fold, 200-fold or more. In certain embodiments, the target gene is SOX.
  • In certain embodiments, the target gene comprises two or more target polynucleotide sequences. In certain embodiments, at least two of said same or different PUF domains are fused to a demethylase domain or a demethylase enhancer domain.
  • In embodiments, the demethylation protein conjugate includes the sequence of SEQ ID NO:54 or SEQ ID NO:55. In certain embodiments, the demethylation protein conjugate is the sequence of SEQ ID NO:54 or SEQ ID NO:55.
  • In embodiments, demethylation protein conjugate includes the sequence of SEQ ID NO: 104. In certain embodiments, demethylation protein conjugate is the sequence of SEQ ID NO: 104. In certain embodiments, demethylation protein conjugate includes the sequence of SEQ ID NO: 105. In certain embodiments, demethylation protein conjugate is the sequence of SEQ ID NO: 105.
  • In embodiments, demethylation enhancer conjugate includes the sequence of SEQ ID NO: 106. In certain embodiments, demethylation enhancer conjugate is the sequence of SEQ ID NO: 106. In certain embodiments, demethylation enhancer conjugate includes the sequence of SEQ ID NO: 107. In certain embodiments, demethylation enhancer conjugate is the sequence of SEQ ID NO:107.
  • In embodiments, demethylation enhancer conjugate includes the sequence of SEQ ID NO: 108. In certain embodiments, demethylation enhancer conjugate is the sequence of SEQ ID NO: 108. In certain embodiments, demethylation enhancer conjugate includes the sequence of SEQ ID NO: 109. In certain embodiments, demethylation enhancer conjugate is the sequence of SEQ ID NO:109.
    • Additional Complexes
  • Another aspect of the invention provides a complex comprising any one of the polynucleotide of the invention, and the modified Cas9 protein, e.g., nuclease-deficient wt Cas9 protein or dCas9 protein. In certain embodiments, the complex comprises a nuclease-deficient wt Cas9 protein.
  • In certain embodiments, the complex may further comprise one or more PUF domain or fusion thereof bound to the one or more PBS(s). In certain embodiments, each of the PUF domain is fused to an effector domain. In certain embodiments, at least two of the PUF domains are fused to different effector domains.
  • In certain embodiments, the nuclease-deficient wt Cas9 protein (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein), the PUF domain, and/or the effector domain further comprises a nuclear localization signal (NLS).
  • In certain embodiments, the complex is bound to the target polynucleotide sequence through the DNA-targeting sequence of the polynucleotide.
  • In certain embodiments, the effector domain is a TET (Ten-Eleven Translocation) protein, or a fragment thereof that retains demethylase catalytic activity. For example, the TET protein may be a TET methylcytosine dioxygenase.
  • In certain embodiments, the PUF domain fusion protein comprises a TET1 functional domain fused to the C-terminus of the PUF domain (e.g., PUFa).
  • In certain embodiments, the PUF domain fusion protein comprises a Dnmt functional domain fused to the N-terminus of the PUF domain (e.g., PUFa).
    • Cells
  • In another aspect, a cell including a demethylation complex as provided herein including embodiments thereof is provided. In certain embodiments, the cell is a mammalian cell. In certain embodiments, the cell is a cancer cell. In certain embodiments, the cell is a cancer cell, and/or the target gene is hMLH1 with a hypermethylated promoter region. For example, the target polynucleotide sequence may be within the hypermethylated promoter region of hMLH1, and methylation of the target polynucleotide sequence is associated with down-regulation of hMLH1 in cancer cells.
  • In certain embodiments, the cancer cell is from a stomach cancer, esophageal cancer, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), and colorectal cancer (such as HNPCC). The stomach cancer may include foveolar type tumors, and stomach cancer in high-incidence Kashmir Valley.
  • Another aspect of the invention provides a host cell including any one of the subject vector, polynucleotide, and complex.
  • In certain embodiments, the host cell further includes a second vector encoding the nuclease-deficient wt Cas9 protein (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein). In certain embodiments, the second vector further encodes a demethylation (effector) domain fused to the nuclease-deficient wt Cas9 protein (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein). The expression of the Cas9 protein (e.g., wt, nickase, or dCas9 protein) can be under the control of a constitutive promoter or an inducible promoter.
  • In certain embodiments, the host cell may further include a third vector encoding the one or more PUF domains, each fused to demethylation (effector) domain. The expression of the one or more PUF domains can be independently under the control of a constitutive promoter or an inducible promoter.
  • In certain embodiments, the second vector may further encode a nuclear localization signal (NLS) fused to the nuclease-deficient wt Cas9 protein (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein) or the methylation or demethylation (effector) domain, and/or the third vector may further encode a nuclear localization signal (NLS) fused to the PUF domain or the methylation or demethylation (effector) domain.
  • In certain embodiments, sequences that can be encoded by different vectors may be on the same vector. For example, in certain embodiments, the second vector may be the same as the vector, and/or the third vector may be the same as the vector or the second vector.
  • The host cell may be in a live animal, or may be a cultured cell.
    • Methods
  • The methods and complexes provided herein provide, inter alia, for a versatile delivery platform of demethylation activities. Using the methods and complexes provided herein demethylation protein conjugates including a demethylation domain and a demethylation enhancer domain (e.g., demethylation enzymes and demethylation enhancers or functional fragments thereof) or a combination of a demethylation protein conjugate and a demethylation enhancer conjugate, may be delivered to a cell sequentially or concomitantly. Delivery of a demethylation protein conjugate provided herein or a combination of a demethylation protein conjugate and a demethylation enhancer conjugate to a cell, allows for fine tuning the methylation status of a targeted gene locus. The invention further provides for the delivery of a plurality of demethylation protein conjugates, wherein the conjugates may be the same or different. Where a plurality of demethylation protein conjugates is delivered to a cell, the conjugates may form part of a plurality of conjugates, each linked to a PUF domain, and/or they may be directly fused to the nuclease-deficient RNA-guided DNA endonuclease enzyme (e.g., dCas9). Further, and by virtue of the target-gene specificity of the guide RNA, the present invention allows for the delivery of enhanced demethylation activities to different target sites in a cell at the same time. Applicants were the first to show that due to the pairing of the demethylation domains (e.g., TET1 domain) with very specific enhancer proteins (e.g., GADD45A or NEIL2), demethylation using the complexes provided herein is more efficient compared to, for example, demethylation in the absence of the enhancer domain or compared to directly linking demethylation activities to the nuclease-deficient RNA-guided DNA endonuclease enzyme (e.g., dCas9).
  • For the methods of demethylating provided herein including embodiments thereof, any of the element of the complexes described above may be used. Thus, in certain embodiments, the method includes delivering a first polynucleotide encoding a nuclease-deficient RNA-guided DNA endonuclease enzyme as provided herein including embodiments thereof (e.g., dCas9). Thus, the method may include delivering a second polynucleotide, which is the polynucleotide described herein including embodiments thereof and which encodes a DNA-targeting sequence, a binding sequence and one or more PUF binding site (PBS) sequences provided herein.
  • In another aspect, a method of demethylating a target nucleic acid sequence in a mammalian cell is provided. The method includes:
      • (a) providing a mammalian cell containing a target nucleic acid requiring demethylation;
      • (b) delivering to the mammalian cell a first polynucleotide encoding a nuclease-deficient RNA-guided DNA endonuclease enzyme;
      • (c) delivering to the mammalian cell a second polynucleotide including:
        • (i) a DNA-targeting sequence that is complementary to a target polynucleotide sequence;
        • (ii) a binding sequence for the nuclease-deficient RNA-guide DNA endonuclease enzyme; and
        • (iii) one or more PUF binding site (PBS) sequences,
        • wherein the nuclease-deficient RNA-guided DNA endonuclease enzyme is bound to the second polynucleotide via the binding sequence;
      • (d) delivering to the mammalian cell a third polynucleotide encoding a demethylation protein conjugate comprising:
        • (i) a PUF domain having a C-terminus;
        • (ii) a demethylation enhancer domain, having a N-terminus and a C-terminus,
        • wherein the N-terminus of the demethylation enhancer domain is operably linked to the C-terminus of the PUF domain; and
        • (iii) a TET demethylation domain operably linked to the C-terminus of the demethylation enhancer domain, whereby the delivered demethylation protein conjugate demethylates the target nucleic acid sequence in the cell.
  • In one aspect, a demethylation complex is provided. The demethylation complex includes:
      • (a) a ribonucleoprotein complex including:
        • (i) a nuclease-deficient RNA-guided DNA endonuclease enzyme; and
        • (ii) a polynucleotide including:
          • (1) a DNA-targeting sequence that is complementary to a target polynucleotide sequence;
          • (2) a binding sequence for the nuclease-deficient RNA-guided DNA endonuclease enzyme;
          • (3) a first PUF binding site (PBS) sequence; and
          • (4) a second PUF binding site (PBS) sequence,
          • wherein the nuclease-deficient RNA-guided DNA endonuclease enzyme is bound to the polynucleotide via the binding sequence;
      • (b) a demethylation protein conjugate including:
        • (i) a first PUF domain having a C-terminus, and
        • (ii) a TET demethylation domain operably linked to the C-terminus of the first PUF domain,
        • wherein the demethylation protein conjugate binds to the ribonucleoprotein complex via the first PUF domain binding to the first PBS sequence; and
      • (c) a demethylation enhancer conjugate including:
        • (i) a second PUF domain; and
        • (ii) a demethylation enhancer domain operably linked to the second PUF domain,
          wherein the demethylation enhancer conjugate binds to the ribonucleoprotein complex via the second PUF domain binding to the second PBS sequence to form a demethylation complex.
  • In another aspect, a method of demethylating a target nucleic acid sequence in a mammalian cell is provided. The method includes:
      • (a) providing a mammalian cell containing a target nucleic acid requiring demethylation;
      • (b) delivering to the mammalian cell a first polynucleotide encoding a nuclease-deficient RNA-guided DNA endonuclease enzyme;
      • (c) delivering to the mammalian cell a second polynucleotide including:
        • (i) a DNA-targeting sequence that is complementary to a target polynucleotide sequence;
        • (ii) a binding sequence for the nuclease-deficient RNA-guide DNA endonuclease enzyme;
        • (iii) a first PUF binding site (PBS) sequence, and
        • (iv) a second PUF binding site (PBS) sequence,
        • wherein the nuclease-deficient RNA-guided DNA endonuclease enzyme is bound to the second polynucleotide via the binding sequence;
      • (d) delivering to the mammalian cell a third polynucleotide encoding a demethylation protein conjugate including:
        • (i) a first PUF domain; and
        • (ii) a demethylation domain, the demethylation domain operably linked to the C-terminus of the first PUF domain, and
      • (e) delivering to the mammalian cell a fourth polynucleotide encoding a demethylation enhancer conjugate including:
        • (i) a second PUF domain; and
        • (ii) a demethylation enhancer domain operably linked to the second PUF domain, whereby the delivered demethylation protein conjugate demethylates the target nucleic acid sequence in the cell.
  • In certain embodiments, the demethylation protein conjugate binds to the ribonucleoprotein complex via the PUF domain binding to the one or more PBS sequences to form a demethylation complex. In certain embodiments, the first polynucleotide is contained within a first vector. In certain embodiments, the second polynucleotide is contained within a second vector. In certain embodiments, the third polynucleotide is contained within a third vector. In certain embodiments, the first, second or third vector is the same. In certain embodiments, the delivering is performed by transfection.
  • In certain embodiments, the demethylation protein conjugate binds to the ribonucleoprotein complex via the first PUF domain binding to the first PBS sequence. In certain embodiments, the demethylation enhancer conjugate binds to the ribonucleoprotein complex via the second PUF domain binding to the second PBS sequence. In certain embodiments, the demethylation enhancer domain is operably linked to the N-terminus of the second PUF domain. In certain embodiments, the demethylation enhancer domain is operably linked to the C-terminus of the second PUF domain. In certain embodiments, the first polynucleotide is contained within a first vector. In certain embodiments, the second polynucleotide is contained within a second vector. In certain embodiments, the third polynucleotide is contained within a third vector. In certain embodiments, the fourth polynucleotide is contained within a fourth vector. In certain embodiments, either the first, second, third or fourth vector is the same. In certain embodiments, the delivering is performed by transfection.
  • In certain embodiments, the method of the invention utilizes a plurality or a library of the vectors, each encoding a polynucleotide of the invention, wherein two of the vectors differ in the encoded polynucleotides in their respective DNA-targeting sequences, Cas9-binding sequences, and/or the copy number, identity (sequence, binding specificity, etc.), or relative order of the PBS. In a related embodiment, instead of using vectors, non-vector coding sequences are used.
  • In certain embodiments, the method further comprises introducing into the cell a plurality of any one of the subject vectors, wherein two of the vectors differ in the encoded polynucleotides in their respective DNA-targeting sequences, Cas9-binding sequences, and/or the copy number, identity, or relative order of the PBS. In a related embodiment, instead of using vectors, non-vector coding sequences are used.
    • Methods of Treatment
  • The methods of enhanced demethylating a target nucleic acid in a cell may be used, inter alia, for the treatment of diseases related to or caused by abnormal DNA methylation (e.g., cancer). A role for both epigenetic (DNA methylation) and genetic (mutations) actions of cytidine deaminases in cancer has been proposed, and a possible role in demethylation which is widespread. The present invention has practical application in ameliorating/treating the cancer disease process by altering the demethylation or demethylation status within the cancer cell. Using the methods and compositions provided herein methylated genes can be targeted for demethylation in vivo, which may lead to their expression (methylation being a repressive modification most of the time).
  • Most if not all cancers undergo epigenetic changes, including significantly the methylation and silencing of tumor suppressor genes. Demethylation of tumor suppressor genes can ameliorate cancer phenotype. Hence, a method of targeting demethylation in vivo to tumor suppressor genes is a very promising avenue to cancer therapy.
  • Targeting of cytidine deaminase activity to genes of interest in cancer can include, for example, fusion of the cytidine deaminase to a tumor suppressor DNA binding domain, (such as the zinc finger DNA core binding region of the p53 protein). It is believed that in many cancers, mutation of the DNA binding domain of p53 can contribute to transformation. In addition, the promoter regions of many tumor suppressor genes, including p53 targets, are methylated in cancer cells.
  • The molecules and pharmaceutical compositions of the present invention can be assessed for their anti-cancer/anti-tumorigenic effects by utilizing in vitro and ex vivo assays. In one suitable assay, a nucleic acid vector that expresses a molecule of the invention is transfected into a cancer cell. Appropriate controls are established comprising the cancer cell line transfected with vector backbone only, or vector plus a molecule of the invention in which the cytidine deaminase domain is rendered non-functional described in more detail below. Induced apoptosis in the cancer cell line transfected with the molecules of the invention but not in the control cells would be indicative of an anti-cancer effect for the molecule of the invention.
  • In another aspect, a method of treating cancer in a subject in need thereof is provided. The method includes, administering to a subject a therapeutically effective amount of a demethylation complex or methylation complex as provided herein including embodiments thereof, thereby treating cancer in the subject. In a preferred embodiment, the method includes administering to a subject a therapeutically effective amount of a demethylation complex as provided herein.
  • In another aspect, pharmaceutical composition is provided. The pharmaceutical composition includes therapeutically effective amount of a demethylation complex as provided herein including embodiments thereof and a pharmaceutically acceptable excipient.
  • Additional applications for the methods and compositions provided herein include modulating gene expression during development. For example, the presence of a site specific DNA binding domain allows for targeted demethylation of specific subsets of genes activated at particular times in development or during the cell cycle. For instance, the DNA binding domains of the (e.g., Oct4 or SOX-2) proteins when fused to a PUF domain could provide for a demethylation activity that is directed towards genes that are involved in cell fate decisions relating to promotion of a pluripotent or stem cell-like phenotype. Alternatively, the demethylation domain may be linked via a linker to PUF binding domain. DNA binding domains that could optionally be utilized include those from T-box transcription factors or steroid hormone receptor DNA binding domains such as the RAR and RXR DNA binding domains. Nevertheless, the present demethylation protein conjugate may be sufficient to demethylate the promoters of a pluripotent gene and alter the methylation status of a cell during differentiation.
    • Further Methods
  • Another aspect of the invention provides a method of modulating transcription and/or methylation state of a target gene in a cancer cell according to any method of the invention, wherein the cancer cell is associated with or characterized by abonormal DNA methylation.
  • A related aspect of the invention provides a method of modulating transcription and/or methylation state of a target gene in a cancer cell in a patient according to any method of the invention, wherein the cancer cell is associated with or characterized by abonormal DNA methylation.
  • Another related aspect of the invention provides a method for treating a patient in need of treatment a disease or condition associated with abnormal DNA methylation, such as CpG methylation, of a target gene, the method comprising allowing the formation of the complex of the invention near or at the target gene to modulate transcription and/or methylation state of the target gene in the patient.
  • Another related aspect of the invention provides a method for treating a patient in need of treatment a disease or condition associated with abnormal DNA methylation (such as CpG methylation) of a target gene, the method comprising modulating transcription and/or methylation state of the target gene in the patient according to any of the subject methods.
  • Another related aspect of the invention provides a method for treating a patient in need of treatment a disease or condition associated with abnormal DNA methylation (such as CpG methylation) of a target gene, the method comprising allowing the formation of the complex of the invention near or at the target gene to modulate transcription and/or methylation state of the target gene in the patient.
  • In a related aspect, the invention provides a method of treating cancer in a patient in need of treatment, wherein said cancer is associated with or characterized by abnormal DNA methylation of hMLH1, the method comprising modulating transcription and/or methylation state of hMLH1 in the patient according to any one of the methods of the invention. For example, in certain embodiment, the PUF domain fusion protein may comprise a TET1 functional domain fused to the C-terminus of the PUF domain such as PUFa. In certain embodiments, the methylation level of the hypermethylated promoter region of hMLH1 is decreased. In certain embodiments, transcription/translation of hMLH1 is increased.
  • In certain embodiments, the target gene is hMLH1.
  • In certain embodiments, the disease is a cancer. In certain embodiments, the disease is an imprinting disorder. In certain embodiments, the disease is a neurological disease.
  • In certain embodiments, the cancer is associated with or characterized by hyper- or hypomethylation of a tumor suppressor gene or an oncogene, respectively.
  • In certain embodiments, the cancer is a stomach cancer (including foveolar type tumors, and stomach cancer in high-incidence Kashmir Valley), esophageal cancer, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), and colorectal cancer (such as HNPCC).
  • Yet another aspect of the invention provides a method of assembling the complex of the invention at the target polynucleotide sequence, the method comprising contacting or bringing to the vicinity of the target polynucleotide sequence: (1) any one of the subject polynucleotide, or any one of the subject vector, or the plurality of vectors; (2) the nuclease-deficient wt Cas9 protein (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein), or any one of the subject second vector encoding the nuclease-deficient wt Cas9 protein (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein); and, (3) one or more of the PUF domains, each fused to an effector domain, or any one of the third vector encoding the PUF domain fusions. In certain embodiments, the fusion is with a DNA methyltransferase or a demethylase.
  • In certain embodiments, the complex is assembled inside a cell, the target polynucleotide sequence is a part of the genomic DNA of the cell, and wherein the subject vector, second vector, and third vector are introduced into the cell.
  • A related aspect of the invention provides a method of modulating transcription of a plurality of target genes in a cell, the method comprising: introducing into the cell the subject plurality of the vectors, a coding sequence for a dCas9 protein, and a coding sequence for one or more PUF domain fusions, wherein each of the target genes comprises a target polynucleotide sequence that permits (1) the assembly, at the target polynucleotide sequence, of a tripartite complex of a polynucleotide encoded by one of the plurality of the vector, the dCas9 protein, and a PUF domain fusion; and (2) transcription modulation of the target gene comprising the target polynucleotide sequence.
  • In a related aspect, the invention also provides a method of epigenetic modulation (e.g., modulating the epigenetic states of chromatin not directly related to transcriptional activity), at a plurality of target genes in a cell, the method comprising: introducing into the cell the subject plurality of the vectors, a coding sequence for a nuclease-deficient wt Cas9 protein, and a coding sequence for one or more PUF domain fusions, wherein each of the target genes comprises a target polynucleotide sequence that permits (1) the assembly, at the target polynucleotide sequence, of a tripartite complex of a polynucleotide encoded by one of the plurality of the vector, the wt Cas9 protein or the Cas9 nickase, and a PUF domain fusion; and (2) epigenetic modulation of the target gene comprising the target polynucleotide sequence. The method can be useful, for example, to change epigenetic state (e.g., opening up the chromatin) at the same time to gain access/stability of nuclease-deficient wt Cas9 protein (e.g., dCas9) binding to closed chromatin sites (e.g., to increase cut and genome editing at those sites).
  • In certain embodiments, the transcription of at least one target gene is enhanced/stimulated, while the transcription of at least another target gene is inhibited.
  • In one aspect of the invention provides a method of modulating transcription and/or methylation state of a target gene having a target polynucleotide sequence in a cell, the method comprises:
      • (a) introducing into the cell a coding sequence for a PUF domain fusion protein, wherein said PUF domain fusion protein comprises a PUF domain, and a DNA methyltransferase activity domain or a DNA demethylase activity domain;
      • (b) introducing into the cell a coding sequence for a dCas9 protein; and,
      • (c) introducing into the cell a polynucleotide or a coding sequence for said polynucleotide, wherein said polynucleotide comprising:
        • (i) a DNA-targeting sequence that is complementary to the target polynucleotide sequence;
        • (ii) one or more copies of PUF binding site (PBS) sequence, wherein each of said one or more copies of PBS bind to the same or a different PUF domain fusion protein; and,
        • (iii) a Cas9-binding sequence capable of binding to the dCas9 protein;
      • wherein said PUF domain fusion protein, said dCas9 protein, and said polynucleotide form a complex at the target polynucleotide sequence within the target gene of said cell, thereby modulating the transcription and/or methylation state of the target gene.
  • It should be noted that the coding sequence for a PUF domain fusion protein, the coding sequence for the nuclease-deficient RNA-guided DNA endonuclease (dCas9 protein), and the polynucleotide (or a vector encoding the polynucleotide) can be introduced into the cell together (e.g., by including all coding sequences on the same vector, by co-transfecting different vectors encoding different coding sequences, etc.), or separately, in any order or sequence as desired. In certain preferred embodiments, the coding sequence for a PUF domain fusion protein, the coding sequence for a nuclease-deficient RNA-guided DNA endonuclease (dCas9 protein), and the polynucleotide (or a vector encoding the polynucleotide) are co-introduced into the cell.
  • In addition, it is not intended that the (a), (b), and (c) steps of the invention necessarily have to be performed in any specific order, if they are to be performed separately.
  • The target polynucleotide sequence can be any DNA sequence. In certain embodiments, the target polynucleotide sequence comprises, or is adjacent to, one or more transcription regulatory element(s). In certain embodiments, the transcription regulatory element(s) comprises one or more of: a core promoter, a proximal promoter element, an enhancer, a silencer, an insulator, and a locus control region.
    • Kits
  • In another aspect, a kit is provided. The kit includes:
      • (i) a ribonucleoprotein complex as provided herein including embodiments thereof or a nucleic acid encoding the same; and
      • (ii) a demethylation protein conjugate as provided herein including embodiments thereof or a nucleic acid encoding the same.
  • In another aspect, a kit is provided. The kit includes:
      • (i) a ribonucleoprotein complex as provided herein including embodiments thereof or a nucleic acid encoding the same;
      • (ii) a demethylation protein conjugate as provided herein including embodiments thereof or a nucleic acid encoding the same; and
      • (iii) a demethylation enhancer conjugate as provided herein including embodiments thereof or a nucleic acid encoding the same.
  • In embodiments, a subject kit may include: a) a polynucleotide of the present invention, or a nucleic acid (e.g., vector) including a nucleotide sequence encoding the same; optionally, b) a subject nuclease-deficient wt Cas9 protein (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein), or a vector encoding the same (including an expressible mRNA encoding the same); and optionally, c) one or more subject demethylation or methylation protein conjugate (PUF domain fusion) each including a PUF domain fused to a demethylation or methylation domain (effector domain) that may be the same or different among the different demethylation or methylation protein conjugates (PUF domain fusions), or a vector encoding the same (including an expressible mRNA encoding the same).
  • In certain embodiments, one or more of a)-c) may be encoded by the same vector.
  • In certain embodiments, the kit also comprises one or more buffers or reagents that facilitate the introduction of any one of a)-c) into a host cell, such as reagents for transformation, transfection, or infection.
  • For example, a subject kit can further include one or more additional reagents, where such additional reagents can be selected from: a buffer; a wash buffer; a control reagent; a control expression vector or RNA polynucleotide; a reagent for in vitro production of the nuclease-deficient wt Cas9 protein or dCas9 or PUF domain fusion from DNA; and the like.
  • Components of a subject kit can be in separate containers; or can be combined in a single container.
  • In addition to above-mentioned components, a subject kit can further include instructions for using the components of the kit to practice the subject methods. The instructions for practicing the subject methods are generally recorded on a suitable recording medium. For example, the instructions may be printed on a substrate, such as paper or plastic, etc. As such, the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or subpackaging) etc. In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. CD-ROM, diskette, flash drive, etc. In yet other embodiments, the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.
  • With the invention generally described above, various features of the invention will be further elaborated below. It should be understood that features of the invention, even when described in the context of separate embodiments, or even separate embodiments under different aspects of the invention, may be provided in combination in a single embodiment. Conversely, various features of the invention described in the context of a single embodiment, may also be provided separately or in any suitable subcombination. All combinations of the embodiments pertaining to the invention are specifically embraced by the present invention and are disclosed herein just as if each and every combination was individually and explicitly disclosed. In addition, all sub-combinations of the various embodiments and elements thereof are also specifically embraced by the present invention and are disclosed herein just as if each and every such sub-combination was individually and explicitly disclosed herein.
    • Definitions
  • Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art. See, e.g., Singleton et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY 2nd ed., J. Wiley & Sons (New York, N.Y. 1994); Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL, Cold Springs Harbor Press (Cold Springs Harbor, N Y 1989). Any methods, devices and materials similar or equivalent to those described herein can be used in the practice of this invention. The following definitions are provided to facilitate understanding of certain terms used frequently herein and are not meant to limit the scope of the present disclosure.
  • “Nucleic acid” refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single-, double- or multiple-stranded form, or complements thereof. The term “polynucleotide” refers to a linear sequence of nucleotides. The term “nucleotide” typically refers to a single unit of a polynucleotide, i.e., a monomer. Nucleotides can be ribonucleotides, deoxyribonucleotides, or modified versions thereof. Examples of polynucleotides contemplated herein include single and double stranded DNA, single and double stranded RNA (including siRNA and mRNA), and hybrid molecules having mixtures of single and double stranded DNA and RNA. Nucleic acids can be linear or branched. For example, nucleic acids can be a linear chain of nucleotides or the nucleic acids can be branched, e.g., such that the nucleic acids comprise one or more arms or branches of nucleotides. Optionally, the branched nucleic acids are repetitively branched to form higher ordered structures such as dendrimers and the like.
  • Nucleic acids, including nucleic acids with a phosphothioate backbone can include one or more reactive moieties. As used herein, the term reactive moiety includes any group capable of reacting with another molecule, e.g., a nucleic acid or polypeptide through covalent, non-covalent or other interactions. By way of example, the nucleic acid can include an amino acid reactive moiety that reacts with an amio acid on a protein or polypeptide through a covalent, non-covalent or other interaction.
  • The terms also encompass nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphodiester derivatives including, e.g., phosphoramidate, phosphorodiamidate, phosphorothioate (also known as phosphothioate), phosphorodithioate, phosphonocarboxylic acids, phosphonocarboxylates, phosphonoacetic acid, phosphonoformic acid, methyl phosphonate, boron phosphonate, or O-methylphosphoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press); and peptide nucleic acid backbones and linkages. Other analog nucleic acids include those with positive backbones; non-ionic backbones, modified sugars, and non-ribose backbones (e.g. phosphorodiamidate morpholino oligos or locked nucleic acids (LNA)), including those described in U.S. Pat. Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, Carbohydrate Modifications in Antisense Research, Sanghui & Cook, eds. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids. Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g., to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made. In certain embodiments, the internucleotide linkages in DNA are phosphodiester, phosphodiester derivatives, or a combination of both.
  • As used herein, the range of values provided includes the specified value. As recognized by a person of ordinary skill in the art such specified value would reasonably include a standard deviation using measurements generally acceptable in the art. In certain embodiments, the standard deviation includes a range extending to +/−10% of the specified value.
  • The terms “polypeptide,” “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues, wherein the polymer may be conjugated to a moiety that does not consist of amino acids. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers. The terms apply to macrocyclic peptides, peptides that have been modified with non-peptide functionality, peptidomimetics, polyamides, and macrolactams. A “fusion protein” refers to a chimeric protein encoding two or more separate protein sequences that are recombinantly expressed as a single moiety.
  • The term “peptidyl” and “peptidyl moiety” means a monovalent peptide.
  • The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid. The terms “non-naturally occurring amino acid” and “unnatural amino acid” refer to amino acid analogs, synthetic amino acids, and amino acid mimetics which are not found in nature.
  • Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
  • An amino acid or nucleotide base “position” is denoted by a number that sequentially identifies each amino acid (or nucleotide base) in the reference sequence based on its position relative to the N-terminus (or 5′-end). Due to deletions, insertions, truncations, fusions, and the like that must be taken into account when determining an optimal alignment, in general the amino acid residue number in a test sequence determined by simply counting from the N-terminus will not necessarily be the same as the number of its corresponding position in the reference sequence. For example, in a case where a variant has a deletion relative to an aligned reference sequence, there will be no amino acid in the variant that corresponds to a position in the reference sequence at the site of deletion. Where there is an insertion in an aligned reference sequence, that insertion will not correspond to a numbered amino acid position in the reference sequence. In the case of truncations or fusions there can be stretches of amino acids in either the reference or aligned sequence that do not correspond to any amino acid in the corresponding sequence.
  • The terms “numbered with reference to” or “corresponding to,” when used in the context of the numbering of a given amino acid or polynucleotide sequence, refers to the numbering of the residues of a specified reference sequence when the given amino acid or polynucleotide sequence is compared to the reference sequence.
  • “Conservatively modified variants” applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are “silent variations,” which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence with respect to the expression product, but not with respect to actual probe sequences.
  • As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.
  • The following eight groups each contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M).
  • “Percentage of sequence identity” is determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.
  • The terms “identical” or percent “identity,” in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., 60% identity, optionally 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identity over a specified region, e.g., of the entire polypeptide sequences of the invention or individual domains of the polypeptides of the invention), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Such sequences are then said to be “substantially identical.” This definition also refers to the complement of a test sequence. Optionally, the identity exists over a region that is at least 50 nucleotides in length, or more preferably over a region that is 100 to 500 or 1000 or more nucleotides in length.
  • For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.
  • A “comparison window”, as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of, e.g., a full length sequence or from 20 to 600, 50 to 200, or 100 to 150 amino acids or nucleotides in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman (1988) Proc. Nat'l. Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manual alignment and visual inspection (see, e.g., Ausubel et al., Current Protocols in Molecular Biology (1995 supplement)).
  • An example of an algorithm that is suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1977) Nuc. Acids Res. 25:3389-3402, and Altschul et al. (1990) J. Mol. Biol. 215:403-410, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) or 10, M=5, N=−4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915) alignments (B) of 50, expectation (E) of 10, M=5, N=−4, and a comparison of both strands.
  • The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5787). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than 0.2, more preferably less than 0.01, and most preferably less than 0.001.
  • An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross-reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequence.
  • A “label” or a “detectable moiety” is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include 32P, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins or other entities which can be made detectable, e.g., by incorporating a radiolabel into a peptide or antibody specifically reactive with a target peptide. Any appropriate method known in the art for conjugating an antibody to the label may be employed, e.g., using methods described in Hermanson, Bioconjugate Techniques 1996, Academic Press, Inc., San Diego.
  • A “bioactive moiety” as provided herein refers to a moiety that upon administration to a cell, tissue or organism has a detectable effect on the biological function of said cell, tissue or organism. In certain embodiments, the detectable effect is a biological effect. In certain embodiments, the detectable effect is a therapeutic effect. In certain embodiments, the detectable effect is a diagnostic effect.
  • A “labeled protein or polypeptide” is one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the labeled protein or polypeptide may be detected by detecting the presence of the label bound to the labeled protein or polypeptide. Alternatively, methods using high affinity interactions may achieve the same results where one of a pair of binding partners binds to the other, e.g., biotin, streptavidin.
  • “Biological sample” or “sample” refer to materials obtained from or derived from a subject or patient. A biological sample includes sections of tissues such as biopsy and autopsy samples, and frozen sections taken for histological purposes. Such samples include bodily fluids such as blood and blood fractions or products (e.g., serum, plasma, platelets, red blood cells, and the like), sputum, tissue, cultured cells (e.g., primary cultures, explants, and transformed cells) stool, urine, synovial fluid, joint tissue, synovial tissue, synoviocytes, fibroblast-like synoviocytes, macrophage-like synoviocytes, immune cells, hematopoietic cells, fibroblasts, macrophages, T cells, etc. A biological sample is typically obtained from a eukaryotic organism, such as a mammal such as a primate e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish.
  • A “cell” as used herein, refers to a cell carrying out metabolic or other function sufficient to preserve or replicate its genomic DNA. A cell can be identified by well-known methods in the art including, for example, presence of an intact membrane, staining by a particular dye, ability to produce progeny or, in the case of a gamete, ability to combine with a second gamete to produce a viable offspring. Cells may include prokaryotic and eukaryotic cells. Prokaryotic cells include but are not limited to bacteria. Eukaryotic cells include but are not limited to yeast cells and cells derived from plants and animals, for example mammalian, insect (e.g., spodoptera) and human cells.
  • The word “expression” or “expressed” as used herein in reference to a gene means the transcriptional and/or translational product of that gene. The level of expression of a DNA molecule in a cell may be determined on the basis of either the amount of corresponding mRNA that is present within the cell or the amount of protein encoded by that DNA produced by the cell (Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 18.1-18.88).
  • Expression of a transfected gene can occur transiently or stably in a cell. During “transient expression” the transfected gene is not transferred to the daughter cell during cell division. Since its expression is restricted to the transfected cell, expression of the gene is lost over time. In contrast, stable expression of a transfected gene can occur when the gene is co-transfected with another gene that confers a selection advantage to the transfected cell. Such a selection advantage may be a resistance towards a certain toxin that is presented to the cell.
  • The term “exogenous” refers to a molecule or substance (e.g., nucleic acid or protein) that originates from outside a given cell or organism. Conversely, the term “endogenous” refers to a molecule or substance that is native to, or originates within, a given cell or organism.
  • The terms “transfection”, “transduction”, “transfecting” or “transducing” can be used interchangeably and are defined as a process of introducing a nucleic acid molecule and/or a protein to a cell. Nucleic acids may be introduced to a cell using non-viral or viral-based methods. The nucleic acid molecule can be a sequence encoding complete proteins or functional portions thereof. Typically, a nucleic acid vector, comprising the elements necessary for protein expression (e.g., a promoter, transcription start site, etc.). Non-viral methods of transfection include any appropriate method that does not use viral DNA or viral particles as a delivery system to introduce the nucleic acid molecule into the cell. Exemplary non-viral transfection methods include calcium phosphate transfection, liposomal transfection, nucleofection, sonoporation, transfection through heat shock, magnetifection and electroporation. For viral-based methods, any useful viral vector can be used in the methods described herein. Examples of viral vectors include, but are not limited to retroviral, adenoviral, lentiviral and adeno-associated viral vectors. In some aspects, the nucleic acid molecules are introduced into a cell using a retroviral vector following standard procedures well known in the art. The terms “transfection” or “transduction” also refer to introducing proteins into a cell from the external environment. Typically, transduction or transfection of a protein relies on attachment of a peptide or protein capable of crossing the cell membrane to the protein of interest. See, e.g., Ford et al. (2001) Gene Therapy 8:1-4 and Prochiantz (2007) Nat. Methods 4:119-20.
  • A nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, “operably linked” means that the DNA sequences being linked are near each other, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
  • The term “gene” means the segment of DNA involved in producing a protein; it includes regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons). The leader, the trailer as well as the introns include regulatory elements that are necessary during the transcription and the translation of a gene. Further, a “protein gene product” is a protein expressed from a particular gene.
  • For specific proteins described herein (e.g., dCas9), the named protein includes any of the protein's naturally occurring forms, or variants or homologs that maintain the protein transcription factor activity (e.g., within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to the native protein). In some embodiments, variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g. a 50, 100, 150 or 200 continuous amino acid portion) compared to a naturally occurring form. In other embodiments, the protein is the protein as identified by its NCBI sequence reference. In other embodiments, the protein is the protein as identified by its NCBI sequence reference or functional fragment or homolog thereof.
  • Thus, a “methylcytosine dioxygenase TET1” or “TET1” protein as referred to herein includes any of the recombinant or naturally-occurring forms of the TET1 dioxygenase or variants or homologs thereof that maintain TET1 dioxygenase enzyme activity (e.g. within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to TET1). In some aspects, the variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g. a 50, 100, 150 or 200 continuous amino acid portion) compared to a naturally occurring TET1 protein. In certain embodiments, the TET1 protein is substantially identical to the protein identified by the UniProt reference number Q8NFU7 or a variant or homolog having substantial identity thereto.
  • Thus, a “methylcytosine dioxygenase TET2” or “TET2” protein as referred to herein includes any of the recombinant or naturally-occurring forms of the TET2 dioxygenase or variants or homologs thereof that maintain TET2 dioxygenase enzyme activity (e.g. within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to TET2). In some aspects, the variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g. a 50, 100, 150 or 200 continuous amino acid portion) compared to a naturally occurring TET2 protein. In certain embodiments, the TET2 protein is substantially identical to the protein identified by the UniProt reference number Q6N021 or a variant or homolog having substantial identity thereto.
  • Thus, a “methylcytosine dioxygenase TET3” or “TET3” protein as referred to herein includes any of the recombinant or naturally-occurring forms of the TET3 dioxygenase or variants or homologs thereof that maintain TET3 dioxygenase enzyme activity (e.g. within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to TET3). In some aspects, the variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g. a 50, 100, 150 or 200 continuous amino acid portion) compared to a naturally occurring TET3 protein. In certain embodiments, the TET3 protein is substantially identical to the protein identified by the UniProt reference number 043151 or a variant or homolog having substantial identity thereto.
  • The TET family of enzymes (e.g., TET1, TET2, TET3) catalyze the conversion of 5mC to 5hmC as well as its further oxidation into 5-formylcytosine (5fC) and 5 carboxylcytosine (5caC) (Ito et al., 2010). TET dioxygenases oxidize the methyl group at C5 to yield 5-hydroxymethyl-(hmC) (Kriaucionis and Heintz, 2009), 5-formyl-(fC) (Maiti and Drohat, 2011) and 5-carboxylcytosine (caC) (He et al., 2011).
  • A “Growth Arrest and DNA-Damage-inducible Alpha” or “GADD45A” protein as referred to herein includes any of the recombinant or naturally-occurring forms of the GADD45A protein or variants or homologs thereof that maintain GADD45A protein activity/function (e.g. within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to GADD45A). In some aspects, the variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g. a 50, 100, 150 or 200 continuous amino acid portion) compared to a naturally occurring GADD45A protein. In certain embodiments, the GADD45A protein is substantially identical to the protein identified by the UniProt reference number P24522 or a variant or homolog having substantial identity thereto.
  • GADD45A forms part of the regulatory protein family in NER- and BER-based DNA demethylation (e.g., Growth Arrest and DNA Damage Protein 45a,-b,-g). GADD45 proteins are devoid of any obvious enzymatic activity and act as adapters between demethylation target genes and the DNA repair machinery. Without being bound to any particular theory, it is generally believed that GADD45a and TET1 directly bind each other.
  • Thus, a “NEIL2 glycosylase” or “NEIL2” protein as referred to herein includes any of the recombinant or naturally-occurring forms of the NEIL2 glycosylase or variants or homologs thereof that maintain NEIL2 glycosylase enzyme activity (e.g. within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to NEIL2). In some aspects, the variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g. a 50, 100, 150 or 200 continuous amino acid portion) compared to a naturally occurring NEIL2 glycosylase. In certain embodiments, the NEIL2 glycosylase is substantially identical to the protein identified by the UniProt reference number Q969S2 or a variant or homolog having substantial identity thereto.
  • NEIL glycosylases are capable of excising formylated and carboxylated cytosine in chromatins. NEIL glycosylases can also initiate BER after TET-mediated cytosine oxidation. NEIL glycosylases may therefore constitute an alternative pathway for active demethylation and reactivation of epigenetically silenced genes.
  • A “DNMT3a”, “DNA (cytosine-5)-methyltransferase 3A” or “DNA methyltransferase 3a” protein as referred to herein includes any of the recombinant or naturally-occurring forms of the DNMT3a enzyme or variants or homologs thereof that maintain DNMT3a enzyme activity (e.g. within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to DNMT3a). In some aspects, the variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g. a 50, 100, 150 or 200 continuous amino acid portion) compared to a naturally occurring DNMT3a protein. In certain embodiments, the DNMT3a protein is substantially identical to the protein identified by the UniProt reference number Q9Y6K1 or a variant or homolog having substantial identity thereto.
  • A “DNMT3L”, “DNA (cytosine-5)-methyltransferase 3L” or “DNA methyltransferase 3L” protein as referred to herein includes any of the recombinant or naturally-occurring forms of the DNMT3L enzyme or variants or homologs thereof that maintain DNMT3L enzyme activity (e.g. within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to DNMT3L). In some aspects, the variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g. a 50, 100, 150 or 200 continuous amino acid portion) compared to a naturally occurring DNMT3L protein. In certain embodiments, the DNMT3L protein is substantially identical to the protein identified by the UniProt reference number Q9UJW3 or a variant or homolog having substantial identity thereto.
  • MLH1 (MutL homolog 1) is a human homolog of the E. coli DNA mismatch repair gene, mutL, which mediates protein-protein interactions during mismatch recognition, strand discrimination, and strand removal. The human gene, hMLH1, is located on Chromosome 3. Defects in hMLH1 are commonly associated with the microsatellite instability (MSI) observed in hereditary nonpolyposis colorectal cancer (HNPCC). In addition, deficient expression of the hMLH1 has been observed in many cancers, including stomach cancer (including foveolar type tumors, and stomach cancer in high-incidence Kashmir Valley), esophageal cancer, head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), and colorectal cancer (such as HNPCC). In these cancers, the majority of deficiencies of hMLH1 were due to methylation of the promoter region of the hMLH1 gene.
    • CAS9 Proteins
  • As used herein, the term “Cas9 protein” as referred to herein includes a nuclease-deficient wt Cas9 protein in which one of the two catalytic sites for endonuclease activity (RuvC and HNH) is defective or lacks activity, and a dCas9 protein in which both catalytic sites for endonuclease activity are defective or lack activity. In certain embodiments, the Cas9 protein is a nuclease-deficient wt Cas9 protein. In certain embodiments, the Cas9 protein lacks nuclease activity or is nuclease-deficient. In certain embodiments, the Cas9 protein is a nickase (e.g., for example, the nickase can be a Cas9 Nickase with a mutation at a position corresponding to D10A of S. pyogenes Cas9; or the nickase can be a Cas9 Nickase with a mutation at a position corresponding to H840A of S. pyogenes Cas9). In certain embodiments, the Cas9 protein is a dCas9 (e.g., a dCas9 with mutations at positions corresponding to D10A and H840A of S. pyogenes Cas9).
  • In certain embodiments, a “modified Cas9 protein” refers to a Cas9 that is not a wt Cas9 protein. In certain embodiments, the modified Cas9 protein is a dCas9. In certain embodiments, the modified Cas9 protein is a nickase.
  • The modified Cas9 protein (nickase or dCas9) may have reduced nuclease activity, or lacks nuclease activity at one or both endonuclease catalytic sites. In certain embodiments, the dCas9 protein lacks endonuclease activity due to point mutations at both endonuclease catalytic sites (RuvC and HNH) of wild type Cas9. For example, the point mutations may be D10A and H840A, respectively, in the S. pyogenes Cas9, or in the corresponding residues in species other than S. pyogenes. In certain embodiments, the modified Cas9 protein lacks endonuclease catalytic activity at one but not both sites of wt Cas9, and is able to create a nick on a dsDNA target (Cas9 nickase).
  • In certain embodiments, the Cas9 nickase protein lacks endonuclease activity due to point mutations at one endonuclease catalytic sites (RuvC and HNH) of wild type Cas9. The point mutations can be D10A or H840A.
  • In certain embodiments, the dCas9 protein is nuclease-deficient but retains DNA-binding ability when complexed with the polynucleotide.
  • In certain embodiments, the dCas9 protein lacks endonuclease activity due to point mutations at both endonuclease catalytic sites (RuvC and HNH) of wild type Cas9. The point mutations can be D10A and H840A.
  • In certain embodiments, the modified Cas9 protein has reduced or lacks endonuclease (e.g., endodeoxyribonuclease) activity. For example, a modified Cas9 suitable for use in a method of the present invention may be a Cas9 nickase, or exhibits less than 20%, less than 15%, less than 10%, less than 5%, less than 1%, or less than 0.1%, of the endonuclease (e.g., endodeoxyribonuclease) activity of a wild-type Cas9 polypeptide, e.g., a wild-type Cas9 polypeptide comprising an amino acid sequence as depicted in FIG. 3 and SEQ ID NO: 8 of WO 2013/176772 (incorporated herein by reference in its entirety and for all purposes). In some embodiments, the dCas9 has substantially no detectable endonuclease (e.g., endodeoxyribonuclease) activity. In some embodiments when a dCas9 has reduced catalytic activity (e.g., when a Cas9 protein has a D10, G12, G17, E762, H840, N854, N863, H982, H983, A984, D986, and/or a A987 mutation, e.g., D10A, G12A, G17A, E762A, H840A, N854A, N863A, H982A, H983A, A984A, and/or D986A), the polypeptide can still bind to target DNA in a site-specific manner, because it is still guided to a target polynucleotide sequence by a DNA-targeting sequence of the subject polynucleotide, as long as it retains the ability to interact with the Cas9-binding sequence of the subject polynucleotide.
  • Any one of the Cas9 proteins, homologs or fragments thereof, having at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or 100% amino acid sequence identity to the Cas9 proteins disclosed in International Application No.: PCT/US2013/032589, published as WO 2013/176772, which is hereby incorporated by reference in its entirety and for all purposes, are contemplated for the complexes and methods provided herein.
  • In some cases, the nuclease-deficient wt Cas9 protein (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein) is optionally a fusion polypeptide including: i) a Cas9 protein (e.g., nuclease-deficient wt Cas9 protein or dCas9 protein) a covalently linked heterologous polypeptide (also referred to as a “fusion partner”), which can be the same or different from the fusion partner fused to the PUF domains (infra).
  • “Patient” or “subject in need thereof” refers to a living organism suffering from or prone to a disease or condition that can be treated by administration of a composition or pharmaceutical composition as provided herein. Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals. In some embodiments, a patient is human.
  • The terms “disease” or “condition” refer to a state of being or health status of a patient or subject capable of being treated with a compound, pharmaceutical composition, or method provided herein. In certain embodiments, the disease is cancer (e.g. lung cancer, ovarian cancer, osteosarcoma, bladder cancer, cervical cancer, liver cancer, kidney cancer, skin cancer (e.g., Merkel cell carcinoma), testicular cancer, leukemia, lymphoma (Mantel cell lymphoma), head and neck cancer, colorectal cancer, prostate cancer, pancreatic cancer, melanoma, breast cancer, neuroblastoma).
  • As used herein, the term “cancer” refers to all types of cancer, neoplasm or malignant tumors found in mammals, including leukemias, lymphomas, melanomas, neuroendocrine tumors, carcinomas and sarcomas. Exemplary cancers that may be treated with a compound, pharmaceutical composition, or method provided herein include lymphoma (e.g., Mantel cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, marginal zona lymphoma, Burkitt's lymphoma), sarcoma, bladder cancer, bone cancer, brain tumor, cervical cancer, colon cancer, esophageal cancer, gastric cancer, head and neck cancer, kidney cancer, myeloma, thyroid cancer, leukemia, prostate cancer, breast cancer (e.g. triple negative, ER positive, ER negative, chemotherapy resistant, herceptin resistant, HER2 positive, doxorubicin resistant, tamoxifen resistant, ductal carcinoma, lobular carcinoma, primary, metastatic), ovarian cancer, pancreatic cancer, liver cancer (e.g., hepatocellular carcinoma), lung cancer (e.g. non-small cell lung carcinoma, squamous cell lung carcinoma, adenocarcinoma, large cell lung carcinoma, small cell lung carcinoma, carcinoid, sarcoma), glioblastoma multiforme, glioma, melanoma, prostate cancer, castration-resistant prostate cancer, breast cancer, triple negative breast cancer, glioblastoma, ovarian cancer, lung cancer, squamous cell carcinoma (e.g., head, neck, or esophagus), colorectal cancer, leukemia (e.g., lymphoblastic leukemia, chronic lymphocytic leukemia, hairy cell leukemia), acute myeloid leukemia, lymphoma, B cell lymphoma, or multiple myeloma. Additional examples include, cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head & neck, esophagus, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus or Medulloblastoma, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, Paget's Disease of the Nipple, Phyllodes Tumors, Lobular Carcinoma, Ductal Carcinoma, cancer of the pancreatic stellate cells, cancer of the hepatic stellate cells, or prostate cancer.
  • The term “associated” or “associated with” in the context of a substance or substance activity or function associated with a disease (e.g., cancer (e.g. leukemia, lymphoma, B cell lymphoma, or multiple myeloma)) means that the disease (e.g. cancer, (e.g. leukemia, lymphoma, B cell lymphoma, or multiple myeloma)) is caused by (in whole or in part), or a symptom of the disease is caused by (in whole or in part) the substance or substance activity or function.
  • As used herein, “treatment” or “treating,” or “palliating” or “ameliorating” are used interchangeably herein. These terms refer to an approach for obtaining beneficial or desired results including but not limited to therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder. For prophylactic benefit, the compositions may be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made. Treatment includes preventing the disease, that is, causing the clinical symptoms of the disease not to develop by administration of a protective composition prior to the induction of the disease; suppressing the disease, that is, causing the clinical symptoms of the disease not to develop by administration of a protective composition after the inductive event but prior to the clinical appearance or reappearance of the disease; inhibiting the disease, that is, arresting the development of clinical symptoms by administration of a protective composition after their initial appearance; preventing re-occurring of the disease and/or relieving the disease, that is, causing the regression of clinical symptoms by administration of a protective composition after their initial appearance. For example, certain methods herein treat cancer (e.g. lung cancer, ovarian cancer, osteosarcoma, bladder cancer, cervical cancer, liver cancer, kidney cancer, skin cancer (e.g., Merkel cell carcinoma), testicular cancer, leukemia, lymphoma, head and neck cancer, colorectal cancer, prostate cancer, pancreatic cancer, melanoma, breast cancer, neuroblastoma). For example certain methods herein treat cancer by decreasing or reducing or preventing the occurrence, growth, metastasis, or progression of cancer; or treat cancer by decreasing a symptom of cancer. Symptoms of cancer (e.g. lung cancer, ovarian cancer, osteosarcoma, bladder cancer, cervical cancer, liver cancer, kidney cancer, skin cancer (e.g., Merkel cell carcinoma), testicular cancer, leukemia, lymphoma, head and neck cancer, colorectal cancer, prostate cancer, pancreatic cancer, melanoma, breast cancer, neuroblastoma) would be known or may be determined by a person of ordinary skill in the art.
  • As used herein the terms “treatment,” “treat,” or “treating” refers to a method of reducing the effects of one or more symptoms of a disease or condition characterized by expression of the protease or symptom of the disease or condition characterized by expression of the protease. Thus in the disclosed method, treatment can refer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of an established disease, condition, or symptom of the disease or condition. For example, a method for treating a disease is considered to be a treatment if there is a 10% reduction in one or more symptoms of the disease in a subject as compared to a control. Thus the reduction can be a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any percent reduction in between 10% and 100% as compared to native or control levels. It is understood that treatment does not necessarily refer to a cure or complete ablation of the disease, condition, or symptoms of the disease or condition. Further, as used herein, references to decreasing, reducing, or inhibiting include a change of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater as compared to a control level and such terms can include but do not necessarily include complete elimination.
  • An “effective amount” is an amount sufficient to accomplish a stated purpose (e.g. achieve the effect for which it is administered, treat a disease, reduce enzyme activity, reduce one or more symptoms of a disease or condition). An example of an “effective amount” is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which could also be referred to as a “therapeutically effective amount.” A “reduction” of a symptom or symptoms (and grammatical equivalents of this phrase) means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s). A “prophylactically effective amount” of a drug is an amount of a drug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of an injury, disease, pathology or condition, or reducing the likelihood of the onset (or reoccurrence) of an injury, disease, pathology, or condition, or their symptoms. The full prophylactic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a prophylactically effective amount may be administered in one or more administrations. An “activity decreasing amount,” as used herein, refers to an amount of antagonist required to decrease the activity of an enzyme or protein relative to the absence of the antagonist. A “function disrupting amount,” as used herein, refers to the amount of antagonist required to disrupt the function of an enzyme or protein relative to the absence of the antagonist. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products. For example, for the given parameter, an effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Efficacy can also be expressed as “-fold” increase or decrease. For example, a therapeutically effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control. The exact amounts will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).
  • As used herein, the term “administering” means oral administration, administration as a suppository, topical contact, intravenous, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject. Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc. By “co-administer” it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies, for example cancer therapies such as chemotherapy, hormonal therapy, radiotherapy, or immunotherapy. The compounds of the invention can be administered alone or can be co-administered to the patient. Co-administration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound). Thus, the preparations can also be combined, when desired, with other active substances (e.g. to reduce metabolic degradation). The compositions of the present invention can be delivered by transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
  • Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the complexes provided herein suspended in diluents, such as water, saline or PEG 400; (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as liquids, solids, granules or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions. Tablet forms can include one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers. Lozenge forms can comprise the active ingredient in a flavor, e.g., sucrose, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, carriers known in the art.
  • Pharmaceutical compositions can also include large, slowly metabolized macromolecules such as proteins, polysaccharides such as chitosan, polylactic acids, polyglycolic acids and copolymers (such as latex functionalized Sepharose™, agarose, cellulose, and the like), polymeric amino acids, amino acid copolymers, and lipid aggregates (such as oil droplets or liposomes). Additionally, these carriers can function as immunostimulating agents (i.e., adjuvants).
  • Suitable formulations for rectal administration include, for example, suppositories, which consist of the packaged nucleic acid with a suppository base. Suitable suppository bases include natural or synthetic triglycerides or paraffin hydrocarbons. In addition, it is also possible to use gelatin rectal capsules which consist of a combination of the compound of choice with a base, including, for example, liquid triglycerides, polyethylene glycols, and paraffin hydrocarbons.
  • Formulations suitable for parenteral administration, such as, for example, by intraarticular (in the joints), intravenous, intramuscular, intratumoral, intradermal, intraperitoneal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the practice of this invention, compositions can be administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically or intrathecally. Parenteral administration, oral administration, and intravenous administration are the preferred methods of administration. The formulations of compounds can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials.
  • Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. Cells transduced by nucleic acids for ex vivo therapy can also be administered intravenously or parenterally as described above.
  • The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. The composition can, if desired, also contain other compatible therapeutic agents.
  • The combined administration contemplates co-administration, using separate formulations or a single pharmaceutical formulation, and consecutive administration in either order, wherein preferably there is a time period while both (or all) active agents simultaneously exert their biological activities.
  • Effective doses of the compositions provided herein vary depending upon many different factors, including means of administration, target site, physiological state of the patient, whether the patient is human or an animal, other medications administered, and whether treatment is prophylactic or therapeutic. However, a person of ordinary skill in the art would immediately recognize appropriate and/or equivalent doses looking at dosages of approved compositions for treating and preventing cancer for guidance.
  • “Pharmaceutically acceptable excipient” and “pharmaceutically acceptable carrier” refer to a substance that aids the administration of an active agent to and absorption by a subject and can be included in the compositions of the present invention without causing a significant adverse toxicological effect on the patient. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer's, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, polyvinyl pyrrolidine, and colors, and the like. Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances, and the like, that do not deleteriously react with the compounds of the invention. One of skill in the art will recognize that other pharmaceutical excipients are useful in the present invention.
  • The term “pharmaceutically acceptable salt” refers to salts derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
  • The term “preparation” is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
  • The pharmaceutical preparation is optionally in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. The unit dosage form can be of a frozen dispersion.
  • The compositions of the present invention may additionally include components to provide sustained release and/or comfort. Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Pat. Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes. The compositions of the present invention can also be delivered as microspheres for slow release in the body. For example, microspheres can be administered via intradermal injection of drug-containing microspheres, which slowly release subcutaneously (see Rao, J. Biomater Sci. Polym. Ed. 7:623-645, 1995; as biodegradable and injectable gel formulations (see, e.g., Gao Pharm. Res. 12:857-863, 1995); or, as microspheres for oral administration (see, e.g., Eyles, J. Pharm. Pharmacol. 49:669-674, 1997). In certain embodiments, the formulations of the compositions of the present invention can be delivered by the use of liposomes which fuse with the cellular membrane or are endocytosed, i.e., by employing receptor ligands attached to the liposome, that bind to surface membrane protein receptors of the cell resulting in endocytosis. By using liposomes, particularly where the liposome surface carries receptor ligands specific for target cells, or are otherwise preferentially directed to a specific organ, one can focus the delivery of the compositions of the present invention into the target cells in vivo. (See, e.g., Al-Muhammed, J. Microencapsul. 13:293-306, 1996; Chonn, Curr. Opin. Biotechnol. 6:698-708, 1995; Ostro, Am. J. Hosp. Pharm. 46:1576-1587, 1989). The compositions of the present invention can also be delivered as nanoparticles.
    • Other Suitable Sequences
  • For the complexes and methods provided herein including embodiments thereof the polynucleotides (e.g., first or second polynucleotide) may include a stability control sequence (e.g., transcriptional terminator segment) which influences the stability of the respective polynucleotide it forms part of (e.g., an RNA (e.g., a subject polynucleotide). One example of a suitable stability control sequence is a transcriptional terminator segment (i.e., a transcription termination sequence). A transcriptional terminator segment of a subject polynucleotide can have a total length of from 10 nucleotides to 100 nucleotides, e.g., from 10 nucleotides (nt) to 20 nt, from 20 nt to 30 nt, from 30 nt to 40 nt, from 40 nt to 50 nt, from 50 nt to 60 nt, from 60 nt to 70 nt, from 70 nt to 80 nt, from 80 nt to 90 nt, or from 90 nt to 100 nt. For example, the transcriptional terminator segment can have a length of from 15 nucleotides (nt) to 80 nt, from 15 nt to 50 nt, from 15 nt to 40 nt, from 15 nt to 30 nt or from 15 nt to 25 nt.
  • In some cases, the transcription termination sequence is one that is functional in a eukaryotic cell. In some cases, the transcription termination sequence is one that is functional in a prokaryotic cell. Non-limiting examples of nucleotide sequences that can be included in a stability control sequence (e.g., transcriptional termination segment, or in any segment of the DNA-targeting RNA to provide for increased stability) include sequences set forth in SEQ ID NO: 683-696 of WO 2013/176772 (incorporated herein by reference in its entirety and for all purposes), see, for example, SEQ ID NO: 795 of WO 2013/176772, a Rho-independent transcription termination site.
    • Modulation of Transcription
  • The demethylation of methylation protein conjugates provided herein are targeted by the DNA-targeting sequence of the subject polynucleotide to a specific location (i.e., target polynucleotide sequence) in the target DNA, and exert locus-specific modification of the target DNA (e.g., modifying the local chromatin status). In some cases, the changes are transient (e.g., transcription repression or activation). In some cases, the changes are inheritable (e.g., when epigenetic modifications are made to the target DNA or to proteins associated with the target DNA, e.g., nucleosomal histones).
  • The biological effects of a method using the complexes provided herein including embodiments thereof can be detected by any convenient method (e.g., gene expression assays; chromatin-based assays, e.g., Chromatin immunoPrecipitation (ChiP), Chromatin in vivo Assay (CiA), etc.; and the like).
  • Thus, in certain embodiments, a transcription modulation method of the present invention provides for selective modulation (e.g., reduction or increase) of a target nucleic acid in a host cell. For example, “selective” reduction of transcription of a target nucleic acid reduces transcription of the target nucleic acid by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or greater than 90%, compared to the level of transcription of the target nucleic acid in the absence of a DNA-targeting sequence/modified Cas9 polypeptide/PUF domain-fusion complex. Selective reduction of transcription of a target nucleic acid reduces transcription of the target nucleic acid, but does not substantially reduce transcription of a non-target nucleic acid, e.g., transcription of a non-target nucleic acid is reduced, if at all, by less than 10% compared to the level of transcription of the non-target nucleic acid in the absence of the DNA-targeting sequence/modified Cas9 polypeptide/PUF domain-fusion complex.
  • On the other hand, “selective” increased transcription of a target DNA can increase transcription of the target DNA by at least 1.1 fold (e.g., at least 1.2 fold, at least 1.3 fold, at least 1.4 fold, at least 1.5 fold, at least 1.6 fold, at least 1.7 fold, at least 1.8 fold, at least 1.9 fold, at least 2 fold, at least 2.5 fold, at least 3 fold, at least 3.5 fold, at least 4 fold, at least 4.5 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, at least 10 fold, at least 12 fold, at least 15 fold, or at least 20-fold) compared to the level of transcription of the target DNA in the absence of the complexes provided herein including embodiments thereof (e.g., DNA-targeting sequence/modified Cas9 polypeptide/PUF domain-fusion complex). Selective increase of transcription of a target DNA increases transcription of the target DNA, but does not substantially increase transcription of a non-target DNA, e.g., transcription of a non-target DNA is increased, if at all, by less than 5-fold (e.g., less than 4-fold, less than 3-fold, less than 2-fold, less than 1.8-fold, less than 1.6-fold, less than 1.4-fold, less than 1.2-fold, or less than 1.1-fold) compared to the level of transcription of the non-targeted DNA in the absence of the complexes provided herein including embodiments thereof (e.g., DNA-targeting sequence/modified Cas9 polypeptide/PUF domain-fusion complex).
  • In some embodiments, multiple subject polynucleotides are used simultaneously in the same cell to simultaneously modulate transcription at different locations on the same target DNA or on different target DNAs. In some embodiments, two or more subject polynucleotides target the same gene or transcript or locus. In some embodiments, two or more subject polynucleotides target different unrelated loci. In some embodiments, two or more subject polynucleotides target different, but related loci.
  • Because the subject polynucleotides are small and robust, they can be simultaneously present on the same expression vector and can even be under the same transcriptional control if so desired. In some embodiments, two or more (e.g., 3 or more, 4 or more, 5 or more, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, or 50 or more) subject polynucleotides are simultaneously expressed in a target cell, from the same or different vectors. The expressed subject polynucleotides can be differently recognized by orthogonal nuclease-deficient RNA-guided DNA endonucleases (dCas9 proteins) from different bacteria, such as S. pyogenes, S. thermophilus, L. innocua, and N. meningitidis.
  • To express multiple subject polynucleotides, the artificial RNA processing system mediated by the Csy4 endoribonuclease described in international application PCT/US2016/021491 and published as WO2016148994 A8, which is hereby incorporated by reference and for all purposes, may be used for the invention provided herein.
    • Host Cells
  • A method of the present invention to modulate transcription may be employed to induce transcriptional modulation in mitotic or post-mitotic cells in vivo and/or ex vivo and/or in vitro. Because the subject polynucleotide provides specificity by hybridizing to target polynucleotide sequence of a target DNA, a mitotic and/or post-mitotic cell can be any of a variety of host cell, where suitable host cells include, but are not limited to, a bacterial cell; an archaeal cell; a single-celled eukaryotic organism; a plant cell; an algal cell, e.g., Botryococcus braunii, Chlamydomonas reinhardtii, Nannochloropsis gaditana, Chlorella pyrenoidosa, Sargassum patens, C. agardh, and the like; a fungal cell; an animal cell; a cell from an invertebrate animal (e.g., an insect, a cnidarian, an echinoderm, a nematode, etc.); a eukaryotic parasite (e.g., a malarial parasite, e.g., Plasmodium falciparum; a helminth; etc.); a cell from a vertebrate animal (e.g., fish, amphibian, reptile, bird, mammal); a mammalian cell, e.g., a rodent cell, a human cell, a non-human primate cell, etc. Suitable host cells include naturally-occurring cells; genetically modified cells (e.g., cells genetically modified in a laboratory, e.g., by the “hand of man”); and cells manipulated in vitro in any way. In some cases, a host cell is isolated or cultured.
  • Any type of cell may be of interest (e.g., a stem cell, e.g. an embryonic stem (ES) cell, an induced pluripotent stem (iPS) cell, a germ cell; a somatic cell, e.g. a fibroblast, a hematopoietic cell, a neuron, a muscle cell, a bone cell, a hepatocyte, a pancreatic cell; an in vitro or in vivo embryonic cell of an embryo at any stage, e.g., a 1-cell, 2-cell, 4-cell, 8-cell, etc. stage zebrafish embryo; etc.). Cells may be from established cell lines or they may be primary cells, where “primary cells,” “primary cell lines,” and “primary cultures” are used interchangeably herein to refer to cells and cells cultures that have been derived from a subject and allowed to grow in vitro for a limited number of passages, i.e. splittings, of the culture. For example, primary cultures include cultures that may have been passaged 0 times, 1 time, 2 times, 4 times, 5 times, 10 times, or 15 times, but not enough times go through the crisis stage. Primary cell lines can be are maintained for fewer than 10 passages in vitro. Target cells are in many embodiments unicellular organisms, or are grown in culture.
  • If the cells are primary cells, such cells may be harvest from an individual by any convenient method. For example, leukocytes may be conveniently harvested by apheresis, leukocytapheresis, density gradient separation, etc., while cells from tissues such as skin, muscle, bone marrow, spleen, liver, pancreas, lung, intestine, stomach, etc. are most conveniently harvested by biopsy. An appropriate solution may be used for dispersion or suspension of the harvested cells. Such solution will generally be a balanced salt solution, e.g. normal saline, phosphate-buffered saline (PBS), Hank's balanced salt solution, etc., conveniently supplemented with fetal calf serum or other naturally occurring factors, in conjunction with an acceptable buffer at low concentration, e.g., from 5-25 mM. Convenient buffers include HEPES, phosphate buffers, lactate buffers, etc. The cells may be used immediately, or they may be stored, frozen, for long periods of time, being thawed and capable of being reused. In such cases, the cells will usually be frozen in 10% dimethyl sulfoxide (DMSO), 50% serum, 40% buffered medium, or other solutions commonly used in the art to preserve cells at such freezing temperatures, and thawed in a manner as commonly known in the art for thawing frozen cultured cells.
  • Introducing Nucleic Acid into a Host Cell
  • A subject polynucleotide, a nucleic acid comprising a nucleotide sequence encoding same, or a nucleic acid comprising a nucleotide sequence encoding the subject nuclease-deficient RNA-guided DNA endonuclease (dCas9 protein) or demethylation or methylation protein conjugate (PUF domain fusion), can be introduced into a host cell by any of a variety of well-known methods.
  • Methods of introducing a nucleic acid into a host cell are known in the art, and any known method can be used to introduce a nucleic acid (e.g., vector or expression construct) into a stem cell or progenitor cell. Suitable methods include, include e.g., viral or bacteriophage infection, transfection, conjugation, protoplast fusion, lipofection, electroporation, calcium phosphate precipitation, polyethyleneimine (PEI)-mediated transfection, DEAE-dextran mediated transfection, liposome-mediated transfection, particle gun technology, calcium phosphate precipitation, direct micro injection, nanoparticle-mediated nucleic acid delivery (see, e.g., Panyam et al., Adv. Drug Deliv. Rev., pii: S0169-409×(12)00283-9.doi:10.1016/j.addr.2012.09.023), and the like.
  • Thus the present invention also provides an isolated nucleic acid comprising a nucleotide sequence encoding a subject polynucleotide. In some cases, a subject nucleic acid also comprises a nucleotide sequence encoding a nuclease-deficient RNA-guided DNA endonuclease (dCas9 protein) and/or a demethylation or methylation protein conjugate (PUF domain fusion).
  • In some embodiments, a subject method involves introducing into a host cell (or a population of host cells) one or more nucleic acids (e.g., vectors) comprising nucleotide sequences encoding a subject polynucleotide and/or a nuclease-deficient RNA-guided DNA endonuclease (dCas9 protein) and/or a demethylation or methylation protein conjugate (PUF domain fusion). In some embodiments a host cell comprising a target DNA is in vitro. In some embodiments a host cell comprising a target DNA is in vivo. Suitable nucleic acids comprising nucleotide sequences encoding a subject polynucleotide and/or a nuclease-deficient RNA-guided DNA endonuclease (dCas9 protein) and/or a subject demethylation or methylation protein conjugate (PUF domain fusion) include expression vectors, where the expression vectors may be recombinant expression vector.
  • In some embodiments, the recombinant expression vector is a viral construct, e.g., a recombinant adeno-associated virus construct (see, e.g., U.S. Pat. No. 7,078,387), a recombinant adenoviral construct, a recombinant lentiviral construct, a recombinant retroviral construct, etc.
  • Suitable expression vectors include, but are not limited to, viral vectors (e.g. viral vectors based on vaccinia virus; poliovirus; adenovirus (see, e.g., Li et al., Invest Opthalmol. Vis. Sci., 35:2543-2549, 1994; Borras et al., Gene Ther., 6:515-524, 1999; Li and Davidson, Proc. Natl. Acad. Sci. USA, 92:7700-7704, 1995; Sakamoto et al., Hum. Gene Ther., 5:1088-1097, 1999; WO 94/12649, WO 93/03769; WO 93/19191; WO 94/28938; WO 95/11984 and WO 95/00655); adeno-associated virus (see, e.g., Ali et al., Hum. Gene Ther., 9:81-86, 1998, Flannery et al., Proc. Natl. Acad. Sci. USA, 94:6916-6921, 1997; Bennett et al., Invest Opthalmol Vis Sci 38:2857-2863, 1997; Jomary et al., Gene Ther., 4:683-690, 1997, Rolling et al., Hum. Gene Ther., 10:641-648, 1999; Ali et al., Hum. Mol. Genet., 5:591-594, 1996; Srivastava in WO 93/09239, Samulski et al., J. Vir., 63:3822-3828, 1989; Mendelson et al., Virol., 166: 154-165, 1988; and Flotte et al., Proc. Natl. Acad. Sci. USA, 90: 10613-10617, 1993); SV40; herpes simplex virus; human immunodeficiency virus (see, e.g., Miyoshi et al., Proc. Natl. Acad. Sci. USA, 94: 10319-23, 1997; Takahashi et al., J. Virol., 73:7812-7816, 1999); a retroviral vector (e.g., Murine Leukemia Virus, spleen necrosis virus, and vectors derived from retroviruses such as Rous Sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, a lentivirus, HIV virus, myeloproliferative sarcoma virus, and mammary tumor virus); and the like.
  • Numerous suitable expression vectors are known to those skilled in the art, and many are commercially available. The following vectors are provided by way of example; for eukaryotic host cells: pXT1, pSGS (Stratagene), pSVK3, pBPV, pMSG, and pSVLSV40 (Pharmacia). However, any other vector may be used so long as it is compatible with the host cell. Any one of the vectors described in international application PCT/US2016/021491 and published as WO2016148994 A8, which is hereby incorporated by reference and for all purposes, is contemplated for the complexes and methods provided herein including embodiments thereof.
    • Exemplary Utilities
  • A method for modulating transcription according to the present invention finds use in a variety of applications, including research applications; diagnostic applications; industrial applications; and treatment applications.
  • Research applications may include, e.g., determining the effect of reducing or increasing transcription of a target nucleic acid on, e.g., development, metabolism, expression of a downstream gene, and the like.
  • High through-put genomic analysis can be carried out using a subject transcription modulation method, in which only the DNA-targeting sequence of the subject polynucleotide needs to be varied, while the binding sequence (Cas9-binding sequence) and the PBS sequence can (in some cases) be held constant. A library (e.g., a subject library) comprising a plurality of nucleic acids used in the genomic analysis would include: a promoter operably linked to a subject polynucleotide-encoding nucleotide sequence, where each nucleic acid would include a different DNA-targeting sequence, a common binding sequence (Cas9-binding sequence), and a common PBS sequence. A chip could contain over 5×104 unique polynucleotide of the invention.
  • Applications would include large-scale phenotyping, gene-to-function mapping, and meta-genomic analysis as described in international application PCT/US2016/021491 and published as WO2016148994 A8, which is hereby incorporated by reference and for all purposes.
  • The subject methods disclosed herein can also find use in the field of metabolic engineering as described in international application PCT/US2016/021491 and published as WO2016148994 A8, which is hereby incorporated by reference and for all purposes.
  • The methods disclosed herein can also be used to design integrated networks (i.e., a cascade or cascades) of control as described in international application PCT/US2016/021491 and published as WO2016148994 A8, which is hereby incorporated by reference and for all purposes.
  • A subject transcription modulation method can also be used for drug discovery and target validation as described in international application PCT/US2016/021491 and published as WO2016148994 A8, which is hereby incorporated by reference and for all purposes.
  • It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.
    • EXAMPLES Example 1: sgRNA Scaffold Remains Functional with Insertion of 47 Copies of Engineered Pumilio Binding Sites
  • This example demonstrates that the subject 3-component CRISPR/Cas complex/system can have at least 47 copies of the engineered 8-mer Pumilio homologue domain-binding sequences (PBSs) at the 3′ end of sgRNA, without substantially affecting the function of the dCas9/sgRNA complex.
  • In particular, to test whether appending PBS to the 3′ end of sgRNA affects sgRNA function, a series of modified Tet-targeting (sgTetO) or non-targeting control (sgControl) sgRNA were generated, with 0 copy, 5 copies, 15 copies, 25 copies, and 47 copies of the 8-mer Pumilio homologue domain-binding sequence (PBS) for PUF (3-2) (also simply referred to as PUFa) [PBS32 or PBSa: SEQ ID NO:8 (5′-UGUAUgUA-3′)], PUF(6-2/7-2) (also simply referred to as PUFb) [PBS6272 or PBSb: SEQ ID NO:9 (5′-UugAUAUA-3′)]. See FIG. 1A. The ability of these constructs to direct the dCas9-VP64 transcriptional activator to activate tdTomato expression in a HEK293T/TetO::tdTomato cell line was tested.
  • Cells were transfected with dCas9-VP64 with the different sgRNA scaffolds, and were analyzed by fluorescent-activated cell sorting (FACS) two days after transfection (FIG. 1B). All the control non-targeting sgRNAs did not activate tdTomato expression. Meanwhile, all the Tet-targeting sgRNAs with different number of PBS could direct dCas9-VP64 to activate tdTomato expression, showing that insertion of at least 47 copies of 8-mer sites do not substantially impact the activity of sgRNA in directing dCas9-VP64 to its targets (FIG. 1C).
  • Under the test condition, and for both PUFa-VP64/PBSa and PUFb-VP64/PBSb, 5-10 copies of PBS appended to the sgRNA were best able to activate the target transgene. Meanwhile, 15, 20, and 47 copies of PBS led to slightly lower, albeit still substantial transgene activation (FIG. 1C).
    • Example 2: The Subject 3-Component CRISPR/Cas Complexes/Systems are Orthogonal to Each Other Due to the Specificity of the Engineered Pumilio with the Cognate 8-Mer Binding Sites
  • This example demonstrates that specificity between the differently programmed PUF domains and their corresponding sgRNA with their cognate 8-mer motifs provide independence or orthogonality between each of the subject 3-component CRISPR/Cas complex/system.
  • Fusions of PUF(3-2)::VP64 and PUF(6-2/7-2)::VP64, which interacts with sgRNA (sgRNA-PBS32) with 5′-UGUAUgUA-3′ binding sites and sgRNA-PBS6272 with 5′-UugAUAUA-3′ binding sites, respectively, were created, and their activity to turn on tdTomato expression in conjunction with dCas9 was tested. In addition, two additional pairs, PUFw-VP64 recognizing PBSw (5′-UGUAUAUA-3′) and PUFc-VP64 recognizing PBSc (5′-UugAUgUA-3′), were also constructed to test their ability to activate the same TetO::tdTomato expression in conjunction with dCas9 (FIG. 1D).
  • As shown in FIG. 1D, PUF::VP64 can activate tdTomato expression only when the sgRNA with the cognate binding sites were provided. This demonstrates that the subject 3-component CRISPR/Cas complex/system provides independence or orthogonality of effector function based on the pairing of PUF domains and their 8-mer binding sites on the sgRNA-PBS. Impressively, although PBSa and PBSw binding sites only differ by one nucleotide, their gene activation remains target-specific, demonstrating the high specificity of the subject 3-component CRISPR/Cas complex/system.
    • Example 3: The Subject 3-Component CRISPR/Cas Complex/System Allows Assembly of Protein Complex at Target Loci
  • This example demonstrates that protein complexes with two or more different protein components can be assembled on sgRNA and operate at defined loci using the subject system.
  • Specifically, p65-HSF1 has recently been shown to be a potent activator domain. An sgRNA with both PBS32 and PBS6272 positioned next to each other, and PUF(3-2)::VP64 and PUF(6-2/7-2)::p65-HSF1 fusions that would occupy the two different sites, were generated (FIG. 2A). Co-transfection of both PUF(3-2)::VP64 and PUF(6-2/7-2)::p65-HSF1 induced a tdTomato fluorescence, with an intensity the sum of the fluorescent intensity resulting from transfecting the single activators alone. This indicates that sgRNA with binding sites for both PUF(3-2) and PUF(6-2/7-2) allows both fusion proteins of both types to assemble on the targeted genomic locus.
  • A recent paper has tested both VP64 and p65HSF1 as transcriptional activation domains, and found p65HSF1 to be a more potent activator. To directly compare these two transcriptional activation domains, p65HSF1 PUF fusion (PUFa-p65HSF1) and VP64 PUF fusion (PUFa-VP64) were used to activate the TetO::tdTomato transgene using sgRNA with different number of PBSa (FIG. 2C). PUFa-p65HSF1 provided up to 3 times more activation as did PUFa-VP64. Activation was observed even with only one PBSa (previously not observed with PUFa-VP64 module). Thus p65HSF1 is confirmed to be a more potent transcriptional activation domain than VP64.
  • Cloning. A list of vectors, links to their Addgene entries are provided in Table S below. Detailed description of cloning strategies and sequences are given below.
  • PUFa [PUF(3-2)] and PUFb [PUF(6-2/7-2)] with N-terminal NLS were amplified from constructs containing these coding sequences with primers containing SgrAI and PacI sites and were used to replace SgrAI-dCas9-FseI from pAC164:pmax-dCas9Master_VP64 to create pAC1355:pmax-NLSPUFa_VP64 and pAC1356:pmax-NLSPUFb_VP64. A fusion PCR with 5′ fragment up to repeat 4 of NLSPUFb and 3′ fragment from repeat 5 to the end of NLSPUFa was used to create pAC1357:pmax-NLSPUFw_VP64. A fusion PCR of 5′ fragment of NLSPUFa with 3′ fragment of NLSPUb was used to create pAC1358:pmax-NLSPUFc_VP64.
  • p65HSF1 activator ORF was amplified from MS2-P65-HSF1_GFP (Addgene: 61423) with FseI PacI sites to replace VP64 fragment in pAC164 to create pAC1410:pmax-dCas9_p65HSF1, and replace VP64 in pAC1355 and pAC1358 to create pAC1393: pmax-NLSPUFa_p65HSF1 and pAC1411:pmax-NLSPUFc_p65HSF1, respectively.
  • The FseI-p65HSF1-PacI fragment was released from pAC1393 and ligated with SgrAI-NLSPUMb fragment released from pAC1356 and pAC1360 digested with SgrAI-PacI as vector to create pAC1413: PB3-neo(-)-pmax-NLSPUFb_p65HSF1. The BFPKRAB fragment was amplified from pHR-SFFV-dCas9-BFP-KRAB (Addgene #46911) and was used to replace Clover fragment from pAC1360 to create pAC1414: PB3-neo(-)-pmax-BFPKRAB_NLSPUFa. Then, an NheI-CAGGS-NLSPUFb_p65HSF1-NheI fragment was amplified from pAC1413 and inserted into pAC1414 digested with NheI to create a dual expression vector for BFPKRAB-NLSPUFa and NLSPUFb-p65HSF1 (pAC1414: PB3-NLSPUFb_p65HSF1(-)neo(-)-BFPKRAB2_NLSPUFa).
  • Four gateway donor vectors with improved linker sequences and three extra NLS on the N-terminal and one additional NLS on the C-terminal of PUF as well as cloning sites for N-terminal (SgrAI,ClaI) and C-terminal (FseI-PacI) insertions were created (pAC1404-1408). HAT sequence was amplified from mouse Crebbp gene using mouse cDNA with primers containing FseI-PacI site and inserted into pAC164 to create pAC1364: pmax-dCas9Master_CBPHAT and into pAC1405 to create pAC1415: pCR8-4×NLSPUFa_2×NLS_CBPHAT. HAT sequence was amplified with another pair of primers containing SgrAI-AclI site and cloned into SgrAI-ClaI site of pAC1405 to create pAC1416: pCR8-CBPHAT_4×NLSPUFa_2×NLS. pAC1415 and pAC1416 were recombined into pAC90:pmax-DEST (Addgene #48222) to create expression vectors pAC1417: pmax-4×NLSPUFa_2×NLS_CBPHAT and pAC1418: pmax-CBPHAT_4×NLSPUFa_2×NLS, respectively. FseI-mCherry-PacI fragment was amplified from a plasmid containing mCherry sequence and ligated with SgrAI-dCas9-FseI to PB3-neo(-)-pmax to generate pAC1419: PB3-neo(-)-pmax-dCas9Master_mCherry.
  • Expression vectors for sgRNA-PBS were constructed as follows: First, a sgRNA scaffold based on sgF+E with BbsI for oligo cloning of guide sequence and with 3′ BsaI (right upstream of the terminator) for insertion of PBS were ordered as a gBlock (IDT), and were cloned into pX330 (Addgene #42230) replacing the AflIII-NotI region to create vector pAC1394: pX-sgFE-BsaI(AGAT). Then, oligos encoding 5×PBSa sites each separated by ggc-spacer flanked by 5′-AGAT-3′ overhangs on one side and 5′-ATCT-3′ on the other side were treated with T4PNK and annealed and ligated into pAC1394 digested with BsaI (to create compatible overhangs). Clones were then screened for 1 copy (5×PBS), 2 copies (10×PBS), etc of the oligo insertions for the different number of PBS. For 1×PBS and 2×PBS vectors, they were constructed using oligo containing one PBS site. Guide sequence for each target were then cloned onto the sgRNA-PBS expression vectors via BbsI site as previously described. For sgRNA expression vectors with GFP expression markers, they were constructed by transferring the sgRNA-PBS expression cassette from the pX vectors onto a PB-GFP vector via AscI site. The different sgRNA expression constructs are listed in Table S1.
  • Cell Culture for Experiments. HEK293T cells were cultivated in Dulbecco's modified Eagle's medium (DMEM)(Sigma) with 10% fetal bovine serum (FBS)(Lonza), 4% Glutamax (Gibco), 1% Sodium Pyruvate (Gibco) and penicillin-streptomycin (Gibco). Incubator conditions were 37° C. and 5% CO2. For activation experiments, cells were seeded into 12-well plates at 100,000 cells per well the day before being transfected with 200 ng of dCas9 construct, 100 ng of modified sgRNA and 100 ng of PUF-fusion with Attractene transfection reagent (Qiagen). After transfection, cells were grown for 48 hrs and harvested for either RNA extraction or fluorescent-activated cell sorting (FACS). For dual activation-repression experiments, transfection remained the same, however cells were seeded into 12-well plates at 150,000 cells per well and were grown for 72 hrs before being harvested for FACS. For experiments with OCT4 and SOX2 dual activation-repression, cells were triple-sorted by BFP (for the activator-repressor module PUFb-p65HSF1/BFPKRAB-PUFa), mCherry (for dCas9mCherry) and GFP (for the sgRNA-PBS on vectors co-expressing EGFP) before RNA extraction. For imaging experiments, cells were seeded into 6-well plates with 22×22×1 microscope cover glass at 300,000 cells per well the day before being transfected with 50 ng of dCas9 construct, 500 ng of modified sgRNA, and 50 ng of a PUF-fluorescent fusion with Attractene transfection reagent. After transfection, cells were grown for 48 hrs then immunostained.
  • Quantitative RT-PCR Analysis. Cells were harvested with trypsin, washed with Dulbecco's phosphate-buffered saline (dPBS), centrifuged at 125 g for 5 mins and then RNA was extracted using RNeasy Plus Mini Kit (Qiagen). A cDNA library was made using Applied Biosystems High Capacity RNA-to-cDNA kit with 1 μg of RNA. TaqMan Gene expression assays (Applied Biosystems) were designed using GAPDH (Hs03929097, VIC) as endogenous control and OCT4 (Hs00999632, FAM) and SOX2 (Hs01053049, FAM) as targets. TaqMan Universal Master Mix II, with UNG (Applied Biosystems) was used for Quantitative PCR (qPCR), with 2 μl of 1:10 diluted cDNA used for each reaction. Activation was analyzed with the Applied Biosystems ViiA7 instrument. Gene expression levels were calculated by “delta delta Ct” algorithm and normalized to control samples.
  • Fluorescent-Activated Cell Sorting. Cells were trypisinized and fixed for 10 min with 2% paraformaldehyde. Afterwards, the cells were centrifuged at 125 g for 5 min and resuspended in dPBS. Samples were analyzed on a FACScalibur flow cytometer using CellQuest Pro software (BD Bioscience). thousands events were collected in each run.
  • Sequences of some of the constructs used in the examples above and the related sequences are listed herein below.
  • >NLSPUFa_VP64 Key: NLS PUFa VP64
    SEQ ID NO: 32
    MGILPPKKKRKVSRGRSRLLEDFRNNRYPNLQLREIAGHIMEFSQDQHGS
    RFIQLKLERATPAERQLVFNEILQAAYQLMVDVFGNYVIQKFFEFGSLEQ
    KLALAERIRGHVLSLALQMYGSRVIEKALEFIPSDQQNEMVRELDGHVLK
    CVKDQNGNHVVQKCIECVQPQSLQFIIDAFKGQVFALSTHPYGCRVIQRI
    LEHCLPDQTLPILEELHQHTEQLVQDQYGNYVIQHVLEHGRPEDKSKIVA
    EIRGNVLVLSQHKFASNVVEKCVTHASRTERAVLIDEVCTMNDGPHSALY
    TMMKDQYANYVVQKMIDVAEPGQRKIVMHKIRPHIATLRKYTYGKHILAK
    LEKYYMKNGVDLGGPAGSGRADALDDFDLDMLGSDALDDFDLDMLGSDAL
    DDFDLDMLGSDALDDFDLDMLYID
  • In the above sequence, the NLS sequence is residues 6-12, PUFa (SEQ ID NO:2) is residues 15-363, and VP64 is residues 371-421.
  • >NLSPUFb_VP64 Key: NLS PUFb VP64
    SEQ ID NO: 33
    MGILPPKKKRKVSRGRSRLLEDFRNNRYPNLQLREIAGHIMEFSQDQHGS
    RFIQLKLERATPAERQLVFNEILQAAYQLMVDVFGNYVIQKFFEFGSLEQ
    KLALAERIRGHVLSLALQMYGCRVIQKALEFIPSDQQNEMVRELDGHVLK
    CVKDQNGNHVVQKCIECVQPQSLQFIIDAFKGQVFALSTHPYGCRVIQRI
    LEHCLPDQTLPILEELHQHTEQLVQDQYGSYVIEHVLEHGRPEDKSKIVA
    EIRGNVLVLSQHKFANNVVQKCVTHASRTERAVLIDEVCTMNDGPHSALY
    TMMKDQYANYVVQKMIDVAEPGQRKIVMHKIRPHIATLRKYTYGKHILAK
    LEKYYMKNGVDLGGPAGSGRADALDDFDLDMLGSDALDDFDLDMLGSDAL
    DDFDLDMLGSDALDDFDLDMLYID
  • In the above sequence, the NLS sequence is residues 6-12, PUFb (SEQ ID NO:3) is residues 15-363, and VP64 is residues 371-421.
  • >NLSPUFw_VP64 Key: NLS PUFw VP64
    SEQ ID NO: 34
    MGILPPKKKRKVSRGRSRLLEDFRNNRYPNLQLREIAGHIMEFSQDQHGS
    RFIQLKLERATPAERQLVFNEILQAAYQLMVDVFGNYVIQKFFEFGSLEQ
    KLALAERIRGHVLSLALQMYGCRVIQKALEFIPSDQQNEMVRELDGHVLK
    CVKDQNGNHVVQKCIECVQPQSLQFIIDAFKGQVFALSTHPYGCRVIQRI
    LEHCLPDQTLPILEELHQHTEQLVQDQYGNYVIQHVLEHGRPEDKSKIVA
    EIRGNVLVLSQHKFASNVVEKCVTHASRTERAVLIDEVCTMNDGPHSALY
    TMMKDQYANYVVQKMIDVAEPGQRKIVMHKIRPHIATLRKYTYGKHILAK
    LEKYYMKNGVDLGGPAGSGRADALDDFDLDMLGSDALDDFDLDMLGSDAL
    DDFDLDMLGSDALDDFDLDMLYID
  • In the above sequence, the NLS sequence is residues 6-12, PUFw (SEQ ID NO:5) is residues 15-363, and VP64 is residues 371-421.
  • >NLSPUFc_VP64 Key: NLS PUFc VP64
    SEQ ID NO: 35
    MGILPPKKKRKVSRGRSRLLEDFRNNRYPNLQLREIAGHIMEFSQDQHGS
    RFIQLKLERATPAERQLVFNEILQAAYQLMVDVFGNYVIQKFFEFGSLEQ
    KLALAERIRGHVLSLALQMYGSRVIEKALEFIPSDQQNEMVRELDGHVLK
    CVKDQNGNHVVQKCIECVQPQSLQFIIDAFKGQVFALSTHPYGCRVIQRI
    LEHCLPDQTLPILEELHQHTEQLVQDQYGSYVIEHVLEHGRPEDKSKIVA
    EIRGNVLVLSQHKFANNVVQKCVTHASRTERAVLIDEVCTMNDGPHSALY
    TMMKDQYANYVVQKMIDVAEPGQRKIVMHKIRPHIATLRKYTYGKHILAK
    LEKYYMKNGVDLGGPAGSGRADALDDFDLDMLGSDALDDFDLDMLGSDAL
    DDFDLDMLGSDALDDFDLDMLYID
  • In the above sequence, the NLS sequence is residues 6-12, PUFc (SEQ ID NO:4) is residues 15-363, and VP64 is residues 371-421.
    • Example 4: Targeted DNA Demethylation and Methylation Using the Subject 3-Component CRISPR/Cas Complex/System (Casilio) and dCas9-Tethered Enzymes
  • For the sake of simplicity, the subject 3-component CRISPR/Cas Complex/System may also be referred to as “Casilio” herein.
  • Using Casilio-ME with a Tet1 effector, the Example demonstrated a robust activation of hMLH1 transcription, a gene that is epigenetically silenced in HEK293T cells and other cancer cells due to hypermethylation in the promoter regions. Reactivation of hMLH1 transcription leads to (restoration of) expression of MLH1 protein. The Example showed that Casilio-ME-mediated delivery of TET1 activity to hMLH1 promoter region induced a robust cytosine demethylation within the targeted CpG island, providing a proof-of-principal that Casilio-ME is a robust platform to editing methylcytosine mark of the epigenome.
  • On the other hand, it was also shown that targeting Casilio-ME with a Dnmt effector to the SOX2 promoter leads to gene repression, demonstrating the potential of directed Dnmt-mediated DNA methylation to modify gene expression or epigenetic states at desired loci.
    • Results
  • Effect of Casilio-mediated delivery of demethylation enzymes to specific genomic locus on gene expression. To develop simple yet effective tools that enable delivery of demethylation enzymes to specific genomic locus to permit targeted alteration of its epigenetic methylation state, the Casilio-ME system was engineered. This is built on the three-component Casilio platform (see PCT/US2016/021491; 62/132,644; and 62/221,249; also see Cheng, A. W., et al., Casilio: a versatile CRISPR-Cas9-Pumilio hybrid for gene regulation and genomic labeling. Cell Res, 2016. 26(2): p. 254-7, incorporated by reference) that uses nuclease-deficient dCas9, modified sgRNAs containing sites for Pumilio (PUF) RNA binding domain (sgRNA-PBS) and an effector module made of Pumilio RNA binding domain fused to an effector protein. dCas9 binds DNA when complexed with sgRNA without producing double-stranded breaks, serving as a RNA-programmable DNA binding protein whose specificity is determined by a sequence in the sgRNA component of the system. PUF domains can be programmed to bind to any 8-mer RNA sequences (PBS) appended in multiple copies to the 3′ end of the sgRNA without interfering with the sgRNA-mediated DNA binding of dCas9 (Cheng, A. W., et al., Casilio: a versatile CRISPR-Cas9-Pumilio hybrid for gene regulation and genomic labeling. Cell Res, 2016. 26(2): p. 254-7). The presence of PBS in multiple copies on sgRNA allows tethering of multiple copies of PUF-effector module(s) to genomic sites, and therefore potentiates achieving strong amplification of the response to any effector module in application.
  • To enable a Casilio-mediated cytosine demethylation and subsequent gene activation at specific genomic locus, TET1-effector modules were constructed as N-terminal or C-terminal fusions of PUFa to TET1 catalytic domain that includes residues 1418 to 2136 (TET1(CD)). The promoter region of hMLH1, whose hypermethylation is known to induce silencing of hMLH1 expression (Deng, G., et al., Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res, 1999. 59(9): p. 2029-33), was chosen as the target for this study.
  • MLH1 protein is a component of the methyl directed mismatch repair system of the cell. hMLH1 is in fact silenced in HEK293T cells as is in other cancer cells, and therefore represents a good cellular model to test TET1-effectors in their ability to induce demethylation-mediated gene activation. Nine sgRNAs were designed around the promoter region whose methylation is associated with down-regulation of hMLH1 in cancer cells (FIG. 3A) (Deng, G., et al., Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res, 1999. 59(9): p. 2029-33).
  • To test the system, HEK293T cells were transfected with Casilio-ME components including Ct or Nt-fusion TET1-effector and a combination of 3 or 2 sgRNAs. Relative levels of hMLH1 mRNA were determined in TaqMan assays by using RNA extracted from cells 60 hours post-transfection and GAPDH as endogenous control for normalization of qRT-PCR measurements. This showed that PUFa-TET1(CD)C-terminal fusion effector restored a robust hMLH1 expression that reached 135 fold over background in the presence sgRNAs 3+7 (FIG. 3B). However, TET1(CD)-PUFa N-terminal effector fusion showed a much weaker activation (20 fold at best) in the presence of the same sgRNA combo, presumably due to steric hindrance as TET1(CD) is natively located at the C-terminus of TET1 full length protein. Thus indicating that Casilio-mediated delivery of demethylation enzymes to specific genomic locus enables robust alteration of gene expression.
  • To compare the obtained TET1-mediated activation of hMLH1 expression with an activation induced by recruiting transcription factor and transcription machinery to hMLH1 promoter, TET1-effector was replaced by p65HSF1-effector. Using the same sgRNAs combo, this showed higher activation that reached 200-fold over the background (FIG. 3B). This therefore shows that Casilio-ME-mediated activation of hMLH1 expression can achieve about 70% of the activation obtained by a strong transcription activator module such as p65HSF1, indicating that Casilio-ME is an efficient tool enabling efficient targeting and delivery of demethylation enzymes to alter methylation state of the genome and the associated silencing activities.
  • Effect of delivery of dCas9-tethered demethylation enzymes to specific locus on gene expression. Direct fusions to dCas9 protein had extensively been used to target effectors to specific genomic locus and had also recently been used to deliver TET1(CD) to induce demethylation and associated gene activation (Morita, S., et al., Targeted DNA demethylation in vivo using dCas9-peptide repeat and scFv-TET1 catalytic domain fusions. Nat Biotechnol, 2016; Xu, X., et al., A CRISPR-based approach for targeted DNA demethylation. Cell Discov, 2016. 2: p. 16009).
  • To assess the efficiency of dCas9-TET1(CD) direct fusion to activate hMLH1 expression in HEK293T cells in comparison to Casilio-ME, N-terminal and C-terminal fusions of dCas9 to TET1(CD) were constructed. Using the same combination of sgRNAs as in the Casilio-ME experiments, the dCas9-TET1(CD)C-terminal fusion showed a relatively weak activation of hMLH1, as indicated by the relative change in mRNA levels (FIG. 3C). dCas9-TET1(CD)-induced activation represents at best about 14% of the obtained activation using the Casilio-ME with the same sgRNAs combination in parallel experiment (19-vs 135-fold change in mRNA levels). In contrast, TET1(CD)-dCas9 fusion showed a much weaker activation than its respective C-terminal fusion, indicating a possible steric hindrance affecting TET1 activity when N-terminally fused to either dCas9 or PUFa proteins (FIGS. 3B & 3C).
  • To compare hMLH1 activation obtained with dCas9-TET1 to that of a transcriptional activator, HEK293T cells were transfected with dCas9-p65HSF1 along with the same sgRNA combination. Analysis of mRNA levels showed that dCas9-TET1 activation of hMLH1 was at best twice the activity obtained with transcription activator dCas9 fusion (FIG. 3C), therefore indicating that TET1 targeting to specific locus can activate gene, presumably via alteration of epigenetic DNA methylation at the target site. However hMLH1 activation obtained with Casilio-ME is significantly more efficient than that obtained with dCas9-TET1(CD) direct fusion, indicating the great potential of Casilio-ME platform as an effective and adaptable tool to deciphering the implication of cytosine hypermethylation in numerous biological and pathological systems.
  • Casilio-mediated delivery of demethylation enzymes alters methylation state of targeted genomic locus. Evidence that the shown Casilio-ME-induced activation of hMLH1 transcription is a result of TET1-mediated cytosine demethylation within the targeted promoter region came from DNA sequencing of hMLH1 promoter after bisulfite conversion. Bisulfite treatment of genomic DNA deaminates unmethylated cytosines to produce uracils that are subsequently replicated as thymine. However, methylated cytosines are protected from conversion to uracils, thus allowing one to determine cytosine methylation states at single-nucleotide resolution by direct sequencing.
  • To assess changes in methylation states of CpG island within hMLH1 promoter region after Casilio-ME-mediated transcription activation, time course experiment were carried out where cells were collected 3, 4, 5, and 6 days post transfection, for analysis of cytosine methylation as well as transcription activation, and protein expression. HEK293T were transfected with Casilio-ME components that includes Ct-fusion PUFa-TET1 effector and a combination of 2 sgRNAs (RNA guides 3 and 7). TaqMan assays showed that the activation of hMLH1 transcription was maintained during the course of these transient transfections (FIG. 4A), thus showing a sustained change of hMLH1 mRNA levels during the 6 days of the experiment.
  • Sequencing of hMLH1 promoter DNA fragments that were cloned after bisulfite treatment of extracted genomic DNA and subsequent PCR-amplification showed a dramatic changes of the methylation landscape of the CpGs within hMLH1 promoter as indicated by the increased frequency of bisulfite conversion induced by Casilio-ME targeting (FIG. 4C). While no significant cytosine to uracil conversion was obtained with untransfected HEK293T cells, as expected for a hypermethylated DNA, transfected HEK293T cells showed significant demethylation frequency with highest activities observed close to binding-sites of the targeting RNAs (FIG. 4C (arrows)). The Casilio-ME-mediated demethylation activity was sustained during the course of the experiment and seems to spread away from the binding-sites of the guide RNAs for 300 pb, albeit with a relatively weaker activities.
  • In control experiments, untransfected HEK293 cells, whose hMLH1 promoter is hypomethylated and transcriptionally active, were also analyzed. As shown in FIG. 4C (black columns), the sequenced region showed high frequency of cytosine conversion as expected. Untransfected HEK293T cells treated for 6 days with 5′azacytidine (AzaC) drug, an inhibitor or cytosine methyltransferases, were also analyzed. This also showed an increased bisulfite conversion frequency on multiple CpG sites within the promoter region (FIG. 4C, purple columns).
  • To determine the effect of Casilio-ME targeting on MLH1 protein synthesis, Western blot analyses were performed on total protein extracted from HEK293T transfected cells as well as untransfected HEK293 and AzaC-treated HEK293T cells using anti-hMLH1 monoclonal antibody. The results showed that transfected cells produced detectable amounts of MLH1 protein that reached higher levels by day 5 and 6 post transfection (FIG. 4B). However, the amounts of MLH1 produced by transfected cells are significantly lower that the protein levels produced by HEK293 cells that constitutively express hMLH1. Casilio-ME-mediated induction of MLH1 synthesis is still remarkable and could be improved by, for example, tilling multiple guide RNAs to augment the range and efficiency of CpG demethylation to achieving better activation of hMLH1 expression.
  • Taken the fact that Casilio-ME delivery of TET1 activity to hMLH1 promoter region activated transcription, together with the dramatic induced change of the methylation sate of the associated CpG island, the findings provide a proof-of-principal that the Casilio-ME is a robust platform to editing methylcytosine mark of the epigenome. This technology paves the way to new area of research investigations to address with high resolution the causal-effect relationships of methylcytosine epigenomic marks in numerous biological and pathological systems.
  • Casilio-mediated delivery of methyltranferases silent gene expression. Programmable methyltranferases were constructed by either direct fusions of catalytic domains of Dnmt3a, Dnmt3L, or a hybrid Dnmt3a-3L to N-terminus or C-terminus of dCas9 (FIG. 5A). N- or C-terminal fusions of these effectors to PUFa were also constructed, for use with dCas9 and sgRNA-PBS (Casilio-ME with Dnmt effectors; FIG. 5B). Casilio-ME with a Dnmt3a-PUF achieved more robust repression of SOX2 gene expression compared to direct fusions, demonstrating superior activity using Casilio-ME for directed DNA methylation (FIGS. 6A and 6B).
    • Materials and Methods
  • DNA Demethylation by Tet1 Effectors
  • Cell culture and transfection. HEK293T cells were cultivated in Dulbecco's modified Eagle's medium (DMEM)(Sigma) with 10% fetal bovine serum (FBS)(Lonza), 4% Glutamax (Gibco), 1% Sodium Pyruvate (Gibco) and penicillin-streptomycin (Gibco) in an incubator set to 37° C. and 5% CO2. When indicated cells were treated with 2.5 μM or 5 μM 5-Azacytidine (sigma) as indicated with a daily change of medium containing freshly diluted drug. Cells were seeded into 12-well plates at 150,000 cells per well the day before being transfected with 100 ng of dCas9 construct, 100 ng of modified sgRNA construct and 200 ng of PUF-fusion with Attractene transfection reagent according to manufacturer's instructions (Qiagen). In dCas9-direct fusion experiments, cells were transfected with 200 ng dCas9-fusion constructs and 200 ng of modified sgRNA constructs. Transfected cells were harvested 60 hours after transfection, or otherwise indicated, and cell pellets were used for extractions of RNA, genomic DNA and protein.
  • Quantitative RT-PCR analysis. Cells were harvested, washed with Dulbecco's phosphate-buffered saline (dPBS), centrifuged at 125×g for 5 min and then the flash-frozen pellets were stored at −80° C. RNA was extracted using RNeasy Plus Mini Kit according to the manufacturer's instructions (Qiagen). cDNA libraries were made using Applied Biosystems High Capacity RNA-to-cDNA kit with 200 ng to 1 μg of RNA. TaqMan gene expression assays (Applied Biosystems) were designed using GAPDH (Hs03929097, VIC) as endogenous control and hMLH1 (Hs00179866, FAM) as target. TaqMan Universal Master Mix II, with UNG (Applied Biosystems) was used for Quantitative PCR (qPCR), with 2 μl of diluted cDNA used for each reaction. Activation was analyzed with the Applied Biosystems ViiA7 instrument. Gene expression levels were calculated by “delta delta Ct” algorithm and normalized to control samples.
  • Bisulfite conversion and sequencing. Genomic DNAs were extracted using all AllPrep DNA/RNA/Protein Mini Kit according the manufacturer's instructions (Qiagen). The kit allows extraction of genomic DNA as well as RNA and total protein from the same cellular pellet for parallel downstream analyses. Bisulfite conversion experiments were performed by using EpiTect Fast DNA Bisulfite Kit and extracted genomic DNAs according to manufacturer's instructions (Qiagen). Bisulfite treated DNAs served then as templates to PCR amplify two DNA fragments of 350-400 bp long that cover the whole hMLH1 promoter region using ZymoTaq PreMix according to manufacturer's instructions (Zymo Research). The PCR fragments were then cloned by SLIC into EcoRI-linearized PUC19 plasmid using T4 DNA polymerize (Jeong, J. Y., et al., One-step sequence-and ligation-independent cloning as a rapid and versatile cloning method for functional genomics studies. Appl Environ Microbiol, 2012. 78(15): p. 5440-3). Six independent positive clones for each sample were then subjected to Singer sequencing for determination of the frequency of cytosine to thymine conversion at individual CpG of the hMLH1 promoter region.
  • Western blot analysis. Protein from cell extracts (30 μg) were separated by electrophoresis on 10% SDS-polyacrylamide gels and then transferred to nitrocellulose membranes at 100 V for 1 hour using Bjerrum Schafer-Nielsen Buffer with SDS. Blocked membrane in 5% Blotting-Grade Blocker (BioRad) in TBS-T were then incubated overnight at 4° C. with the indicated antibodies, and the protein bands were detected using Horseradish peroxidase-conjugated secondary antibodies and Clarity Western ECL Substrate according to manufacturer's instructions (BioRad). Gels were imaged using a G:Box (Syngene).
  • DNA Methylation by Dnmt Effectors
  • Establishment of a dCas9-expressing cell line. The day prior to transfection, Lenti-X 293T cells were seeded into 6-well plates at 1.2 million cells per well. The cells were transfected with the supercoiled packaging plasmids (pLP1 (gag/pol), pLP2 (rev), and VSV-G (envelope)) and a dCas9 lentiviral expression plasmid through Lipofectamine 3000 reagent (Invitrogen). At 6 h posttransfection, medium was exchanged for fresh. At 24 h posttransfection, 2 ml of medium containing the lentivirus were collected and centrifuged for 10 minutes at 2,000 rpm to remove cellular debris. The supernatant was filtered utilizing a 45 m pore filter (Millipore), and the lentivirus was frozen at −80° C. until needed. HEK293T cells, seeded into a 12-well plate at 150,000 cells per well, were transduced with 500 μl of the dCas9 lentivirus in culture medium supplemented with 5 μg/ml polybrene for 12 hours, and subsequently selected with Blasticidin antibiotics on the third day post transduction.
  • Transfection. HEK293T, and HEK293T/dCas9 cell lines were seeded into 12-well plates at 150,000 cells per well. Cells were transfected with 200 ng of the Dnmt effector constructs and 200 ng of the sgRNA-PBS with Attractene transfection reagent (Qiagen). At 3 day post-transfection, the cells were sorted for GFP (sgRNA expression constructs are marked by GFP) with fluorescence-activated cell sorting (FACS) and re-plated into 12 or 24-well plates.
  • Quantitative reverse-transcription PCR. Cells were harvested 7-10 day post-transfection with 100 μl of trypsin, 500 μl of DMEM, and 500 μl of Dulbecco's phosphate-buffered saline (dPBS), and centrifuged at 700 g for 5 minutes. RNA was extracted from the pelleted cells utilizing the RNeasy Plus Mini Kit (Qiagen). cDNA synthesis was performed using the Applied Biosystems High Capacity RNA-to-cDNA kit with 2 μg of RNA. TaqMan Gene expression assays (Applied Biosystems) were completed with GAPDH as the endogenous control and SOX2 as target.
    • Sequences
  • List of sgRNA spacer sequences targeting the MLH1 and SOX2 genes.
  •
    MLH1 sgRNA SEQ ID NO: 36
    spacer sequences ACAGAGTTGAGAAATTTGAC
    SEQ ID NO: 37
    GTCAAATTTCTCAACTCTGT
    SEQ ID NO: 38
    GCTCCTAAAAACGAACCAAT
    SEQ ID NO: 39
    AAACGAACCAATAGGAAGAG
    SEQ ID NO: 40
    CTTCAGCGGCAGCTATTGAT
    SEQ ID NO: 41
    GCATCTCTGCTCCTATTGGC
    SEQ ID NO: 42
    GCGCCAGATCACCTCAGCAG
    SEQ ID NO: 43
    GCAGAGCGGAGGAGGTGCT
    SEQ ID NO: 44
    GAAGGAAGAACGTGAGCACG
    SEQ ID NO: 45
    GGCAGTAGCCGCTTCAGGGA
    SEQ ID NO: 46
    GCGCAAGCGCATATCCTTCT
    SOX2 sgRNA SEQ ID NO: 47
    spacer sequences GCATGTGACGGGGGCTGTCA
    SEQ ID NO: 48
    GCTGCCGGGTTTTGCATGAA
    SEQ ID NO: 49
    GCCGGCCGCGCGGGGGAGGC
    SEQ ID NO: 50
    GGCAGGCGAGGAGGGGGAGG
  • List of Protein Sequences
  • Name Protein Sequence
    TET1(CD) ELPTCSCLDRVIQKDKGPYYTHLGAGPSVAAVREIMENRYGQKGNAIRIEIVVYTG
    SEQ ID NO: 51 KEGKSSHGCPIAKWVLRRSSDEEKVLCLVRQRTGHHCPTAVMVVLIMVWDGIPLPM
    ADRLYTELTENLKSYNGHPTDRRCTLNENRTCTCQGIDPETCGASFSFGCSWSMYF
    NGCKFGRSPSPRRFRIDPSSPLHEKNLEDNLQSLATRLAPIYKQYAPVAYQNQVEY
    ENVARECRLGSKEGRPFSGVTACLDFCAHPHRDIHNMNNGSTVVCTLTREDNRSLG
    VIPQDEQLHVLPLYKLSDTDEFGSKEGMEAKIKSGAIEVLAPRRKKRTCFTQPVPR
    SGKKRAAMMTEVLAHKIRAVEKKPIPRIKRKNNSTTTNNSKPSSLPTLGSNTETVQ
    PEVKSETEPHFILKSSDNTKTYSLMPSAPHPVKEASPGFSWSPKTASATPAPLKND
    ATASCGFSERSSTPHCTMPSGRLSGANAAAADGPGISQLGEVAPLPTLSAPVMEPL
    INSEPSTGVTEPLTPHQPNHQPSFLTSPQDLASSPMEEDEQHSEADEPPSDEPLSD
    DPLSPAEEKLPHIDEYWSDSEHIFLDANIGGVAIAPAHGSVLIECARRELHATTPV
    EHPNRNHPTRLSLVFYQHKNLNKPQHGFELNKIKFEAKEAKNKKMKASEQKDQAAN
    EGPEQSSEVNELNQIPSHKALTLTHDNVVTVSPYALTHVAGPYNHWV
    TET1(CD)- MGPAELPTCSCLDRVIQKDKGPYYTHLGAGPSVAAVREIMENRYGQKGNAIRIEIV
    dCas9 VYTGKEGKSSHGCPIAKWVLRRSSDEEKVLCLVRQRTGHHCPTAVMVVLIMVWDGI
    SEQ ID NO: 52 PLPMADRLYTELTENLKSYNGHPTDRRCTLNENRTCTCQGIDPETCGASFSFGCSW
    SMYFNGCKFGRSPSPRRFRIDPSSPLHEKNLEDNLQSLATRLAPIYKQYAPVAYQN
    QVEYENVARECRLGSKEGRPFSGVTACLDFCAHPHRDIHNMNNGSTVVCTLTREDN
    RSLGVIPQDEQLHVLPLYKLSDTDEFGSKEGMEAKIKSGAIEVLAPRRKKRTCFTQ
    PVPRSGKKRAAMMTEVLAHKIRAVEKKPIPRIKRKNNSTTTNNSKPSSLPTLGSNT
    ETVQPEVKSETEPHFILKSSDNTKTYSLMPSAPHPVKEASPGFSWSPKTASATPAP
    LKNDATASCGFSERSSTPHCTMPSGRLSGANAAAADGPGISQLGEVAPLPTLSAPV
    MEPLINSEPSTGVTEPLTPHQPNHQPSFLTSPQDLASSPMEEDEQHSEADEPPSDE
    PLSDDPLSPAEEKLPHIDEYWSDSEHIFLDANIGGVAIAPAHGSVLIECARRELHA
    TTPVEHPNRNHPTRLSLVFYQHKNLNKPQHGFELNKIKFEAKEAKNKKMKASEQKD
    QAANEGPEQSSEVNELNQIPSHKALTLTHDNVVTVSPYALTHVAGPYNHWVIDGGG
    GSGGGGSGGGGSMYPYDVPDYASPKKKRKVEASDKKYSIGLAIGTNSVGWAVITDE
    YKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRIC
    YLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIY
    HLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTY
    NQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGL
    TPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSD
    ILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYA
    GYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHL
    GELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEET
    ITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVK
    YVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVE
    DRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYA
    HLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQL
    IHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMG
    RHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQN
    EKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNR
    GKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQ
    LVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVR
    EINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKA
    TAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLS
    MPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVL
    VVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPK
    YSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQ
    LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHL
    FTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD
    SPKKKRKVEASGGGGSGGGGSGGGGSGPA
    dCas9- MIDGGGGSGGGGSGGGGSMYPYDVPDYASPKKKRKVEASDKKYSIGLAIGTNSVGW
    TET1(CD) AVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTR
    SEQ ID NO: 53 RKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHE
    KYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFI
    QLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLI
    ALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSD
    AILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQ
    SKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSI
    PHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMT
    RKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYN
    ELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSV
    EISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEE
    RLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFAN
    RNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDE
    LVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVE
    NTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLT
    RSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKA
    GFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDF
    QFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSE
    QEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFAT
    VRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPT
    VAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDL
    IIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPE
    DNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQA
    ENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDL
    SQLGGDSPKKKRKVEASGGGGSGGGGSGGGGSGPAELPTCSCLDRVIQKDKGPYYT
    HLGAGPSVAAVREIMENRYGQKGNAIRIEIVVYTGKEGKSSHGCPIAKWVLRRSSD
    EEKVLCLVRQRTGHHCPTAVMVVLIMVWDGIPLPMADRLYTELTENLKSYNGHPTD
    RRCTLNENRTCTCQGIDPETCGASFSFGCSWSMYFNGCKFGRSPSPRRFRIDPSSP
    LHEKNLEDNLQSLATRLAPIYKQYAPVAYQNQVEYENVARECRLGSKEGRPFSGVT
    ACLDFCAHPHRDIHNMNNGSTVVCTLTREDNRSLGVIPQDEQLHVLPLYKLSDTDE
    FGSKEGMEAKIKSGAIEVLAPRRKKRTCFTQPVPRSGKKRAAMMTEVLAHKIRAVE
    KKPIPRIKRKNNSTTTNNSKPSSLPTLGSNTETVQPEVKSETEPHFILKSSDNTKT
    YSLMPSAPHPVKEASPGFSWSPKTASATPAPLKNDATASCGFSERSSTPHCTMPSG
    RLSGANAAAADGPGISQLGEVAPLPTLSAPVMEPLINSEPSTGVTEPLTPHQPNHQ
    PSFLTSPQDLASSPMEEDEQHSEADEPPSDEPLSDDPLSPAEEKLPHIDEYWSDSE
    HIFLDANIGGVAIAPAHGSVLIECARRELHATTPVEHPNRNHPTRLSLVFYQHKNL
    NKPQHGFELNKIKFEAKEAKNKKMKASEQKDQAANEGPEQSSEVNELNQIPSHKAL
    TLTHDNVVTVSPYALTHVAGPYNHWVID
    TET1-PUFa MGPAELPTCSCLDRVIQKDKGPYYTHLGAGPSVAAVREIMENRYGQKGNAIRIEIV
    SEQ ID NO: 54 VYTGKEGKSSHGCPIAKWVLRRSSDEEKVLCLVRQRTGHHCPTAVMVVLIMVWDGI
    PLPMADRLYTELTENLKSYNGHPTDRRCTLNENRTCTCQGIDPETCGASFSFGCSW
    SMYFNGCKFGRSPSPRRFRIDPSSPLHEKNLEDNLQSLATRLAPIYKQYAPVAYQN
    QVEYENVARECRLGSKEGRPFSGVTACLDFCAHPHRDIHNMNNGSTVVCTLTREDN
    RSLGVIPQDEQLHVLPLYKLSDTDEFGSKEGMEAKIKSGAIEVLAPRRKKRTCFTQ
    PVPRSGKKRAAMMTEVLAHKIRAVEKKPIPRIKRKNNSTTTNNSKPSSLPTLGSNT
    ETVQPEVKSETEPHFILKSSDNTKTYSLMPSAPHPVKEASPGFSWSPKTASATPAP
    LKNDATASCGFSERSSTPHCTMPSGRLSGANAAAADGPGISQLGEVAPLPTLSAPV
    MEPLINSEPSTGVTEPLTPHQPNHQPSFLTSPQDLASSPMEEDEQHSEADEPPSDE
    PLSDDPLSPAEEKLPHIDEYWSDSEHIFLDANIGGVAIAPAHGSVLIECARRELHA
    TTPVEHPNRNHPTRLSLVFYQHKNLNKPQHGFELNKIKFEAKEAKNKKMKASEQKD
    QAANEGPEQSSEVNELNQIPSHKALTLTHDNVVTVSPYALTHVAGPYNHWVIDGGG
    GSDPKKKRKVDPKKKRKVDPKKKRKVGSTGSRNDGGGGSGGGGSGGGGSGRAGILP
    PKKKRKVSRGRSRLLEDFRNNRYPNLQLREIAGHIMEFSQDQHGSRFIQLKLERAT
    PAERQLVFNEILQAAYQLMVDVFGNYVIQKFFEFGSLEQKLALAERIRGHVLSLAL
    QMYGSRVIEKALEFIPSDQQNEMVRELDGHVLKCVKDQNGNHVVQKCIECVQPQSL
    QFIIDAFKGQVFALSTHPYGCRVIQRILEHCLPDQTLPILEELHQHTEQLVQDQYG
    NYVIQHVLEHGRPEDKSKIVAEIRGNVLVLSQHKFASNVVEKCVTHASRTERAVLI
    DEVCTMNDGPHSALYTMMKDQYANYVVQKMIDVAEPGQRKIVMHKIRPHIATLRKY
    TYGKHILAKLEKYYMKNGVDLGDPKKKRKVDPKKKRKVGGRGGGGSGGGGSGGGGS
    GPA
    PUFa-TET1 MIDGGGGSDPKKKRKVDPKKKRKVDPKKKRKVGSTGSRNDGGGGSGGGGSGGGGSG
    SEQ ID NO: 55 RAGILPPKKKRKVSRGRSRLLEDFRNNRYPNLQLREIAGHIMEFSQDQHGSRFIQL
    KLERATPAERQLVFNEILQAAYQLMVDVFGNYVIQKFFEFGSLEQKLALAERIRGH
    VLSLALQMYGSRVIEKALEFIPSDQQNEMVRELDGHVLKCVKDQNGNHVVQKCIEC
    VQPQSLQFIIDAFKGQVFALSTHPYGCRVIQRILEHCLPDQTLPILEELHQHTEQL
    VQDQYGNYVIQHVLEHGRPEDKSKIVAEIRGNVLVLSQHKFASNVVEKCVTHASRT
    ERAVLIDEVCTMNDGPHSALYTMMKDQYANYVVQKMIDVAEPGQRKIVMHKIRPHI
    ATLRKYTYGKHILAKLEKYYMKNGVDLGDPKKKRKVDPKKKRKVGGRGGGGSGGGG
    SGGGGSGPAELPTCSCLDRVIQKDKGPYYTHLGAGPSVAAVREIMENRYGQKGNAI
    RIEIVVYTGKEGKSSHGCPIAKWVLRRSSDEEKVLCLVRQRTGHHCPTAVMVVLIM
    VWDGIPLPMADRLYTELTENLKSYNGHPTDRRCTLNENRTCTCQGIDPETCGASFS
    FGCSWSMYFNGCKFGRSPSPRRFRIDPSSPLHEKNLEDNLQSLATRLAPIYKQYAP
    VAYQNQVEYENVARECRLGSKEGRPFSGVTACLDFCAHPHRDIHNMNNGSTVVCTL
    TREDNRSLGVIPQDEQLHVLPLYKLSDTDEFGSKEGMEAKIKSGAIEVLAPRRKKR
    TCFTQPVPRSGKKRAAMMTEVLAHKIRAVEKKPIPRIKRKNNSTTTNNSKPSSLPT
    LGSNTETVQPEVKSETEPHFILKSSDNTKTYSLMPSAPHPVKEASPGFSWSPKTAS
    ATPAPLKNDATASCGFSERSSTPHCTMPSGRLSGANAAAADGPGISQLGEVAPLPT
    LSAPVMEPLINSEPSTGVTEPLTPHQPNHQPSFLTSPQDLASSPMEEDEQHSEADE
    PPSDEPLSDDPLSPAEEKLPHIDEYWSDSEHIFLDANIGGVAIAPAHGSVLIECAR
    RELHATTPVEHPNRNHPTRLSLVFYQHKNLNKPQHGFELNKIKFEAKEAKNKKMKA
    SEQKDQAANEGPEQSSEVNELNQIPSHKALTLTHDNVVTVSPYALTHVAGPYNHWV
    ID
    hDNMT3a NHDQEFDPPKVYPPVPAEKRKPIRVLSLFDGIATGLLVLKDLGIQVDRYIASEVCE
    (609-909) DSITVGMVRHQGKIMYVGDVRSVTQKHIQEWGPFDLVIGGSPCNDLSIVNPARKGL
    SEQ ID NO: 56 YEGTGRLFFEFYRLLHDARPKEGDDRPFFWLFENVVAMGVSDKRDISRFLESNPVM
    IDAKEVSAAHRARYFWGNLPGMNRPLASTVNDKLELQECLEHGRIAKFSKVRTITT
    RSNSIKQGKDQHFPVFMNEKEDILWCTEMERVFGFPVHYTDVSNMSRLARQRLLGR
    SWSVPVIRHLFAPLKEYFACV
    mDnmt3L GPMEIYKTVSAWKRQPVRVLSLFRNIDKVLKSLGFLESGSGSGGGTLKYVEDVTNV
    (208-421) VRRDVEKWGPFDLVYGSTQPLGSSCDRCPGWYMFQFHRILQYALPRQESQRPFFWI
    SEQ ID NO: 57 FMDNLLLTEDDQETTTRFLQTEAVTLQDVRGRDYQNAMRVWSNIPGLKSKHAPLTP
    KEEEYLQAQVRSRSKLDAPKVDLLVKNCLLPLREYFKYFSQNSLPL
    Dnmt3a3L NHDQEFDPPKVYPPVPAEKRKPIRVLSLFDGIATGLLVLKDLGIQVDRYIASEVCE
    SEQ ID NO: 58 DSITVGMVRHQGKIMYVGDVRSVTQKHIQEWGPFDLVIGGSPCNDLSIVNPARKGL
    YEGTGRLFFEFYRLLHDARPKEGDDRPFFWLFENVVAMGVSDKRDISRFLESNPVM
    IDAKEVSAAHRARYFWGNLPGMNRPLASTVNDKLELQECLEHGRIAKFSKVRTITT
    RSNSIKQGKDQHFPVFMNEKEDILWCTEMERVFGFPVHYTDVSNMSRLARQRLLGR
    SWSVPVIRHLFAPLKEYFACVSSGNSNANSRGPSFSSGLVPLSLRGSHMGPMEIYK
    TVSAWKRQPVRVLSLFRNIDKVLKSLGFLESGSGSGGGTLKYVEDVTNVVRRDVEK
    WGPFDLVYGSTQPLGSSCDRCPGWYMFQFHRILQYALPRQESQRPFFWIFMDNLLL
    TEDDQETTTRFLQTEAVTLQDVRGRDYQNAMRVWSNIPGLKSKHAPLTPKEEEYLQ
    AQVRSRSKLDAPKVDLLVKNCLLPLREYFKYFSQNSLPL
    Dnmt3a-dCas9 MGPANHDQEFDPPKVYPPVPAEKRKPIRVLSLFDGIATGLLVLKDLGIQVDRYIAS
    SEQ ID NO: 59 EVCEDSITVGMVRHQGKIMYVGDVRSVTQKHIQEWGPFDLVIGGSPCNDLSIVNPA
    RKGLYEGTGRLFFEFYRLLHDARPKEGDDRPFFWLFENVVAMGVSDKRDISRFLES
    NPVMIDAKEVSAAHRARYFWGNLPGMNRPLASTVNDKLELQECLEHGRIAKFSKVR
    TITTRSNSIKQGKDQHFPVFMNEKEDILWCTEMERVFGFPVHYTDVSNMSRLARQR
    LLGRSWSVPVIRHLFAPLKEYFACVIDGGGGSGGGGSGGGGSMYPYDVPDYASPKK
    KRKVEASDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGA
    LLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFL
    VEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMI
    KFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSK
    SRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDD
    LDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQ
    DLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGT
    EELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEK
    ILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNF
    DKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFK
    TNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNE
    ENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKL
    INGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHE
    HIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSR
    ERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLS
    DYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAK
    LITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDEN
    DKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYP
    KLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIR
    KRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKR
    NSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIME
    RSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNEL
    ALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVIL
    ADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTS
    TKEVLDATLIHQSITGLYETRIDLSQLGGDSPKKKRKVEASGGGGSGGGGSGGGGS
    GPA
    Dnmt3L-dCas9 MGPAGPMEIYKTVSAWKRQPVRVLSLFRNIDKVLKSLGFLESGSGSGGGTLKYVED
    SEQ ID NO: 60 VTNVVRRDVEKWGPFDLVYGSTQPLGSSCDRCPGWYMFQFHRILQYALPRQESQRP
    FFWIFMDNLLLTEDDQETTTRFLQTEAVTLQDVRGRDYQNAMRVWSNIPGLKSKHA
    PLTPKEEEYLQAQVRSRSKLDAPKVDLLVKNCLLPLREYFKYFSQNSLPLIDGGGG
    SGGGGSGGGGSMYPYDVPDYASPKKKRKVEASDKKYSIGLAIGTNSVGWAVITDEY
    KVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICY
    LQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYH
    LRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYN
    QLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLT
    PNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDI
    LRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAG
    YIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLG
    ELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETI
    TPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKY
    VTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVED
    RFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAH
    LFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLI
    HDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGR
    HKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNE
    KLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRG
    KSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQL
    VETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVRE
    INNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKAT
    AKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSM
    PQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPIVAYSVLV
    VAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY
    SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQL
    FVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLF
    TLINLGAPAAFKYFDTTIDRKRYISTKEVLDATLIHQSITGLYETRIDLSQLGGDS
    PKKKRKVEASGGGGSGGGGSGGGGSGPA
    Dnmt3a3L- MGPANHDQEFDPPKVYPPVPAEKRKPIRVLSLFDGIATGLLVLKDLGIQVDRYIAS
    dCas9 EVCEDSITVGMVRHQGKIMYVGDVRSVIQKHIQEWGPFDLVIGGSPCNDLSIVNPA
    SEQ ID NO: 61 RKGLYEGTGRLFFEFYRLLHDARPKEGDDRPFFWLFENVVAMGVSDKRDISRFLES
    NPVMIDAKEVSAAHRARYFWGNLPGMNRPLASTVNDKLELQECLEHGRIAKFSKVR
    TITTRSNSIKQGKDQHFPVFMNEKEDILWCTEMERVFGFPVHYTDVSNMSRLARQR
    LLGRSWSVPVIRHLFAPLKEYFACVSSGNSNANSRGPSFSSGLVPLSLRGSHMGPM
    EIYKTVSAWKRQPVRVLSLFRNIDKVLKSLGFLESGSGSGGGILKYVEDVINVVRR
    DVEKWGPFDLVYGSTQPLGSSCDRCPGWYMFQFHRILQYALPRQESQRPFFWIFMD
    NLLLTEDDQETTIRFLQTEAVTLQDVRGRDYQNAMRVWSNIPGLKSKHAPLIPKEE
    EYLQAQVRSRSKLDAPKVDLLVKNCLLPLREYFKYFSQNSLPLIDGGGGSGGGGSG
    GGGSMYPYDVPDYASPKKKRKVEASDKKYSIGLAIGINSVGWAVITDEYKVPSKKF
    KVLGNIDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSN
    EMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVD
    STDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENP
    INASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLITNFKSNF
    DLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEI
    TKAPLSASMIKRYDEHHQDLILLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGAS
    QEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILR
    RQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEE
    VVDKGASAQSFIERMINFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRK
    PAFLSGEQKKAIVDLLFKINRKVIVKQLKEDYFKKIECFDSVEISGVEDRFNASLG
    TYHDLLKIIKDKDFLDNEENEDILEDIVLILTLFEDREMIEERLKTYAHLFDDKVM
    KQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLIF
    KEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIV
    IEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYL
    QNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLIRSDKNRGKSDNVPS
    EEVVKKMKNYWRQLLNAKLITQRKFDNLIKAERGGLSELDKAGFIKRQLVETRQIT
    KHVAQILDSRMNIKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHA
    HDAYLNAVVGIALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYS
    NIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVK
    KTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKG
    KSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELEN
    GRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKH
    YLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGA
    PAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGDSPKKKRKV
    EASGGGGSGGGGSGGGGSGPA
    dCas9-Dnmt3a MIDGGGGSGGGGSGGGGSMYPYDVPDYASPKKKRKVEASDKKYSIGLAIGTNSVGW
    SEQ ID NO: 62 AVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTR
    RKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHE
    KYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFI
    QLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLI
    ALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSD
    AILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQ
    SKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSI
    PHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMT
    RKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYN
    ELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSV
    EISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEE
    RLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFAN
    RNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDE
    LVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVE
    NTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLT
    RSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKA
    GFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDF
    QFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSE
    QEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFAT
    VRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPT
    VAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDL
    IIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPE
    DNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQA
    ENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDL
    SQLGGDSPKKKRKVEASGGGGSGGGGSGGGGSGPANHDQEFDPPKVYPPVPAEKRK
    PIRVLSLFDGIATGLLVLKDLGIQVDRYIASEVCEDSITVGMVRHQGKIMYVGDVR
    SVTQKHIQEWGPFDLVIGGSPCNDLSIVNPARKGLYEGTGRLFFEFYRLLHDARPK
    EGDDRPFFWLFENVVAMGVSDKRDISRFLESNPVMIDAKEVSAAHRARYFWGNLPG
    MNRPLASTVNDKLELQECLEHGRIAKFSKVRTITTRSNSIKQGKDQHFPVFMNEKE
    DILWCTEMERVFGFPVHYTDVSNMSRLARQRLLGRSWSVPVIRHLFAPLKEYFACV
    ID
    dCas9-Dnmt3L MIDGGGGSGGGGSGGGGSMYPYDVPDYASPKKKRKVEASDKKYSIGLAIGTNSVGW
    SEQ ID NO: 63 AVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTR
    RKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHE
    KYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFI
    QLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLI
    ALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSD
    AILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQ
    SKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSI
    PHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMT
    RKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYN
    ELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSV
    EISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEE
    RLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFAN
    RNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDE
    LVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVE
    NTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLT
    RSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKA
    GFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDF
    QFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSE
    QEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFAT
    VRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPT
    VAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDL
    IIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPE
    DNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQA
    ENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDL
    SQLGGDSPKKKRKVEASGGGGSGGGGSGGGGSGPAGPMEIYKTVSAWKRQPVRVLS
    LFRNIDKVLKSLGFLESGSGSGGGTLKYVEDVTNVVRRDVEKWGPFDLVYGSTQPL
    GSSCDRCPGWYMFQFHRILQYALPRQESQRPFFWIFMDNLLLTEDDQETTTRFLQT
    EAVTLQDVRGRDYQNAMRVWSNIPGLKSKHAPLTPKEEEYLQAQVRSRSKLDAPKV
    DLLVKNCLLPLREYFKYFSQNSLPLID
    dCas9- MIDGGGGSGGGGSGGGGSMYPYDVPDYASPKKKRKVEASDKKYSIGLAIGTNSVGW
    Dnmt3a3L AVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTR
    SEQ ID NO: 64 RKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHE
    KYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFI
    QLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLI
    ALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSD
    AILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQ
    SKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSI
    PHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMT
    RKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYN
    ELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSV
    EISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEE
    RLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFAN
    RNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDE
    LVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVE
    NTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLT
    RSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKA
    GFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDF
    QFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSE
    QEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFAT
    VRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPT
    VAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDL
    IIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPE
    DNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQA
    ENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDL
    SQLGGDSPKKKRKVEASGGGGSGGGGSGGGGSGPANHDQEFDPPKVYPPVPAEKRK
    PIRVLSLFDGIATGLLVLKDLGIQVDRYIASEVCEDSITVGMVRHQGKIMYVGDVR
    SVTQKHIQEWGPFDLVIGGSPCNDLSIVNPARKGLYEGTGRLFFEFYRLLHDARPK
    EGDDRPFFWLFENVVAMGVSDKRDISRFLESNPVMIDAKEVSAAHRARYFWGNLPG
    MNRPLASTVNDKLELQECLEHGRIAKFSKVRTITTRSNSIKQGKDQHFPVFMNEKE
    DILWCTEMERVFGFPVHYTDVSNMSRLARQRLLGRSWSVPVIRHLFAPLKEYFACV
    SSGNSNANSRGPSFSSGLVPLSLRGSHMGPMEIYKTVSAWKRQPVRVLSLFRNIDK
    VLKSLGFLESGSGSGGGTLKYVEDVTNVVRRDVEKWGPFDLVYGSTQPLGSSCDRC
    PGWYMFQFHRILQYALPRQESQRPFFWIFMDNLLLTEDDQETTTRFLQTEAVTLQD
    VRGRDYQNAMRVWSNIPGLKSKHAPLTPKEEEYLQAQVRSRSKLDAPKVDLLVKNC
    LLPLREYFKYFSQNSLPLID
    Dnmt3a-PUFa MGPANHDQEFDPPKVYPPVPAEKRKPIRVLSLFDGIATGLLVLKDLGIQVDRYIAS
    SEQ ID NO: 65 EVCEDSITVGMVRHQGKIMYVGDVRSVTQKHIQEWGPFDLVIGGSPCNDLSIVNPA
    RKGLYEGTGRLFFEFYRLLHDARPKEGDDRPFFWLFENVVAMGVSDKRDISRFLES
    NPVMIDAKEVSAAHRARYFWGNLPGMNRPLASTVNDKLELQECLEHGRIAKFSKVR
    TITTRSNSIKQGKDQHFPVFMNEKEDILWCTEMERVFGFPVHYTDVSNMSRLARQR
    LLGRSWSVPVIRHLFAPLKEYFACVIDGGGGSDPKKKRKVDPKKKRKVDPKKKRKV
    GSTGSRNDGGGGSGGGGSGGGGSGRAGILPPKKKRKVSRGRSRLLEDFRNNRYPNL
    QLREIAGHIMEFSQDQHGSRFIQLKLERATPAERQLVFNEILQAAYQLMVDVFGNY
    VIQKFFEFGSLEQKLALAERIRGHVLSLALQMYGSRVIEKALEFIPSDQQNEMVRE
    LDGHVLKCVKDQNGNHVVQKCIECVQPQSLQFIIDAFKGQVFALSTHPYGCRVIQR
    ILEHCLPDQTLPILEELHQHTEQLVQDQYGNYVIQHVLEHGRPEDKSKIVAEIRGN
    VLVLSQHKFASNVVEKCVTHASRTERAVLIDEVCTMNDGPHSALYTMMKDQYANYV
    VQKMIDVAEPGQRKIVMHKIRPHIATLRKYTYGKHILAKLEKYYMKNGVDLGDPKK
    KRKVDPKKKRKVGGRGGGGSGGGGSGGGGSGPA
    Dnmt3L-PUFa MGPAGPMEIYKTVSAWKRQPVRVLSLFRNIDKVLKSLGFLESGSGSGGGTLKYVED
    SEQ ID NO: 66 VTNVVRRDVEKWGPFDLVYGSTQPLGSSCDRCPGWYMFQFHRILQYALPRQESQRP
    FFWIFMDNLLLTEDDQETTTRFLQTEAVTLQDVRGRDYQNAMRVWSNIPGLKSKHA
    PLTPKEEEYLQAQVRSRSKLDAPKVDLLVKNCLLPLREYFKYFSQNSLPLIDGGGG
    SDPKKKRKVDPKKKRKVDPKKKRKVGSTGSRNDGGGGSGGGGSGGGGSGRAGILPP
    KKKRKVSRGRSRLLEDFRNNRYPNLQLREIAGHIMEFSQDQHGSRFIQLKLERATP
    AERQLVFNEILQAAYQLMVDVFGNYVIQKFFEFGSLEQKLALAERIRGHVLSLALQ
    MYGSRVIEKALEFIPSDQQNEMVRELDGHVLKCVKDQNGNHVVQKCIECVQPQSLQ
    FIIDAFKGQVFALSTHPYGCRVIQRILEHCLPDQTLPILEELHQHTEQLVQDQYGN
    YVIQHVLEHGRPEDKSKIVAEIRGNVLVLSQHKFASNVVEKCVTHASRTERAVLID
    EVCTMNDGPHSALYTMMKDQYANYVVQKMIDVAEPGQRKIVMHKIRPHIATLRKYT
    YGKHILAKLEKYYMKNGVDLGDPKKKRKVDPKKKRKVGGRGGGGSGGGGSGGGGSG
    PA
    PUFa-Dnmt3a MIDGGGGSDPKKKRKVDPKKKRKVDPKKKRKVGSTGSRNDGGGGSGGGGSGGGGSG
    SEQ ID NO: 67 RAGILPPKKKRKVSRGRSRLLEDFRNNRYPNLQLREIAGHIMEFSQDQHGSRFIQL
    KLERATPAERQLVFNEILQAAYQLMVDVFGNYVIQKFFEFGSLEQKLALAERIRGH
    VLSLALQMYGSRVIEKALEFIPSDQQNEMVRELDGHVLKCVKDQNGNHVVQKCIEC
    VQPQSLQFIIDAFKGQVFALSTHPYGCRVIQRILEHCLPDQTLPILEELHQHTEQL
    VQDQYGNYVIQHVLEHGRPEDKSKIVAEIRGNVLVLSQHKFASNVVEKCVTHASRT
    ERAVLIDEVCTMNDGPHSALYTMMKDQYANYVVQKMIDVAEPGQRKIVMHKIRPHI
    ATLRKYTYGKHILAKLEKYYMKNGVDLGDPKKKRKVDPKKKRKVGGRGGGGSGGGG
    SGGGGSGPANHDQEFDPPKVYPPVPAEKRKPIRVLSLFDGIATGLLVLKDLGIQVD
    RYIASEVCEDSITVGMVRHQGKIMYVGDVRSVTQKHIQEWGPFDLVIGGSPCNDLS
    IVNPARKGLYEGTGRLFFEFYRLLHDARPKEGDDRPFFWLFENVVAMGVSDKRDIS
    RFLESNPVMIDAKEVSAAHRARYFWGNLPGMNRPLASTVNDKLELQECLEHGRIAK
    FSKVRTITTRSNSIKQGKDQHFPVFMNEKEDILWCTEMERVFGFPVHYTDVSNMSR
    LARQRLLGRSWSVPVIRHLFAPLKEYFACVID
    PUFa-Dnmt3L MIDGGGGSDPKKKRKVDPKKKRKVDPKKKRKVGSTGSRNDGGGGSGGGGSGGGGSG
    SEQ ID NO: 68 RAGILPPKKKRKVSRGRSRLLEDFRNNRYPNLQLREIAGHIMEFSQDQHGSRFIQL
    KLERATPAERQLVFNEILQAAYQLMVDVFGNYVIQKFFEFGSLEQKLALAERIRGH
    VLSLALQMYGSRVIEKALEFIPSDQQNEMVRELDGHVLKCVKDQNGNHVVQKCIEC
    VQPQSLQFIIDAFKGQVFALSTHPYGCRVIQRILEHCLPDQTLPILEELHQHTEQL
    VQDQYGNYVIQHVLEHGRPEDKSKIVAEIRGNVLVLSQHKFASNVVEKCVTHASRT
    ERAVLIDEVCTMNDGPHSALYTMMKDQYANYVVQKMIDVAEPGQRKIVMHKIRPHI
    ATLRKYTYGKHILAKLEKYYMKNGVDLGDPKKKRKVDPKKKRKVGGRGGGGSGGGG
    SGGGGSGPAGPMEIYKTVSAWKRQPVRVLSLFRNIDKVLKSLGFLESGSGSGGGTL
    KYVEDVTNVVRRDVEKWGPFDLVYGSTQPLGSSCDRCPGWYMFQFHRILQYALPRQ
    ESQRPFFWIFMDNLLLTEDDQETTTRFLQTEAVTLQDVRGRDYQNAMRVWSNIPGL
    KSKHAPLTPKEEEYLQAQVRSRSKLDAPKVDLLVKNCLLPLREYFKYFSQNSLPLI
    D
    PUFa-Dnmt3a3L MIDGGGGSDPKKKRKVDPKKKRKVDPKKKRKVGSTGSRNDGGGGSGGGGSGGGGSG
    SEQ ID NO: 69 RAGILPPKKKRKVSRGRSRLLEDFRNNRYPNLQLREIAGHIMEFSQDQHGSRFIQL
    KLERATPAERQLVFNEILQAAYQLMVDVFGNYVIQKFFEFGSLEQKLALAERIRGH
    VLSLALQMYGSRVIEKALEFIPSDQQNEMVRELDGHVLKCVKDQNGNHVVQKCIEC
    VQPQSLQFIIDAFKGQVFALSTHPYGCRVIQRILEHCLPDQTLPILEELHQHTEQL
    VQDQYGNYVIQHVLEHGRPEDKSKIVAEIRGNVLVLSQHKFASNVVEKCVTHASRT
    ERAVLIDEVCTMNDGPHSALYTMMKDQYANYVVQKMIDVAEPGQRKIVMHKIRPHI
    ATLRKYTYGKHILAKLEKYYMKNGVDLGDPKKKRKVDPKKKRKVGGRGGGGSGGGG
    SGGGGSGPANHDQEFDPPKVYPPVPAEKRKPIRVLSLFDGIATGLLVLKDLGIQVD
    RYIASEVCEDSITVGMVRHQGKIMYVGDVRSVTQKHIQEWGPFDLVIGGSPCNDLS
    IVNPARKGLYEGTGRLFFEFYRLLHDARPKEGDDRPFFWLFENVVAMGVSDKRDIS
    RFLESNPVMIDAKEVSAAHRARYFWGNLPGMNRPLASTVNDKLELQECLEHGRIAK
    FSKVRTITTRSNSIKQGKDQHFPVFMNEKEDILWCTEMERVFGFPVHYTDVSNMSR
    LARQRLLGRSWSVPVIRHLFAPLKEYFACVSSGNSNANSRGPSFSSGLVPLSLRGS
    HMGPMEIYKTVSAWKRQPVRVLSLFRNIDKVLKSLGFLESGSGSGGGTLKYVEDVT
    NVVRRDVEKWGPFDLVYGSTQPLGSSCDRCPGWYMFQFHRILQYALPRQESQRPFF
    WIFMDNLLLTEDDQETTTRFLQTEAVTLQDVRGRDYQNAMRVWSNIPGLKSKHAPL
    TPKEEEYLQAQVRSRSKLDAPKVDLLVKNCLLPLREYFKYFSQNSLPLID
  • List of Protein Sequences
  • Name sgRNA-PBS sequence
    sgSOX2-1-5xPBSa GCATGTGACGGGGGCTGTCAgtttAagagctaTGCTGGAAACAGCAta
    SEQ ID NO: 70 gcaagttTaaataaggctagtccgttatcaacttgaaaaagtggcacc
    gagtcggtgcCAATTGggtctccagatTGTATGTAGCCTGTATGTAGC
    CTGTATGTAGCCTGTATGTAGCCTGTATGTAagatCTTTTTTT
    sgSOX2-2-5xPBSa GCTGCCGGGTTTTGCATGAAgtttAagagctaTGCTGGAAACAGCAta
    SEQ ID NO: 71 gcaagttTaaataaggctagtccgttatcaacttgaaaaagtggcacc
    gagtcggtgcCAATTGggtctccagatTGTATGTAGCCTGTATGTAGC
    CTGTATGTAGCCTGTATGTAGCCTGTATGTAagatCTTTTTTT
    sgSOX2-3-5xPBSa GCCGGCCGCGCGGGGGAGGCgtttAagagctaTGCTGGAAACAGCAta
    SEQ ID NO: 72 gcaagttTaaataaggctagtccgttatcaacttgaaaaagtggcacc
    gagtcggtgcCAATTGggtctccagatTGTATGTAGCCTGTATGTAGC
    CTGTATGTAGCCTGTATGTAGCCTGTATGTAagatCTTTTTTT
    sgSOX2-4-5xPBSa GGCAGGCGAGGAGGGGGAGGgtttAagagctaTGCTGGAAACAGCAta
    SEQ ID NO: 73 gcaagttTaaataaggctagtccgttatcaacttgaaaaagtggcacc
    gagtcggtgcCAATTGggtctccagatTGTATGTAGCCTGTATGTAGC
    CTGTATGTAGCCTGTATGTAGCCTGTATGTAagatCTTTTTTT
    sgMLH1-PBSa  SEQ ID NO: 74
    sequences  ACAGAGTTGAGAAATTTGACgtttAagagctaTGCTGGAAACAGCAta
    gcaagttTaaataaggctagtccgttatcaacttgaaaaagtggcacc
    gagtcggtgcCAATTGggtctccagatTGTATGTAGCCTGTATGTAGC
    CTGTATGTAGCCTGTATGTAGCCTGTATGTAagatCTTTTTTT
    SEQ ID NO: 75
    GTCAAATTTCTCAACTCTGTgtttAagagctaTGCTGGAAACAGCAta
    gcaagttTaaataaggctagtccgttatcaacttgaaaaagtggcacc
    gagtcggtgcCAATTGggtctccagatTGTATGTAGCCTGTATGTAGC
    CTGTATGTAGCCTGTATGTAGCCTGTATGTAagatCTTTTTTT
    SEQ ID NO: 76
    GCTCCTAAAAACGAACCAATgtttAagagctaTGCTGGAAACAGCAta
    gcaagttTaaataaggctagtccgttatcaacttgaaaaagtggcacc
    gagtcggtgcCAATTGggtctccagatTGTATGTAGCCTGTATGTAGC
    CTGTATGTAGCCTGTATGTAGCCTGTATGTAagatCTTTTTTT
    SEQ ID NO: 77
    AAACGAACCAATAGGAAGAGgtttAagagctaTGCTGGAAACAGCAta
    gcaagttTaaataaggctagtccgttatcaacttgaaaaagtggcacc
    gagtcggtgcCAATTGggtctccagatTGTATGTAGCCTGTATGTAGC
    CTGTATGTAGCCTGTATGTAGCCTGTATGTAagatCTTTTTTT
    SEQ ID NO: 78
    CTTCAGCGGCAGCTATTGATgtttAagagctaTGCTGGAAACAGCAta
    gcaagttTaaataaggctagtccgttatcaacttgaaaaagtggcacc
    gagtcggtgcCAATTGggtctccagatTGTATGTAGCCTGTATGTAGC
    CTGTATGTAGCCTGTATGTAGCCTGTATGTAagatCTTTTTTT
    SEQ ID NO: 79
    GCATCTCTGCTCCTATTGGCgtttAagagctaTGCTGGAAACAGCAta
    gcaagttTaaataaggctagtccgttatcaacttgaaaaagtggcacc
    gagtcggtgcCAATTGggtctccagatTGTATGTAGCCTGTATGTAGC
    CTGTATGTAGCCTGTATGTAGCCTGTATGTAagatCTTTTTTT
    SEQ ID NO: 80
    GCGCCAGATCACCTCAGCAGgtttAagagctaTGCTGGAAACAGCAta
    gcaagttTaaataaggctagtccgttatcaacttgaaaaagtggcacc
    gagtcggtgcCAATTGggtctccagatTGTATGTAGCCTGTATGTAGC
    CTGTATGTAGCCTGTATGTAGCCTGTATGTAagatCTTTTTTT
    SEQ ID NO: 81
    GCAGAGCGGAGGAGGTGCTgtttAagagctaTGCTGGAAACAGCAtag
    caagttTaaataaggctagtccgttatcaacttgaaaaagtggcaccg
    agtcggtgcCAATTGggtctccagatTGTATGTAGCCTGTATGTAGCC
    TGTATGTAGCCTGTATGTAGCCTGTATGTAagatCTTTTTTT
    SEQ ID NO: 82
    GAAGGAAGAACGTGAGCACGgtttAagagctaTGCTGGAAACAGCAta
    gcaagttTaaataaggctagtccgttatcaacttgaaaaagtggcacc
    gagtcggtgcCAATTGggtctccagatTGTATGTAGCCTGTATGTAGC
    CTGTATGTAGCCTGTATGTAGCCTGTATGTAagatCTTTTTTT
    SEQ ID NO: 83
    GGCAGTAGCCGCTTCAGGGAgtttAagagctaTGCTGGAAACAGCAta
    gcaagttTaaataaggctagtccgttatcaacttgaaaaagtggcacc
    gagtcggtgcCAATTGggtctccagatTGTATGTAGCCTGTATGTAGC
    CTGTATGTAGCCTGTATGTAGCCTGTATGTAagatCTTTTTTT
    SEQ ID NO: 84
    GCGCAAGCGCATATCCTTCTgtttAagagctaTGCTGGAAACAGCAta
    gcaagttTaaataaggctagtccgttatcaacttgaaaaagtggcacc
    gagtcggtgcCAATTGggtctccagatTGTATGTAGCCTGTATGTAGC
    CTGTATGTAGCCTGTATGTAGCCTGTATGTAagatCTTTTTTT
    • Example 11 Targeted DNA Demethylation and Methylation Using Programmable Casilio and dCas9-Tethered Enzymes
  • Active erasure of methylcytosine (mC) from genomic DNA involves TET1 mediated iterative mC oxidation, and the base-excision repair (BER) or nucleotide-excision repair (NER) pathways that subsequently convert oxidized intermediates to unmethylated cytosine. Interestingly, mC demethylation efficiency appears to be enhanced by GADD45A protein (Growth Arrest and DNA-Damage-inducible Alpha), a multi-faceted nuclear factor involved in maintenance of genomic stability, DNA repair and suppression of cell growth (Niehrs and Schafer, Trends Cell Biol 22(4): 220-227, 2012; Barreto et al., Nature 445(7128):671-675, 2007; Schuermann et al., DNA Repair (Amst) 44:92-102, 2016). GADD45A was also found to interact with TET1 and with the BER enzyme Thymine DNA Glycosylase TDG (Kienhofer et al., Differentiation 90(1-3):59-68, 2015; Li et al., Nucleic Acids Res 43(8):3986-3997, 2015).
  • To enhance the efficiency of our recently developed Casilio-ME platform to demethylate targeted genomic loci, we sought to augment Casilio-ME by enabling simultaneous recruitment of TET1 catalytic domain and GADD45A to a specific genomic locus to streamline mC erasure processes. The presence of GADD45A at close proximity to TET1(CD) or as protein fusion to TET1(CD) at targeted genomic site stimulates TET1 activity and/or recruit key player(s) of the DNA repair machinery to efficiently couple mC oxidation with DNA repair, and the outcome of Casilio-ME dual targeting leads to greater alteration of gene expression compared to targeting TET1(CD) alone.
  • Results
  • We therefore made plasmid encoded GADD45A protein fusions to PUFa-TET1(CD) (FIG. 7A) and measured the efficiency of activation of hMLH1 expression in the presence of each of the GADD45A protein fusions relative to the hMLH1 activation obtained with PUFa-TET1(CD) alone. This showed that PUFa-TET1(CD) effector in the presence of six guides RNAs showed a significant activation of the hMLH1 expression that was 30% more than that obtained with the transcription activator effector p65HSF1 (FIGS. 7B & 7C (columns 3 and 8)). Interestingly, when GADD45A was fused to the TET1(CD) effector via the PUFa domain to generate GADD45A-PUFa-TET1(CD), hMLH1 expression was enhanced approximately 9 fold (FIGS. 7A & 7C (columns 3 and 5)) as indicated by the increased relative expression in TaqMan assays. Meanwhile, hMLH1 activation was enhanced only 4 fold when GADD45A was directly fused to TET1(CD) in the PUFa-GADD45A-TET1(CD) effector (FIG. 7C (columns 3 and 4)), indicating that GADDA45A is more exposed when present at the N-terminus of the effector fusion to make required interactions to stimulate TET1 and/or down stream DNA repair activities. This indeed shows a proof of principal that harnessing GADD45A and TET1(CD) as two-in-one effector considerably boost the efficiency of Casilio-ME mediated gene activation. The activation is likely to be mediated by an enhanced activity of the TET1(CD) component and/or an efficient coupling of the mC oxidation with DNA repair pathways that restore unmethylated cytosine.
  • Another way to dually target the two components GADD45A and TET1(CD) to a genomic site to alter its methylation state and associated gene expression is to fuse the proteins to two independent PUFs, for example, PUFa for TET1(CD) and PUFc for GADD45A, and use a modified gRNA scaffold that comprises the corresponding PUF binding sites (PBS) (FIG. 7A). Dual expression of PUFa-TET1(CD) and PUFc-GADD45A in the presence of corresponding gRNAs-PBSac showed significant stimulation of the TET1(CD) mediated hMLH1 activation, with GADD45A-PUFc showing higher activity compared to PUFc-GADD45A fusions (FIG. 7E, column 4, 5, 6). Similar trends were obtained when a Flag-tag was appended to GADD45A fusion (FIG. 7E, column 4, 11, 12). However, no hMLH1 expression was detected when GADD45A was expressed in the presence of a catalytically dead TET1(CD)(H1671Y D1673A)-PUFa fusion, indicating that the obtained GADD45A mediated stimulation of gene activation require oxidative activity of TET1. Similarly, no activity was detected when GADDA45A fusion was expressed in the absence of TET1(CD) fusion, indicating that GADD45A alone does not mediate the observed gene activation. In addition, no additional stimulation of the gene activation was obtained when GADD45A PUFc fusions were co-expressed with PUFa-TET1(CD) and gRNAs containing PBSa only (FIG. 7D). Taken together, the data indicate that Casilio mediated targeting of GADD45A stimulates TET1-mediated gene activation and the stimulation is dependent on both TET1 activity and tethering of GADD45A and TET1(CD) to a close proximity via an RNA scaffold.
  • In summary, dual targeting of TET1(CD) and GADD45A using Casilio platform enable remarkable alteration of gene activation by providing a two-in-one effector that presumably permits stimulation of oxidative activity of TET1 required for alteration of the methylation state and recruitment of key player(s) of DNA repair pathways necessary to restore unmethylated cytosine to the targeted genomic sites.
  • It is of interest to point out that different levels of activation of methylation-silenced gene could be obtained by merely changing the configuration and the type of effectors GADD45A and TET1(CD) fusions, with GADD45A-PUFa-TET1(CD) giving the highest activity. This provides our Casilio-ME platform with a unique capability to fine tune gene activation to reach the required expression levels to restore phonotypes or to reverse a disease state that is associated with hypermethylation-silenced gene.
  • Evidence that GADD45A mediated enhancement of Casilio-ME efficiency to activate methylation-silenced gene is associated with an increased MLH1 protein synthesis came from Western blot analysis of whole cells extracts using anti-hMLH1 monoclonal antibody. This showed that detectable amounts of MLH1 protein in cell that expressed GADD45A-TET1(CD) fusion, with GADD45A-PUFa-TET1(CD) showing higher protein amounts as indicated by bands intensity (FIG. 7D). This is consistent with different levels of stimulation obtained in TaqMan assays. In contrast, cells that expressed PUFa-TET1(CD) fusion alone did not show any detectable amounts of MLH1 when these transfected cells were collected 3 day after transfection (we showed earlier that 5-day incubation was required to detect significant amount of MLH1 with PUFa-TET1(CD) mediated activation (FIGS. 7C & 7E). The data together showed that addition GADD45A to the Casilio-ME platform increased its efficiency to activate methylation silenced gene.
  • List of Sequences
  • List of sgRNA spacer sequences targeting the MLH1 gene and sequence coding for gRNA scaffold with PBSac.
  • MLH1 sgRNA-spacer sequences
    (SEQ ID NO: 87)
    ACAGAGTTGAGAAATTTGAC
    (SEQ ID NO: 88)
    GTCAAATTTCTCAACTCTGT
    (SEQ ID NO: 89)
    GCTCCTAAAAACGAACCAAT
    (SEQ ID NO: 90)
    AAACGAACCAATAGGAAGAG
    (SEQ ID NO: 91)
    CTTCAGCGGCAGCTATTGAT
    (SEQ ID NO: 92)
    GCATCTCTGCTCCTATTGGC
    (SEQ ID NO: 93)
    GCGCCAGATCACCTCAGCAG
    (SEQ ID NO: 94)
    GCAGAGCGGAGGAGGTGCT
    (SEQ ID NO: 95)
    GAAGGAAGAACGTGAGCACG
    (SEQ ID NO: 96)
    GGCAGTAGCCGCTTCAGGGA
    (SEQ ID NO: 97)
    GCGCAAGCGCATATCCTTCT
    (SEQ ID NO: 98)
    CTGACGCAGACGCTCCACCA
    (SEQ ID NO: 99)
    ATTCGTGCTCAGCCTCGTAG
    (SEQ ID NO: 100)
    CTCCACCACCAAATAACGCT
    gRNA scaffold-PBSa-PBSc
    (SEQ ID NO: 101)
    CACCGGGTCTTCGAGAAGACCTGTTTAAGAGCTATGCTGGAAACA
    GCATAGCAAGTTTAAATAAGGCTAGTCCGTTATCAACTTGAAAAA
    GTGGCACCGAGTCGGTGCCAATTGGGTCTCCAGATTGTATGTAGC
    CTGTATGTAGCCTGTATGTAGCCTGTATGTAGCCTGTATGTAAGA
    TCCAATTGGGTCTCCAGATTTGATGTAGCCTTGATGTAGCCTTGA
    TGTAGCCTTGATGTAGCCTTGATGTAAGATCTTTTTTTG
  • List of protein sequences used in this example is provided below.
  • Name Protein Sequence
    TET1(CD) ELFTCSCLDRVIQKDKGPYYTHLGAGPSVAAVREIMENRYGQKGNAI
    (SEQ ID NO: 102) RIEIVVYTGKEGKSSHGCPIAKWVLRRSSDEEKVLCLVRQRTGHHCP
    TAVMVVLIMVWDGIPLPMADRLYTELTENLKSYNGHPTDRRCTLNEN
    RTCTCQGIDPETCGASFSFGCSWSMYFNGCKFGRSPSPRRFRIDPSS
    PLHEKNLEDNLQSLATRLAPIYKQYAPVAYQNQVEYENVARECRLGS
    KEGRPFSGVTACLDFCAHPHRDIHNMNNGSTVVCTLTREDNRSLGVI
    PQDEQLHVLPLYKLSDTDEFGSKEGMEAKIKSGAIEVLAPRRKKRTC
    FTQPVPRSGKKRAAMMTEVLAHKIRAVEKKPIPRIKRKNNSTTTNNS
    KPSSLPTLGSNTETVQPEVKSETEPHFILKSSDNTKTYSLMPSAPHP
    VKEASPGFSWSPKTASATPAPLKNDATASCGFSERSSTPHCTMPSGR
    LSGANAAAADGPGISQLGEVAPLPTLSAPVMEPLINSEPSTGVTEPL
    TPHQPNHQPSFLTSPQDLASSPMEEDEQHSEADEPPSDEPLSDDPLS
    PAEEKLPHIDEYWSDSEHIFLDANIGGVAIAPAHGSVLIECARRELH
    ATTPVEHPNRNHPTRLSLVFYQHKNLNKPQHGFELNKIKFEAKEAKN
    KKMKASEQKDQAANEGPEQSSEVNELNQIPSHKALTLTHDNVVTVSP
    YALTHVAGPYNHWV
    PUFa-TET1(CD) MIDGGGGSDPKKKRKVDPKKKRKVDPKKKRKVGSTGSRNDGGGGSGG
    (SEQ ID NO: 103) GGSGGGGSGRAGILPPKKKRKVSRGRSRLLEDFRNNRYPNLQLREIA
    GHIMEFSQDQHGSRFIQLKLERATPAERQLVFNEILQAAYQLMVDVF
    GNYVIQKFFEFGSLEQKLALAERIRGHVLSLALQMYGSRVIEKALEF
    IPSDQQNEMVRELDGHVLKCVKDQNGNHVVQKCIECVQPQSLQFIID
    AFKGQVFALSTHPYGCRVIQRILEHCLPDQTLPILEELHQHTEQLVQ
    DQYGNYVIQHVLEHGRPEDKSKIVAEIRGNVLVLSQHKFASNVVEKC
    VTHASRTERAVLIDEVCTMNDGPHSALYTMMKDQYANYVVQKMIDVA
    EPGQRKIVMHKIRPHIATLRKYTYGKHILAKLEKYYMKNGVDLGDPK
    KKRKVDPKKKRKVGGRGGGGSGGGGSGGGGSGPAELPTCSCLDRVIQ
    KDKGPYYTHLGAGPSVAAVREIMENRYGQKGNAIRIEIVVYTGKEGK
    SSHGCPIAKWVLRRSSDEEKVLCLVRQRTGHHCPTAVMVVLIMVWDG
    IPLPMADRLYTELTENLKSYNGHPTDRRCTLNENRTCTCQGIDPETC
    GASFSFGCSWSMYFNGCKFGRSPSPRRFRIDPSSPLHEKNLEDNLOS
    LATRLAPIYKQYAPVAYQNQVEYENVARECRLGSKEGRPFSGVTACL
    DFCAHPHRDIHNMNNGSTVVCTLTREDNRSLGVIPQDEQLHVLPLYK
    LSDTDEFGSKEGMEAKIKSGAIEVLAPRRKKRTCFTQPVPRSGKKRA
    AMMTEVLAHKIRAVEKKPIPRIKRKNNSTTTNNSKPSSLPTLGSNTE
    TVQPEVKSETEPHFILKSSDNTKTYSLMPSAPHPVKEASPGFSWSPK
    TASATPAPLKNDATASCGFSERSSTPHCTMPSGRLSGANAAAADGPG
    ISQLGEVAPLPTLSAPVMEPLINSEPSTGVTEPLTPHQPNHQPSFLT
    SPQDLASSPMEEDEQHSEADEPPSDEPLSDDPLSPAEEKLPHIDEYW
    SDSEHIFLDANIGGVAIAPAHGSVLIECARRELHATTPVEHPNRNHP
    TRLSLVFYQHKNLNKPQHGFELNKIKFEAKEAKNKKMKASEQKDQAA
    NEGPEQSSEVNELNQTPSHKALTLTHDNVVTVSPYALTHVAGPYNHW
    VID
    GADD45A-PUFa- MTLEEFSAGEQKTERMDKVGDALEEVLSKALSQRTITVGVYEAAKLL
    TET1(CD) NVDPDNVVLCLLAADEDDDRDVALQIHFTLIQAFCCENDINILRVSN
    (SEQ ID NO: 104) PGRLAELLLLETDAGPAASEGAEQPPDLHCVLVTNPHSSQWKDPALS
    QLICFCRESRYMDQWVPVINLPERSRTGAATMIDGGGGSDPKKKRKV
    DPKKKRKVDPKKKRKVGSTGSRNDGGGGSGGGGSGGGGSGRAGILPP
    KKKRKVSRGRSRLLEDFRNNRYPNLQLREIAGHIMEFSQDQHGSRFI
    QLKLERATPAERQLVFNEILQAAYQLMVDVFGNYVIQKFFEFGSLEQ
    KLALAERIRGHVLSLALQMYGSRVIEKALEFIPSDQQNEMVRELDGH
    VLKCVKDQNGNHVVQKCIECVQPQSLQFIIDAFKGQVFALSTHPYGC
    RVIQRILEHCLPDQTLPILEELHQHTEQLVQDQYGNYVIQHVLEHGR
    PEDKSKIVAEIRGNVLVLSQHKFASNVVEKCVTHASRTERAVLIDEV
    CTMNDGPHSALYTMMKDQYANYVVQKMIDVAEPGQRKIVMHKIRPHI
    ATLRKYTYGKHILAKLEKYYMKNGVDLGDPKKKRKVDPKKKRKVGGR
    GGGGSGGGGSGGGGSGPAELPTCSCLDRVIQKDKGPYYTHLGAGPSV
    AAVREIMENRYGQKGNAIRIEIVVYTGKEGKSSHGCPIAKWVLRRSS
    DEEKVLCLVRQRTGHHCPTAVMVVLIMVWDGIPLPMADRLYTELTEN
    LKSYNGHPTDRRCTLNENRTCTCQGIDPETCGASFSFGCSWSMYFNG
    CKFGRSPSPRRFRIDPSSPLHEKNLEDNLQSLATRLAPIYKQYAPVA
    YQNQVEYENVARECRLGSKEGRPFSGVTACLDFCAHPHRDIHNMNNG
    STVVCTLTREDNRSLGVIPQDEQLHVLPLYKLSDTDEFGSKEGMEAK
    IKSGAIEVLAPRRKKRTCFTQPVPRSGKKRAAMMTEVLAHKIRAVEK
    KPIPRIKRKNNSTTTNNSKPSSLPTLGSNTETVQPEVKSETEPHFIL
    KSSDNTKTYSLMPSAPHPVKEASPGFSWSPKTASATPAPLKNDATAS
    CGFSERSSTPHCTMPSGRLSGANAAAADGPGISQLGEVAPLPTLSAP
    VMEPLINSEPSTGVTEPLTPHQPNHQPSFLTSPQDLASSPMEEDEQH
    SEADEPPSDEPLSDDPLSPAEEKLPHIDEYWSDSEHIFLDANIGGVA
    IAPAHGSVLIECARRELHATTPVEHPNRNHPTRLSLVFYQHKNLNKP
    QHGFELNKIKFEAKEAKNKKMKASEQKDQAANEGPEQSSEVNELNQI
    PSHKALTLTHDNVVTVSPYALTHVAGPYNHWVID
    PUFa-hGADD45A- MIDGGGGSDPKKKRKVDPKKKRKVDPKKKRKVGSTGSRNDGGGGSGG
    TET1(CD) GGSGGGGSGRAGILPPKKKRKVSRGRSRLLEDFRNNRYPNLQLREIA
    (SEQ ID NO: 105) GHIMEFSQDQHGSRFIQLKLERATPAERQLVFNEILQAAYQLMVDVF
    GNYVIQKFFEFGSLEQKLALAERIRGHVLSLALQMYGSRVIEKALEF
    IPSDQQNEMVRELDGHVLKCVKDQNGNHVVQKCIECVQPQSLQFIID
    AFKGQVFALSTHPYGCRVIQRILEHCLPDQTLPILEELHQHTEQLVQ
    DQYGNYVIQHVLEHGRPEDKSKIVAEIRGNVLVLSQHKFASNVVEKC
    VTHASRTERAVLIDEVCTMNDGPHSALYTMMKDQYANYVVQKMIDVA
    EPGQRKIVMHKIRPHIATLRKYTYGKHILAKLEKYYMKNGVDLGDPK
    KKRKVDPKKKRKVGGRGGGSGGGSGGGSGGGSGGGSGGGSLTLEEFS
    AGEQKTERMDKVGDALEEVLSKALSQRTITVGVYEAAKLLNVDPDNV
    VLCLLAADEDDDRDVALQIHFTLIQAFCCENDINILRVSNPGRLAEL
    LLLETDAGPAASEGAEQPPDLHCVLVTNPHSSQWKDPALSQLICFCR
    ESRYMDQWVPVINLPERSRGRGGGGSGGGGSGGGGSGPAELPTCSCL
    DRVIQKDKGPYYTHLGAGPSVAAVREIMENRYGQKGNAIRIEIVVYT
    GKEGKSSHGCPIAKWVLRRSSDEEKVLCLVRQRTGHHCPTAVMVVLI
    MVWDGIPLPMADRLYTELTENLKSYNGHPTDRRCTLNENRTCTCQGI
    DPETCGASFSFGCSWSMYFNGCKFGRSPSPRRFRIDPSSPLHEKNLE
    DNLQSLATRLAPIYKQYAPVAYQNQVEYENVARECRLGSKEGRPFSG
    VTACLDFCAHPHRDIHNMNNGSTVVCTLTREDNRSLGVIPQDEQLHV
    LPLYKLSDTDEFGSKEGMEAKIKSGAIEVLAPRRKKRTCFTQPVPRS
    GKKRAAMMTEVLAHKIRAVEKKPIPRIKRKNNSTTTNNSKPSSLPTL
    GSNTETVQPEVKSETEPHFILKSSDNTKTYSLMPSAPHPVKEASPGF
    SWSPKTASATPAPLKNDATASCGFSERSSTPHCTMPSGRLSGANAAA
    ADGPGISQLGEVAPLPTLSAPVMEPLINSEPSTGVTEPLPTHQPNHQ
    PSFLTSPQDLASSPMEEDEQHSEADEPPSDEPLSDDPLSPAEEKLPH
    IDEYWSDSEHIFLDANIGGVAIAPAHGSVLIECARRELHATTPVEHP
    NRNHPTRLSLVFYQHKNLNKPQHGFELNKIKFEAKEAKNKKMKASEQ
    KDQAANEGPEQSSEVNELNQIPSHKALTLTHDNVVTVSPYALTHVAG
    PYNHWVID
    PUFc-hGADD45A-HA MIDGGGGSDPKKKRKVDPKKKRKVDPKKKRKVGSTGSRNDGGGGSGG
    (SEQ ID NO: 106) GGSGGGGSGRAGILPPKKKRKVSRGRSRLLEDFRNNRYPNLQLREIA
    GHIMEFSQDQHGSRFIQLKLERATPAERQLVFNEILQAAYQLMVDVF
    GNYVIQKFFEFGSLEQKLALAERIRGHVLSLALQMYGSRVIEKALEF
    IPSDQQNEMVRELDGHVLKCVKDQNGNHVVQKCIECVQPQSLQFIID
    AFKGQVFALSTHPYGCRVIQRILEHCLPDQTLPILEELHQHTEQLVQ
    DQYGSYVIEHVLEHGRPEDKSKIVAEIRGNVLVLSQHKFANNVVQKC
    VTHASRTERAVLIDEVCTMNDGPHSALYTMMKDQYANYVVQKMIDVA
    EPGQRKIVMHKIRPHIATLRKYTYGKHILAKLEKYYMKNGVDLGDPK
    KKRKVDPKKKRKVGGRGGGGSGGGGSGGGGSGPALTLEEFSAGEQKT
    ERMDKVGDALEEVLSKALSQRTITVGVYEAAKLLNVDPDNVVLCLLA
    ADEDDDRDVALQIHFTLIQAFCCENDINILRVSNPGRLAELLLLETD
    AGPAASEGAEQPPDLHCVLVTNPHSSQWKDPALSQLICFCRESRYMD
    QWVPVINLPERSRYPYDVPDYA
    hGADD45A-HA-PUFc MTLEEFSAGEQKTERMDKVGDALEEVLSKALSQRTITVGVYEAAKLL
    (SEQ ID NO: 107) NVDPDNVVLCLLAADEDDDRDVALQIHFTLIQAFCCENDINILRVSN
    PGRLAELLLLETDAGPAASEGAEQPPDLHCVLVTNPHSSQWKDPALS
    QLICFCRESRYMDQWVPVINLPERSRYPYDVPDYAIDGGGGSDPKKK
    RKVDPKKKRKVDPKKKRKVGSTGSRNDGGGGSGGGGSGGGGSGRAGI
    LPPKKKRKVSRGRSRLLEDFRNNRYPNLQLREIAGHIMEFSQDQHGS
    RFIQLKLERATPAERQLVFNEILQAAYQLMVDVFGNYVIQKFFEFGS
    LEQKLALAERIRGHVLSLALQMYGSRVIEKALEFIPSDQQNEMVREL
    DGHVLKCVKDQNGNHVVQKCIECVQPQSLQFIIDAFKGQVFALSTHP
    YGCRVIQRILEHCLPDQTLPILEELHQHTEQLVQDQYGSYVIEHVLE
    HGRPEDKSKIVAEIRGNVLVLSQHKFANNVVQKCVTHASRTERAVLI
    DEVCTMNDGPHSALYTMMKDQYANYVVQKMIDVAEPGQRKIVMHKIR
    PHIATLRKYTYGKHILAKLEKYYMKNGVDLGDPKKKRKVDPKKKRKV
    GGRGGGGSGGGGSGGGGSGPA
    NLS-Flag-PUFc- MNVGGGGSDPKKKRKVDPKKKRKVDPKKKRKVGSTGSRGGGGSGGGG
    hGADD45A-HA SGGGGSMDYKDHDGDYKDHDIDYKDDDDKGGGGSGRAGILPPKKKRK
    (SEQ ID NO: 108) VSRGRSRLLEDFRNNRYPNLQLREIAGHIMEFSQDQHGSRFIQLKLE
    RATPAERQLVFNEILQAAYQLMVDVFGNYVIQKFFEFGSLEQKLALA
    ERIRGHVLSLALQMYGSRVIEKALEFIPSDQQNEMVRELDGHVLKCV
    KDQNGNHVVQKCIECVQPQSLQFIIDAFKGQVFALSTHPYGCRVIQR
    ILEHCLPDQTLPILEELHQHTEQLVQDQYGSYVIEHVLEHGRPEDKS
    KIVAEIRGNVLVLSQHKFANNVVQKCVTHASRTERAVLIDEVCTMND
    GPHSALYTMMKDQYANYVVQKMIDVAEPGQRKIVMHKIRPHIATLRK
    YTYGKHILAKLEKYYMKNGVDLGPRGSGGGRGGGGSDPKKKRKVDPK
    KKRKVGGGGSGGGGSGGGGSGPALTLEEFSAGEQKTERMDKVGDALE
    EVLSKALSQRTITVGVYEAAKLLNVDPDNVVLCLLAADEDDDRDVAL
    QIHFTLIQAFCCENDINILRVSNPGRLAELLLLETDAGPAASEGAEO
    PPDLHCVLVTNPHSSQWKDPALSQLICFCRESRYMDQWVPVINLPER
    SRYPYDVPDYA
    hGADD45A-HA-NLS- MTLEEFSAGEQKTERMDKVGDALEEVLSKALSQRTITVGVYEAAKLL
    Flag-PUFc NVDPDNVVLCLLAADEDDDRDVALQIHFTLIQAFCCENDINILRVSN
    (SEQ ID NO: 109) PGRLAELLLLEIDAGPAASEGAEQPPDLHCVLVTNPHSSQWKDPALS
    QLICFCRESRYMDQWVPVINLPERSRYPYDVPDYAIDGGGGSDPKKK
    RKVDPKKKRKVDPKKKRKVGSTGSRGGGGSGGGGSGGGGSMDYKDHD
    GDYKDHDIDYKDDDDKGGGGSGRAGILPPKKKRKVSRGRSRLLEDFR
    NNRYPNLQLREIAGHIMEFSQDQHGSRFIQLKLERATPAERQLVFNE
    ILQAAYQLMVDVFGNYVIQKFFEFGSLEQKLALAERIRGHVLSLALQ
    MYGSRVIEKALEFIPSDQQNEMVRELDGHVLKCVKDQNGNHVVQKCI
    ECVQPQSLQFIIDAFKGQVFALSTHPYGCRVIQRILEHCLPDQTLPI
    LEELHQHTEQLVQDQYGSYVIEHVLEHGRPEDKSKIVAEIRGNVLVL
    SQHKFANNVVQKCVTHASRTERAVLIDEVCTMNDGPHSALYTMMKDQ
    YANYVVQKMIDVAEPGQRKIVMHKIRPHIATLRKYTYGKHILAKLEK
    YYMKNGVDLGPRGSGGGRGGGGSDPKKKRKVDPKKKRKVGGGGSGGG
    GSGGGGSGPA
    PUFa-TET1(CD)-dead MIDGGGGSDPKKKRKVDPKKKRKVDPKKKRKVGSTGSRNDGGGGSGG
    mutant GGSGGGGSGRAGILPPKKKRKVSRGRSRLLEDFRNNRYPNLQLREIA
    (SEQ ID NO: 110) GHIMEFSQDQHGSRFIQLKLERATPAERQLVFNEILQAAYQLMVDVF
    GNYVIQKFFEEGSLEQKLALAERIRGHVLSLALQMYGSRVIEKALEF
    IPSDQQNEMVRELDGHVLKCVKDQNGNHVVQKCIECVQPQSLQFIID
    AFKGQVFALSTHPYGCRVIQRILEHCLPDQTLPILEELHQHTEQLVQ
    DQYGNYVIQHVLEHGRPEDKSKIVAEIRGNVLVLSQHKFASNVVEKC
    VTHASRTERAVLIDEVCTMNDGPHSALYTMMKDQYANYVVQKMIDVA
    EPGQRKIVMHKIRPHIATLRKYTYGKHILAKLEKYYMKNGVDLGDPK
    KKRKVDPKKKRKVGGRGGGGSGGGGSGGGGSGPAELPTCSCLDRVIQ
    KDKGPYYTHLGAGPSVAAVREIMENRYGQKGNAIRIEIVVYTGKEGK
    SSHGCPIAKWVLRRSSDEEKVLCLVRQRTGHHCPTAVMVVLIMVWDG
    IPLPMADRLYTELTENLKSYNGHPTDRRCTLNENRTCTCQGIDPETC
    GASFSFGCSWSMYFNGCKFGRSPSPRRFRIDPSSPLHEKNLEDNLQS
    LATRLAPIYKQYAPVAYQNQVEYENVARECRLGSKEGRPFSGVTACL
    DFCAHP Y R A IHNMNNGSTVVCTLTREDNRSLGVIPQDEQLHVLPLYK
    LSDTDEFGSKEGMEAKIKSGAIEVLAPRRKKRTCFTQPVPRSGKKRA
    AMMTEVLAHKIRAVEKKPIPRIKRKNNSTTTNNSKPSSLPTLGSNTE
    TVQPEVKSETEPHFILKSSDNTKTYSLMPSAPHPVKEASPGFSWSPK
    TASATPAPLKNDATASCGFSERSSTPHCTMPSGRLSGANAAAADGPG
    ISQLGEVAPLPTLSAPVMEPLINSEPSTGVTEPLTPHQPNHQPSFLT
    SPQDLASSPMEEDEQHSEADEPPSDEPLSDDPLSPAEEKLPHIDEYW
    SDSEHIFLDANIGGVAIAPAHGSVLIECARRELHATTPVEHPNRNHP
    TRLSLVFYQHKNLNKPQHGFELNKIKFEAKEAKNKKMKASEQKDQAA
    NEGPEQSSEVNELNQIPSHKALTLTHDNVVTVSPYALTHVAGPYNHW
    VID
    • Example 12 Targeted DNA Demethylation and Methylation Using Programmable Casilio and dCas9-Tethered Enzymes
  • Methylcytosine is an epigenetic mark made by a process that covalently adds a methyl group at position 5 of cytosine ring of a CpG DNA sequence. In mammalian cells, formation of 5-methylcytosine (5mC) mark is catalyzed and maintained by DNA methyltransferases. Demethylation pathways, which remove the methyl group to restore unmethylated DNA, involve the ten-eleven translocation (TET) family of proteins. TET methylcytosine dioxygenases catalyze iterative oxidations of 5mC to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) intermediates. The two latter intermediates, 5fC and 5caC, seem to serve as substrates for the base-excision repair (BER) machinery which cleaves off the oxidized base and replaces it with unmethylated cytosines.
  • DNA glycosylases catalyze the initial and important step that excise the damaged base and generate an apurinic/apyrimidinic site (AP site) substrate that is subsequently processed by the BER machinery to restore the base. Thymine DNA glycosylase (TDG) based BER pathways have been functionally linked to TET1-mediated active demethylation as they have been shown to specifically act on 5fC and 5caC and that NEIL1 and NEIL2 glycosylase/AP-lyase activities facilitate the restoration of unmethylated cytosine by displacing TDG from AP site to create a single strand DNA break substrate for downstream processing of BER machinery.
  • We used our previously developed Casilio-ME that was built on our original Casilio platform, that enables targeted delivery of TET1 activity, to concomitantly deliver TET1 and DNA glycosylase effectors to CpG island of hMLH1 promoter region and compare efficiencies of demethylation by using activation of methylation-silenced gene as a readout. We showed that amongst the DNA glycosylase effectors tested, TDG, NEIL1, NEIL2 and NEIL3, only NEIL2 enhanced the TET1-mediated activation of hMLH1. We obtained a robust boost of gene activation when NEIL2 was co-delivered with TET1 either as a single chain protein fusion or as separate effectors. The ability of NEIL2 to enhance TET1-mediated gene activation required targeting of NEIL2 effector to promoter regions. Coupling TET1 oxidative activities with NEIL2 glycosylase/AP-lyase activities using a simple and programmable Casilio platform enables robust demethylation-mediated transcription activation of methylation-silenced gene, providing thus a proof-of-principal that Casilio platform allows an unprecedented feature to harnessing players of independent pathways to synergize their association activities. This finding augments the capability of our Casilio-ME platform and paves the way to developing new applications to study important biological processes and to developing new therapies for methylation associated diseases.
  • Results
  • Casilio-Mediated Co-Delivery of TET1 and DNA Glycosylases as Two-in One Effectors
  • In this study, we determined whether co-delivery of DNA glycosylases and the catalytic domain of TET1 (TET1(CD)) to targeted genomic loci could have a synergistic effect and enhance TET1-mediated gene activation. We made Casilio-based plasmids encoding DNA glycosylase protein fusions to PUFa-TET1(CD) (FIG. 8A, 8C). We then measured the efficiency of hMLH1 activation in cells transfected with either PUFa-TET1(CD) or with each of the plasmids encoding DNA glycosylase protein fusions (NEIL1, NEIL2, NEIL3 or TDG).
  • We showed that PUFa-TET1(CD) effector activates hMLH1 expression as expected (FIG. 8B (white column). However, and to our surprise, only NEIL2 effector fusion showed an enhanced activation of hMLH1 (FIG. 8B column 4 and 5). In sharp contrast, TDG, NEIL1, and NEIL3 effector fusions did not show any enhancing effect on the activation of hMLH1 (FIG. 8B, D). In the presence of NEIL2, hMLH1 activation was 3-fold higher of that obtained with TET1 effector alone, whereas no or an inhibitory effect was obtained with NEIL1, NEIL3 and TDG respectively. This data shows that NEIL2 (and not NEIL1 and NEIL3) specifically associated activities boost 5mC erasure process leading to higher gene activation.
  • To confirm the synergistic affect obtained with NEIL2 glycosylase/AP lyase enzyme, we conducted the experiments to include a non-targeting guide RNA (gRNA) as a control for specificity. As shown in FIG. 9A-9B, a four-fold increase in gene activation was obtained when NEIL2 was present in the PUFa-TET1CD fusion as indicated by the increased relative expression in TaqMan assays. Similar activation was obtained regardless of whether NEIL2 was fused to either PUFa amino or carboxyl termini (FIG. 9A, 9B).
  • In contrast, no activation was obtained when a non-targeting gRNA replaced hMLH1 gRNAs, indicating that specific targeting of the effectors to MLH1 promoter regions is required for the observed activation (FIG. 9B). This provides proof that harnessing NEIL2 and TET1(CD) as two-in-one effector considerably boost the efficiency of Casilio-ME mediated gene activation. We speculated the observed gain in efficiency of MLH1 activation may likely be mediated by an effective coupling of mC oxidation by TET1 to NEIL2-mediated BER pathways to streamline restoration of unmethylated cytosine at the targeted site.
  • Casilio-Mediated Co-Delivery of TET1 and NEIL2 as Independent Effector Modules
  • Using Casilio platform, we examined an alternative way to dually target the TET1(CD) and NEIL2 effectors to a genomic site to tether these enzymes to two independent PUF proteins programmed to bind distinct RNA sequences. To that end, we fused TET1(CD) to PUFa and NEIL2 to PUFc, and used a modified gRNA scaffold that comprised cognate PUF binding sites (PBSa and PBSc) (FIG. 10A).
  • Dual expression of PUFa-TET1(CD) and PUFc-NEIL2 in the presence of gRNAs with both PBSa/c showed significant stimulation of the TET1(CD) mediated hMLH1 activation (FIG. 10B). NEIL2, when fused to either ends of PUFc, showed 7-fold increase in hMLH1 expression as indicated by RT-quantitative PCR (FIG. 10B). Evidence that NEIL2-mediated stimulation requires co-targeting of the effectors came from experiments where NEIL2 and TET1(CD) PUF-fusions were expressed in the presence of gRNA scaffold that comprised PBSa but lacked PBSc (FIG. 11A). This data showed that co-expression of NEIL2 and TETleffectors had no effect on TET1-mediated gene activation when the gRNA lacked the PBSc (FIG. 11B), indicating that the obtained synergistic effect does not come from a general effect of overexpression of NEIL2 but requires its targeting to a close proximity of TET1 effector to enable coupling of their associated activities and efficient mC erasure and gene activation.
  • Taken together, the present data clearly indicate that Casilio mediated targeting of NEIL2 stimulates TET1-mediated gene activation in manner that requires bridging NEIL2 and TET1 to a close proximity as a single chain fusion or via PUF-mediated binding to an RNA scaffold. Higher levels of activation were achieved with NEIL2 independent modules, providing thus a handle to tuning gene activity by using NEIL2/TET1 effectors as two-in-one or independent effector modules.
  • In sum, dual targeting of TET1(CD) and NEIL2 using Casilio platform enable remarkable alteration of gene activation by providing NEIL2 effector modules that presumably permit coupling of TET1 oxidative activities with NEIL2 initiation of BER leading to subsequent recruitment of key player(s) of DNA repair pathways necessary to restore unmethylated cytosine to targeted genomic sites.
  • Materials and Methods
  • Cell Culture and Transfection
  • HEK293T cells were cultivated in Dulbecco's modified Eagle's medium (DMEM) (Sigma) with 10% fetal bovine serum (FBS) (Lonza), 4% Glutamax (Gibco), 1% Sodium Pyruvate (Gibco) and penicillin-streptomycin (Gibco) in an incubator set to 37° C. and 5% CO2. Cells were seeded into 12-well plates at 150,000 cells per well the day before being transfected with 100 ng of dCas9 construct, 100 ng of modified sgRNA construct and 200 ng of PUF-fusion with Attractene transfection reagent according to manufacturer's instructions (Qiagen). Transfected cells were harvested 3 days after transfection, or otherwise indicated, and cell pellets were used for RNA extractions.
  • Quantitative RT-PCR Analysis
  • Cells were harvested, washed with Dulbecco's phosphate-buffered saline (dPBS), centrifuged at 125×g for 5 min and then the flash-frozen pellets were stored at −80° C. RNA was extracted using RNeasy Plus Mini Kit according to the manufacturer's instructions (Qiagen). cDNA libraries were made using Applied Biosystems High Capacity RNA-to-cDNA kit with 200 ng to 2 μg of RNA. TaqMan gene expression assays (Applied Biosystems) were designed using GAPDH (Hs03929097, VIC) as endogenous control and hMLH1 (Hs00179866, FAM) as target. TaqMan Universal Master Mix II, with UNG (Applied Biosystems) was used for Quantitative PCR (qPCR), with 2 μl of diluted cDNA used for each reaction. Activation was analyzed with the Applied Biosystems ViiA7 instrument. Gene expression levels were calculated by “delta delta Ct” algorithm and normalized to control samples.
  • Sequences
  • List of sgRNA spacer sequences targeting the hMLH1 gene and sequence coding for gRNA scaffold with PBSa and PBSc.
  •
    MLH1 GACAGAGTTGAGAAATTTGAC (SEQ ID NO: 111)
    sgRNA- GAAACGAACCAATAGGAAGAG (SEQ ID NO: 112)
    spacer GCGCCAGATCACCTCAGCAG (SEQ ID NO: 113)
    GGCAGTAGCCGCTTCAGGGA (SEQ ID NO: 114)
    GCGCAAGCGCATATCCTTCT (SEQ ID NO: 115)
    GCTGACGCAGACGCTCCACCA (SEQ ID NO: 116)
    gRNA GTTTAAGAGCTATGCTGGAAACAGCATAGCAAGTTTAA
    scaffold- ATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACC
    5xPBSa- GAGTCGGTGCCAATTGGGTCTCCAGATTGTATGTAGCC
    5xPBSc TGTATGTAGCCTGTATGTAGCCTGTATGTAGCCTGTAT
    (SEQ ID GTAAGATCCAATTGGGTCTCCAGATTTGATGTAGCCTT
    NO: 117) GATGTAGCCTTGATGTAGCCTTGATGTAGCCTTGATGT
    AAGATCTTTTTTTG
  • List of Protein Sequences
  • Name Protein Sequence
    TET1(CD) ELPTCSCLDRVIQKDKGPYYTHLGAGPSVAAV
    (1418 to 2136) REIMENRYGQKGNAIRIEIVVYTGKEGKSSHG
    (SEQ ID NO: 118) CPIAKWVLRRSSDEEKVLCLVRQRTGHHCPTA
    VMVVLIMVWDGIPLPMADRLYTELTENLKSYN
    GHPTDRRCTLNENRTCTCQGIDPETCGASFSF
    GCSWSMYFNGCKFGRSPSPRRFRIDPSSPLHE
    KNLEDNLQSLATRLAPIYKQYAPVAYQNQVEY
    ENVARECRLGSKEGRPFSGVTACLDFCAHPHR
    DIHNMNNGSTVVCTLTREDNRSLGVIPQDEQL
    HVLPLYKLSDTDEFGSKEGMEAKIKSGAIEVL
    APRRKKRTCFTQPVPRSGKKRAAMMTEVLAHK
    IRAVEKKPIPRIKRKNNSTTTNNSKPSSLPTL
    GSNTETVQPEVKSETEPHFILKSSDNTKTYSL
    MPSAPHPVKEASPGFSWSPKTASATPAPLKND
    ATASCGFSERSSTPHCTMPSGRLSGANAAAAD
    GPGISQLGEVAPLPTLSAPVMEPLINSEPSTG
    VTEPLTPHQPNHQPSFLTSPQDLASSPMEEDE
    QHSEADEPPSDEPLSDDPLSPAEEKLPHIDEY
    WSDSEHIFLDANIGGVAIAPAHGSVLIECARR
    ELHATTPVEHPNRNHPTRLSLVFYQHKNLNKP
    QHGFELNKIKFEAKEAKNKKMKASEQKDQAAN
    EGPEQSSEVNELNQIPSHKALTLTHDNVVTVS
    PYALTHVAGPYNHWV
    PUFa-TET1(CD) MIDGGGGSDPKKKRKVDPKKKRKVDPKKKRKV
    (SEQ ID NO: 119) GSTGSRNDGGGGSGGGGSGGGGSGRAGILPPK
    KKRKVSRGRSRLLEDFRNNRYPNLQLREIAGH
    IMEFSQDQHGSRFIQLKLERATPAERQLVFNE
    ILQAAYQLMVDVFGNYVIQKFFEFGSLEQKLA
    LAERIRGHVLSLALQMYGSRVIEKALEFIPSD
    QQNEMVRELDGHVLKCVKDQNGNHVVQKCIEC
    VQPQSLQFIIDAFKGQVFALSTHPYGCRVIQR
    ILEHCLPDQTLPILEELHQHTEQLVQDQYGNY
    VIQHVLEHGRPEDKSKIVAEIRGNVLVLSQHK
    FASNVVEKCVTHASRTERAVLIDEVCTMNDGP
    HSALYTMMKDQYANYVVQKMIDVAEPGQRKIV
    MHKIRPHIATLRKYTYGKHILAKLEKYYMKNG
    VDLGDPKKKRKVDPKKKRKVGGRGGGGSGGGG
    SGGGGSGPAELPTCSCLDRVIQKDKGPYYTHL
    GAGPSVAAVREIMENRYGQKGNAIRIEIVVYT
    GKEGKSSHGCPIAKWVLRRSSDEEKVLCLVRQ
    RTGHHCPTAVMVVLIMVWDGIPLPMADRLYTE
    LTENLKSYNGHPTDRRCTLNENRTCTCQGIDP
    ETCGASFSFGCSWSMYFNGCKFGRSPSPRRFR
    IDPSSPLHEKNLEDNLQSLATRLAPIYKQYAP
    VAYQNQVEYENVARECRLGSKEGRPFSGVTAC
    LDFCAHPHRDIHNMNNGSTVVCTLTREDNRSL
    GVIPQDEQLHVLPLYKLSDTDEFGSKEGMEAK
    IKSGAIEVLAPRRKKRTCFTQPVPRSGKKRAA
    MMTEVLAHKIRAVEKKPIPRIKRKNNSTTTNN
    SKPSSLPTLGSNTETVQPEVKSETEPHFILKS
    SDNTKTYSLMPSAPHPVKEASPGFSWSPKTAS
    ATPAPLKNDATASCGFSERSSTPHCTMPSGRL
    SGANAAAADGPGISQLGEVAPLPTLSAPVMEP
    LINSEPSTGVTEPLTPHQPNHQPSFLTSPQDL
    ASSPMEEDEQHSEADEPPSDEPLSDDPLSPAE
    EKLPHIDEYWSDSEHIFLDANIGGVAIAPAHG
    SVLIECARRELHATTPVEHPNRNHPTRLSLVF
    YQHKNLNKPQHGFELNKIKFEAKEAKNKKMKA
    SEQKDQAANEGPEQSSEVNELNQIPSHKALTL
    THDNVVTVSPYALTHVAGPYNHWVID
    NEIL1-PUFa- MDYKDDDDKPKKKRKLPEGPELHLASQFVNEA
    TET1(CD) CRALVFGGCVEKSSVSRNPEVPFESSAYRISA
    (SEQ ID NO: 120) SARGKELRLILSPLPGAQPQQEPLALVFRFGM
    SGSFQLVPREELPRHAHLRFYTAPPGPRLALC
    FVDIRRFGRWDLGGKWQPGRGPCVLQEYQQFR
    ENVLRNLADKAFDRPICEALLDQRFFNGIGNY
    LRAEILYRLKIPPFEKARSVLEALQQHRPSPE
    LTLSQKIRTKLQNPDLLELCHSVPKEVVQLGG
    RGYGSESGEEDFAAFRAWLRCYGMPGMSSLQD
    RHGRTIWFQGDPGPLAPKGRKSRKKKSKATQL
    SPEDRVEDALPPSKAPSRTRRAKRDLPKRTAT
    QRPEGTSLQQDPEAPTVPKKGRRKGRQAASGH
    CRPRKVKADIPSLEPEGTSASGAATMIDGGGG
    SDPKKKRKVDPKKKRKVDPKKKRKVGSTGSRN
    DGGGGSGGGGSGGGGSGRAGILPPKKKRKVSR
    GRSRLLEDFRNNRYPNLQLREIAGHIMEFSQD
    QHGSRFIQLKLERATPAERQLVFNEILQAAYQ
    LMVDVFGNYVIQKFFEFGSLEQKLALAERIRG
    HVLSLALQMYGSRVIEKALEFIPSDQQNEMVR
    ELDGHVLKCVKDQNGNHVVQKCIECVQPQSLQ
    FIIDAFKGQVFALSTHPYGCRVIQRILEHCLP
    DQTLPILEELHQHTEQLVQDQYGNYVIQHVLE
    HGRPEDKSKIVAEIRGNVLVLSQHKFASNVVE
    KCVTHASRTERAVLIDEVCTMNDGPHSALYTM
    MKDQYANYVVQKMIDVAEPGQRKIVMHKIRPH
    IATLRKYTYGKHILAKLEKYYMKNGVDLGDPK
    KKRKVDPKKKRKVGGRGGGGSGGGGSGGGGSG
    PAELPTCSCLDRVIQKDKGPYYTHLGAGPSVA
    AVREIMENRYGQKGNAIRIEIVVYTGKEGKSS
    HGCPIAKWVLRRSSDEEKVLCLVRQRTGHHCP
    TAVMVVLIMVWDGIPLPMADRLYTELTENLKS
    YNGHPTDRRCTLNENRTCTCQGIDPETCGASF
    SFGCSWSMYFNGCKFGRSPSPRRFRIDPSSPL
    HEKNLEDNLQSLATRLAPIYKQYAPVAYQNQV
    EYENVARECRLGSKEGRPFSGVTACLDFCAHP
    HRDIHNMNNGSTVVCTLTREDNRSLGVIPQDE
    QLHVLPLYKLSDTDEFGSKEGMEAKIKSGAIE
    VLAPRRKKRTCFTQPVPRSGKKRAAMMTEVLA
    HKIRAVEKKPIPRIKRKNNSTTTNNSKPSSLP
    TLGSNTETVQPEVKSETEPHFILKSSDNTKTY
    SLMPSAPHPVKEASPGFSWSPKTASATPAPLK
    NDATASCGFSERSSTPHCTMPSGRLSGANAAA
    ADGPGISQLGEVAPLPTLSAPVMEPLINSEPS
    TGVTEPLTPHQPNHQPSFLTSPQDLASSPMEE
    DEQHSEADEPPSDEPLSDDPLSPAEEKLPHID
    EYWSDSEHIFLDANIGGVAIAPAHGSVLIECA
    RRELHATTPVEHPNRNHPTRLSLVFYQHKNLN
    KPQHGFELNKIKFEAKEAKNKKMKASEQKDQA
    ANEGPEQSSEVNELNQIPSHKALTLTHDNVVT
    VSPYALTHVAGPYNHWVID
    PUFa-NEIL1- MIDGGGGSDPKKKRKVDPKKKRKVDPKKKRKV
    TET1(CD) GSTGSRNDGGGGSGGGGSGGGGSGRAGILPPK
    (SEQ ID NO: 121) KKRKVSRGRSRLLEDFRNNRYPNLQLREIAGH
    IMEFSQDQHGSRFIQLKLERATPAERQLVFNE
    ILQAAYQLMVDVFGNYVIQKFFEFGSLEQKLA
    LAERIRGHVLSLALQMYGSRVIEKALEFIPSD
    QQNEMVRELDGHVLKCVKDQNGNHVVQKCIEC
    VQPQSLQFIIDAFKGQVFALSTHPYGCRVIQR
    ILEHCLPDQTLPILEELHQHTEQLVQDQYGNY
    VIQHVLEHGRPEDKSKIVAEIRGNVLVLSQHK
    FASNVVEKCVTHASRTERAVLIDEVCTMNDGP
    HSALYTMMKDQYANYVVQKMIDVAEPGQRKIV
    MHKIRPHIATLRKYTYGKHILAKLEKYYMKNG
    VDLGDPKKKRKVDPKKKRKVGGRGGGSGGGSG
    GGSGGGSGGGSGGGSLPEGPELHLASQFVNEA
    CRALVFGGCVEKSSVSRNPEVPFESSAYRISA
    SARGKELRLILSPLPGAQPQQEPLALVFRFGM
    SGSFQLVPREELPRHAHLRFYTAPPGPRLALC
    FVDIRRFGRWDLGGKWQPGRGPCVLQEYQQFR
    ENVLRNLADKAFDRPICEALLDQRFFNGIGNY
    LRAEILYRLKIPPFEKARSVLEALQQHRPSPE
    LTLSQKIRTKLQNPDLLELCHSVPKEVVQLGG
    RGYGSESGEEDFAAFRAWLRCYGMPGMSSLQD
    RHGRTIWFQGDPGPLAPKGRKSRKKKSKATQL
    SPEDRVEDALPPSKAPSRTRRAKRDLPKRTAT
    QRPEGTSLQQDPEAPTVPKKGRRKGRQAASGH
    CRPRKVKADIPSLEPEGTSASRGGGGSGGGGS
    GGGGSGPAELPTCSCLDRVIQKDKGPYYTHLG
    AGPSVAAVREIMENRYGQKGNAIRIEIVVYTG
    KEGKSSHGCPIAKWVLRRSSDEEKVLCLVRQR
    TGHHCPTAVMVVLIMVWDGIPLPMADRLYTEL
    TENLKSYNGHPTDRRCTLNENRTCTCQGIDPE
    TCGASFSFGCSWSMYFNGCKFGRSPSPRRFRI
    DPSSPLHEKNLEDNLQSLATRLAPIYKQYAPV
    AYQNQVEYENVARECRLGSKEGRPFSGVTACL
    DFCAHPHRDIHNMNNGSTVVCTLTREDNRSLG
    VIPQDEQLHVLPLYKLSDTDEFGSKEGMEAKI
    KSGAIEVLAPRRKKRTCFTQPVPRSGKKRAAM
    MTEVLAHKIRAVEKKPIPRIKRKNNSTTTNNS
    KPSSLPTLGSNTETVQPEVKSETEPHFILKSS
    DNTKTYSLMPSAPHPVKEASPGFSWSPKTASA
    TPAPLKNDATASCGFSERSSTPHCTMPSGRLS
    GANAAAADGPGISQLGEVAPLPTLSAPVMEPL
    INSEPSTGVTEPLTPHQPNHQPSFLTSPQDLA
    SSPMEEDEQHSEADEPPSDEPLSDDPLSPAEE
    KLPHIDEYWSDSEHIFLDANIGGVAIAPAHGS
    VLIECARRELHATTPVEHPNRNHPTRLSLVFY
    QHKNLNKPQHGFELNKIKFEAKEAKNKKMKAS
    EQKDQAANEGPEQSSEVNELNQIPSHKALTLT
    HDNVVTVSPYALTHVAGPYNHWVID
    NEIL2-PUFa- MDYKDDDDKPKKKRKLPEGPLVRKFHHLVSPF
    TET1(CD) VGQQVVKTGGSSKKLQPASLQSLWLQDTQVHG
    (SEQ ID NO: 122) KKLFLRFDLDEEMGPPGSSPTPEPPQKEVQKE
    GAADPKQVGEPSGQKTLDGSSRSAELVPQGED
    DSEYLERDAPAGDAGRWLRVSFGLFGSVWVND
    FSRAKKANKRGDWRDPSPRLVLHFGGGGFLAF
    YNCQLSWSSSPVVTPTCDILSEKFHRGQALEA
    LGQAQPVCYTLLDQRYFSGLGNIIKNEALYRA
    GIHPLSLGSVLSASRREVLVDHVVEFSTAWLQ
    GKFQGRPQHTQVYQKEQCPAGHQVMKEAFGPE
    DGLQRLTWWCPQCQPQLSEEPEQCQFSGAATM
    IDGGGGSDPKKKRKVDPKKKRKVDPKKKRKVG
    STGSRNDGGGGSGGGGSGGGGSGRAGILPPKK
    KRKVSRGRSRLLEDFRNNRYPNLQLREIAGHI
    MEFSQDQHGSRFIQLKLERATPAERQLVFNEI
    LQAAYQLMVDVFGNYVIQKFFEFGSLEQKLAL
    AERIRGHVLSLALQMYGSRVIEKALEFIPSDQ
    QNEMVRELDGHVLKCVKDQNGNHVVQKCIECV
    QPQSLQFIIDAFKGQVFALSTHPYGCRVIQRI
    LEHCLPDQTLPILEELHQHTEQLVQDQYGNYV
    IQHVLEHGRPEDKSKIVAEIRGNVLVLSQHKF
    ASNVVEKCVTHASRTERAVLIDEVCTMNDGPH
    SALYTMMKDQYANYVVQKMIDVAEPGQRKIVM
    HKIRPHIATLRKYTYGKHILAKLEKYYMKNGV
    DLGDPKKKRKVDPKKKRKVGGRGGGGSGGGGS
    GGGGSGPAELPTCSCLDRVIQKDKGPYYTHLG
    AGPSVAAVREIMENRYGQKGNAIRIEIVVYTG
    KEGKSSHGCPIAKWVLRRSSDEEKVLCLVRQR
    TGHHCPTAVMVVLIMVWDGIPLPMADRLYTEL
    TENLKSYNGHPTDRRCTLNENRTCTCQGIDPE
    TCGASFSFGCSWSMYFNGCKFGRSPSPRRFRI
    DPSSPLHEKNLEDNLQSLATRLAPIYKQYAPV
    AYQNQVEYENVARECRLGSKEGRPFSGVTACL
    DFCAHPHRDIHNMNNGSTVVCTLTREDNRSLG
    VIPQDEQLHVLPLYKLSDTDEFGSKEGMEAKI
    KSGAIEVLAPRRKKRTCFTQPVPRSGKKRAAM
    MTEVLAHKIRAVEKKPIPRIKRKNNSTTTNNS
    KPSSLPTLGSNTETVQPEVKSETEPHFILKSS
    DNTKTYSLMPSAPHPVKEASPGFSWSPKTASA
    TPAPLKNDATASCGFSERSSTPHCTMPSGRLS
    GANAAAADGPGISQLGEVAPLPTLSAPVMEPL
    INSEPSTGVTEPLTPHQPNHQPSFLTSPQDLA
    SSPMEEDEQHSEADEPPSDEPLSDDPLSPAEE
    KLPHIDEYWSDSEHIFLDANIGGVAIAPAHGS
    VLIECARRELHATTPVEHPNRNHPTRLSLVFY
    QHKNLNKPQHGFELNKIKFEAKEAKNKKMKAS
    EQKDQAANEGPEQSSEVNELNQIPSHKALTLT
    HDNVVTVSPYALTHVAGPYNHWVID
    PUFa-NEIL2- MIDGGGGSDPKKKRKVDPKKKRKVDPKKKRKV
    TET1(CD) GSTGSRNDGGGGSGGGGSGGGGSGRAGILPPK
    (SEQ ID NO: 123) KKRKVSRGRSRLLEDFRNNRYPNLQLREIAGH
    IMEFSQDQHGSRFIQLKLERATPAERQLVFNE
    ILQAAYQLMVDVFGNYVIQKFFEFGSLEQKLA
    LAERIRGHVLSLALQMYGSRVIEKALEFIPSD
    QQNEMVRELDGHVLKCVKDQNGNHVVQKCIEC
    VQPQSLQFIIDAFKGQVFALSTHPYGCRVIQR
    ILEHCLPDQTLPILEELHQHTEQLVQDQYGNY
    VIQHVLEHGRPEDKSKIVAEIRGNVLVLSQHK
    FASNVVEKCVTHASRTERAVLIDEVCTMNDGP
    HSALYTMMKDQYANYVVQKMIDVAEPGQRKIV
    MHKIRPHIATLRKYTYGKHILAKLEKYYMKNG
    VDLGDPKKKRKVDPKKKRKVGGRGGGSGGGSG
    GGSGGGSGGGSGGGSLPEGPLVRKFHHLVSPF
    VGQQVVKTGGSSKKLQPASLQSLWLQDTQVHG
    KKLFLRFDLDEEMGPPGSSPTPEPPQKEVQKE
    GAADPKQVGEPSGQKTLDGSSRSAELVPQGED
    DSEYLERDAPAGDAGRWLRVSFGLFGSVWVND
    FSRAKKANKRGDWRDPSPRLVLHFGGGGFLAF
    YNCQLSWSSSPVVTPTCDILSEKFHRGQALEA
    LGQAQPVCYTLLDQRYFSGLGNIIKNEALYRA
    GIHPLSLGSVLSASRREVLVDHVVEFSTAWLQ
    GKFQGRPQHTQVYQKEQCPAGHQVMKEAFGPE
    DGLQRLTWWCPQCQPQLSEEPEQCQFSRGGGG
    SGGGGSGGGGSGPAELPTCSCLDRVIQKDKGP
    YYTHLGAGPSVAAVREIMENRYGQKGNAIRIE
    IVVYTGKEGKSSHGCPIAKWVLRRSSDEEKVL
    CLVRQRTGHHCPTAVMVVLIMVWDGIPLPMAD
    RLYTELTENLKSYNGHPTDRRCTLNENRTCTC
    QGIDPETCGASFSFGCSWSMYFNGCKFGRSPS
    PRRFRIDPSSPLHEKNLEDNLQSLATRLAPIY
    KQYAPVAYQNQVEYENVARECRLGSKEGRPFS
    GVTACLDFCAHPHRDIHNMNNGSTVVCTLTRE
    DNRSLGVIPQDEQLHVLPLYKLSDTDEFGSKE
    GMEAKIKSGAIEVLAPRRKKRTCFTQPVPRSG
    KKRAAMMTEVLAHKIRAVEKKPIPRIKRKNNS
    TTTNNSKPSSLPTLGSNTETVQPEVKSETEPH
    FILKSSDNTKTYSLMPSAPHPVKEASPGFSWS
    PKTASATPAPLKNDATASCGFSERSSTPHCTM
    PSGRLSGANAAAADGPGISQLGEVAPLPTLSA
    PVMEPLINSEPSTGVTEPLTPHQPNHQPSFLT
    SPQDLASSPMEEDEQHSEADEPPSDEPLSDDP
    LSPAEEKLPHIDEYWSDSEHIFLDANIGGVAI
    APAHGSVLIECARRELHATTPVEHPNRNHPTR
    LSLVFYQHKNLNKPQHGFELNKIKFEAKEAKN
    KKMKASEQKDQAANEGPEQSSEVNELNQIPSH
    KALTLTHDNVVTVSPYALTHVAGPYNHWVID
    NEIL3-PUFa- MDYKDDDDKPKKKRKLVEGPGCTLNGEKIRAR
    TET1(CD) VLPGQAVTGVRGSALRSLQGRALRLAASTVVV
    (SEQ ID NO: 124) SPQAAALNNDSSQNVLSLFNGYVYSGVETLGK
    ELFMYFGPKALRIHFGMKGFIMINPLEYKYKN
    GASPVLEVQLTKDLICFFDSSVELRNSMESQQ
    RIRMMKELDVCSPEFSFLRAESEVKKQKGRML
    GDVLMDQNVLPGVGNIIKNEALFDSGLHPAVK
    VCQLTDEQIHHLMKMIRDFSILFYRCRKAGLA
    LSKHYKVYKRPNCGQCHCRITVCRFGDNNRMT
    YFCPHCQKENPQHVDICKLPTRNTIISWTSSR
    VDHVMDSVARKSEEHWTCVVCTLINKPSSKAC
    DACLTSRPIDSVLKSEENSTVFSHLMKYPCNT
    FGKPHTEVKINRKTAFGTTTLVLTDFSNKSST
    LERKTKQNQILDEEFQNSPPASVCLNDIQHPS
    KKTTNDITQLSSKVNISPTISSESKLFSPAHK
    KPKTAHYSSPELKSCNPGYSNSELQINMTDGP
    RTLNPDSPRCSKHNRLCILRVVRKDGENKGRQ
    FYACPLPREAQCGFFEWADLSFPFCNHGKRST
    MKTVLKIGPNNGKNFFVCPLGKEKQCNFFQWA
    ENGPGIKIIPGCGAATMIDGGGGSDPKKKRKV
    DPKKKRKVDPKKKRKVGSTGSRNDGGGGSGGG
    GSGGGGSGRAGILPPKKKRKVSRGRSRLLEDF
    RNNRYPNLQLREIAGHIMEFSQDQHGSRFIQL
    KLERATPAERQLVFNEILQAAYQLMVDVFGNY
    VIQKFFEFGSLEQKLALAERIRGHVLSLALQM
    YGSRVIEKALEFIPSDQQNEMVRELDGHVLKC
    VKDQNGNHVVQKCIECVQPQSLQFIIDAFKGQ
    VFALSTHPYGCRVIQRILEHCLPDQTLPILEE
    LHQHTEQLVQDQYGNYVIQHVLEHGRPEDKSK
    IVAEIRGNVLVLSQHKFASNVVEKCVTHASRT
    ERAVLIDEVCTMNDGPHSALYTMMKDQYANYV
    VQKMIDVAEPGQRKIVMHKIRPHIATLRKYTY
    GKHILAKLEKYYMKNGVDLGDPKKKRKVDPKK
    KRKVGGRGGGGSGGGGSGGGGSGPAELPTCSC
    LDRVIQKDKGPYYTHLGAGPSVAAVREIMENR
    YGQKGNAIRIEIVVYTGKEGKSSHGCPIAKWV
    LRRSSDEEKVLCLVRQRTGHHCPTAVMVVLIM
    VWDGIPLPMADRLYTELTENLKSYNGHPTDRR
    CTLNENRTCTCQGIDPETCGASFSFGCSWSMY
    FNGCKFGRSPSPRRFRIDPSSPLHEKNLEDNL
    QSLATRLAPIYKQYAPVAYQNQVEYENVAREC
    RLGSKEGRPFSGVTACLDFCAHPHRDIHNMNN
    GSTVVCTLTREDNRSLGVIPQDEQLHVLPLYK
    LSDTDEFGSKEGMEAKIKSGAIEVLAPRRKKR
    TCFTQPVPRSGKKRAAMMTEVLAHKIRAVEKK
    PIPRIKRKNNSTTTNNSKPSSLPTLGSNTETV
    QPEVKSETEPHFILKSSDNTKTYSLMPSAPHP
    VKEASPGFSWSPKTASATPAPLKNDATASCGF
    SERSSTPHCTMPSGRLSGANAAAADGPGISQL
    GEVAPLPTLSAPVMEPLINSEPSTGVTEPLTP
    HQPNHQPSFLTSPQDLASSPMEEDEQHSEADE
    PPSDEPLSDDPLSPAEEKLPHIDEYWSDSEHI
    FLDANIGGVAIAPAHGSVLIECARRELHATTP
    VEHPNRNHPTRLSLVFYQHKNLNKPQHGFELN
    KIKFEAKEAKNKKMKASEQKDQAANEGPEQSS
    EVNELNQIPSHKALTLTHDNVVTVSPYALTHV
    AGPYNHWVID
    TDG-PUFa- MDYKDDDDKPKKKRKLEAENAGSYSLQQAQAF
    TET1(CD) YTFPFQQLMAEAPNMAVVNEQQMPEEVPAPAP
    (SEQ ID NO: 125) AQEPVQEAPKGRKRKPRTTEPKQPVEPKKPVE
    SKKSGKSAKSKEKQEKITDTFKVKRKVDRFNG
    VSEAELLTKTLPDILTFNLDIVIIGINPGLMA
    AYKGHHYPGPGNHFWKCLFMSGLSEVQLNHMD
    DHTLPGKYGIGFTNMVERTTPGSKDLSSKEFR
    EGGRILVQKLQKYQPRIAVFNGKCIYEIFSKE
    VFGVKVKNLEFGLQPHKIPDTETLCYVMPSSS
    ARCAQFPRAQDKVHYYIKLKDLRDQLKGIERN
    MDVQEVQYTFDLQLAQEDAKKMAVKEEKYDPG
    YEAAYGGAYGENPCSSEPCGFSSNGLIESVEL
    RGESAFSGIPNGQWMTQSFTDQIPSFSNHCGT
    QEQEEESHATGAATMIDGGGGSDPKKKRKVDP
    KKKRKVDPKKKRKVGSTGSRNDGGGGSGGGGS
    GGGGSGRAGILPPKKKRKVSRGRSRLLEDFRN
    NRYPNLQLREIAGHIMEFSQDQHGSRFIQLKL
    ERATPAERQLVFNEILQAAYQLMVDVFGNYVI
    QKFFEFGSLEQKLALAERIRGHVLSLALQMYG
    SRVIEKALEFIPSDQQNEMVRELDGHVLKCVK
    DQNGNHVVQKCIECVQPQSLQFIIDAFKGQVF
    ALSTHPYGCRVIQRILEHCLPDQTLPILEELH
    QHTEQLVQDQYGNYVIQHVLEHGRPEDKSKIV
    AEIRGNVLVLSQHKFASNVVEKCVTHASRTER
    AVLIDEVCTMNDGPHSALYTMMKDQYANYVVQ
    KMIDVAEPGQRKIVMHKIRPHIATLRKYTYGK
    HILAKLEKYYMKNGVDLGDPKKKRKVDPKKKR
    KVGGRGGGGSGGGGSGGGGSGPAELPTCSCLD
    RVIQKDKGPYYTHLGAGPSVAAVREIMENRYG
    QKGNAIRIEIVVYTGKEGKSSHGCPIAKWVLR
    RSSDEEKVLCLVRQRTGHHCPTAVMVVLIMVW
    DGIPLPMADRLYTELTENLKSYNGHPTDRRCT
    LNENRTCTCQGIDPETCGASFSFGCSWSMYFN
    GCKFGRSPSPRRFRIDPSSPLHEKNLEDNLQS
    LATRLAPIYKQYAPVAYQNQVEYENVARECRL
    GSKEGRPFSGVTACLDFCAHPHRDIHNMNNGS
    TVVCTLTREDNRSLGVIPQDEQLHVLPLYKLS
    DTDEFGSKEGMEAKIKSGAIEVLAPRRKKRTC
    FTQPVPRSGKKRAAMMTEVLAHKIRAVEKKPI
    PRIKRKNNSTTTNNSKPSSLPTLGSNTETVQP
    EVKSETEPHFILKSSDNTKTYSLMPSAPHPVK
    EASPGFSWSPKTASATPAPLKNDATASCGFSE
    RSSTPHCTMPSGRLSGANAAAADGPGISQLGE
    VAPLPTLSAPVMEPLINSEPSTGVTEPLTPHQ
    PNHQPSFLTSPQDLASSPMEEDEQHSEADEPP
    SDEPLSDDPLSPAEEKLPHIDEYWSDSEHIFL
    DANIGGVAIAPAHGSVLIECARRELHATTPVE
    HPNRNHPTRLSLVFYQHKNLNKPQHGFELNKI
    KFEAKEAKNKKMKASEQKDQAANEGPEQSSEV
    NELNQIPSHKALTLTHDNVVTVSPYALTHVAG
    PYNHWVID
    PUFa-TDG- MIDGGGGSDPKKKRKVDPKKKRKVDPKKKRKV
    TET1(CD) GSTGSRNDGGGGSGGGGSGGGGSGRAGILPPK
    (SEQ ID NO: 126) KKRKVSRGRSRLLEDFRNNRYPNLQLREIAGH
    IMEFSQDQHGSRFIQLKLERATPAERQLVFNE
    ILQAAYQLMVDVFGNYVIQKFFEFGSLEQKLA
    LAERIRGHVLSLALQMYGSRVIEKALEFIPSD
    QQNEMVRELDGHVLKCVKDQNGNHVVQKCIEC
    VQPQSLQFIIDAFKGQVFALSTHPYGCRVIQR
    ILEHCLPDQTLPILEELHQHTEQLVQDQYGNY
    VIQHVLEHGRPEDKSKIVAEIRGNVLVLSQHK
    FASNVVEKCVTHASRTERAVLIDEVCTMNDGP
    HSALYTMMKDQYANYVVQKMIDVAEPGQRKIV
    MHKIRPHIATLRKYTYGKHILAKLEKYYMKNG
    VDLGDPKKKRKVDPKKKRKVGGRGGGSGGGSG
    GGSGGGSGGGSGGGSLEAENAGSYSLQQAQAF
    YTFPFQQLMAEAPNMAVVNEQQMPEEVPAPAP
    AQEPVQEAPKGRKRKPRTTEPKQPVEPKKPVE
    SKKSGKSAKSKEKQEKITDTFKVKRKVDRFNG
    VSEAELLTKTLPDILTFNLDIVIIGINPGLMA
    AYKGHHYPGPGNHFWKCLFMSGLSEVQLNHMD
    DHTLPGKYGIGFTNMVERTTPGSKDLSSKEFR
    EGGRILVQKLQKYQPRIAVFNGKCIYEIFSKE
    VFGVKVKNLEFGLQPHKIPDTETLCYVMPSSS
    ARCAQFPRAQDKVHYYIKLKDLRDQLKGIERN
    MDVQEVQYTFDLQLAQEDAKKMAVKEEKYDPG
    YEAAYGGAYGENPCSSEPCGFSSNGLIESVEL
    RGESAFSGIPNGQWMTQSFTDQIPSFSNHCGT
    QEQEEESHAGRGGGGSGGGGSGGGGSGPAELP
    TCSCLDRVIQKDKGPYYTHLGAGPSVAAVREI
    MENRYGQKGNAIRIEIVVYTGKEGKSSHGCPI
    AKWVLRRSSDEEKVLCLVRQRTGHHCPTAVMV
    VLIMVWDGIPLPMADRLYTELTENLKSYNGHP
    TDRRCTLNENRTCTCQGIDPETCGASFSFGCS
    WSMYFNGCKFGRSPSPRRFRIDPSSPLHEKNL
    EDNLQSLATRLAPIYKQYAPVAYQNQVEYENV
    ARECRLGSKEGRPFSGVTACLDFCAHPHRDIH
    NMNNGSTVVCTLTREDNRSLGVIPQDEQLHVL
    PLYKLSDTDEFGSKEGMEAKIKSGAIEVLAPR
    RKKRTCFTQPVPRSGKKRAAMMTEVLAHKIRA
    VEKKPIPRIKRKNNSTTTNNSKPSSLPTLGSN
    TETVQPEVKSETEPHFILKSSDNTKTYSLMPS
    APHPVKEASPGFSWSPKTASATPAPLKNDATA
    SCGFSERSSTPHCTMPSGRLSGANAAAADGPG
    ISQLGEVAPLPTLSAPVMEPLINSEPSTGVTE
    PLTPHQPNHQPSFLTSPQDLASSPMEEDEQHS
    EADEPPSDEPLSDDPLSPAEEKLPHIDEYWSD
    SEHIFLDANIGGVAIAPAHGSVLIECARRELH
    ATTPVEHPNRNHPTRLSLVFYQHKNLNKPQHG
    FELNKIKFEAKEAKNKKMKASEQKDQAANEGP
    EQSSEVNELNQIPSHKALTLTHDNVVTVSPYA
    LTHVAGPYNHWVID
    PUFc-NEIL2 MIDGGGGSDPKKKRKVDPKKKRKVDPKKKRKV
    (SEQ ID NO: 127) GSTGSRNDGGGGSGGGGSGGGGSGRAGILPPK
    KKRKVSRGRSRLLEDFRNNRYPNLQLREIAGH
    IMEFSQDQHGSRFIQLKLERATPAERQLVFNE
    ILQAAYQLMVDVFGNYVIQKFFEFGSLEQKLA
    LAERIRGHVLSLALQMYGSRVIEKALEFIPSD
    QQNEMVRELDGHVLKCVKDQNGNHVVQKCIEC
    VQPQSLQFIIDAFKGQVFALSTHPYGCRVIQR
    ILEHCLPDQTLPILEELHQHTEQLVQDQYGSY
    VIEHVLEHGRPEDKSKIVAEIRGNVLVLSQHK
    FANNVVQKCVTHASRTERAVLIDEVCTMNDGP
    HSALYTMMKDQYANYVVQKMIDVAEPGQRKIV
    MHKIRPHIATLRKYTYGKHILAKLEKYYMKNG
    VDLGDPKKKRKVDPKKKRKVGGRGGGGSGGGG
    SGGGGSGPALPEGPLVRKFHHLVSPFVGQQVV
    KTGGSSKKLQPASLQSLWLQDTQVHGKKLFLR
    FDLDEEMGPPGSSPTPEPPQKEVQKEGAADPK
    QVGEPSGQKTLDGSSRSAELVPQGEDDSEYLE
    RDAPAGDAGRWLRVSFGLFGSVWVNDFSRAKK
    ANKRGDWRDPSPRLVLHFGGGGFLAFYNCQLS
    WSSSPVVTPTCDILSEKFHRGQALEALGQAQP
    VCYTLLDQRYFSGLGNIIKNEALYRAGIHPLS
    LGSVLSASRREVLVDHVVEFSTAWLQGKFQGR
    PQHTQVYQKEQCPAGHQVMKEAFGPEDGLQRL
    TWWCPQCQPQLSEEPEQCQFS
    NEIL2-PUFc MPEGPLVRKFHHLVSPFVGQQVVKTGGSSKKL
    (SEQ ID NO: 128) QPASLQSLWLQDTQVHGKKLFLRFDLDEEMGP
    PGSSPTPEPPQKEVQKEGAADPKQVGEPSGQK
    TLDGSSRSAELVPQGEDDSEYLERDAPAGDAG
    RWLRVSFGLFGSVWVNDFSRAKKANKRGDWRD
    PSPRLVLHFGGGGFLAFYNCQLSWSSSPVVTP
    TCDILSEKFHRGQALEALGQAQPVCYTLLDQR
    YFSGLGNIIKNEALYRAGIHPLSLGSVLSASR
    REVLVDHVVEFSTAWLQGKFQGRPQHTQVYQK
    EQCPAGHQVMKEAFGPEDGLQRLTWWCPQCQP
    QLSEEPEQCQFSIDGGGGSDPKKKRKVDPKKK
    RKVDPKKKRKVGSTGSRNDGGGGSGGGGSGGG
    GSGRAGILPPKKKRKVSRGRSRLLEDFRNNRY
    PNLQLREIAGHIMEFSQDQHGSRFIQLKLERA
    TPAERQLVFNEILQAAYQLMVDVFGNYVIQKF
    FEFGSLEQKLALAERIRGHVLSLALQMYGSRV
    IEKALEFIPSDQQNEMVRELDGHVLKCVKDQN
    GNHVVQKCIECVQPQSLQFIIDAFKGQVFALS
    THPYGCRVIQRILEHCLPDQTLPILEELHQHT
    EQLVQDQYGSYVIEHVLEHGRPEDKSKIVAEI
    RGNVLVLSQHKFANNVVQKCVTHASRTERAVL
    IDEVCTMNDGPHSALYTMMKDQYANYVVQKMI
    DVAEPGQRKIVMHKIRPHIATLRKYTYGKHIL
    AKLEKYYMKNGVDLGDPKKKRKVDPKKKRKVG
    GRGGGGSGGGGSGGGGSGPA
    dCas9 MIDGGGGSGGGGSGGGGSMYPYDVPDYASPKK
    (SEQ ID NO: 129) KRKVEASDKKYSIGLAIGTNSVGWAVITDEYK
    VPSKKFKVLGNTDRHSIKKNLIGALLFDSGET
    AEATRLKRTARRRYTRRKNRICYLQEIFSNEM
    AKVDDSFFHRLEESFLVEEDKKHERHPIFGNI
    VDEVAYHEKYPTIYHLRKKLVDSTDKADLRLI
    YLALAHMIKFRGHFLIEGDLNPDNSDVDKLFI
    QLVQTYNQLFEENPINASGVDAKAILSARLSK
    SRRLENLIAQLPGEKKNGLFGNLIALSLGLTP
    NFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQI
    GDQYADLFLAAKNLSDAILLSDILRVNTEITK
    APLSASMIKRYDEHHQDLTLLKALVRQQLPEK
    YKEIFFDQSKNGYAGYIDGGASQEEFYKFIKP
    ILEKMDGTEELLVKLNREDLLRKQRTFDNGSI
    PHQIHLGELHAILRRQEDFYPFLKDNREKIEK
    ILTFRIPYYVGPLARGNSRFAWMTRKSEETIT
    PWNFEEVVDKGASAQSFIERMTNFDKNLPNEK
    VLPKHSLLYEYFTVYNELTKVKYVTEGMRKPA
    FLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFK
    KIECFDSVEISGVEDRFNASLGTYHDLLKIIK
    DKDFLDNEENEDILEDIVLTLTLFEDREMIEE
    RLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKL
    INGIRDKQSGKTILDFLKSDGFANRNFMQLIH
    DDSLIFKEDIQKAQVGQGDSLHEHIANLAGSP
    AIKKGILQTVKVVDELVKVMGRHKPENIVIEM
    ARENQTTQKGQKNSRERMKRIEEGIKELGSQI
    LKEHPVENTQLQNEKLYLYYLQNGRDMYVDQE
    LDINRLSDYDVDAIVPQSFLKDDSIDNKVLTR
    SDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKL
    ITQRKFDNLTKAERGGLSELDKAGFIKRQLVE
    TRQIIKHVAQILDSRMNTKYDENDKLIREVKV
    ITLKSKLVSDFRKDFQFYKVREINNYHHAHDA
    YLNAVVGTALIKKYPKLESEFVYGDYKVYDVR
    KMIAKSEQEIGKATAKYFFYSNIMNFFKTEIT
    LANGEIRKRPLIETNGETGEIVWDKGRDFATV
    RKVLSMPQVNIVKKTEVQTGGFSKESILPKRN
    SDKLIARKKDWDPKKYGGFDSPTVAYSVLVVA
    KVEKGKSKKLKSVKELLGITIMERSSFEKNPI
    DFLEAKGYKEVKKDLIIKLPKYSLFELENGRK
    RMLASAGELQKGNELALPSKYVNFLYLASHYE
    KLKGSPEDNEQKQLFVEQHKHYLDEIIEQISE
    FSKRVILADANLDKVLSAYNKHRDKPIREQAE
    NIIHLFTLTNLGAPAAFKYFDTTIDRKRYTST
    KEVLDATLIHQSITGLYETRIDLSQLGGDSPK
    KKRKVEASGGGGSGGGGSGGGGSGPA
    • REFERENCES
    • Barreto G., Schlfer A., Marhold J., Stach D., Swaminathan S. K., Handa V., Doderlein G., Maltry N., Wu W., Lyko F., Niehrs C. Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature. 2007; 445:671-675.
    • Le May N., Mota-Fernandes D., Velez-Cruz R., Iltis I., Biard D., Egly J. M. NER factors are recruited to active promoters and facilitate chromatin modification for transcription in the absence of exogenous genotoxic attack. Mol. Cell. 2010; 38:54-66
    • Schmitz K. M., Schmitt N., Hoffmann-Rohrer U., Schäfer A., Grummt I., Mayer C. TAF12 recruits Gadd45a and the nucleotide excision repair complex to the promoter of rRNA genes leading to active DNA demethylation. Mol. Cell. 2009; 33:344-353
    • Kriaucionis S., Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science. 2009; 324:929-930
    • Maiti A., Drohat A. C. Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites. J. Biol. Chem. 2011; 286:35334-35338.
    • He Y. F., Li B. Z., Li Z., Liu P., Wang Y., Tang Q., Ding J., Jia Y., Chen Z., Li L., Sun Y., Li X., Dai Q., Song C. X., Zhang K., He C., Xu G. L. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science. 2011; 333:1303-1307.
    • Ito, S., et al., Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature, 2010. 466(7310): p. 1129-33.
    • Kienhofer, S., et al., GADD45a physically and functionally interacts with TET1. Differentiation, 2015. 90(1-3): p. 59-68.
    • Muller, U., et al., TET-mediated oxidation of methylcytosine causes TDG or NEIL glycosylase dependent gene reactivation. Nucleic Acids Res, 2014. 42(13): p. 8592-604.

Claims (113)

What is claimed is:
1. A demethylation complex, comprising:
(a) a ribonucleoprotein complex comprising:
(i) a nuclease-deficient RNA-guided DNA endonuclease enzyme; and
(ii) a polynucleotide comprising:
(1) a DNA-targeting sequence that is complementary to a target polynucleotide sequence;
(2) a binding sequence for said nuclease-deficient RNA-guided DNA endonuclease enzyme; and
(3) one or more PUF binding site (PBS) sequences,
wherein said nuclease-deficient RNA-guided DNA endonuclease enzyme is bound to said polynucleotide via said binding sequence; and
(b) a demethylation protein conjugate comprising:
(i) a PUF domain having a C-terminus and a N-terminus;
(ii) a TET demethylation domain operably linked to the C-terminus of said PUF domain; and
(iii) a demethylation enhancer domain operably linked to the N-terminus of said PUF domain, to form a protein conjugate, and
wherein said demethylation protein conjugate binds to said ribonucleoprotein complex via said PUF domain binding to said one or more PBS sequences to form a demethylation complex.
2. The complex of claim 1, wherein said TET demethylation domain is a TET1 domain, a TET2 domain or a TET3 domain.
3. The complex of claim 2, wherein said TET 1 domain has the sequence of SEQ ID NO:51.
4. The complex of one of claims 1-3, wherein said demethylation enhancer domain is a Growth Arrest and DNA-Damage-inducible Alpha (GADD45A) domain.
5. The complex of claim 4, wherein said GADD45 domain has the amino acid sequence of SEQ ID NO:85.
6. The complex of one of claims 1-3, wherein said demethylation enhancer domain is a NEIL2 domain.
7. The complex of claim 5, wherein said NEIL2 domain has the amino acid sequence of SEQ ID NO:86.
8. The complex of one of claims 1-7, wherein said nuclease-deficient RNA-guided DNA endonuclease enzyme comprises a nuclear localization signal (NLS).
9. The complex of one of claims 1-8, wherein said nuclease-deficient RNA-guided DNA endonuclease enzyme is dCas9.
10. The complex of one of claims 1-9, wherein said target polynucleotide sequence is part of a gene.
11. The complex of one of claims 1-9, wherein said target polynucleotide sequence is part of a transcriptional regulatory sequence.
12. The complex of one of claims 1-9 or 11, wherein said target polynucleotide sequence is part of a promoter, enhancer or silencer.
13. The complex of one of claims 1-12, wherein said target polynucleotide sequence is a hypermethylated nucleic acid sequence.
14. The complex of one of claims 1-13, wherein said target polynucleotide sequence is a hypermethylated CpG sequence.
15. The complex of one of claims 1-9 or 11-14, wherein said target polynucleotide sequence is part of an hMLH1 promoter.
16. The complex of one of claims 1-10 or 13-14, wherein said target polynucleotide sequence is part of a Sox gene.
17. The complex of one of claims 1-16, wherein said one or more PBS sequences contain 8 nucleotides in length.
18. The complex of one of claims 1-17, wherein said one or more PBS sequences are identical.
19. The complex of one of claims 1-18, wherein said polynucleotide comprises 1 to 50 PBS sequences.
20. The complex of one of claims 1-19, wherein one or more PBS sequences comprise the nucleotide sequence of SEQ ID NO: 1.
21. The complex of one of claims 1-20, wherein said PUF domain comprises a PUFa domain, a PUFb domain, a PUFc domain, or a PUFw domain.
22. The complex of claim 21, wherein said PUFa domain has the amino acid sequence of SEQ ID NO:2.
23. The complex of claim 21, wherein said PUFb domain has the amino acid sequence of SEQ ID NO:3.
24. The complex of claim 21, wherein said PUFc domain has the amino acid sequence of SEQ ID NO:4.
25. The complex of claim 21, wherein said PUFw domain has the amino acid sequence of SEQ ID NO:5.
26. A method of demethylating a target nucleic acid sequence in a mammalian cell, comprising:
(a) providing a mammalian cell containing a target nucleic acid requiring demethylation;
(b) delivering to said mammalian cell a first polynucleotide encoding a nuclease-deficient RNA-guided DNA endonuclease enzyme;
(c) delivering to said mammalian cell a second polynucleotide comprising:
(i) a DNA-targeting sequence that is complementary to a target polynucleotide sequence;
(ii) a binding sequence for said nuclease-deficient RNA-guide DNA endonuclease enzyme, and
(iii) one or more PUF binding site (PBS) sequences,
wherein said nuclease-deficient RNA-guided DNA endonuclease enzyme is bound to said second polynucleotide via said binding sequence;
(d) delivering to said mammalian cell a third polynucleotide encoding a demethylation protein conjugate comprising:
(i) a PUF domain having a C-terminus and a N-terminus;
(ii) a TET demethylation domain operably linked to the C-terminus of said PUF domain; and
(iii) a demethylation enhancer domain operably linked to the N-terminus of said PUF domain, to form a protein conjugate, and
whereby said delivered demethylation protein conjugate demethylates said target nucleic acid sequence in said cell.
27. The method of claim 26, wherein said demethylation protein conjugate binds to said ribonucleoprotein complex via said PUF domain binding to said one or more PBS sequences to form a demethylation complex.
28. The method of claim 26 or 27, wherein said first polynucleotide is contained within a first vector.
29. The method of one of claims 26-28, wherein said second polynucleotide is contained within a second vector.
30. The method of one of claims 26-29, wherein said third polynucleotide is contained within a third vector.
31. The method of one of claims 26-30, wherein either said first, second or third vector is the same.
32. The method of one of claims 26-31, wherein said delivering is performed by transfection.
33. A kit comprising:
(i) a ribonucleoprotein complex of one of claims 1-25 or a nucleic acid encoding the same; and
(ii) a demethylation protein conjugate of one of claims 1-25 or a nucleic acid encoding the same.
34. The kit of claim 33, further comprising a transfection agent.
35. The kit of claim 33 or 34, further comprising a sample collection device for collecting a sample from a cancer patient.
36. A demethylation complex, comprising:
(a) a ribonucleoprotein complex comprising:
(i) a nuclease-deficient RNA-guided DNA endonuclease enzyme; and
(ii) a polynucleotide comprising:
(1) a DNA-targeting sequence that is complementary to a target polynucleotide sequence;
(2) a binding sequence for said nuclease-deficient RNA-guided DNA endonuclease enzyme; and
(3) one or more PUF binding site (PBS) sequences,
wherein said nuclease-deficient RNA-guided DNA endonuclease enzyme is bound to said polynucleotide via said binding sequence; and
(b) a demethylation protein conjugate comprising:
(i) a PUF domain having a C-terminus;
(ii) a demethylation enhancer domain, having a N-terminus and a C-terminus, wherein said N-terminus of said demethylation enhancer domain is operably linked to the C-terminus of said PUF domain; and
(iii) a TET demethylation domain operably linked to the C-terminus of said demethylation enhancer domain; and
wherein said demethylation protein conjugate binds to said ribonucleoprotein complex via said PUF domain binding to said one or more PBS sequences to form a demethylation complex.
37. The complex of claim 36, wherein said TET demethylation domain is a TET1 domain, a TET2 domain or a TET3 domain.
38. The complex of claim 37, wherein said TET1 domain has the sequence of SEQ ID NO:51.
39. The complex of one of claims 36-38, wherein said demethylation enhancer domain is a Growth Arrest and DNA-Damage-inducible Alpha (GADD45A) domain.
40. The complex of claim 39, wherein said GADD45 domain has the amino acid sequence of SEQ ID NO:85.
41. The complex of one of claims 36-38, wherein said demethylation enhancer domain is a NEIL2 domain.
42. The complex of claim 41, wherein said NEIL2 domain has the amino acid sequence of SEQ ID NO:86.
43. The complex of one of claims 36-42, wherein said nuclease-deficient RNA-guided DNA endonuclease enzyme comprises a nuclear localization signal (NLS).
44. The complex of one of claims 36-43, wherein said nuclease-deficient RNA-guided DNA endonuclease enzyme is dCas9.
45. The complex of one of claims 36-44, wherein said target polynucleotide sequence is part of a gene.
46. The complex of one of claims 36-44, wherein said target polynucleotide sequence is part of a transcriptional regulatory sequence.
47. The complex of one of claims 36-44 or 46, wherein said target polynucleotide sequence is part of a promoter, enhancer or silencer.
48. The complex of one of claims 36-47, wherein said target polynucleotide sequence is a hypermethylated nucleic acid sequence.
49. The complex of one of claims 36-48, wherein said target polynucleotide sequence is a hypermethylated CpG sequence.
50. The complex of one of claims 36-44 or 46-49, wherein said target polynucleotide sequence is part of an hMLH1 promoter.
51. The complex of one of claims 36-45 or 48-49, wherein said target polynucleotide sequence is part of a Sox gene.
52. The complex of one of claims 36-51, wherein said one or more PBS sequences contain 8 nucleotides in length.
53. The complex of one of claims 36-52, wherein said one or more PBS sequences are identical.
54. The complex of one of claims 36-53, wherein said polynucleotide comprises 1 to 50 PBS sequences.
55. The complex of one of claims 36-54, wherein one or more PBS sequences comprise the nucleotide sequence of SEQ ID NO: 1.
56. The complex of one of claims 36-55, wherein said PUF domain comprises a PUFa domain, a PUFb domain, a PUFc domain, or a PUFw domain.
57. The complex of claim 56, wherein said PUFa domain has the amino acid sequence of SEQ ID NO:2.
58. The complex of claim 56, wherein said PUFb domain has the amino acid sequence of SEQ ID NO:3.
59. The complex of claim 56, wherein said PUFc domain has the amino acid sequence of SEQ ID NO:4.
60. The complex of claim 56, wherein said PUFw domain has the amino acid sequence of SEQ ID NO:5.
61. A method of demethylating a target nucleic acid sequence in a mammalian cell, comprising:
(a) providing a mammalian cell containing a target nucleic acid requiring demethylation;
(b) delivering to said mammalian cell a first polynucleotide encoding a nuclease-deficient RNA-guided DNA endonuclease enzyme;
(c) delivering to said mammalian cell a second polynucleotide comprising:
(i) a DNA-targeting sequence that is complementary to a target polynucleotide sequence;
(ii) a binding sequence for said nuclease-deficient RNA-guide DNA endonuclease enzyme; and
(iii) one or more PUF binding site (PBS) sequences,
wherein said nuclease-deficient RNA-guided DNA endonuclease enzyme is bound to said second polynucleotide via said binding sequence;
(d) delivering to said mammalian cell a third polynucleotide encoding a demethylation protein conjugate comprising:
(i) a PUF domain having a C-terminus;
(ii) a demethylation enhancer domain, having a N-terminus and a C-terminus,
wherein said N-terminus of said demethylation enhancer domain is operably linked to the C-terminus of said PUF domain; and
(iii) a TET demethylation domain operably linked to the C-terminus of said demethylation enhancer domain, whereby said delivered demethylation protein conjugate demethylates said target nucleic acid sequence in said cell.
62. The method of claim 61, wherein said demethylation protein conjugate binds to said ribonucleoprotein complex via said PUF domain binding to said one or more PBS sequences to form a demethylation complex.
63. The method of claim 61 or 62, wherein said first polynucleotide is contained within a first vector.
64. The method of one of claims 61-63, wherein said second polynucleotide is contained within a second vector.
65. The method of one of claims 61-64, wherein said third polynucleotide is contained within a third vector.
66. The method of one of claims 61-65, wherein either said first, second or third vector is the same.
67. The method of one of claims 61-66, wherein said delivering is performed by transfection.
68. A kit comprising:
(i) a ribonucleoprotein complex of one of claims 36-60 or a nucleic acid encoding the same; and
(ii) a demethylation protein conjugate of one of claims 36-60 or a nucleic acid encoding the same.
69. The kit of claim 68, further comprising a transfection agent.
70. The kit of claim 68 or 69, further comprising a sample collection device for collecting a sample from a cancer patient.
71. A demethylation complex, comprising:
(a) a ribonucleoprotein complex comprising:
(i) a nuclease-deficient RNA-guided DNA endonuclease enzyme; and
(ii) a polynucleotide comprising:
(1) a DNA-targeting sequence that is complementary to a target polynucleotide sequence;
(2) a binding sequence for said nuclease-deficient RNA-guided DNA endonuclease enzyme;
(3) a first PUF binding site (PBS) sequence; and
(4) a second PUF binding site (PBS) sequence,
wherein said nuclease-deficient RNA-guided DNA endonuclease enzyme is bound to said polynucleotide via said binding sequence;
(b) a demethylation protein conjugate comprising:
(i) a first PUF domain having a C-terminus, and
(ii) a TET demethylation domain operably linked to the C-terminus of said first PUF domain,
wherein said demethylation protein conjugate binds to said ribonucleoprotein complex via said first PUF domain binding to said first PBS sequence; and
(c) a demethylation enhancer conjugate comprising:
(i) a second PUF domain; and
(ii) a demethylation enhancer domain operably linked to said second PUF domain,
wherein said demethylation enhancer conjugate binds to said ribonucleoprotein complex via said second PUF domain binding to said second PBS sequence to form a demethylation complex.
72. The complex of claim 71, wherein said TET demethylation domain is a TET1 domain, a TET2 domain or a TET3 domain.
73. The complex of claim 72, wherein said TET1 domain has the sequence of SEQ ID NO:51.
74. The complex of one of claims 71-73, wherein said demethylation enhancer domain is a Growth Arrest and DNA-Damage-inducible Alpha (GADD45A) domain.
75. The complex of claim 74, wherein said GADD45 domain has the amino acid sequence of SEQ ID NO:85.
76. The complex of one of claims 71-73, wherein said demethylation enhancer domain is a NEIL2 domain.
77. The complex of claim 76, wherein said NEIL2 domain has the sequence of SEQ ID NO:86.
78. The complex of one of claims 71-77, wherein said first PUF domain is a PUFa domain.
79. The complex of claim 78, wherein said PUFa domain has the sequence of SEQ ID NO:2.
80. The complex of one of claims 71-79, wherein said second PUF domain is a PUFc domain.
81. The complex of claim 80, wherein said PUFc domain has the sequence of SEQ ID NO:4.
82. The complex of one of claims 71-81, wherein said demethylation enhancer domain is operably linked to the N-terminus of said second PUF domain.
83. The complex of one of claims 71-81, wherein said demethylation enhancer domain is operably linked to the C-terminus of said second PUF domain.
84. The complex of one of claims 71-83, wherein said nuclease-deficient RNA-guided DNA endonuclease enzyme comprises a nuclear localization signal (NLS).
85. The complex of one of claims 71-43, wherein said nuclease-deficient RNA-guided DNA endonuclease enzyme is dCas9.
86. The complex of one of claims 71-85, wherein said target polynucleotide sequence is part of a gene.
87. The complex of one of claims 71-85, wherein said target polynucleotide sequence is part of a transcriptional regulatory sequence.
88. The complex of one of claims 71-85 or 87, wherein said target polynucleotide sequence is part of a promoter, enhancer or silencer.
89. The complex of one of claims 71-88, wherein said target polynucleotide sequence is a hypermethylated nucleic acid sequence.
90. The complex of one of claims 71-89, wherein said target polynucleotide sequence is a hypermethylated CpG sequence.
91. The complex of one of claims 71-85 or 87-90, wherein said target polynucleotide sequence is part of an hMLH1 promoter.
92. The complex of one of claims 71-86 or 89-90, wherein said target polynucleotide sequence is part of a Sox gene.
93. The complex of one of claims 71-92, wherein said first or said second PBS sequence contains 8 nucleotides in length.
94. The complex of one of claims 71-93, wherein said first or said second PBS sequences comprise the nucleotide sequence of SEQ ID NO:1.
95. The complex of one of claims 71-94, wherein said first or said second PUF domain comprises a PUFa domain, a PUFb domain, a PUFc domain, or a PUFw domain.
96. The complex of claim 95, wherein said first or said second PUFa domain has the amino acid sequence of SEQ ID NO:2.
97. The complex of claim 95, wherein said first or said second PUFb domain has the amino acid sequence of SEQ ID NO:3.
98. The complex of claim 95, wherein said first or said second PUFc domain has the amino acid sequence of SEQ ID NO:4.
99. The complex of claim 95, wherein said first or said second PUFw domain has the amino acid sequence of SEQ ID NO:5.
100. A method of demethylating a target nucleic acid sequence in a mammalian cell, comprising:
(a) providing a mammalian cell containing a target nucleic acid requiring demethylation;
(b) delivering to said mammalian cell a first polynucleotide encoding a nuclease-deficient RNA-guided DNA endonuclease enzyme;
(c) delivering to said mammalian cell a second polynucleotide comprising:
(i) a DNA-targeting sequence that is complementary to a target polynucleotide sequence;
(ii) a binding sequence for said nuclease-deficient RNA-guide DNA endonuclease enzyme;
(iii) a first PUF binding site (PBS) sequence, and
(iv) a second PUF binding site (PBS) sequence,
wherein said nuclease-deficient RNA-guided DNA endonuclease enzyme is bound to said second polynucleotide via said binding sequence;
(d) delivering to said mammalian cell a third polynucleotide encoding a demethylation protein conjugate comprising:
(i) a first PUF domain; and
(ii) a demethylation domain, said demethylation domain operably linked to the C-terminus of said first PUF domain, and
(e) delivering to said mammalian cell a fourth polynucleotide encoding a demethylation enhancer conjugate comprising:
(i) a second PUF domain; and
(ii) a demethylation enhancer domain operably linked to said second PUF domain, whereby said delivered demethylation protein conjugate demethylates said target nucleic acid sequence in said cell.
101. The method of claim 100, wherein said demethylation protein conjugate binds to said ribonucleoprotein complex via said first PUF domain binding to said first PBS sequence.
102. The method of claim 100 or 101, wherein said demethylation enhancer conjugate binds to said ribonucleoprotein complex via said second PUF domain binding to said second PBS sequence.
103. The method of one of claims 100-102, wherein said demethylation enhancer domain is operably linked to the N-terminus of said second PUF domain.
104. The method of one of claims 100-102, wherein said demethylation enhancer domain is operably linked to the C-terminus of said second PUF domain.
105. The method of one of claims 100-104, wherein said first polynucleotide is contained within a first vector.
106. The method of one of claims 100-105, wherein said second polynucleotide is contained within a second vector.
107. The method of one of claims 100-106, wherein said third polynucleotide is contained within a third vector.
108. The method of one of claims 100-107, wherein said fourth polynucleotide is contained within a fourth vector.
109. The method of one of claims 100-108, wherein either said first, second, third or fourth vector is the same.
110. The method of one of claims 100-109, wherein said delivering is performed by transfection.
111. A kit comprising:
(i) a ribonucleoprotein complex of one of claims 71-99 or a nucleic acid encoding the same;
(ii) a demethylation protein conjugate of one of claims 71-99 or a nucleic acid encoding the same, and
(iii) a demethylation enhancer conjugate of one of claims 71-99 or a nucleic acid encoding the same.
112. The kit of claim 111, further comprising a transfection agent.
113. The kit of claim 111 or 112, further comprising a sample collection device for collecting a sample from a cancer patient.
US16/333,137 2016-09-13 2017-09-13 Targeted enhanced dna demethylation Pending US20190218261A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/333,137 US20190218261A1 (en) 2016-09-13 2017-09-13 Targeted enhanced dna demethylation

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662393944P 2016-09-13 2016-09-13
US201762485210P 2017-04-13 2017-04-13
US201762535113P 2017-07-20 2017-07-20
US16/333,137 US20190218261A1 (en) 2016-09-13 2017-09-13 Targeted enhanced dna demethylation
PCT/US2017/051411 WO2018053037A1 (en) 2016-09-13 2017-09-13 Targeted enhanced dna demethylation

Publications (1)

Publication Number Publication Date
US20190218261A1 true US20190218261A1 (en) 2019-07-18

Family

ID=61619233

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/333,134 Active 2040-09-13 US11780895B2 (en) 2016-09-13 2017-09-13 Targeted DNA demethylation and methylation
US16/333,137 Pending US20190218261A1 (en) 2016-09-13 2017-09-13 Targeted enhanced dna demethylation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US16/333,134 Active 2040-09-13 US11780895B2 (en) 2016-09-13 2017-09-13 Targeted DNA demethylation and methylation

Country Status (7)

Country Link
US (2) US11780895B2 (en)
EP (2) EP3512565A4 (en)
JP (1) JP7063885B2 (en)
CN (1) CN109982710A (en)
AU (1) AU2017327384B2 (en)
CA (1) CA3036695A1 (en)
WO (2) WO2018053037A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11434491B2 (en) 2018-04-19 2022-09-06 The Regents Of The University Of California Compositions and methods for gene editing
US11434484B2 (en) * 2015-03-13 2022-09-06 The Jackson Laboratory Three-component CRISPR/Cas complex system and uses thereof
US11780895B2 (en) 2016-09-13 2023-10-10 The Jackson Laboratory Targeted DNA demethylation and methylation

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3047011A1 (en) 2017-01-26 2018-08-02 The Regents Of The University Of California Targeted gene demethylation in plants
JP2022513159A (en) * 2018-11-29 2022-02-07 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド How to regulate RNA
US20220333172A1 (en) * 2019-08-16 2022-10-20 The Jackson Laboratory Live cell imaging of non-repetitive genomic loci
CN111755072B (en) * 2020-08-04 2021-02-02 深圳吉因加医学检验实验室 Method and device for simultaneously detecting methylation level, genome variation and insertion fragment
CN114835816B (en) * 2021-01-14 2023-12-22 中国科学院遗传与发育生物学研究所 Method for regulating methylation level of specific region of plant genome DNA
WO2023247789A1 (en) 2022-06-24 2023-12-28 European Molecular Biology Laboratory Crispr-based modular tool for the specific introduction of epigenetic modifications at target loci

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140315985A1 (en) * 2013-03-14 2014-10-23 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
FR2588189B1 (en) 1985-10-03 1988-12-02 Merck Sharp & Dohme LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DK0495421T3 (en) 1991-01-15 1996-12-09 Alcon Lab Inc Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
JP3534749B2 (en) 1991-08-20 2004-06-07 アメリカ合衆国 Adenovirus-mediated gene transfer into the gastrointestinal tract
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (en) 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
CA2145641C (en) 1992-12-03 2008-05-27 Richard J. Gregory Pseudo-adenovirus vectors
WO1995000655A1 (en) 1993-06-24 1995-01-05 Mc Master University Adenovirus vectors for gene therapy
ES2328585T3 (en) 1993-10-25 2009-11-16 Canji, Inc. VENUE OF ADENOVIRUS RECOMBINANT AND METHOD OF USE.
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6613318B1 (en) 1999-03-25 2003-09-02 The United States Of America As Represented By The Department Of Health And Human Services Methods for identifying inhibitors of GADD45 polypeptide activity, and inhibitors of such activity
US8193332B2 (en) * 2004-04-09 2012-06-05 Genecare Research Institute Co., Ltd. Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
WO2010075303A1 (en) * 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
WO2010074758A2 (en) * 2008-12-24 2010-07-01 The Johns Hopkins University Compositions for promoting epigenetic dna demethylation and methods of use therefore
US8889394B2 (en) * 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
WO2011160052A2 (en) 2010-06-18 2011-12-22 The University Of North Carolina At Chapel Hill Methods and compositions for sequence specific rna endonucleases
DE102010026500A1 (en) 2010-07-07 2012-01-12 Arthrogen Gmbh Process for the preparation of autologous proteins
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US9890364B2 (en) * 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10330674B2 (en) * 2015-01-13 2019-06-25 Massachusetts Institute Of Technology Pumilio domain-based modular protein architecture for RNA binding
ES2886901T3 (en) * 2015-03-13 2021-12-21 Jackson Lab A complex three component CRISPR/Cas system and uses thereof
WO2018035495A1 (en) * 2016-08-19 2018-02-22 Whitehead Institute For Biomedical Research Methods of editing dna methylation
CA3036695A1 (en) 2016-09-13 2018-03-22 The Jackson Laboratory Targeted enhanced dna demethylation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140315985A1 (en) * 2013-03-14 2014-10-23 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11434484B2 (en) * 2015-03-13 2022-09-06 The Jackson Laboratory Three-component CRISPR/Cas complex system and uses thereof
US11780895B2 (en) 2016-09-13 2023-10-10 The Jackson Laboratory Targeted DNA demethylation and methylation
US11434491B2 (en) 2018-04-19 2022-09-06 The Regents Of The University Of California Compositions and methods for gene editing

Also Published As

Publication number Publication date
JP7063885B2 (en) 2022-05-09
US11780895B2 (en) 2023-10-10
EP3512535A1 (en) 2019-07-24
WO2018053037A1 (en) 2018-03-22
CA3036695A1 (en) 2018-03-22
JP2019528718A (en) 2019-10-17
US20200071369A1 (en) 2020-03-05
AU2017327384A1 (en) 2019-04-11
EP3512565A4 (en) 2020-05-06
AU2017327384B2 (en) 2021-05-20
CN109982710A (en) 2019-07-05
EP3512535A4 (en) 2020-05-06
WO2018053035A1 (en) 2018-03-22
EP3512565A1 (en) 2019-07-24

Similar Documents

Publication Publication Date Title
US11780895B2 (en) Targeted DNA demethylation and methylation
US10793842B2 (en) Cas9 variants and methods of use thereof
US11118194B2 (en) Modified site-directed modifying polypeptides and methods of use thereof
US11008555B2 (en) Variant Cas9 polypeptides comprising internal insertions
US11208638B2 (en) Heterodimeric Cas9 and methods of use thereof
JP7044373B2 (en) Nuclease-independent targeted gene editing platform and its uses
ES2960803T3 (en) Methods and compositions for RNA-directed modification of target DNA and for modulation of RNA-directed transcription
US20180320202A1 (en) Compositions and methods for modifying a target nucleic acid
KR20230169449A (en) Rna-guided nucleic acid modifying enzymes and methods of use thereof
US20220315914A1 (en) Variant type v crispr/cas effector polypeptides and methods of use thereof
US20200291369A1 (en) Improved CRISPR-Cas9 Genome Editing Tool
KR20220019794A (en) Targeted gene editing constructs and methods of use thereof
CN113423831A (en) Nuclease-mediated repeat amplification
KR20180102025A (en) Composition for Genome Editing Comprising C2c1 Endonuclease and Method of Genome Editing Using the Same
US9816077B2 (en) Use of integrase for targeted gene expression
US20200224194A1 (en) Expression systems that facilitate nucleic acid delivery and methods of use
WO2022197839A1 (en) Crispr/cas effector-histone modifier fusion proteins and methods of use thereof

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING

AS Assignment

Owner name: THE JACKSON LABORATORY, MAINE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHENG, ALBERT;TAGHBALOUT, AZIZ;JILLETTE, NATHANIEL;REEL/FRAME:058487/0844

Effective date: 20210813

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED